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i) Abstract 
 
The purpose of this multi-partnered project was the production of a fully integrated POC system, 
combining automated nucleic acid extraction in a centrifugally operated microfluidic disk (the 
LabDisk), with loop mediated isothermal amplification (LAMP) and optical detection, capable of 
detecting the sexually transmitted pathogens Neisseria gonorrhoeae, Chlamydia trachomatis, 
Mycoplasma genitalium and Trichomonas vaginalis in clinical urine and swab samples. LAMP is a 
novel nucleic acid amplification method, designed to amplify target nucleic acid in a highly specific 
and rapid manner, under isothermal conditions. 
The work detailed in this thesis presents the development of a rapid total nucleic acid extraction 
process, based on the capture of target nucleic acid by magnetic silica beads, optimised for use on 
the LabDisk platform. The extraction process was capable of the purification of target nucleic acid 
from a clinical sample within 5 minutes, and was robust when challenged with a range of inhibitory 
compounds potentially encountered in samples for STI testing. The system was capable of tolerating 
N. gonorrhoeae (1 x 105 CFU/ml) urine suspensions containing samples containing 50% total blood 
volume, 1x108 E. coli cells per ml, and 10mg/ml of BSA, without any effects on the downstream 
amplification time of the N. gonorrhoeae specific LAMP assay.  A freeze dried lysis buffer pellet was 
developed, that was able to increase the sample volume, thereby decreasing the time to detection, 
whilst minimising the stored fluid volume on the LabDisk. 
LAMP assays were designed for the detection N. gonorrhoeae and M. genitalium, and the limits of 
detection and specificity of the assays were evaluated. The N. gonorrhoeae ORF1 assay was able to 
detect a minimum of 20 copies of the N. gonorrhoeae genome per reaction, whilst the M. genitalium 
pdhD assay was capable of detecting 16 genome copies. The tolerance of the ORF1 LAMP assay to 
urea, and blood, was found to be 1.8M, and 20% reaction volume, respectively. The increased 
tolerance of the LAMP assay to these inhibitors in comparison to PCR demonstrates the suitability of 
LAMP when processing urine samples for STI’s. 
To our knowledge this is the first application of LAMP technology for the detection of these 
organisms, and the first attempt at commercialising a fully integrated molecular diagnostics system 
based on LAMP.  
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ii) Project overview 
 
This work details our contribution to a multi partner, Technology Strategy Board (TSB) funded,  
project “Fighting Infection Through Detection”, which was carried out with the purpose of designing 
a point of care (POC) nucleic acid amplification testing (NAAT) system for the simultaneous detection 
of a number of sexually transmitted pathogens from urine and swab samples. The remit of the 
original grant call required the system to be fully automated , integrating every step of the assay 
process, including nucleic acid extraction, and target amplification and detection, in order to provide 
a “sample in, answer out” process.  The target organisms were Chlamydia trachomatis and Neisseria 
gonorrhoeae; the most common bacterial sexually transmitted pathogens, and significant public 
health concerns. At a later stage the organisms Mycoplasma genitalium and Trichomonas vaginalis 
were added to the target s of the assays. The amplification step was carried out using loop mediated 
isothermal amplification (LAMP); a rapid isothermal DNA amplification technology, which provided a 
reaction fast enough to be utilised in a point of care setting, and without the requirement of 
expensive thermal cycling equipment. 
At the end of the first year of the project, it was decided that the assay would be processed using 
LabDisk; a centrifugally operated microfluidic disk system designed by IMTEK (Freiburg, Germany). 
The rights to use a LabDisk designed for the processing of a 1ml sample using a magnetic silica bead 
based extraction method were purchased from IMTEK. 
 
ii.i) Project partners  
 
Mast Group Ltd, Liverpool, UK 
Mast Group Ltd was the commercial project partner, and had originally applied for TSB funding for 
the project. Their responsibilities in the project involved determination of the machine 
requirements, manufacturing, technical consultation and development of the LAMP reaction mix. 
Public Health England, South West Virology lab (PHE) 
PHE were tasked with LAMP assay design, the testing of LAMP assays with clinical samples, and 
laboratory trials of the prototype and finished machines. They designed a number of LAMP assays 
utilised during the work produced in this thesis; the C. trachomatis 0332 LAMP assay and 16S rRNA 
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taqman assay, the N. gonorrhoeae PorA and GroEL LAMP assays, the M. genitalium 16S rRNA assay 
and the T. vaginalis DNA rpt assay. 
University of Liverpool, Department of Electrical Engineering and Electronics (UoL) 
UoL were responsible for the design of the electrical circuitry and control units of the device, 
software programming, and development of the optical detection system. 
 
Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences (LJMU); the 
research described in this thesis 
During this work I developed a total nucleic acid extraction procedure, based around the magnetic 
silica solid phase extraction methodology used on the King Fisher Ml platform. The developed 
methodology will then be integrated into the microfluidic LabDisk platform by MAST Group Ltd. The 
development process involved optimising the component concentrations of the lysis and wash 
buffers, determining the required incubation times, and investigating the use of a heat shock during 
the lysis process to increase the speed of the procedure. I was then able to develop stable freeze 
dried lysis pellets to minimise stored fluid volumes on the LabDisk system. I carried out an inhibitor 
study, by challenging the system with a range of common inhibitory substances than may be 
expected in clinical STI samples, such as blood and protein, in order to demonstrate the robustness 
of the methodology. The suitability of the system to process all of the target organisms was 
demonstrated. Additionally I evaluated a range of swab types and transport media, in order to 
optimise the sample acquisition process. 
My research also included the design and evaluation of two LAMP assays; the N. gonorrhoeae ORF1 
LAMP assay, and M. genitalium pdhD LAMP assay. The M. genitalium pdhD LAMP assay was 
compared with two commonly used PCR assays from the literature, in a small sensitivity study. I then 
investigated the tolerance of the N. gonorrhoeae ORF1 LAMP assay to urea and blood, and 
demonstrated the ability of this assay to use heated urine lysates as a sample, without negatively 
impacting assay sensitivity. During the work, I also determined the limits of detection of all the LAMP 
assays produced by myself and the PHE during the course of the project. 
 
 
 
22 
 
Chapter 1 
Sample preparation in a microfluidic device for the 
detection of sexually transmitted pathogens in urine 
and swab samples, at the point of care 
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1.1. Introduction 
 
Point of care (POC) is an emerging field of medical diagnostics, involving the testing of patient 
samples at or near the patient site. Typically this ranges from tests performed directly at the patients 
bedsides, in a physician’s office, operating theatres or outside a medical setting entirely; for example 
at the sites of accidents or in remote areas (Junker et al., 2010). The primary advantage of this 
decentralization of diagnostic testing away from a dedicated regional or hospital laboratory is the 
dramatic reduction seen in time between sample acquisition and analysis (turnaround time). 
Performing diagnostic tests at the point of care  typically reduces pre-analysis sample transport and 
processing and removes post analysis result validation, report transfer and data entry (St-Louis, 
2000). This reduction in turnaround time enables a more rapid diagnosis, leading to improved 
patient management and the faster onset of an appropriate treatment programme (Bissonnette and 
Bergeron, 2010). In a hospital setting, this reduction in turnaround time can minimise length of 
hospital stay, reduce outlay of resources and ensure optimum use of professional time. POC tests 
are required to be as simple as possible, requiring minimal sample or reagent handling, ideally 
providing a ‘sample in, answer out’ system (Easley et al., 2006). A key characteristic of POC testing is 
the removal of the need for skilled technical staff; the tests are generally carried out by healthcare 
professionals with minimal laboratory training, or in the case of a handful of home testing kits (e.g. 
blood glucose monitoring), the patient themselves (Holland and Kiechle, 2005). However, it worth 
noting that the effectiveness of POC tests depends to some extent on their correct application by 
the user, which depends on the ease of use of the system and also the provision of any required 
training. 
POC testing can be particularly valuable in diagnosing conditions in which rapid treatment onset is 
greatly beneficial to clinical outcomes, such as sepsis (Kemmler et al., 2009). In fact, POC testing is 
only of any benefit if the results produced will lead to immediate therapeutic decisions; otherwise 
less costly and, generally speaking, more accurate lab based diagnostics remain the optimum 
solution. For example, testing for the anticoagulation status of patients taking Heparin, an 
anticoagulant, was found to be more accurate when carried out in a centralised laboratory, 
compared to POC testing. However, POC testing dramatically reduced turnaround time and enabled 
clinicians to alter the treatment regime much more rapidly, improving patient care (Solomon et al., 
1998). Economic factors also play a part in determining an appropriate situation for POC testing. POC 
tests are typically more expensive on a result per patient basis than tests taking place in a 
centralised diagnostic laboratory (St-Louis, 2000). POC testing for glucose levels in diabetes patients 
has been shown to lie variably between 1.1 to 4.6 times the cost for the laboratory based 
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counterpart (Nosanchuk and Keefner, 1995). However, despite this, POC blood glucose 
measurement is now becoming widespread, due to the improvement in patient satisfaction and 
effective monitoring. The importance of determining the cost effectiveness of developing a POC 
programme before implementation has been recognised, and various studies have provided 
evaluations of prospective disease areas, such as HIV in Africa (Vickerman et al., 2006). One of the 
most common class of POC diagnostic tests currently in use are lateral flow tests, the best known 
example of which is the home pregnancy test. These immunochromatographic assays rely on 
capillary action to draw the sample through a membrane or strip of paper, where it reacts with 
labelling and capture reagents in order to form a visible mark indicating a positive result (Chin et al., 
2012). Lateral flow tests are commonly used in developing countries for pathogen detection, due to 
their low cost and ease of use, for targets including malaria and HIV (Murray et al., 2008; 
Vijayakumar et al., 2005). 
Currently, the most frequently employed individual POC test is the blood glucose test, used for 
diabetes screening and home blood glucose monitoring by diabetic or hypoglycaemic patients. 
Home blood glucose monitoring enables sufferers of type 1 diabetes to frequently assess their own 
glucose levels in order to determine an appropriate Insulin dose. This diagnostic tool provides them 
with the necessary information for effective self administration of medication, minimising the 
impact of the disease on the patient. These tests rely on invasive blood sampling, typically requiring 
a drop of fingerstick blood. A Biochemical reaction (reliant on either Glucose Oxidase, Glucose 
Dehydrogenase or Hexokinase activity) is then used to determine blood glucose (Kiechle and Main, 
2000). The majority of POC tests for blood glucose measure plasma glucose levels rather than whole 
blood glucose levels, due to difficulties in lysing the red blood cells prior to the reaction. This can 
present problems in patients with an abnormally low or high proportion of red blood cells in their 
whole blood (haematocrit extremes), leading to an over or underestimation of glucose 
concentration (Kiechle and Main, 2000). Despite this reduced accuracy, POC monitoring is seen as 
the optimum disease management solution due to the benefits it brings to the life of the patient. 
POC testing has also been applied to microbial diagnostics, with assay development focused on the 
detection of pathogens which cause disease of which the clinical outcome will greatly benefit from 
early diagnosis and treatment. For example, POC testing for the causative bacteria of respiratory 
infections, such as Streptococcus pneumoniae, Legionella pneumophila and Haemophilus influenzae 
is of great benefit towards patient outcomes (Charles and Grayson, 2007). This is due to both the 
difficulty in detection of the organisms by standard culture methods, rapid disease progression in 
absence of treatment, and rapid response to treatment if administered during early stages of 
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infection. A clinically used antigen test for legionella detection in urine samples has a sensitivity of 
94%, and specificity of ~100%. This is compared with culture which has a specificity of between 10% 
and 80% (due to difficulty of culturing the organism), and takes 3 – 7 days (Stürenburg and Junker, 
2009). Pneumonia caused by legionella can be fatal without an appropriate antimicrobial therapy, 
requiring antibiotic agents not indicated by other causes of pneumonia, and POC testing enables this 
to be administered much faster, significantly improving disease prognosis (Stürenburg and Junker, 
2009). Sepsis, a bacterial infection of the blood, urine or skin, resulting in a whole body inflammatory 
state, is another medical condition in which rapid diagnosis is vital. A study of the outcome of 2154 
sepsis patients (Kumar et al., 2006) showed that the survival rate of 83% for patients treated within 
1 hour of the onset of symptoms dropped by 7% for every hour after that. Although the need has 
been identified, difficulties have been encountered developing a rapid POC test for  sepsis diagnosis, 
and the fastest option remains the clinical observation of systemic inflammatory response 
syndrome, confirmed via nucleic acid amplification tests (NAAT), such as PCR. However studies have 
been carried out to identify suitable biomarkers for POC testing, typically components of the 
inflammatory response system (Meybohm et al., 2013). 
The largest challenge facing the development of POC diagnostics for routine clinical use is the 
difficulty in coupling the characteristics which enable POC use, e.g. the lack of need for specially 
trained staff or expensive equipment, with the sensitivities required for the test to be a valuable tool 
clinically. Currently available rapid diagnostic tests carried out at point of care offer a poorer 
performance in both sensitivity and specificity compared with molecular diagnostic testing carried 
out by skilled practitioners in a dedicated laboratory environment (Bissonnette and Bergeron, 2010). 
 
1.1.1 POC nucleic acid testing 
 
Nucleic acid testing (NAT) is currently routinely carried out for the detection of infectious disease, 
most frequently in the form of PCR based tests. PCR is an enzyme driven process, allowing for the 
exponential amplification of short nucleotide sequences in vitro (Mullis and Faloona, 1987). The 
process requires a pair of oligonucleotide primers; short nucleic acid sequences designed to be 
complementary to the 3’ end of both the sense and antisense strands of the DNA target, in 
combination with a further source of deoxynucleotide triphoshpates (dNTPs) and a thermostable 
DNA polymerase. Thermocycling is employed to change the state of the reaction to allow for DNA 
melting, primer annealing, and subsequent extension, which results in a duplication of the original 
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target strand. As the reaction progresses the generated DNA fragments are also used as targets for 
amplification, resulting in an exponential increase of target DNA per cycle of extension. A successful 
amplification can be detected at the end point of the reaction, for example by separation of DNA 
fragments using agarose gel electrophoresis. The detection can also occur in real time, using 
intercalating dyes or specific oligonucleotide probes to generate a signal which is detected as the 
amplification proceeds, removing the need for post-PCR processing. This is known as Real-time PCR, 
which requires more complex equipment than standard PCR methods, as the detection system is 
integrated into the thermocycler. 
A distinct advantage of PCR based diagnostic methods, when compared with non molecular options 
such as immunoassays, are the higher sensitivities achievable. The limit of detection of commercial 
Real-time PCR assays is typically ~10 copies per reaction (EGFR PCR kit, Qiagen; Herpes Simplex Virus 
LHSV PCR test, Mayo Medical Laboratories), which is in agreement with levels widely reported in the 
literature (Poon et al., 2003; Welzel et al., 2006). A recent comparison of a rapid antigen 
immunoassay (Direct Antigen 1-2-3 Group A Strep test kit, BD Diagnostic Systems, Sparks, Md.) and a 
Real time PCR assay (LightCycler Strep A assay, Roche Applied Science, Indiapolis, Ind) for the 
detection of Group A Streptococci  (Uhl et al., 2003), found the sensitivity of the PCR based method 
to be 93%, compared with 55% for the immunoassay. This difference in sensitivity is typical between 
the two assay types. Selection of a DNA target that occurs at more than one point in the target 
organisms genome, or a sequence included in a gene residing in a multi-copy plasmid, can increase 
the ratio of the detectable target to the pathogen itself, further increasing specificity (Roorda et al., 
2011).  
Reverse transcription PCR (RT-PCR) is a PCR variant allowing for the detection of RNA, which is 
converted into a complementary DNA copy before amplification by the inclusion of a reverse 
transcriptase enzyme in the reaction tube (Bustin, 2002). As well as having a massive impact on the 
study of RNA and gene expression, this technique has also lead to improvements in NAT. Most 
metabolically active pathogenic organisms will contain high levels of specific mRNA transcripts, and 
by targeting these with specific primers during RT-PCR, a much higher starting copy number is 
achieved. This results in an increase in assay sensitivity and an improvement in the limit of detection. 
RT-PCR also allows for nucleic acid amplification from clinically relevant RNA viruses, such as HIV and 
Hepatitis B.  
PCR based methods also allow for multiplexing, where multiple primer sets are included in each 
assay, allowing for simultaneous detection of multiple targets. Detection can be carried out at the 
reaction end point via agarose gel electrophoresis, as long as the product from each primer set is of 
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a different length. Alternatively, specific probes can be used to track the amplification of each primer 
set in real time, although this does limit the number of targets per assay. Multiplex PCR tests have 
been developed for the simultaneous detection of multiple pathogenic bacteria species from a single 
sample, including the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma 
genitalium, Ureaplasma urealyticum, Corynebacterium spp. and Pseudomonas aeruginosa from 
urine samples (Lee et al., 2007), and the detection of seven respiratory viruses in sputum samples 
(Hindiyeh et al., 2001). 
 
1.1.2. Isothermal methods 
 
A major advancement in the field of NAAT and molecular diagnostics has been the development of 
novel isothermal amplification methodologies, capable of amplifying specific nucleic acid targets 
without the use of thermal cycling required by PCR. The ability of isothermal assays to operate at a 
single reaction temperature removes the need for expensive thermal cycling equipment, as the 
assays can be carried out in a water bath, or single temperature heating block. This increases the 
portability of the instrumentation required to process the assay, making isothermal reactions more 
amenable to POC testing. Isothermal assays are also typically quicker than standard PCR based 
assays, as a single reaction temperature allows the reaction to proceed at a maximum speed, 
without regular temperature changes (Gill and Ghaemi, 2008). 
Recombinase polymerase amplification (RPA) is an isothermal amplification technology that relies on 
the actions of three proteins; a recombinase, a strand displacement polymerase, and a single-
stranded DNA binding protein (SSB) (Euler et al., 2012), and sold commercially by TwistDx (UK). The 
recombinase, polymerase and SSB form a complex, and catalyse the unwinding of the DNA template, 
recombinase-mediated primer annealing, and subsequent DNA synthesis mediated via the actions of 
the polymerase (Daher et al., 2014). The reaction requires a set of two primers, upstream and 
downstream of the amplicon, which are easily designed, in a similar fashion to PCR primers (Euler et 
al., 2013). The reaction can operate between 25oC and 42oC, meaning it has modest heating 
requirements for operation, and also withstands temperature fluctuations between these values. 
RPA can be monitored in real-time via the inclusion of Exo probes (TwistDx, UK), which generated a 
fluorescence signal during DNA synthesis, which can be monitored by a fluorometer. A real-time 
reverse transcription RPA assay for foot and mouth disease virus (FMDV) has been developed, with a 
sensitivity of 98% and specificity of 100% when testing clinical samples (Abd El Wahed et al., 2013). 
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The study found that the assay would be easily transportable to quarantine stations or farms, 
providing the benefits of sensitive molecular testing, with a minimum waiting time enabling instant 
results. 
The novel combination of an RPA assay, coupled with the visual detection of amplified product using 
a lateral flow dipstick, has shown promise as a POC assay. A test for malaria designed in this manner 
was shown to have a limit of detection of four malaria parasites per test, a 100% specificity and 
sensitivity in the small sample tested, and provided a result within 15 minutes (Kersting et al., 2014). 
The test requires that the RPA reaction is carried out first as a standard tube assay, although by 
using freeze dried reagents the only pipetting step required is the introduction of the sample. After a 
15 minute incubation, the sample is diluted in buffer, and the dipstick is added to the solution. The 
reaction is visualised by the binding of the labelled amplicon binding to polyclonal anti-
carboxyfluorescein antibodies conjugated to gold nanoparticles, manifesting as a visible line on the 
dipstick (Kersting et al., 2014). 
Helicase-dependent amplification (HDA) is another isothermal amplification technology, and is 
modelled after the in vivo process of DNA replication, utilising a DNA helicase to separate double 
stranded DNA into single strands (Vincent et al., 2004). A set of sequence specific oligonucleotide 
primers is then used to hybridise to the single stranded target, followed by DNA polymerase 
mediated DNA synthesis. The reaction is maintained at 37oC, and requires no temperature changes. 
Like PCR, detection can either be carried out using end-point agarose gel electrophoresis, or in real-
time via the inclusion of fluorescent probes or intercalating dyes such as SYBR green (Vincent et al., 
2004; Goldmeyer et al., 2007). A HDA assay for toxigenic Clostridium difficile has been developed, 
with detection carried out using a Type 2 BESt cassettes (BioHelix, US), a lateral flow device enabling 
visual detection of the target and control amplicons. The test requires prior DNA extraction from 
fecal samples, which would prevent its use at the true POC, but same day results are available using 
the test (Chow et al., 2008). The limit of detection of the assay was found to be 20 genome copies 
per reaction, which translated to a clinical sensitivity of 100%, and specificity of 100% compared with 
a PCR test. The combination of a HDA assay for Mycobacterium tuberculosis with a novel 
nanoparticle based detection method has shown potential as a near patient testing assay, making 
use of a portable handheld potentiostat (Torres-Chavolla and Alocilja, 2011). The integration of a 
HDA assay within a fully integrated microfuidic chip combining solid phase DNA extraction with HDA 
amplification and optical detection of fluorescence has been demonstrated (Mahalanabis et al., 
2010). The chip based assay was able to detect 10 CFU of E. coli, required no manipulation after 
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sample application, and the disposable nature of the closed chip removes the risk of amplicon 
contamination for subsequent assays.  
Two of the earliest isothermal amplification methods to be developed were transcription mediated 
amplification (TMA), and nucleic acid sequence based amplification (NASBA), which both function via 
similar principles, and were originally designed for the amplification of RNA, but can be modified to 
target a DNA sequence (Guatelli et al., 1990; Compton, 1991). In both reactions an initial thermal 
denaturation step separates double stranded RNA, allowing the annealing of an ssDNA primer which 
carries a 5’ T7 polymerase promoter. The synthesis of a complementary DNA strand from the 
attached primer is carried out via the action of a reverse transcriptase, producing an RNA/DNA 
heterodimer. In the TMA reaction the reverse transcriptase enzyme hydrolyses the original RNA 
portion of the heterodimer, whilst in the NASBA reaction this occurs via the action of RNase H. The 
remaining ssDNA strand from the heterodimer then anneals to the second primer, with DNA 
synthesis occurring via the reverse transcriptase, producing a dsDNA strand tagged with the T7 
polymerase promoter. The recognition of this promoter results in the T7 RNA polymerase enzyme 
producing multiple ssRNA copies from this dsDNA template, feeding back into the reaction. TMA has 
been appropriated by GenProbe (US) for use in their commercially available Aptima assays, which 
can be run on their high throughput automated systems such as the Tigris and Panther. Available 
FDA approved assays include the Aptima Combo 2, for the simultaneous detection of C. trachomatis 
and N. gonnorhoeae (Gaydos et al., 2003), a HPV assay (Dockter et al., 2009)and trichomoniasis 
assay (Andrea and Chapin, 2011). A number of research use only assays are available, including one 
for M. genitalium detection (Hardick et al., 2006). The sensitivity and specificity of the Aptima assays 
are comparable to other NAATS, with sensitivity values typically ranging between 94% and 100% 
depending on the assay and sample type (Gaydos et al., 2003; Hardick et al., 2006; Andrea and 
Chapin, 2011). 
Strand displacement amplification is another isothermal amplification technology, which utilises the 
activity of a restriction enzyme to create a “nick” in the dsDNA template, from which a polymerase 
enzyme can extend the 3’ end of the nick, displacing the downstream strand (Walker et al., 1992). 
The reaction product of the sense displacement becomes the template for the anti-sense equivalent, 
and vice versa, creating an exponential amplification of the target sequence. Becton Dickinson (US) 
produces a range of commercially available SDA assays for use in conjunction with their BD ProbeTec 
ET instrument, for a range of targets. The combined C. trachomatis and N. gonorrhoeae assay has 
sensitivities of 92% for C. trachomatis and 96.4% for N. gonorrhoeae, and the assay specificties were 
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96.1% and 99% for the C. trachomatis and the N. gonorrhoeae assays respectively (Cosentino et al., 
2003).  
 
 
1.1.3. Loop mediated isothermal amplification 
 
Loop-Mediated Isothermal Amplification (LAMP) is a novel nucleic acid amplification method, 
designed to amplify target nucleic acid in a highly specific and rapid manner, under isothermal 
conditions (Notomi et al., 2000). A strand displacement DNA polymerase is used in conjunction with 
a specially designed set of four primers (forward primer: F3, backward primer: B3, Forward inner 
primer: FiP, Backward inner primer: BiP), specific to a total of 6 distinct regions of the target DNA 
sequence. Detection can be carried out in real time using a fluorescent intercalating dye in 
conjunction with a real time detection platform, such as the ESEquant (Qiagen, US), or by visual end 
point detection. Additionally, detection can be carried out by monitoring the reaction turbidity, due 
to the generation and subsequent precipitation of magnesium pyrophosphate, which increases 
during the reaction. LAMP can be used to amplify a DNA target, or amplify an RNA target via the 
addition of a reverse transcriptase to the reaction mix (Parida et al., 2008). 
The LAMP reaction is initiated with one of the F3 or B3 primers annealing to a complementary strand 
of double stranded DNA. The strand displacement polymerase then initiates DNA synthesis, 
displacing and releasing a single strand of DNA (Fig.1.2., 1). A DNA strand complementary to the 
template DNA is then synthesised from the 3’ end of the F2 region of the FIP (2). The F3 primer then 
anneals to the template DNA, just outside of the FiP. DNA synthesis occurs, displacing the FiP linked 
complementary strand, and forming a double strand from the F3 primer (3,4). The strand 
synthesised from the FiP is released and forms a stem loop structure at the 5’ end due to 
complementary F1c and F1 regions (5,6). This strand then forms the target for B3 and BiP strand 
displacement DNA synthesis, forming a double strand of DNA with a linear structure, ultimately 
resulting in the displacement of the BiP linked complementary strand (6,7). The strand forms a 
structure with stem loops on both ends, forming a characteristic barbell shape. This serves as the 
starting point for the amplification cycling in the LAMP reaction. 
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Fig 1.1. (1-8). Diagram showing progression of LAMP reaction from a DNA target. Images taken from 
the Eiken website: loopamp.eiken.co.jp, with permission from the author. 
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The dumbbell like starting structure is then converted into a stem loop DNA strand via self primed 
DNA synthesis. FiP strand displacement DNA synthesis releases the previously synthesised strand, 
which then forms a stem loop structure due to complementary B1c and B1 regions (9). The FIP linked 
complementary strand is then released due to further strand displacement, forming a dumbbell 
structure due to the complementary regions at both the 3’ and 5’ end (11). The result is a single 
stem loop structure, as at the start of the reaction, in addition to a stem loop structure which is 
twice as long (10). BiP and B3 mediated synthesis then act to create similar structures, and DNA 
synthesis continues by displacing double stranded DNA. As a result, various sized DNA amplicons are 
formed by alternately inverted repeats of the original target sequence. 
 
 
Fig.1.1. (8-19). Diagram showing progression of LAMP reaction from a DNA target. Images taken 
from the Eiken website: loopamp.eiken.co.jp 
 
The reaction is capable of producing 109 copies of a DNA target from less than 10 original copies, in 
an hour (Notomi et al., 2000). One of the biggest benefits of this method in comparison to standard 
PCR is the increase in specificity seen, due to the use of 4 primers specific to 6 separate regions of 
the target sequence. Previous studies have shown it to have a tenfold lower limit of detection than a 
PCR assay for the same target sequence, and also be less influenced by inhibitory compounds in 
clinical samples (Kaneko et al., 2007). This makes the assay very well suited for pathogen detection 
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in positive samples with potentially low organism load. A LAMP assay for the detection of Listeria 
monocytogenes from food samples was determined to have a limit of detection of 6 CFU per 
reaction tube, lower than that of a standard PCR assay (Shan et al., 2012). Both the sensitivity and 
specificity over 94 samples was found to be 100%. However, it is thought the sensitivity of the assay 
can differ from assay to assay, possibly due to primer sequence, as a minority of studies have shown 
sensitivity to be no greater than PCR (Jenkins et al., 2011). LAMP assays have been described for a 
wide range of target pathogens including bacteria (Ueda and Kuwabara, 2009) DNA viruses 
(Enomoto et al., 2005), RNA viruses (Parida et al., 2008), and protozoa (Koloren et al., 2010). During 
LAMP assay deisgn, reaction products can be confirmed as being specific to the intended target by 
digesting the amplicon with a suitable restriction endonucleases, and examining the product size 
using agarose gel electrophoresis, or sequencing the product. 
Modifications of the original LAMP process have been described, involving the addition of extra 
primer sets. The most common of these are loop primers, which can be designed using the free 
LAMP primer design software package from Eiken. Loop primers hybridise to the stem-loops of the 
product of the initial phase of the LAMP reaction, generating a larger amplicon and hastening DNA 
synthesis (Nagamine et al., 2002). The inclusion of these primer sets has been shown to reduce the 
time to detection in real time assays by up to 50% (Nagamine et al., 2002). The ability to include 
these primers depends on the sequence of the stem loops, and their sequence length, as the primers 
must sit between the B2 and B1 sites, or F2 and F1 sites (Gandelman et al., 2011). 
In order to provide a more flexible method of accelerating reaction speeds, the use of stem primers 
has been suggested (Gandelman et al., 2011). These primers can be used with or without loop 
primers, and provide a similar increase in amplification speed and generated product. Stem primers 
bind to the stem structures of the LAMP amplicon, can be designed in sense or antisense orientation, 
do not rely on the positioning of the B1/F1 or B2/F2 sites, and can be multiplexed, enabling greater 
flexibility in primer design that the more commonly used loop primers. 
One significant advantage of LAMP over conventional PCR is the constant reaction temperature 
(typically between 63oC and 67oC). This removes the need for expensive thermocycling equipment as 
the reaction can be carried out in a thermal block or even a water bath. A recent innovation was the 
use of a disposable pocket warmer to provide the necessary reaction temperature for a LAMP assay 
for the detection of Bacillus anthracis (Hatano et al., 2010). This test was designed for field use in 
developing countries or for use by the military, and requires no electricity to run. Identical limits of 
detection were seen when using the pocket warmer or a hot block. This provides a way of carrying 
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out sensitive NAAT in any environment, without the need for any more equipment than a simple 
pocket warmer and the components of the assay itself. 
Multiplexing of LAMP reactions is difficult, as the inclusion of four primer sequences required per 
assay, at high concentration, causes a high likelihood of non-specific amplification if multiple sets are 
contained in the same assay. Multiplexing also removes the ability to either detect amplification via 
agarose gel electrophoresis, visual dyes, or intercalating agents, as these methods are not target 
specific. However, multiplexing of LAMP reactions has been reported via the use of DARQ probes; 
quencher labelled FiP or BiP primers, annealed to a fluorescently labelled complementary probe 
sequence, which is realeased during the incorporation of the quencher labelled primers in the LAMP 
reaction (Tanner et al., 2012). The use of DARQ probes has been applied to the detection of four 
SNPs, using four labelled FiP primers of varying sequence. One drawback of this method is that it 
requires that there are no sequence variations in non labelled primers, and hence can only be used 
to detect differences in the target region corresponding to the labelled primers, and cannot be used 
as an internal control. The inability to include an internal control (IC) reaction, as is standard for real-
time PCR assays, is one of the disadvantages of LAMP. However, the main purpose of including an IC 
is to detect reaction inhibition, and the increased robustness of the LAMP reaction to common 
sample inhibitors somewhat alleviates the need for an IC (Francois et al., 2011). 
Quantitative real-time LAMP assays have been developed, which rely on the use of LAMP reactions 
containing known DNA or target gene concentrations to produce a standard curve of the CT value 
against time, which can then be compared with the ct value of LAMP reactions of unknown samples 
(Soleimani et al., 2013). This approach enables a quantification estimate, but is not as accurate as 
quantitative PCR, due to the continuous exponential amplification that occurs, rather than the 
ordered doubling of product per thermal cycle that occurs in a PCR reaction. However, the reliability 
for certain quantitative assays has been reported to be quite high, with a quantitative LAMP assay 
for HIV-1 reporting a standard curve with an R2 of 0.991 (Zeng et al., 2014) 
One issue with the use of LAMP tests in resource poor settings, where the lack of need for thermal 
cycling equipment has the greatest benefit, is the requirement for a cold chain transport network for 
the kits. Although studies have shown LAMP reagents are stable up to 37oC (Thekisoe et al., 2009), 
package inserts of the kits recommend -20oC storage, and the effects of temperature fluctuations 
during transport on kit performance are unknown (Njiru, 2012). To address this, Eiken have 
developed kits containing lyophilised reagents, for the diagnosis of sleeping sickness (Mitashi et al., 
2013), tuberculosis (Boehme et al., 2007) and malaria (Hopkins et al., 2013); three diseases of 
immense importance in the developing world. These kits have been developed in collaboration 
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between Eiken, the World Health Organisation, and the Foundation of New Innovative Diagnostics 
(FIND), a charitable organisation dedicated to the development of novel diagnostic solutions in 
developing countries. The use of lyophilised reagents removes the need for a cold-chain, which 
when combined with the lack of specialised equipment required, increases the affordability of using 
the assays in low resource settings. An evaluation of the use of the tuberculosis assay in clinics in 
Peru, Bangladesh and Tanzania, found the sensitivity of the assay to be 97.7% in smear positive + 
culture positive specimens, and 48.7% in smear negative + culture positive specimens. The specificity 
of the assay was 99% (Boehme et al., 2007). The specificity of the Trypanosome brucei specific 
sleeping sickness assay was found to be 87.3%, with a specificity of 92.8%, indicating that the LAMP 
assay performs equally well as 18S rRNA PCR, whilst being simpler to perform. A field evaluation of 
the malaria assay in Uganda found it to have a sensitivity of 89.5% and specificity of 95.9% compared 
with a three well nested PCR, giving it comparable performance to a single well nested PCR (Hopkins 
et al., 2013). A larger evaluation of the malaria kit found it to have sensitivities and specificities of 
98.4% and 98.1% respectively, providing the sensitivity of nested PCR but with a reduced time to 
result (Polley et al., 2013). FIND recommends that these diagnostic kits are used in conjunction with 
the LoopAmp PURE (Procedure for Ultra Rapid Extraction) DNA extraction kit (Eiken, Japan), which is 
a simple tube based nucleic acid extraction method designed for use in resource poor environments, 
with minimum equipment requirements of access to a 75oC waterbath and a pipette (Ou et al., 
2014). The extraction tube is a closed system, with the lysis of the cells carried out via the 75oC heat 
treatment, and reagent mixing carried out by manually handling the tube, with the eluted DNA 
removed from the extraction tube via manually squeezing. This simple methodology was found to be 
effective at extracting pathogenic nucleic acid from sputum samples (Mitarai et al., 2011), which can 
be challenging to extraction procedures due to their viscocity and abundance of amplification 
inhibitors (Aldous et al., 2005). The application of LAMP in resource poor settings has been aided 
development of novel polymerases, such as the OmniAmp DNA polymerase, which has an improved 
tolerance for freeze drying and temperature changes than the bst polymerase, possesses intrinsic 
reverse transcriptase activity, and has an increased tolerance to inhibitors (Chander et al., 2014). 
 A number of portable detection systems exist, enabling the real-time detection of LAMP 
amplification, without the need for expensive qPCR systems.  The OptiGene Genie systems 
(OptiGene, UK) are portable fluorometers with heating elements capable of processing eight LAMP 
reactions simultaneously (Tomlinson et al., 2010). The newest incarnation, the Genie III, has been 
developed for outdoor use, and has a battery capable of maintaining a days use.  The Optigene 
system does not have integrated sample preparation, and requires the prior purification of nucleic 
acid, or a simple heat treatment of the sample prior to the assay step. 
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The LAMP reaction, due to its speed, lack of equipment requirements, and the opportunity for 
simple visual detection, seems well suited for use in POC testing, and recent studies have sought to 
exploit this. One study has demonstrated a fully integrated microfluidic platform for bacterial 
identification at the POC, using LAMP (Fang et al., 2010). Nucleic acid was released by using an 85oC 
heat shock to lyse the cells. DNA was retained in capture pockets in the chip, which were then filled 
with the LAMP reaction mix. Each well on the chip contained either a positive control, or either 
strain specific or negative control primer set. Calcein, an intercalating dye, was used to provide a 
visually detectable colour change at the end point of the reaction. The limits of detection were 
found to be 27 copies/µl (with limited reproducibility) or 270 copies/µl.  
A recently described POC test has combined LAMP with a novel electrochemical detection method, 
and a flexible fluid handling cassette (Safavieh et al., 2014). The device enabled the detection of 30 
CFU/ml of E. coli, using either real-time or endpoint detection, and without any further fluid 
handling steps after sample application. The device does not include a nucleic acid purification step, 
and instead lyses cells via heat shock in the presence of the LAMP reagents. This relies on the high 
tolerance of LAMP to inhibitory compounds preventing amplification inhibition, and simplifies the 
assay processes. However, this would render the device unsuitable for certain sample types, which 
are inhibitory to LAMP in an unprocessed state, such as sputum samples. The heating required for 
lysis occurs at 65oC, which is insufficient to denature the bst polymerase. The novel detection 
method operates via the inclusion of redox-reactive osmium complex in the LAMP reaction mix. 
During the amplification process, the redox molecule intercalates with the newly synthesised DNA, 
decreasing the free redox in solution, which can be monitored electrochemically. The device is 
simple to operate, and relatively high throughput, processing 12 LAMP reactions simultaneously. 
Despite encouraging attempts such as this to produce a LAMP POC device for clinical use, the assay 
is only commercially available in kit form and requires pre extracted DNA before use. In addition to 
the Kits for malaria, tuberculosis and sleeping sickness diagnosis, kits are also available for norovirus 
strains (Eiken, Japan), in addition to DNA and RNA amplification kits, requiring self-designed primer 
sets (Eiken, Japan). In order to integrate LAMP into a true POC test, various issues must first be 
tackled, including efficient preparation of the raw sample, integrated nucleic acid extraction, and the 
minimisation of reagent handling.  
 
 
37 
 
1.1.4. POC systems 
 
The Atlas Io system (Atlas Genetics, UK) is a fully automated POC NAAT platform, which utilises 
single use assay cartridges enabling automated nucleic acid extraction, amplification, and novel end-
point electrochemical detection. The platform processes a single assay at a time, although stacks 
containing multiple cartridge entry ports are available as additions to the system, and takes 30 
minutes to provide results. The cartridge contains a mixture of freeze dried and liquid reagents, 
housed in blister packs, and a solid phase silica DNA extraction is carried out, followed by a rapid PCR 
amplification, with detection of an amplified product occurring via end-point electrochemical 
detection. The first batch of tests are scheduled for release in 2014, encompassing an STI range 
including C. trachomatis and T. vaginalis, and a hospital acquired infection range, including MRSA. A 
small scale lab evaluation (90 samples) of the T. vaginalis assay found the assay to have a sensitivity 
and specificity of 95.5% and 95.7%, respectively (Pearce et al., 2013). This is a marked improvement 
on current POC testing for this organism, which involves microscopy, which is insensitive. The assay 
performed as well as laboratory based NAAT testing for this organism, whilst enabling rapid 
diagnosis, providing the sensitivity of molecular based testing, whilst being amenable to use at the 
POC. 
The most widespread commercially available POC system is the GeneXpert (Cepheid, USA), a 
platform for processing real-time PCR based assays with fully automated sample preparation, 
amplification and detection on disposable assay-specific cartridges (Helb et al., 2010). The sample 
preparation is carried out using a patented microfluidic cartridge, which incorporates a filter, syringe 
drive, rotary drive and sonic horn. The sample (typically blood or urine) is entered into the cartridge 
where it is initially filtered to isolate any cells contained in the sample, which are then lysed by 
ultrasonic energy delivered by the sonic horn, resulting in the release of nucleic acid. The syringe and 
rotary drives move liquid between the cartridge chambers in order to wash, purify, and concentrate 
the nucleic acid. After the extraction is complete, the nucleic acid extract is moved into the cartridge 
reaction chamber. The PCR reagents, which are lyophilized and held in separate chambers inside the 
cartridge, are then released to the sample and a real time PCR reaction is carried out by the thermal 
cycler inside the core GeneXpert module. The whole process takes between 1hr to 2hrs, from the 
introduction of the raw sample to the generation of results. A number of experimental controls are 
in place in order to guarantee the accuracy of the results generated, including probe checks, 
pressure checks and sample-processing controls. Importantly, each test run has an internal control 
incorporated to ensure that the cartridge and associated reaction chemistry is functioning correctly. 
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The GeneXpert software also has features to enhance internal QC practices. The software tracks 
external controls during the assays and provides trend analysis of the QC data over time, which can 
then be used as evidence of external QC documentation (Marlowe and Wolk, 2008). 
Currently there are FDA approved GenExpert assays available for M. tuberculosis (Marlowe et al., 
2011), C. difficile (Babady et al., 2010) and a combined C. trachomatis and N. gonorrhoeae (CT/NG) 
assay (Tabrizi et al., 2013), all of which have high sensitivities and specificities, and provide results 
within 90 minutes. Cepheid has announced that it plans to release a T. vaginalis assay in the 2014-
2015 product range, enabling testing for trichomoniasis to be carried out using this platform. 
The CT/NG assay enables the simultaneous detection of C. trachomatis and N. gonorrhoeae, from 
both swab and urine samples. These pathogens are frequently tested for simultaneously, due to 
their overlapping symptoms and the high frequency of their co-infection. The assay has been shown 
to have a limit of detection of 10 copies per sample for both target organisms, and a challenge of the 
assay with 372 non-target bacterial strains found that the assay had 100% specificity (Tabrizi et al., 
2013). A large scale test of the assay, involving 1,722 female and 1,387 male samples found the 
Chlamydia assay to have sensitivities of 97.4%, 98.7%, 97.6% and 97.5%, from endocervical swabs, 
vaginal swabs, female urines, and male urines, respectively (Gaydos et al., 2013). The GC assay had 
sensitivities of 100%, 100%, 95.6% and 98%, from endocervical swabs, vaginal swabs, female urines, 
and male urines, respectively. The specificity of either assay for any sample type exceeded 99.8%. 
Although the CT/NG assay does not have regulatory approval for its use in diagnosing rectal infection 
from rectal swab samples, the test has been shown to have a sensitivities of 86% (CT) and 91.1% 
(GC) and specificity of 99.2% (CT) and 100% (GC), with this sample type, compared to the gold 
standard of the Aptima Combo 2 assay (Genprobe, US) (Goldenberg et al., 2012). This level of 
performance was achieved despite the samples being diluted to 6% of their original concentration, 
as the samples used were in a Genprobe transport media, which interfered with the GeneXpert 
extraction process.  
The GeneXpert MTB/RIF assay simultaneously detects the presence o f M. tuberculosis, and also 
mutations in the rpoB gene, present in 95% of rifampin resistant isolates (Zeka et al., 2011). The test 
is most sensitive when processing pulmonary specimens, with sensitivities of 100% and 68.6% for 
smear positive and smear negative specimens, respectively. For extrapulmonary specimens the 
sensitivity was 100% for smear positive and 47.7% for smear negative samples. The assay also 
correctly identified rifampin resistant and susceptible isolates, as confirmed with MIC testing. 
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Field testing of the Cepheid GeneXpert C. trachomatis assay in South Africa has given promising 
results, demonstrating high clinical sensitivity in combination with being well suited for use outside 
of the traditional laboratory environment (Jenson et al., 2013), and the GeneXpert M. tuberculosis 
assay is already being widely used in sub-Saharan Africa (Osman et al., 2014; Lawn et al., 2013). An 
analysis of the predicted impact of the instigation of the GeneXpert TB assay in South Africa found 
that both the number of cases identified and also the cost per test would be increased from normal 
levels, although this analysis did not work out the economic benefits of the increased diagnostic 
efficiency and reduction in transmission caused by the POC testing (Meyer-Rath et al., 2012). The 
study predicted that the number of yearly TB cases diagnosed would be increased by 30%-37%, with 
81% of cases being diagnosed at the first visit, compared with 46% using the current methods. The 
study found that the cost per diagnosis would increase 55%, and ultimately cost the country an 
initial outlay of 22 million USD, supplemented by 287-316 million USD over the next 6 years (Meyer-
Rath et al., 2012). Other cost/benefit studies that have included reductions in spending due to knock 
on effects such as reduced transmission have predicted that the use of the GeneXpert TB  assay 
could actually reduce costs in relation to smear microscopy testing (Millman et al., 2013). 
There are some limitations of the GeneXpert system, which affect its suitability for meeting 
diagnostic needs in rural or underserved areas of developing countries, where certain diseases, such 
as TB, are especially problematic. The system needs a stable electrical supply, and ideally an internet 
link to provide QC data. It also requires a degree of temperature control, with the assay cartridges 
requiring storage at 2oC-28oc, and the machine requiring temperatures below 30oC (Schito et al., 
2012). The machines and cartridges are also expensive; although a reduced pricing has been agreed 
for developing countries where TB is endemic, the machines retail for 15,700 USD for a 4-module 
instrument to 65,500 USD for the larger 16 module instrument (Nicol et al., 2013). 
One current focus of POC assay development is for the detection of M. tuberculosis, the etiological 
agent of the disease tuberculosis. Tuberculosis causes the highest number of deaths worldwide of 
any infectious disease, with 1.45 million deaths occurring in 2010 (WHO, 2011) and is most prevalent 
in developing countries, where access to sensitive NAAT diagnostics is limited. Additionally, the 
methods currently in use are cumbersome and time consuming, and rely upon the presentation of 
symptomatic individuals to healthcare facilities, which results in a high proportion of newly 
presenting cases being past the early and more easily treated stages of the disease. There is also a 
serious issue with patients neglecting to turn up for results, or further test of cure diagnosis, in large 
due to the lengthy turn-around time with current testing methods (Niemz and Boyle, 2012). This has 
led to the identification of tuberculosis as a disease that would greatly benefit from POC, and calls 
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for the development of POC tests for this disease have been made by the World Health Organisation 
(Schito et al., 2012). 
The Genedrive (Epistem, UK), is a POC NAAT system for the detection of M. tuberculosis, currently 
awaiting its commercial release. The system is capable processing sputum samples, using a novel 
filtration system, with a subsequent nucleic acid extraction followed by PCR based amplification and 
detection. Compared with culture, this system was found to have a sensitivity of 90.8% and 
specificity of 100% (Castan et al., 2014). Assays in development include a cancer biomarker panel, 
and personalised medicine biomarkers for a range of conditions. 
The Liat (lab-in-a-tube) Analyzer (IQuum, UK) is a recently released NAT system designed for POC 
diagnostics. FDA approved commercially released tests have included assays for the viruses H1N1, 
and HIV (Tanriverdi et al., 2010), however IVD and biodefence applications are currently in 
development. The system uses PCR and real-time PCR detection and has a turnaround time (tat) of 
as little as 26 minutes. The Liat Analyzer system consists of an analyzer module coupled with a 
disposable flexible tube, which acts a sample vessel, and in which the entire assay takes place. All 
the necessary reagents for the assay are held in separate tube compartments and multiple sample 
processing actuators in the analyzer module compress the tube to selectively manipulate reagent 
release and sample movement. Sample preparation is based on conventional solid-phase extraction 
with magnetic particles. Magnetic beads are incubated with a sample for target enrichment, 
captured using magnets and then washed to remove potential inhibitory reagents. Nucleic acids are 
then eluted from the beads and transferred between tube segments for PCR and rt-PCR detection. 
Limits of detection of 57 copies per ml have been demonstrated for the HIV assay, giving the assay a 
similar analytical sensitivity to commercially available lab-based NAAT systems (Tanriverdi et al., 
2010). 
 
1.1.5. Sample Preparation 
 
One of the biggest challenges to overcome in the design of a point of care nucleic acid amplification 
testing (NAAT) system for pathogen diagnostics is the integration of the sample preparation process. 
The majority of commercially available NAAT based assays are complex (more than 15 steps) and 
time consuming (assay times of more than 4 hours), mainly due to the need for manual preparation 
of nucleic acid from a raw sample before the detection step (Dineva et al., 2007). Currently only one 
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widely commercially available system, the Cepheid GenExpert, has fully integrated sample 
processing, whilst a handful of other fully integrated NAAT platforms are nearing release. 
The advantages of full integration of the sample preparation process with the assay and detection 
steps are numerous. The automation of the process removes the need for skilled laboratory 
personnel to prepare the sample, enabling healthcare professionals such as clinicians or nurses to 
carry out the test directly in a clinical setting. This greatly reduces the time taken between taking the 
sample and obtaining the results of the test, allowing a true point of care testing service to be 
offered, with all the benefits that entails. It also massively reduces the amount of time required to 
operate the test, the user simply has to introduce the sample and initiate the test. The fact that no 
laboratory equipment is needed also makes the system suitable for use in areas without dedicated 
lab support, such as remote locations or developing countries. Integrated sample handling also 
reduces the contact the operator has with the sample; ideally the sample should be in a contained 
environment once introduced to the device. This is important for biosafety, especially when testing 
samples suspected positive for highly infectious pathogens such as B. anthracis or HIV. 
In the proposed device, a urine or swab sample would need to be processed to the stage were a 
sample of the target nucleic acid can be introduced to the assay step. This would require isolation of 
any target organisms from the urine, lysis of the cells to remove nucleic acid, extraction and 
purification of the nucleic acid and finally washing of the nucleic acid to remove any potential 
inhibitors of the PCR reaction, which in urine include haemoglobin, urea and calcium ions (Betsou et 
al., 2003). The nucleic acid may then need to be moved to a separate assay chamber but this will 
depend on the design of the device. 
 
1.1.6. Sampling 
 
Sampling for sexually transmitted pathogens is carried out either by taking a urine sample from the 
patient, or by taking a swab from a suitable genital site. Potential sites for swab sampling include the 
urethra, endocervix, and vagina in female patients, and the urethral meatus in males. Extragenital 
sites such as the rectum and pharynx are can also be sampled via swab for sexually transmitted 
infections, dependent on the patient’s sexual history. The optimum site of swab sampling can vary 
between infections caused by different organisms; for example higher yields of C. trachomatis can 
be obtained from an endocervical swab than a vulvovaginal swab, whilst the opposite is true for T. 
vaginalis. The majority of data available relating to the variance between sampling sites for sexually 
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transmitted infections on organism load, and downstream assay sensitivity, is related to C. 
trachomatis and N. gonorrhoeae, as these organisms are the two most commonly tested for, and the 
only targets of national screening programmes in the UK and US. 
The development of NAAT for sexually transmitted infections has allowed for the use of urine 
testing, as the improved sensitivities of the assay negate the typical reduction in organism load 
encountered in urine samples in comparison with swab samples (Michel et al., 2007). Urine sampling 
is minimally invasive, and convenient for patients, who are more likely to present for testing for 
asymptomatic infection if they know invasive sampling will not be performed (Garland and Tabrizi, 
2004). Urine sampling is currently carried out for C. trachomatis and N. gonorrrhoeae NAAT testing 
in the UK, with first void urine (FVU) being the preferred sample type. The use of FVU sampling 
stems from the improved sensitivities obtained when C. trachomatis culture is carried out from FVU, 
rather than midstream urine. However, the sensitivity of current NAAT tests are relatively equivalent 
for each sample type, due to the improved detection limits of NAAT testing compared with those of 
culture (Mangin et al., 2012). The higher sensitivity of NAAT testing has also reduced the importance 
of the voiding interval on C. trachomatis testing, with a large study involving 1649 men finding no 
significant difference in positivity between men with a voiding interval of 2 hours or over, compared 
with those with a voiding interval of less than 2 hours (Manavi and Young, 2006). The two most 
commonly used sampling sites for detecting C. trachomatis in women in the community setting, or 
screening programmes, are first void urine and self-collected vulvovaginal swabs, due to their 
minimally invasive nature and high sensitivity of down-stream NAAT testing using these sample 
types. A study involving 146 paired vulvovaginal and urine samples from women with C. trachomatis 
infection found the sensitivity of the subsequent NAAT testing to be 97.3% and 91.8% for the swab 
and urine samples, respectively (Skidmore et al., 2006). Urine sampling has also been shown to be as 
effective in detecting C. trachomatis as cervical swabs during NAAT testing, in some populations 
(Haugland et al., 2010).  
A study aiming to determine the organism load obtained when sampling for C. trachomatis from a 
range of anatomical sites in both men and women found that the mean number of C. trachomatis 
elementary bodies (EB’s) obtained from FVU and urethral swabs in men were 821 and 1,200 per 
100µl of sample, respectively (Michel et al., 2007). In female patients, the mean number of C. 
trachomatis EB’s obtained from endocerivical swabs, self-collected vaginal swabs (SCVS), urethral 
swabs and FVU were 2,231, 773, 162, and 47 EBs per 100µl of sample, respectively. The high 
organism load found in male FVU samples make FVU an ideal, non-invasive sample type for testing 
males, without compromising assay sensitivity. In comparison, FVU in female samples yielded a 
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mean organism load of 47 cells per 100µl, only 5.7% of the yield found in male FVU. FVU serves as a 
urethral washout, releasing any bacterial cells in the urethra. Whilst genital infection in males always 
arises from inoculum of the urethra during sexual activity, this is not the case in females, when the 
primary site of infection is likely to be the cervix or epithelia of the vaginal canal, and infection of the 
urethra is rarely encountered in the absence of a cervical infection (Bradley et al., 1985). This results 
in a lower organism load at this site in females, especially during the early stages of infection. The 
high organism load detected in the SCVS samples, which are less invasive than endocervical swabs, 
show that this sample site is effective in sampling for this organism.  
The use of FVU in N. gonorrhoea testing in females is more reliable, with one large scale study 
finding the sensitivity of NAAT testing for this organism to be 88.6% when using this sample type, 
compared with 100% for SCVS, and 95.5% for endocervical swab samples (Fang et al., 2008). In men, 
as with C. trachomatis testing, there is little discrepancy in sensitivity between the use of FVU 
samples and urethral swabs for NAAT testing. One study found the sensitivities obtained by a PCR 
assay using urethral swabs and FVU to be 97.3% and 94.4% respectively (Crotchfelt et al., 1997). 
Sampling for T. vaginalis from female patients is carried out using a vaginal swab or urine sample; T. 
vaginalis rarely infects the cervix and the organism load will be far higher in the vagina (Garber, 
2005). The use of urine for T. vaginalis detection in females is not recommended due to the 
reduction in sensitivity seen when using this sample type, even with molecular methods. One study 
found the sensitivity of a T. vaginalis PCR assay to be 89% when vaginal swab samples were used, 
and 64% using urine samples (Lawing et al., 2000). In men, the use of FVU samples has been shown 
to improve the sensitivity of subsequent PCR testing, compared with the use of urethral swabs 
(Schwebke and Lawing, 2002). 
Testing for M. genitalium is carried out less regularly than for C. trachomatis, N. gonorrhoeae or T. 
vaginalis in the UK, due to its lower prevalence, mild or absent symptoms, and relative lack of 
serious disease sequelae. Testing is almost exclusively carried out by NAAT, from either swab or 
urine samples (Shipitsyna et al., 2010). One study found the sensitivity of a home-brew PCR assay 
when used in combination with vaginal swab samples, endocervical swab samples, and urine 
samples to be 85.7%, 74.3%, 61.4% respectively (Lillis et al., 2011). The use of FVU samples in males 
gives equivalent sensitivity as the use of urethral swab samples, 87% compared with 91% in one 
study (Mena et al., 2002). FVU samples are regarded as a suitable sample type from males for all of 
the organisms used in our study. 
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An important factor in diagnosing STIs from swab samples is the structure and composition of the 
swab itself. Several variations in design are available, which differ in their ability to capture and then 
release bacteria present in the urogenital tract, and will have a big effect on the overall sensitivity of 
the process. A recent addition to the varieties of swabs approved for STI diagnosis are flocked swabs, 
commercialised by Copan as FLOQswabs. These swabs consist of a plastic tip, to which Nylon fibres 
are attached at right angles, in a process termed “flocking” which the electrochemical attachment of 
the fibred. The benefit of this is that it creates a highly absorbent open structure, and ensures that 
cells remain trapped on the surface of the swab rather than being absorbed into the core area, as 
happens with cotton or fibre wound swabs. The use of these swabs has been shown to improve the 
sensitivity of NAAT testing for C. trachomatis and N. gonorrhoeae (Chernesky et al., 2006), and to 
perform equally as well as Dacron swabs for diagnosing T. vaginalis using a TMA assay (Jang et al., 
2012). The high performance of Copan FLOQswabs has been confirmed for the capture of T. 
vaginalis, C. trachomatis, N. gonorrhoeae and M. genitalium (http://www.copanitalia.com/KC012-
Copan-Flock-Tech-Brochure.pdf); all of the target organisms of our developed diagnostic assay. 
 
1.1.7. PCR inhibitors in urine 
 
Several standard components of urine, and components of urine present due to disease or an 
underlying physiological condition, are known to be inhibitory to nucleic acid amplification by PCR. 
Generally inhibitors will exert their effects at one of three possible stages of the PCR process; the 
lysis of the target cells, nucleic acid degradation or capture, or the amplification of the target DNA by 
the polymerase enzyme. Reaction inhibition can be total or partial; its effect can range from a minor 
reduction in detection sensitivity to total reaction failure.  
The most significant PCR inhibitor routinely found in urine samples is urea. It exerts its inhibitory 
effects via denaturing DNA polymerases, reducing enzymatic activity and therefore DNA 
amplification (Saulnier and Andremont, 1992). Urea has a similar solubility to DNA and therefore is 
not completely removed during classic extraction protocol, and will be present in the final DNA 
preparation, where it will then inhibit PCR (Moreira, 1998). Urine has been shown to inhibit PCR at a 
concentration of over 50mM (Khan et al., 1991). The normal concentration of urea in urine in adults 
is 330mM although this is highly variable. Taq polymerase is a magnesium dependent enzyme and 
relies on the availability of Mg2+ ions in order to function. The concentration of Mg2+ ions has a large 
effect on the success and specificity of the PCR. Ca2+ ions, which are present in urine, can interfere 
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with the interaction of Mg2+ ions and Taq polymerase, and therefore can inhibit DNA amplification 
(Bickley et al., 1996). 
Blood present in the urine sample has been shown to have an inhibitory effect on DNA amplification. 
Blood is not an expected component of urine but may be present in patients who have recently 
experienced kidney trauma, or who have a urinary tract infection. Serum proteins in blood can act as 
blocking proteins, preventing polymerase enzymes from binding with target DNA, and haemoglobin 
is also known to inhibit PCR (Wilson, 1997). The anitocoagulant heparin, released by basophils and 
mast cells, is also known to inhibit PCR amplification. A haemoglobin concentration in the sample of 
1 mg ml-1 and a heparin concentration of 13 mg ml-1 have been shown to completely inhibit the PCR 
reaction (Perch-Nielsen et al., 2003). It has been shown that the level of whole blood in the PCR 
reaction volume should be kept at lower than 4% in order to enable effective DNA amplification 
(Wilson, 1997). However, some studies have found that the concentration of blood present in a 
urine sample has no inhibitory effect on PCR detection of C. trachomatis (Toye et al., 1998).  
A recent study carried out in order to investigate the sensitivity of PCR for the detection of C. 
trachomatis compared to culture methods (Pasternack et al., 1996) found that PCR inhibition was 
seen in 15.4% of 39 samples positive for C. trachomatis, resulting in false negative result.  This level 
of false negative results among true positive patients would be a major obstacle when considering 
use of PCR for diagnosis of C. trachomatis in a clinical setting. However, the same study found that 
when special precautions were taken to eliminate the inhibitors effect, 97.4% of 39 samples positive 
for C. trachomatis were correctly identified. This underlines the sensitivities that can be 
accomplished using PCR detection if steps are taken to remove the impact of PCR inhibitors from the 
system.  
A key step in the sample preparation process will be the removal of compounds inhibitory to PCR 
prior to the detection assay. Filtering or washing by centrifugation can be used to remove inhibitory 
compounds which are extracellular or unbound to the cells. Although effective and easy to carry out 
in a laboratory setting, such methods are fairly labour intensive and are unsuited for incorporation 
into a microsystem. One of the simplest techniques for the removal of inhibitors is to fixate the 
target cells or target DNA (depending on which stage of the process the inhibitors will be removed), 
and then wash away and discard any other materials, including the inhibitors using wash buffers. 
The buffers can be housed on chip (Baier et al., 2009) or added to their respective chambers present 
on a microfluidic chip prior to use by the operator (Xu et al., 2010). The buffers could also be housed 
inside the actual machine itself, with the required amount being injected into the chip circuit via 
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buffer inlets on the chip. This basic process of inhibitor washing can be carried out in a number of 
different ways. 
Previous chips for nucleic acid testing have successfully removed inhibitors by using solid phase 
extraction (SPE) to fix the DNA subsequent to target cell lysis. This process is followed by one or 
more washing steps, where a washing buffer is passed through the SPE chamber which removes all 
fluids and cellular debris, leaving only the DNA behind. The wash buffer is then disposed of via an 
outlet channel (Baier et al., 2009). The composition of the washing buffers used can vary. One study 
(Baier et al., 2009) used a two -step washing procedure to remove inhibitors from a 30µl SPE 
chamber; firstly 230µl of a washing buffer composed of 75% ethanol and 25% 3M Guanidinium 
isothiocyanate (GuCN) was used. This was followed by 120µl of 96% ethanol. The GuCN is present in 
the first wash in order to denature proteins, especially DNase enzymes which may be present in the 
chamber, and is also used as a binding salt during SPE. Some components of commercially available 
wash buffers, including GuCN, are thought to inhibit PCR reactions to a certain degree (Xu et al., 
2010), so a final wash of ethanol is used to remove any components introduced in the first wash. 
 
It is also possible to remove inhibitors prior to cell lysis. One such method of accomplishing this in a 
microsystem uses dielectrophoresis (DEP) as a selective filter to withhold target cells whilst the 
inhibitory compounds are removed (Perch-Nielsen et al., 2003). DEP is a force exerted on a dielectric 
particle when it is subjected to a non-uniform electric field. By using DEP it is possible to attract the 
target cells to electrodes in a microfluidic chamber, whilst molecules with different dielectric 
properties, such as any inhibitory compounds, are free to move through the system. Buffers can 
then be applied to wash away any inhibitors before the DEP force is removed, releasing the cells, 
and leaving a concentrated population of cells ready for the next stage of the sample preparation 
process. 
  
1.1.8. Sample preparation using microfluidics 
 
One of the most efficient ways to address the challenge of fully integrating the sample processing 
steps is to use microfluidic technologies to carry out these processes ‘on-chip’.  Microfluidics 
involves the scaling of macroscopic processes down to the microscopic level, using the precise 
control of fluids and gases at very low volumes (typically at the nanolitre and picolitre level). By 
keeping sample and reagent volumes low, reaction times are shortened, and molecular processes 
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can be carried out much more rapidly, which is of upmost importance for molecular diagnostics 
(Mairhofer et al., 2009). Single use microfluidic cartridges or chips can be designed to carry out all 
sample preparation steps to the raw sample, either after being pre loaded with reagents during 
manufacture, or loaded prior to use by the operator. These cartridges or chips can be made using 
polymers via injection moulding, an inexpensive process which results in disposable single-use chips 
being financially viable (Baier et al., 2009). Disposable microfluidic cartridges are utilised in the 
GenExpert system (Cepheid). These contain syringe and rotary drives to move the reagents and 
sample throughout the microfluidic circuit and an ultrasonic horn to lyse the cells.  
A variety of different methods for various stages of the extraction of DNA from organisms in a 
biological sample have been attempted on chip. These include filtration, magnetically activated cell 
sorting (MACS) and acoustophoresis for organism isolation and a variety of methods for cell lysis, 
including mechanical, thermal, chemical and electrical methods. 
 
1.1.9. Sample Concentration 
 
Initially the sample will consist of a minimum of 1ml of urine taken from a urine sample given by the 
patient.  The majority of microfluidic systems would be unable to process a sample of this size, and it 
may be necessary to reduce the volume to a manage level for the microfluidic chip to process, whilst 
retaining the maximum amount of pathogenic material to enable sensitive and rapid detection. The 
sample can be concentrated by isolating the target organisms from the bulk liquid, which can then 
be ejected as waste. A number of methods to accomplish this have successfully been implemented 
‘on chip’. 
 
1.1.10 Filtration 
 
One of the easiest ways to concentrate the cells present in the sample would be to filter the bulk 
liquid, capturing the cells and enabling the remaining liquid to be discarded as waste. The cells could 
then be lysed at the site of the filter and their contents washed to the next phase of the process in 
order for the DNA content to be isolated. This method of cell isolation is utilised in the microfluidic 
cartridges of the commercially available GenExpert system (Cepheid). Conventional computer 
controlled (CNC) machining has been used to create various designs of microfilters for the 
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separation of cells from biological samples from glass-silicon, including comb shaped filters, weir 
type filters and torturous channels. The use of weir type filters to isolate white blood cells from 
whole blood has been demonstrated, and was able to achieve a capture efficiency of 7%, whilst 
eliminating >99% of red blood cells(Yuen et al., 2001). Simple nylon filters capable of isolating 
human cells from the sample have also been incorporated into microfluidic sample preparation 
chips, with the cell lysis step being carried out directly on the filtrate (Baier et al., 2009).  
 
One major issue with this method of cell concentration is that the filter can become clogged by 
material in the bulk liquid or excess cells, reducing or preventing flow through the filter. A number of 
potential remedies to this problem have been developed. One such method is to reverse the 
pressure present in the system, back flushing the filter chamber to dislodge any debris (Wei et al., 
2011). This typically requires extra design requirements, such as valves or extra channels, and a 
pumping system able to reverse its flow. In order to detect filter clogging a pressure sensor is also 
required (Baier et al., 2009). Another issue encountered when using filters in this way is the 
mechanical lysis of cells upon contact with the filter pores. The mechanical pressure exerted upon 
the cells, especially under high liquid velocity, can deform or lyse the cells, causing the lysed cell and 
its contents to be pushed through the filter along with the bulk liquid (Kuo et al., 2010). However, It 
has been shown that by carefully considering the hydrodynamic environment housing the filter 
during system design this problem can be minimised (Kuo et al., 2010).  
Recent developments in the use of porous membranes for particle sorting have yielded the ability to 
create poly(dimethylsiloxane) (PDMS) membranes with accurately determined pore sizes down to 
size of 6.4 µm, and pores of multiple sizes, in predetermined arrangement (Wei et al., 2011). A 
particle sorter made using this principle was able to separate polystyrene beads of various diameters 
with an efficiency greater than 99.9%. This can enable a much greater degree of selectivity in the 
filtration process, although there would be difficulties in implementing this technology in a device 
for the simultaneous detection of multiple organisms of differing sizes. 
 
It has also been demonstrated that a filtration process could be used to isolate the DNA itself after 
lysis of the cells. Nanofilters can be used as molecular sieves, enabling the separation of DNA from a 
bulk liquid (Han et al., 2008). This process is likely to be less reliable than a solid phase extraction 
method due to the possibility of the nanofilters being clogged by cellular debris or protein in the 
urine sample; however, it is very rapid and can operate in a continuous fashion (Han et al., 2008). 
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1.1.11. Magnetically activated cell sorting (MACS) 
 
Another potential method for isolating the cells from the sample is the use of magnetically activated 
cell sorting (MACS), or a variation of this technique. MACS relies on target specific antibodies 
attached to magnetic beads or nanoparticles (Schmitz et al., 1994). These magnetic particles are 
then incubated with the sample, allowing the antibodies to bind to their specific antigens on the 
surface of the target cell, creating a strong attachment between the target cells and magnetic 
particles. The cell suspension is then transferred to a column placed in a strong magnetic field, 
where the beads and attached cells remain on the column, whilst the other components of the cell 
suspension are washed through and can be discarded as waste (Miltenyi et al., 1990). The cells can 
then be eluted from the column and analysed. Variations of this technique are used during sample 
preparation in a variety of point of point of care diagnostic devices, including the Liat Analyzer 
(IQuum), Philips Magnotech technology (Philips & Biomerioux) and FL rapid PCR system (Enigma 
Diagnostics). The process relies on the presence of a specific surface antigen which is present on the 
target cell but no other components or cells in the sample. If any non-target cells also express the 
antigen then they will also be captured, reducing the selectivity of the system. A multi-target system 
would require antibody conjugated magnetic beads for each target. This process also requires the 
specific antibodies, which if commercially available are expensive, and if not, will require synthesis.  
One commercially available MACS system is the Dynabeads system (Invitrogen, US). Dynabeads are 
superparamagnetic spherical polymer particles, available in several sizes, which can be pre-coupled 
with a large variety of ligands, including antibodies, antigens, proteins or DNA/RNA probes. 
Dynabeads have successfully been used for cell concentration during sample preparation on 
microfluidic chips for nucleic acid testing, in an experimental context (Liu et al., 2004).  
The main advantage of MACS is its high specificity, which is highly advantageous if a low number of 
target molecules are present in the sample in combination with a potentially large population of non 
target cells, as is the case when detecting low numbers of pathogenic cells in a clinical sample. The 
separation of astrocytes and microglia from a cell suspension using MACS has been demonstrated, 
with the use of magnetic beads coupled to microglia specific antibodies enabling the selection of a 
>99% pure population of microglia, completely free from astrocytes (Marek et al., 2008). However, 
as in NAAT diagnostics the specificity is inherent in the amplification assay, a catch-all method of 
sample concentration may be the most efficient, and cheapest option. 
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A variation of MACS known as multi target MACS has been developed in a microfluidic chip to enable 
the capture of two distinct cell populations from the same sample in a continuous flow manner, and 
their collection from separate outlets (Adams et al., 2008). Two cell populations were tagged with 
magnetic tags with differing magnetization and size. The device was engineered so that the 
combined effects of the hydrodynamic force produced flow within the microchannel and the 
magnetophoretic force produced from the design of the ferromagnetic structures within the 
microchannel result in the selective purification of the target cells into multiple independent outlets 
dependent on the characteristics of their tags. The design was capable of sorting multiple bacterial 
cell types with a purity of >90% and >500-fold enrichment at a throughput of 109 cells per hour. The 
drawbacks of this system include the expense of having two sets of magnetic tags coupled to 
different antibodies, and the slow flow rate of the system. The system is operated at a flow rate of 
47ml/hr; however of this 47ml volume only 5ml is made up of the actual sample, meaning it can 
process 5ml of sample per hour. In order to process a 1ml sample the processing time would be 12 
minutes, which is excessively long for this process in a diagnostic system intended for use at the 
POC. 
 
1.1.12. Cell Lysis in a microfluidic system 
 
One of the initial stages of an on-chip nucleic acid extraction procedure is the lysis of target cells in 
the sample, which is necessary in order to access the intracellular DNA, which will then need to be 
extracted and presented to the assay step for amplification. This step occurs directly after any pre-
concentration step, if present, or can occur directly after sample application. The methods available 
for lysing cells in a microfluidic system fall into four broad categories; chemical, thermal, mechanical 
and electrical.  
1.1.13. Chemical Lysis 
 
Chemical lysis of bacterial cells involves the use of compounds capable of inducing outer cell wall 
permeability, creating holes in the cell membrane, and causing the cells intracellular contents to be 
released. Organic solvents (such as DMSO, methanol and benzene), chaotropic agents, antibiotics 
and chelating agents are all capable of inducing lysis in bacterial cells. Detergents can be used, but 
require a pretreatment step to degrade the cell wall before they can act on the cell membrane.  
Lysozymes can also be employed as an effective lytic agent when dealing with gram positive or gram 
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negative bacterial cells. These enzymes work by catalyzing hydrolysis of 1,4 beta linkages, which act 
to bind N-acetylmuramic acid and N-acetyl-D-glucosamine residues present in the peptidoglycan cell 
wall. However, lysozyme mediated lysis of Gram-negative bacteria has been shown to occur 
independently of the enzymes muramidase activity, indicating another pathway is responsible (Nash 
et al., 2006). Chaotropic salts, such as guanidinium thiocyanate and guanidinium chloride, are useful 
for the lysis of cells for nucleic acid extractions. Not only do they disrupt bacterial cell membranes, 
they also denature RNAses, preventing the degradation of RNA by these enzymes. 
An important consideration when utilising chemical lysis in a microsystem is that the inhibitory 
effect elicited on PCR reactions by many chemical lysis agents means that they need to be removed 
from the sample prior to the amplification stage. This typically means washing buffer needs to be 
introduced to the sample during DNA extraction, removing inhibitors and leaving the DNA ready for 
the assay step. This has an impact on the complexity of the device, with lysis agent and washing 
buffer needing to be stored on chip, typically in quite significant volumes. It also increases the time 
taken for the device to extract PCR ready DNA from the raw sample.  
Bench-top DNA extraction kits, commonly used for DNA extraction from clinical samples for 
pathogen detection in laboratories, frequently employ the use of lysis buffers in order to lyse the 
cells, in order to release the DNA. Lysis buffers containing NH4CL as their active ingredient are 
frequently used to lyse erythrocytes, although they are ineffective at lysing bacterial cells. Lysis 
occurs as NH3 diffuses into the cells where it is converted into NH4+ ions in order to maintain the 
intracellular pH equilibrium. This results in a need for counter-ions, which are generated by the 
conversion of intracellular CO2 into HCO3- ions, catalysed by the carbonic anhydrase enzyme. The 
accumulated HCO3- ions are then exchanged for extracellular Cl- ions, present due to the lysis buffer, 
through the band 3 anion translocator (Sethu et al., 2004). The build up of Cl- and NH4+ ions inside 
the cell leads to osmotic swelling, which results in cellular lysis. The use of an NH4CL based lysis 
buffer has been demonstrated during the lysis of erythrocytes in a microfluidic device (Sethu et al., 
2004), which enabled almost complete lysis (99.4%) of the sample. 
A significant issue with the use of lysis buffers which needs to be overcome before it can be used in a 
rapid POC diagnostics microsystem is the ratio of lysis buffer needed compared to the volume of 
sample. A typical extraction kit using a NH4CL-based lysis buffer would recommend the application of 
15ml of buffer to 1ml of sample and then a 5 minute incubation period (Sethu et al., 2004). This 
would increase the sample volume to an unmanageable volume for a microsystem to rapidly 
process. However, a number of microfluidic chips have used chemical lysis in order to release the 
DNA from the cells prior to DNA extraction with relative success. One study  addressed the problem 
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of high buffer to sample volume ratios by using a comprehensive computational fluid dynamics (CFD) 
simulation to determine the optimum channel dimensions and shape for buffer/sample mixing 
(Chen et al., 2007). A T-type mixing model, sandwich type mixing model with lined channel and a 
sandwich type mixing model with coiled channel were all evaluated. The sandwich type mixing 
model with coiled channel was predicted to have a far greater degree of mixing, and therefore an 
improved rate of lysis. As the rate of lysis in the macroscale environment is diffusion limited (Sethu 
et al., 2004), optimising the mixing of buffer and sample can lead to significant decreases in the time 
taken to lyse the cells. Mixing in a microfluidic chip is exclusively caused by diffusion due to the 
laminar flow through the channels, resulting in a slow rate of mixing.  
Although this study was able to demonstrate a significant increase in the efficiency of chemical lysis 
on-chip, the fastest sample flow rate they were able to obtain whilst retaining lysis efficiency was 
5μl/min, which would be far too slow for use in a microsystem which needs to achieve detection 
from an unprocessed sample in under 15 minutes. The lowest ration of lysis buffer to sample volume 
they were able to achieve was 5:1, which is an improvement on typical bench top extraction kits, but 
not by a large enough margin to be effective in a rapid POC system 
 
1.1.14 Mechanical Lysis 
 
Mechanical lysis relies on mechanical force applied directly to the target cells to puncture the cell 
membrane or wall. Mechanical methods are amongst the most simple to carry out in a microfluidic 
environment, many rely on internal static features which can be built into the microfluidic channels 
themselves. However, mechanical methods are associated with some disadvantages when used to 
lyse cells for DNA extraction. Mechanical lysis tends to cause bacterial cell membrane to disintegrate 
into very small fragments, making the isolation of DNA from the resulting mixture more difficult. The 
DNA needs to be purified from the complex mixture of all the released intracellular components, 
including membrane fragments and proteins.  
 
1.1.15. Filtration 
 
One of the simplest ways to mechanically lyse the cells is to pass them through a filter at high flow 
rates. The rate of lysis can be improved by considering the structure of the filter. Features such as 
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nanostructured barbs added to the filter structure increase cell lysis on contact (Carlo et al., 2003). 
Whilst having many advantages, such as the simplification of the process, and reduction in the need 
of moving parts or heating elements, the process remains quite inefficient. The rate of lysis caused 
by a standard filter to red blood cells at a flow rate of 300µl per min lies between 1.9% and 3.2%, 
which can be increased to between 4.8% and 7.5% upon the addition of nanoscale barbs (Carlo et 
al., 2003). 
 
1.1.16. Ultrasonication 
 
Ultrasonication is a method of mechanically lysing cells using high frequency ultrasound waves. 
Ultrasonic generators are used to create sonic pressure waves throughout the sample liquid, causing 
microbubbles which then implode, generating enough localized pressure to damage cell 
membranes, resulting in cell lysis. The ultrasonic energy is generated by piezoelectric generators 
made of lead zirconate titanate crystals. The energy generated is then transmitted down a metal 
horn attached to the chamber in which the ultrasonication is taking place, causing the chamber to 
resonate, typically between 15-25 kHz (Huang et al., 2002). This method is employed in the 
GeneXpert system (Cepheid, US), which uses a generator in the main module to transmit ultrasonic 
energy down the ultrasonic horn present in each single use cartridge. This method is well suited to 
lysing robust bacterial species such as M. tuberculosis, which are difficult to break down due to the 
presence of a waxy cell wall (Verschoor et al., 2012). This method does have its disadvantages 
however, as the ultrasonic processors generate considerable heat during their activation and also 
have a larger energy requirement than other methods of cell lysis, such as chemical methods and 
most other mechanical methods.  
 
1.1.17. Thermal lysis 
 
Thermal lysis relies on the generation of a sufficiently high temperature to break down the bacterial 
cell wall. This is one of the most rapid methods for cellular lysis and one of the most amenable to 
miniaturisation and inclusion in a microsystem. Due to the high temperatures the released 
intracellular proteins tend to become denatured, however the DNA is able to withstand 
comparatively higher temperatures and so can be extracted intact. Total lysis of E. coli in a glass 
microchip has been demonstrated by heating the chip to 94oC for 4 minutes  (Waters et al., 1998). 
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The lysis of over 90% of E.coli cells in a microfluidic chip by exposure to 93oC for just 15 seconds has 
been reported (Privorotskaya et al., 2010). This was achieved using silicon microcantilever heaters 
coated with a layer of 100nm thick electrically insulating ultrananocrystalline diamond layer, which 
were then electrically heated.  
A comparison of the quantity of DNA released from E.coli via thermal lysis and ultasonication 
(considered one of the optimal methods of lysis for preserving DNA) carried out using real time PCR 
found comparable amounts between the two methods, indicating that the high temperature has 
minimal effect on the quality of DNA released (Baek et al., 2010). The high power requirements for 
heating the sample to 90oC – 100oC are an important consideration when designing a portable 
device, which may be battery powered. Due to the small sample volumes present in a microsystem 
this power requirement to reach these temperatures are comparatively low when compared to 
standard lab heaters or thermal cyclers, but even a small addition to the systems power requirement 
can impact the amount of tests which can be processed before recharging.  
 
1.1.18. Laser irradiated magnetic bead system (LIMBS) 
 
LIMBS is a novel technique for the acceleration of thermal cellular lysis in biological samples in a 
microfluidic environment (Lee et al., 2006). The sample is integrated with magnetic microbeads, and 
then an 808 nm, 1.0W laser is used to irradiate the sample for a period of 40 seconds. The 
microbeads facilitate lysis by dissipating the light energy of the laser uniformly throughout the 
sample as thermal energy, resulting in the thermal lysis of cells in the surrounding liquid. The 40 
second irradiation is sufficient to lyse E. coli and gram negative bacteria in blood, and also the 
hepatitis B virus mixed with human serum. 
Gold nanorods have also been used in microfluidic chambers to generate sufficient heat to lyse E. 
Coli cells following irradiation by a 808nm, 1.0W laser (Cheong et al., 2008). The longitudinal 
resonance of the gold nanorods converts the near infra red energy into thermal energy, increasing 
the temperature in the 8µl chamber to 95oC after an irradiation period of 70 seconds. The gold 
nanoparticles where not inhibitory to the qPCR reaction to any degree, demonstrating that they do 
not interfere with PCR amplification. The chamber size used in the tests, 8µl, would require an 
extremely high level of sample concentration when dealing with a 1ml sample, in order to ensure all 
cells in the sample were present in the chamber prior to lysis. Alternatively a larger chamber could 
be used, but whether the thermal energy generated in this method would be sufficient in a larger 
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chamber remains to be seen. This could be rectified by using a more powerful laser, which has been 
shown to increase temperature when used in this manner (Cheong et al., 2008). 
 
1.1.19. Electrical lysis 
 
Electrical lysis employs the use of electrical fields to increase membrane permeability or fully disrupt 
the cell wall/membrane. This method is well suited to incorporation into a microfluidic system as on 
chip systems can require as little as ~500V to generate a sufficient electric field to lyse bacterial cells, 
due to the small sizes involved minimising the distance between electrodes (Kim et al., 2009). This 
negates the need for a bulky generator and reduces the energy requirements needed, when 
compared to carrying the procedure out in the macroscale. It is a reagent free process, and both 
quicker and cheaper than chemical lysis. Electrical lysis can be achieved by exposing cells to high 
intensity pulsed electric fields (PEFs). The pulse length and electrical field strength required for lysis 
is dependent on the morphology of the target cell type, but the strength of the field needs to be 
sufficient to raise the cell membrane potential to ~1.1V (Kim et al., 2009), typically between 500 V 
and 1000 V. Electrical lysis of red blood cells using a dc-biased ac electrical field has been 
demonstrated in a constriction microchannel (Church et al., 2010). A fixed voltage of 160V was 
across the microchannel, producing 1600V/cm at the site of lysis. It was found that by increasing the 
ac component of the field the rate of lysis could also be increased. When 160 V pure dc was applied, 
very few cells were lysed. Partial lysis was seen at 80 V dc, 80 V ac, whilst complete lysis occurred 
upon the application of 40 V dc, 120 V ac. It was found that cells could be lysed as rapidly as 80ms 
after entering the electric field. 
 
1.1.20. DNA extraction on a microfluidic chip 
 
The next phase of the extraction process, subsequent to the lysis of cellular material in the sample, is 
the isolation and purification of the nucleic acid from the rest of the sample mixture, which includes 
numerous proteins, fragments of cell wall and cell membrane, and potentially any reagents used 
during the lysis process. The nucleic acid, once purified, requires transferring to the reaction phase 
in order to undergo amplification and detection. Maximisation of the efficiency of the extraction 
method, maximise the concentration of nucleic acid at the start of the amplification reaction, which 
leads to an improved sensitivity and reaction speed. 
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1.1.21. Solid Phase Extraction 
 
Solid phase extraction (SPE) is the most frequently used technique for on-chip DNA extraction, and 
also the simplest. SPE utilises the affinity of solutes suspended in a liquid, such as the DNA in the 
sample, for a solid which the liquid is passed through. By passing the sample through a solid 
structure which DNA has a high affinity for, it is possible to retain the DNA whilst the rest of the 
sample can be removed. The DNA can then be eluted from the solid structure to which it is bound 
using a low ionic strength buffer, and then analysed.  
 
1.1.22. Silica based SPE 
 
A typical technique for SPE on chip involves silica based surface affinity, which utilises the ability of 
nucleic acid to bind with silica or glass in high ionic strength solutions due to decreases in the 
electrostatic repulsion (Kim et al., 2009). The bound DNA is then washed with a non-polar solvent to 
remove any contaminating protein and then eluted using a low ionic strength buffer. A simple 
microfluidic chip housing an extraction channel containing only 1 nanogram of silica resin has been 
shown to be capable of extracting 70% of the DNA released from lysed white blood cells (Tian et al., 
2000), showing the efficiency of this method even in its most basic form.  
A rapid and simple method for SPE on chip has been demonstrated using the chaotropic agent 
guanadinium thiocyanate, which facilitates the binding of the DNA to silica particles (Boom et al., 
1990). Guanadine salts are chaotropic agents, meaning that they can disrupt the bonds between 
water molecules in solution. This enables the formation of salt bridges between the negatively 
charged nucleic acid molecules, and negatively charged silica. These bonds form between the 
negatively charged oxygen atoms in the silica matrix and negatively charged oxygen atoms in the 
phosphate backbone of nucleic acids (Tan and Yiap, 2009).  
 Using this reagent has the added benefits of deactivating nucleases also released from the lysed 
bacterial cells. In this method guanadinium thiocyanate was also the reagent responsible for the lysis 
of the cells prior to SPE. Guanadine hydrochloride can also be used in this manner and poses far less 
of a health risk. This methodology has been adapted for use in a fully integrated microfluidic chip for 
the automated extraction of nucleic acid from human cells (Baier et al., 2009). A silica filter material 
was used as the stationary phase in the SPE. Three layers of the silica filter were placed in a 30μl 
chamber, which the sample would flow through after cell lysis was completed. Any cellular debris 
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was then removed with an alcohol wash and the DNA was then eluted from the filters with a Tris-
EDTA buffer. 
The capture efficiency of silica based microfluidic devices is highly dependent on the surface area of 
silica available on which the DNA can bind. For example, in one study a silica chamber with a surface 
area 16% of that of another captured 78% less DNA (Christel et al., 1999). By carefully designing 
silica containing SPE chambers to ensure maximum surface area, DNA capture efficiency can be 
increased. A recent novel microfluidic chip for DNA extraction utilised silica based monoliths to 
maximise DNA capture (Shaw et al., 2009), which was found to be a robust and highly reproducible 
in a microfluidics device. One study (Chen et al., 2007) detailed a fully integrated microfluidic device, 
including automated cell sorting, cell lysis and DNA purification. The DNA extraction step was carried 
out using a microfabricated porous silicon matrix, made by an anodizing technique using an 
ethanol/HF buffer electrolyte. A thermal oxidisation step was then carried out during manufacture 
to generate silanol groups on the surface, which act as nucleic acid absorption sites during the 
extraction. The silanol density was increased by the anodising and oxidation steps, increasing the 
absorption sites within the matrix. The chip was tested with raw blood samples and it was found 
that it could extract 37.5ng of purified genomic DNA from 1µl of blood sample. When compared to a 
bench top centrifugation based extraction kit, it was found the chip required 50 minutes running 
time to generate the same amount of DNA. Silica based SPE has been successfully integrated in a 
microfluidic chip in numerous studies, demonstrating great flexibility and reproducibility. The main 
disadvantages of this method of DNA extraction on chip is that the devices can be expensive and 
labour intense to fabricate, and do not lend themselves as easily to mass production as other DNA 
extraction methods such as polymer based SPE. 
 
1.1.23. Polymer based SPE 
 
Polymer based extraction chambers can be used as an alternative to silion based extraction 
chambers for SPE in a microfluidic chip. Materials such as poly(methyl methacrylate) (PMMA), or 
poly-carbonate (PC) have been used as a cheaper, more reproducible alternative to silicon as 
surfaces for DNA absorption on chip (Price et al., 2009). Typically these techniques rely on 
electrostatic interactions between the negatively charged DNA and modified polymer surfaces. 
The production of a novel microfluidic DNA extraction device composed of photoactivated 
polycarbonate (PPC), with its surface patterned using UV LiGA (a German acronym for Lithography, 
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electroplating and molding), a microfabrication technique capable of creating high aspect ratio 
surface features, has been described (Witek et al., 2006). The extraction surface of the chip was 
covered with an ordered array of 5:1 aspect ratio posts, providing an increased surface area for 
nucleic acid binding. This surface was then exposed to UV radiation, creating carboxylate groups to 
assist in the absorbance of the nucleic acid. DNA is able to bind to carboxy-coated surfaces under a 
high concentration of poly (ethylene glycol) (PEG) and salts, which were present in the DNA 
extraction channel on chip (3% PEG, 0.4 M NaCl, 70% ethanol). Protein and debris were then 
removed by an ethanol wash which was applied through the chip and then DNA was then eluted. 
The chip demonstrated a high extraction efficiency, with 85% of a purified DNA sample retrieved. 
PCR amplifiable bacterial DNA was also extracted from a blood sample spiked with E. coli DNA. The 
whole process of extracting DNA took 25 minutes, which does not include the steps needed to 
remove the DNA from the cells, or originally concentrate the cells. However it is possible that this 
process could be optimised further.  
DNA extraction chips utilising a surface coating of the linear polysaccharide chitosan have been 
developed (Cao et al., 2006), which take advantage of the pH dependent binding of nucleic acid to 
chitosan. Chitosan has a cationic charge at a pH of 5, resulting in an electrostatic attraction to 
negatively charged DNA. However at pH 9 this charge is neutralised, meaning any bound DNA 
dissociates. A microfluidic chip containing an extraction chamber housing chitosan covered 
microbeads has been applied to the extraction of DNA from blood (Cao et al., 2006). These beads 
bound DNA in a pH 5 solution, with the DNA then being eluted using a pH 9.1 Tris buffer. The 
recovery rate of human genomic DNA from a sample of lysed whole blood was found to be 68%, 
with a the purity of the extracted DNA being sufficient for PCR amplification.  
 
1.1.24. Nanoporous membrane filtration 
 
Nanoporous membranes have been used to selectively filter nucleic acid from bulk liquids by a 
combination of sieving and electrostatic interactions (Jungkyu et al., 2006). Nanoporous aluminium 
oxide membranes (AOM) have been used to purify genomic DNA from lysed whole blood in a 
macrosystem (Elgort et al., 2004). AOM is commercially available under the trade names Anopore or 
Anodisc (Whatman inc, US), and can be obtained with pore sizes of 20nm, 100nm and 200nm. The 
membranes are 60µm thick and have a porosity of 50% which allows for high liquid flow rates. A 
study examining the optimisation of AOM filtration for DNA extraction on a microfluidic device 
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found that higher pH, salt concentration and anionic sample solutions all yielded higher capture 
efficiencies due to an increase in attraction between the AOM surface and DNA (Jungkyu et al., 
2006). It was also found that a nanopore diameter of 100nm was optimum when extracting DNA 
from complex biological samples.  
 
 
 
1.1.25. LabDisk 
 
The automation of laboratory processes using microfluidics, also known as lab-on-a-chip technology, 
enables complex, multi-step processes, which would normally be carried out manually by skilled 
technicians to be automated in a microfluidic environment. These devices typically use plastic chips 
or cassettes, complete with channels and chambers for the manipulation of small volumes of liquids 
and reagents, and various systems have been produced capable of automating DNA extraction (Baier 
et al., 2009), blood fractionation (Amasia and Madou, 2010), immunoassays (Noroozi et al., 2011), 
cell sorting (Burger et al., 2012), and a range of other processes. 
The movement of fluids in microfluidic systems can be achieved in a number of ways. Capillary 
forces can be used to passively draw liquid along a channel, without the application of any external 
forces, but this process is slow, and it is difficult to move large volumes in this manner. Micropumps 
and microvalves are commonly employed on microfluidic devices in order to manipulate fluid flow, 
although these are expensive and prone to breaking (Nguyen et al., 2002). Additionally, microfluidic 
diagnostic devices are ideally self-contained and disposable, with all electrical equipment housed in 
the operating unit. Micropumps are too expensive to house on disposable chips, and the integration 
of pumps in the operating machine that could interact with each disk would be complex and 
expensive. 
One novel method for addressing this issue is by the use of centrifugally operated microfluidic disks, 
which can be operated by spinning at varying speeds, in order to move and mix fluids using 
centrifugal, Euler and Coriolis forces (Ducrée et al., 2007). The applications of centrifugally driven 
microfluidic systems have included haematocrit determination from blood samples (Ducrée et al., 
2007), magnetic bead based DNA purification (Strohmeier et al., 2013), rt-PCR (Strohmeier et al., 
2014), and fully integrated multiplex immunoassays (Noroozi et al., 2011). 
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The LabDisk, developed by IMTEK (Freiburg, Germany), is a microfluidic disk that can be operated by 
centrifugal control (Fig.1.3.), provided by a specially modified ESEQuant tube scanner (Qiagen, US), 
capable of applying the necessary centrifugal control to the LabDisk, and also housing an optical 
detection system (Fig.1.4.). The current control system is considered ill-suited for commercial use as 
a POC device as it can only handle a single LabDisk at a time, possesses single channel optics, suffers 
from temperature fluctuations, has no anti-contamination measures, and cannot integrate with 
existing medical software systems used in the UK. 
 
 
 
 
Fig.1.2. Schematic diagram of a LabDisk designed for the extraction of nucleic acid from a 200µl 
sample, with subsequent recombinase polymerase amplification (RPA) and fluorescence detection. 
(a) Chambers housing the sample and magnetic beads (i1), lysis buffer (i2), isopropanol (i3), wash 1 
(i4), wash 2 (i5), and elution buffer (i6). (b) Magnetic silica bead based extraction is carried out via 
the movement of the beads from the lysis buffer to the elution buffer, via two wash buffer 
chambers, by holding the beads in position with a fixed magnet and then moving the disk around 
that point. (c) The eluted nucleic acid is then used to rehydrate the RPA reaction mix. (d) The eluted 
nucleic acid is then aliquoted into the reaction wells, rehydrating the primers dried into the wells, 
and the isothermal reaction begins by heating the disk to the required temperature. Detection is 
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carried out by the optical detection of fluorescence generated by the intercalating dye present in the 
RPA reaction mix. Image taken from Strohmeier et al (2012). 
 
 
Fig.1.3. (a) The LabDisk control unit utilised by IMTEK, currently in development. (b) The plinth for 
the LabDisk. (c) USB connection between the control unit and operating PC. Image taken from 
Strohmeier et al., (2012) 
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Aims 
 To optimise the composition of the lysis buffer, and lysis process, in terms of speed and 
efficiency. 
 To determine the tolerance of the extraction system, in combination with LAMP detection, 
for the presence of common amplification inhibitors found in clinical samples. 
 To investigate the delivery of the lysis reagents in a dried format, in order to reduce on-disk 
fluid volumes. 
 To optimise the swab acquisition process, determining the optimum swab type, transport 
media, and protocol for sample application 
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1.2. Materials and Methods 
 
1.2.1. Culture of N. gonorrhoeae 
 
N. gonorrhoeae (ATCC 19424) was cultured on chocolate agar (blood agar base, Sigma Aldrich, UK; 
defibrinated horse blood, TCS, UK) at 37oC at 5% CO2. Broth cultures were maintained under the 
same conditions, in brain heart infusion broth (Oxoid, UK). 
 
1.2.2. Culture of Escherichia coli 
 
E. coli K-12 (lab strain) was cultured on nutrient agar (Oxoid, UK) incubated at 37oC. Broth cultures 
were maintained under the same conditions in nutrient broth (Oxoid, UK). 
 
1.2.3. Use of human urine  
 
For each experiment where human urine was used, the urine was a mix of urine taken from one 
individual over a 12 hour period. Urine was stored at 6oC and used no later than 24 hours after 
excretion. 
 
1.2.4. Public Health England (PHE) N. gonorrhoeae LAMP primer sets 
 
Sequences were provided by PHE for N. gonorrhoeae LAMP primer sets, specific to the 
GroEL and PorA genes. The primer sequences are shown in Table 1.1. 
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LAMP Primer Sequence Length (bp) 
N. gonorrhoeae 
GroEL F3 
ACTTTATCAACGACGCGGAA 
18 
N. gonorrhoeae 
GroEL B3 
ACGGTTTTCAGGATGCCG 19 
N. gonorrhoeae 
GroEL FiP 
AGGTCGCGGATGTTGCTGATTTAAATCGCCGGTCTGGACA 40 
N. gonorrhoeae 
GroEL BiP 
TGGAACAAGTGGCGAAAGCCAGACCAAAGTCGCCAAGGC 40 
N. gonorrhoeae 
GroEL Loop F3 
GTCGAACAGCAAAACAAACGG 21 
N. gonorrhoeae 
GroEL Loop B2 
CCCGCTGTTGATTATCGCTGAAG 23 
Table 1.1. Sequences of the N. gonorrhoeae GroEL LAMP primer sets, designed by Public Health 
England Southwest. 
 
1.2.5. LAMP Reactions 
 
LAMP reactions were set up using reagents from a Mast Isoplex DNA amplification kit (Mast Group 
Ltd, UK), as follows; 5µl five times LAMP reaction buffer, 12µl molecular grade water, 1µl 
intercalating dye (propriety dye, emission in FAM channel), 1µl of 8U/µl Bst polymerase (New 
England Biolabs, USA), 1µl of primer mix containing 40pmol of FiP and BiP primers, and 5pmol of F3 
and B3 primers. Loop primers, if present, were included at a 25pmol/µl concentration in the primer 
mix. Finally 5µl of DNA sample or water was added to the reaction. Reactions were carried out in a 
ESEQuant Tube Scanner (Qiagen Inc., CA), at 63oC for 60 minutes. Reactions were terminated by 
heating to 80oC for 1 minute in order to denature the Bst polymerase. 
 
1.2.6. Reaction Product Detection 
 
Detection of reaction products from the PCR and LAMP reactions was carried out primarily by 
electrophoresis, using 1.5% w/v agarose gels with transillumination and photography provided by a 
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BioRad Gel/Chem Doc system (Bio-Rad Inc, UK). LAMP reactions were also monitored in real-time 
using the ESEQuant Tube Scanner (Qiagen Inc, UK), through the FAM channel. The “Tube Scanner 
Studio” software package was used to analyse the real time data and produce a manually set 
threshold line for the purposes of determining time to amplification. For experiments involving a 
larger number of simultaneously carried out reactions, an ABI 7500 real-time PCR system was used 
for the amplification and detection of product. The ABI software was used to manually set a 
threshold line for the determination of cycle threshold (ct) values. 
 
1.2.7. Total nucleic acid extraction from E. coli culture using a magnetic silica based total nucleic 
acid extraction method. 
 
A 10ml sample of an overnight culture of E.coli K-12 in nutrient broth was added to 100ml of 
nutrient broth in a shaking incubator at 37oC. After 3 hours of incubation the OD600 of the culture 
was monitored every 30 minutes until an OD600 of 0.4 was reached, indicating the culture had 
entered growth phase and mRNA expression would subsequently be high.  
The extractions were carried out using a Kingfisher Ml automated nucleic acid extraction platform. A 
single 5 well strip was added to the Kingfisher Ml tray for each of the 3 extractions to be carried out. 
Each well of the strips was then filled with the correct buffer, according to Table 1.2: 
 
Well Buffer Volume (µl) Time in Buffer 
1 Lysis 750 + 10 Magnasil 10 mins 
2 Wash 1 750 30 secs 
3 Wash 2 750 30 secs 
4 Wash 3 750 30 secs 
5 H20 75 10 mins 
Table 1.2. Buffers, volumes and duration of each step of the extraction process automated by the 
KingFisher ML system. 
 
The composition of the standard buffers are shown in Tables 1.3. – 1.6; 
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X1 Lysis Buffer (101.5ml) 
Guanidinium isothiocyanate 50g 
0.1M Tris/HCl pH 6.4 42.5ml 
0.2M EDTA pH 8.0 9ml 
Isopropanol 50ml 
Table.1.3. The composition of the standard lysis buffer 
 
Wash Buffer 1: Isopropanol Wash (105ml) 
Isopropanol 25ml 
Ethanol 25ml 
H2O 50ml 
4M NaCl 5ml 
Table.1.4. The composition of wash buffer 1 
 
Wash Buffer 2: NEET Wash (105ml) 
Ethanol 50ml 
H2O 50ml 
4M NaCl 5ml 
Table.1.5. The composition of wash buffer 2. 
 
Wash Buffer 3: 75% Etoh (100ml) 
Ethanol 75ml 
H2O 25ml 
Table.1.6. The composition of wash buffer 3. 
 
200µl of the sample to be processed was then added to well 1 of each strip. The correct extraction 
programme was selected, and started. After elution, the eluted nucleic acid was removed and used 
in downstream applications, or stored at -80oC. 
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1.2.8. Agarose gel electrophoresis of nucleic acid 
 
Extracted nucleic acid was examined by electrophoresis, using 1.5% w/v agarose gels, containing 1µl 
of 1omg/ml ethidium bromide solution per 100ml of gel. Transillumination and photography was 
provided by a Gel/Chem Doc system (Bio-Rad Inc, UK). Aliquots of 8µl of nucleic acid was added to 
2µl of 5x DNA loading buffer (Bio-Rad Inc, UK). Electrophoresis was carried out at 80V for 90 
minutes. 
 
1.2.9. Quantification of nucleic acid 
 
DNA was quantified spectrophotometrically using Spectrostar plate reader in conjunction with an 
LVIS plate (BMG Labtech, UK). 
 
1.2.10. A comparison of thermal and chemical lysis methods for total nucleic acid extraction from 
E. coli culture 
 
A 10ml sample of an overnight culture of E. coli K-12 in nutrient broth was added to 100ml of 
nutrient broth in a shaking incubator at 37oC. After three hours of incubation the OD600 of the culture 
was monitored every 30 minutes until an OD600 of 0.4 was reached. Three 1ml samples of this 
culture was then taken; Samples A, B and C. Total nucleic acid was extracted from the samples 
according to the methodology detailed in section 1.2.7, with sample A remaining in the lysis buffer 
for 10 minutes, sample B remaining in the lysis buffer for 30 seconds, and sample C remaining in the 
lysis buffer for 30 seconds, after being heated to 95oC for one minute in a waterbath. 50µl of 
extracted RNA was taken from each sample and visualised on a 2% agarose gel stained with 
ethidium bromide, in order to assess RNA integrity and relative quantity. 
 
1.2.11. Initial evaluation of the effect of chaotropic salt on lysis buffer performance 
 
Nucleic acid extractions were carried out from a cell suspension of N. gonorrhoeae (1 x 105 CFU/ml) 
in urine, using the Kingfisher ML system. Extractions were carried out using the standard guanidine 
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isothiocyanate lysis buffer, a lysis buffer containing an equal molarity of guanidine hydrochloride in 
place of the guanidine isothiocyante, and the guanidine hydrochloride lysis buffer with a 95oC pre 
heating step. The composition of the guanidine hydrochloride lysis buffer is shown in Table 1.7. Five 
replicates were carried out for each lysis buffer.  
Component 
Weight/Volume of components 
GuCN buffer GuHCl buffer 
Guanadine isothiocyante 10g  
Guanadine hydrochloride  8.12g 
0.1M Tris/HCl pH 6.4 8.5ml 8.5ml 
0.2M EDTA pH 8 1.8ml 1.8ml 
Isopropanol (IPA) 10ml 10ml 
Guanadine molarity (buffer) 3.86 M 3.86 M 
Guanidine molarity (final) 3.05 M 3.05 M 
Table.1.7. Composition of the guanidine isothiocyante and guanidine hydrochloride based lysis 
buffers 
 
The extracted nucleic acid from each extraction was then assayed for the presence of N. 
gonorrhoeae nucleic acid using the GC GroEL LAMP assay, and reactions were monitored in real-time 
using a Qiagen ESEQuant Tubescanner. 
 
1.2.12. Effect of guanidine hydrochloride lysis buffer and thermal lysis on a range of dilutions of N. 
gonorrhoeae cell suspension in urine. 
 
Nucleic extractions were carried out on 200µl aliquots of N. gonorrhoeae cell suspension in urine, 
with cell concentrations of 1 x 104, 1 x 103, 1 x 102 and 10 CFU per 200µl, using the guanidine 
isothiocyante based lysis buffer, and the guanidine hydrochloride  buffer with a 95oC 30 second heat 
step either before or after the addition of the sample. These extractions were carried out in 
triplicate for each lysis method, from each dilution of cell suspension. Extracted nucleic acid was 
assayed for the presence of N. gonorrhoeae using the GC GroEL LAMP assay, which was monitored in 
real-time using an ABI-7500. The amplification times were compared to given an indirect 
measurement of the nucleic acid yield and integrity produced using each lysis method.  
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1.2.13. Effect of the duration of the 95oC heating step during lysis on the yield of nucleic acid and 
LAMP amplification time 
 
Nucleic extractions were carried out on 200µl aliquots of N. gonorrhoeae cell suspension in urine, 
with cell concentrations of 1 x 104, 1 x 103, 1 x 102 and 10 CFU per 200µl, using the guanidine 
isothiocyante based lysis buffer, and the guanidine hydrochloride buffer with a 95oC 30 second heat 
step either before or after the addition of the sample. These extractions were carried out in 
triplicate for each lysis method, from each dilution of cell suspension. Extracted nucleic acid was 
assayed for the presence of N. gonorrhoeae using the GC GroEL LAMP assay, which was monitored in 
real-time. The amplification times were compared to given an indirect measurement of the nucleic 
acid yield and integrity produced using each lysis method.  
 
1.2.14. Effect of GuHCl concentration on concentration and quality of extracted DNA 
 
In order to determine the optimal guanidine hydrochloride concentration, nucleic acid extractions 
were carried out from a N. gonorrhoeae cell suspension in urine (1 x 106 CFU/ml) using lysis buffers 
containing guanidine hydrochloride concentrations of 3.5M, 4M, 4.5M, 5M, 5.5M, and 6M. The final 
concentrations after the addition of the sample are shown in Table 1.8.  
 
GuHCl buffer concentration (M) Final GuHCl concentration (M) 
6 4.74 
5.5 4.35 
5 3.95 
4.5 3.55 
4 3.15 
3.5 2.76 
Table 1.8. The final guanidine hydrochloride concentration in the lysis reaction, corresponding to the 
buffer concentration. 
 
The extracted nucleic acid was quantified spectrophotometrically, and the 260nm/280nm ratio was 
taken as a measure of purity. 
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1.2.15. Buffer component concentrations  
 
In order to determine whether the EDTA or Tris/HCl concentrations in the lysis buffer could be 
reduced without negatively effecting the yield or purity of the extracted nucleic acid, lysis buffers 
containing reduced volumes of these components were tested. nucleic acid extractions were carried 
out in triplicate from a N. gonorrhoeae cell suspension in urine (1 x 106 CFU/ml) using lysis buffers 
containing 100%, 75%, 50% 25%, and 0% of the original volume of 0.2M EDTA (Table 4). 
 
Component 
Weight/Volume of components 
100% EDTA 75% EDTA 50% EDTA 25% EDTA 0% EDTA 
Guanadine hydrochloride 8.12g 8.12g 8.12g 8.12g 8.12g 
0.1M Tris/HCl pH 6.4 8.5ml 8.5ml 8.5ml 8.5ml 8.5ml 
0.2M EDTA pH 8 1.8ml 1.35ml 0.9ml 0.45ml - 
Isopropanol (IPA) 10ml 10ml 10ml 10ml 10ml 
H2O - 0.45ml 0.9ml 1.35ml 1.8ml 
Table1.9. Composition of buffers tested with varying concentrations of EDTA 
 
Additionally, nucleic acid extractions were carried out in triplicate from a N. gonorrhoeae cell 
suspension in urine (1 x 106 CFU/ml) using lysis buffers containing 100%, 75%, 50% 25%, and 0% of 
the original volume of 0.1M Tris/HCl (Table 5). 
 
Component 
Weight/Volume of components 
100% 
Tris/HCl 
75% 
Tris/HCl 
50% 
Tris/HCl 
25% 
Tris/HCl 
0% 
Tris/HCl 
Guanadine hydrochloride 8.12g 8.12g 8.12g 8.12g 8.12g 
0.1M Tris/HCl pH 6.4 8.5ml 6.38ml 4.25ml 2.13ml - 
0.2M EDTA pH 8 1.8ml 1.8mll 1.8ml 1.8ml 1.8ml 
Isopropanol (IPA) 10ml 10ml 10ml 10ml 10ml 
H2O - 2.13ml 4.25ml 6.38ml 8.5ml 
Table 1.10. Composition of buffers tested with varying concentrations of Tris/HCl 
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Extracted nucleic acid was quantified spectrophotometrically, with the 260nm/280nm ratio used as 
a measure of purity. 
 
1.2.16. Comparison of 1x and 2x lysis buffer for total nucleic acid recovery from clinical C. 
trachomatis samples, using a silica based total nucleic extraction method. 
 
Nucleic acid extractions were carried out on 4 clinical C. trachomatis samples (2 positive urine 
samples, 1 positive endocervical swab sample, 1 negative urine sample), using the silica based total 
nucleic acid extraction method with both the standard 1x lysis buffer, and a 2x concentrated buffer. 
All extractions were tested for the presence of C. trachomatis nucleic acid with the CT-0332 LAMP 
assay. 
 
1.2.17. Robustness of nucleic acid extraction method in the presence of inhibitory compounds 
 
Nucleic acid extractions were carried out on 100µl aliquots of a suspension of N. gonorrhoeae cells in 
urine (1 x 105 CFU/ml), which were spiked with varying concentrations of whole blood, E. Coli 
culture, or bovine serum albumin (BSA) in 100µl volumes. The red blood cell content in whole 
defibrinated horse blood was quantified using an improved Neubauer haemocytometer. The 
extractions containing blood included 100µl of whole blood containing a concentration of red blood 
cells ranging from 5.5 x 107 to 5.5 x 103. The extractions containing E. coli cells included a range of 
1:10 dilutions of E. coli cell suspension in nutrient broth, from 1 x 108 CFU to 1 x 105 CFU per 100µl. 
The suspension of E. coli was diluted to an OD600 of 1 (determined to be 1 x 109 CFU per ml by a 
previously calibrated growth curve). For the reactions containing BSA, a BSA solution of 20mg/ml 
was created using distilled water. Dilutions of this stock solution were used in 100µl volumes to 
provide final BSA concentrations of 10mg/ml, 2mg/ml, 1mg/ml, 0.5mg/ml and 0.1mg/ml per 
extraction. Extractions were carried out from each sample, and the nucleic acid was tested using the 
GC GroEL LAMP assay for the presence of the N. gonorrhoeae specific target.  The reactions were 
monitored in real-time, and the speed of the reaction was used to examine for any inhibitory effects 
resulting from the inclusion of the potential inhibitory components in the extraction. Reactions were 
not carried out in duplicate or triplicate in order to conserve LAMP reagents. 
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1.2.18. Effect of lysis buffer lyophilisation on nucleic acid extraction 
 
Four 375µl aliquots of 2x lysis buffer were lyophilised in a freeze drier for 6 hours. The freeze dried 
buffer aliquots were then each rehydrated with 375µl of H2O. Magnetic silica based total nucleic acid 
extractions were then carried using the rehydrated lysis buffer from a sample of N. gonorrhoeae cell 
suspension in urine (2 x 106), in duplicate. Extractions were also carried out from the same samples 
using standard 2x lysis buffer, and from cell free water, using both lyophilised and liquid lysis buffer, 
as experimental controls.  5µl from each extracted nucleic acid sample was taken and tested for the 
presence of amplifiable N. gonorrhoeae nucleic acid using the GC GroEL LAMP assay, and the 
reactions were monitored in real-time to determine the presence of any inhibitory effect stemming 
from the use of the freeze dried buffer. 
 
1.2.19. Tablet Manufacture 
 
The lysis tablets were rehydrated with 1ml of sample, and in order to ensure the final GuHCl 
concentration was 3.6M, equal to that of the final concentration of GuHCl obtained using the 2x lysis 
buffer and 200µl sample, the water volume and GuHCl weight was adjusted. The components of the 
2x lysis buffer, and composition of the buffer needed for the 1ml lysis tablets are shown in table 1.11 
and table 1.12, respectively. 
 
 
 
 
 
 
 
 
 
73 
 
Component Weight/Volume 
GuHCl 8.3g 
1M Tris/HCl pH 6.4 0.85ml 
0.2M EDTA pH 8 0.9ml 
H2O 3.2ml 
IPA 5.15ml 
Total measured volume 15.75ml 
GuHCl molarity 5.52M 
GuHCl weight in 1ml 529.3mg 
GuHCl weight in 375µl 197.7mg 
GuHCl molarity in 375µl + 200µl sample 3.6M 
Table 1.11. Composition of the 2x GuHCl lysis buffer 
 
Component Weight/Volume 
GuHCl 8.12g 
1M Tris/HCl pH 6.4 0.85ml 
0.2M EDTA pH 8 0.9ml 
H2O 3.4ml 
H2O (IPA replacement) 5.15ml 
Total measured volume 15.75ml 
GuHCl molarity 5.4M 
GuHCl weight in 1ml 515.8mg 
GuHCl molarity in 1.5ml 3.6M 
Table 1.12. Composition of the 2x GuHCl tablet lysis buffer 
 
To produce lysis tablet 1, aliquots of 5ml of the GuHCl tablet lysis buffer were frozen at -80oC for 24 
hours, and then freeze dried. This freeze dried powder was then weighed into 516mg amounts, 
which were then individually compressed using an F3 single-station tablet press (Manesty, UK), using 
a 12.4mm diameter bevel edged punch and die set. The machine was manually operated by filling 
the die and manually turning the fly wheel through a full compression cycle. Tablets were 
individually stored in sealed plastic bags until use. 
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To produce lysis tablet 2, freeze dried GuHCl lysis buffer (Table 7) was taken and mixed with a range 
of excipients (Table 8). The excipients and ratios chosen are a basic mix that has been optimised by 
researchers in the School of Pharmacy.  
This powder was weighed into 516mg amounts and then compressed into tablets using the same 
method as used during the manufacture of tablet 1. This produced a tablet with the same weight 
and size as tablet 1, but 50% of the active buffer component, meaning two tablets would be needed 
per extraction from a 1ml sample volume.  
 
 
Table 1.13. Composition of lysis tablet 2 
 
1.2.20. Initial test of tablet performance 
 
Nucleic acid extractions were carried out from a suspension of N. gonorrhoea in urine (2 x 106) and a 
reduced density cell suspension (2 x 102), using standard liquid lysis buffer, lyophilised lysis buffer, 
lysis tablet 1, and lysis tablet 2. Extractions using the liquid reagent were carried out as previously 
described.  
During the extraction using the lysis tablets, a single lysis tablet 1, or two lysis tablet 2’s were added 
to 1ml of the cell suspension, and 0.5ml of IPA, in a bijoux. The bijoux was gently agitated for 5 
seconds in order to fully dissolve the tablet. A 1ml aliquot of this suspension was then added to the 
first well of a Kingfisher ml extraction strip, along with 10µl of MagnaSil beads. Although this method 
effectively reduced the volume of urine sample in the extraction from 1ml to 660µl, it is still 
preferable to attempting to carry out the extractions manually using a magnet, due to the 
unacceptably high loss of MagnaSil beads. The samples were then extracted using the KingFisher, as 
per the standard protocol. This methodology was also used for the lyophilised buffer. Extracted 
nucleic acid was assayed using the GC GroEL LAMP assay, and reactions were monitored in real-time. 
 
Component Weight 
Freeze dried 2x GuHCl tablet lysis buffer  (active ingredient) 50% 
Lactose (bulking agent) 46% 
Explotab (disintegrant) 3% 
Mag st (lubricant) 1% 
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1.2.21. Lysis buffer pellets  
 
Component Weight/Volume 
for 1ml tablet 1 
Weight/Volume 
for 790µl pellet 
GuHCl 8.12g 13g 
1M Tris/HCl pH 6.4 0.85ml 1.65ml 
0.2M EDTA pH 8 0.9ml 1.75ml 
H2O 3.4ml 3.4ml 
H2O (IPA replacement) 5.15ml 5.15ml 
Total measured volume 15.75ml 20ml 
GuHCl molarity 5.4M 6.8M 
GuHCl weight in 1ml (700µl for tablet 2) 515.8mg 515.8mg 
GuHCl molarity in 1.5ml 3.6M 3.6M 
Table 1.14. Comparison of the composition of the 1ml lysis tablet and 790µl lysis pellet buffers 
 
The 790µl lysis pellet buffer was formulated using the components shown in Table 1.14, in order to 
provide an equal final concentration of reagents as the 1ml lysis tablet, whilst reducing the volume 
of lysis buffer required, and the size of the pellet. 
The lysis pellet buffer was frozen overnight at -80oC in 700µl aliquots in plastic circular moulds 
(2.7cm diameter). These moulds were then placed in the cold chamber of a freeze drier, and freeze 
dried for 24 hours.  Extractions were then carried out using the same methodology as that used with 
the lysis pellets, using one lysis pellet with a 1ml aliquot of sample and 0.5ml of IPA, on N. 
gonorrhoeae cell suspension with concentrations of 1 x 102, 1 x 103, 1 x 104, and 1x 105 CFU per ml. 
Extractions were also carried out on the same suspensions using standard liquid lysis buffer. 
Extractions were carried out for each dilution of N. gonorrhoeae in triplicate and then tested using 
the GC GroEL LAMP assay. Reactions were monitored in real-time using an ABI 7500 rather than the 
ESEQuant, in order to be able to run all assays simultaneously using the same reaction mix. The time 
to amplification of the assay was examined in order to determine any effect on the assay speed 
resulting from the use of the lysis pellets. 
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1.2.22. Lyoprotectants 
 
Lysis buffer pellets were manufactured containing lyoprotectants at arrange of concentrations. The 
lyoprotectants were added as solutions during the manufacture of the liquid lysis buffer, and the 
volume of water added was reduced to account for this. Lysis buffers containing 0%, 1%, 2%, 4%, 8%, 
and 10% polyvinylpyrrolidone (PVP) were made, along with lysis buffers containing 5%, 10% and 15% 
Lyo B, and 5%, 10% and 15% Lyo D. Aliquots of 790µl of these buffers were frozen at -80oC for 24 
hours, in plastic cylindrical moulds with a 2.7cm diameter.  The frozen buffer was then freeze dried 
in the temperature controlled chamber of a Lyotrap freeze drier (LTE) for 24 hours. Extractions were 
carried out using each pellet, following the same methodology as that used previously for the lysis 
pellets, using N. gonorrhoeae suspension in urine (1x 105 CFU per ml). Triplicate extractions were 
carried out for each variety of pellet. The GC GroEL LAMP assay was used to amplify target nucleic 
acid in the extracted samples. The time to amplification in each assay was monitored and compared, 
to test for any inhibitory effect of the various tablet compositions. 
 
1.2.23. Lyoprotectants: PEG 
 
Volumes of the lysis pellet buffer were produced, including varying concentrations of PEG 8000; 0%, 
1%, 2%, 4%, 8%, 10%. The PEG 8000 was added as a solution, and the volume of water added to 
make the buffer up to the correct volume was reduced to account for this. The lysis buffers were 
frozen in individual 790µl aliquots in plastic cylindrical moulds with a 2.7cm diameter, at -80oC for 24 
hours. The frozen buffer was then freeze dried in the refrigerated chamber of a Lyotrap freeze drier 
(LTE) for 24 hours.  
 
1.2.24. Swab performance 
 
An evaluation of the ability of three swab types to recover N. gonorrhoeae cells from a cell 
suspension of varying concentration was carried out. The swabs used for the test were; flocked 
swabs, Sterilin cotton swabs, and Copan cotton swabs. A series of 1:10 dilutions of N. gonorrhoeae 
O/N culture (Brain heart infusion media) were carried out, and 10µl of each dilution was transferred 
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to chocolate agar (in triplicate), to enable quantification of viable cells using the Miles & Misra 
method. Volumes of 10ml were used for each dilution.  
For each swab to be tested, 3x 1ml aliquots of each cell suspension were taken in eppendorf tubes. 
A swab was then placed into a tube and slowly rubbed up and down for 10 seconds. This swab was 
then removed, entered into a 1ml aliquot of sterile BHI media, and rubbed up and down for 10 
seconds, before being disposed of. This media was then vortexed briefly, and 10µl of the media was 
transferred a chocolate agar plate (in triplicate) and left to air dry. The plates were then transferred 
to the incubator, at 37oC and 5% CO2. This process was repeated for all further dilutions of cell 
suspension. Colonies were then counted in order to work out the CFU/ml of the inoculated transport 
media, and then compared to the CFU/ml of the starting suspension in order to give the recovery 
rate. 
 
1.2.25. Effect of Vortexing speed on swab recovery 
 
An experiment was carried out in order to determine the effect of vortexing during the elution of the 
swab in transport media, on recovery rates. Copan flocked swabs were used to collect cells from 1ml 
aliquots of N. gonorrhoeae liquid culture (2x106 cells per ml). Total viable counts were performed 
using the initial cell suspension. The swabs were then placed in 1ml aliquots of Copan transport 
media, and vortexed at either 500rpm or 1000rpm for five seconds. Swabs that were left for five 
seconds without vortexing were used as a control. Total viable counts were then carried out using 
the transport media, in order to determine the overall recovery rate. 
 
1.2.26. Swab buffer performance 
 
An evaluation of three possible transport media were carried out, in order to determine which 
would give the optimum recovery rate from the Copan flocked swab. The three media tested were 
Copan Universal Transport Medium (UTM), PBS, and PBS tween (0.02% Tween 80). A N. gonorrhoeae 
cell suspension of 8.5 x 106 CFU/ml was serially diluted to 8.5 x 103 CFU/ml. Copan flocked swabs 
were used to collect cells from 1ml aliquots of each dilution, and then eluted into the various 
transport media, in triplicate. Total viable counts were then performed to determine the effect of 
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the transport media composition on organism elution, and overall recovery. Vortexing was not used 
to improve the capture rate, as the project partners were still undecided whether vortexing could be 
a viable option. 
 
1.2.27. Evaluation of the use of lysis buffer as swab transport media 
 
Copan flocked swabs were used to collect cells from 1ml aliquots of N. gonorrhoeae broth culture of 
three concentrations; 1 x 106 CFU per ml, 1 x 105 CFUper ml and 1 x 104 CFU per ml, in triplicate. The 
swabs were then taken and placed in either 1ml aliquots of 1x GuHCl lysis buffer or Copan transport 
media. Total nucleic acid extractions were carried out using 200µl of either the lysis buffer or 
transport media, using the KingFisher platform. The extracted nucleic acid from each sample was 
then assayed using the GC GroEL LAMP assay, monitored in real time using an ABI 7500. 
 
1.2.28. Comparison of the effect of swab incubation time in lysis buffer and Copan transport 
media 
 
Copan flocked swabs were used to collect cells from 1ml aliquots of N. gonorrhoeae liquid culture 
(2x106 cells per ml).  The swabs were then taken and placed in either 1ml aliquots of lysis buffer or 
Copan transport media, and then incubated for variable time periods (0, 10, 20, or 30 minutes).  
Total nucleic acid extractions were carried out using 200µl of either the lysis buffer or transport 
media, using the KingFisher platform. The extracted nucleic acid from each sample was then assayed 
using the GC GroEL LAMP assay, monitored in real time using an ABI 7500. 
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1.3. Results 
1.3.1. Total nucleic acid extraction from E. coli culture using a magnetic silica based total nucleic 
acid extraction method. 
 
The nucleic acid extraction method initially under investigation was a magnetic silica based 
extraction system, capable of extracting and purifying both RNA and DNA from microbial cells. The 
process involved the addition of the sample to a lysis buffer containing guanidine salt, which 
simultaneously breaks open the cells and protects the released nucleic acid from nuclease activity 
via its reducing activity. Magnetic silica beads present in the buffer bind released nucleic acid, which 
are then moved between various wash buffers by magnetic forces, facilitating the removal of protein 
contaminants which may have an inhibitory effect on the downstream LAMP reaction. It is important 
that the extraction method is capable of purifying both undegraded genomic DNA, and RNA from the 
urine and swab samples that will be tested. The LAMP assays to be used may amplify RNA 
sequences, via the incorporation of reverse transcriptase, which can lead to increased assay 
sensitivities via the increased starting copy number often afforded by the use of an RNA target.  
E.coli was used in place of N. gonorrhoeae, which was used throughout the extraction development 
process as E. coli can be grown to high cell densities, and is highly metabolically active. E. coli o/n 
culture contains more DNA, and RNA than an equivalent N. gonorrhoeae culture, enabling a better 
determination of nucleic acid quality via gel electrophoresis. 
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Fig.1.4. Agarose gel electrophoresis (1.5%) of total nucleic acid extractions from E.coli culture, using 
the magnetic silica based extraction method. Bands representing 23S rRNA, 16S rRNA and genomic 
DNA are indicated. Hyperladder II (Bioline) used as marker for fragment size. 
The extracted genomic DNA could be seen as a distinct high molecular weight (>10kbp) band, 
indicating the extraction of unfragmented genomic DNA from the sample (Fig.1.4).  
A bright band could also be seen inside the loading well on the gel. This is likely to be cellular 
proteins from the extraction, which are unable to pass through the agarose gel due to their large 
size. Positively charged proteins could bind to the negatively charged DNA, which would in turn bind 
to ethidium bromide molecules in the gel, producing a fluorescent band when exposed to the UV 
light source.  
The two bright bands at 2904bp and 1541bp indicate the 23s and 16s ribosomal RNA subunits 
respectively. The 23s and 16s bands were sharp and unbroken, with equal intensity. The integrity 
and ratio between these two bands are important indicators of overall RNA integrity (Jahn et al., 
2008). 
A light smearing could be seen between the 1000bp and 100bp mark. This could be degraded 
portions of the 23s or 16s fragments, or indicative of the population of low weight undegraded 
mRNA. 
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1.3.2. A comparison of thermal and chemical lysis methods for total nucleic acid extraction from E. 
coli culture 
 
In the magnetic silica based total nucleic acid extraction protocol, the bacterial cells were initially 
lysed in a lysis buffer containing guanidine isothiocyanate and Triton X-100, which act to break open 
the cell membranes and release intracellular nucleic acid. An alternative method would be thermal 
lysis, which uses rapid heating, typically to 95oC, to break open any cells in the sample. Thermal lysis 
is a more rapid process than chemical lysis, however the heat can act to degrade released RNA, 
which would reduce the available LAMP template, if the assay is designed for an RNA target. The 
effect of a 30 second 95oC heat step, followed by a 30 second incubation, on the relative yield and 
purity of extracted nucleic acid was examined. 
 
Fig.1.5. Agarose gel electrophoresis (1.5%) showing comparison of nucleic acid concentration and 
integrity obtained from E. coli using chemical lysis and thermal lysis during the nucleic acid 
extraction procedure. Well A was loaded with 30µl of extracted DNA from cells lysed via a 10 minute 
lysis buffer incubation. Well B was loaded with 30µl of extracted DNA from cells lysed via a 1 min 
lysis buffer incubation. Well C was loaded with 30µl of extracted DNA from cells lysed via a 30 
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second 95oC heat treatment, followed by a 30 second incubation in lysis buffer. Bands representing 
23s rRNA and 16s rRNA are indicated. Hyperladder II (Bioline) used as marker for fragment size. 
In all three samples the genomic DNA, 16s rRNA, and 23s rRNA bands appear as sharp bands, 
showing a low level of degradation during the extraction process (Fig.1.5). Sample C (nucleic acid 
extracted from cells lysed by a 30 second heat treatment of 95oC, followed by a 30 second 
incubation in lysis buffer) yielded a larger level of both DNA and RNA relative to samples A and B, 
evidenced by brighter fluorescence of the genomic DNA and rRNA bands. 
The genomic DNA and rRNA bands of Sample A, nucleic acid extracted from cells lysed by a 10 
minute buffer incubation, exhibited fluorescence similar to those of sample B, in which the cells 
were only exposed to lysis buffer for 1 minute. 
1.3.3. Initial evaluation of the effect of chaotropic salt on lysis buffer performance 
 
The use of heat during the lysis process produced a high yield of nucleic acid, whilst having no 
negative effects on RNA or DNA integrity (Fig.1.5). In the original lysis buffer, the lytic agent was 
guanidine isothiocyanate, a potent chaotropic salt which in addition to lysing cells in the sample also 
reduces proteins, preventing endonuclease activity. If complete cellular lysis could be achieved by 
heating the sample, then guanidine isothiocyanate could be replaced with guanidine hydrochloride, 
which is a less potent lytic agent, but would still provide protection from nucleic acid degradation. 
Guanidine hydrochloride is a safer compound than guanidine isothiocyante, which can produce 
hydrogen cyanide gas when mixed with bleach, and the inclusion of this chemical could lead to less 
stringent regulations on the use of the test. 
A guanidine hydrochloride based lysis buffer, containing the same molarity of chaotropic salt as the 
previously used guanidine isothiocyanate buffer, was produced (Table 1.15). The performance of this 
buffer, with and without a 95oC heat step, was tested alongside the guanidine isothiocyanate lysis 
buffer. 
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Component 
Weight/Volume of components 
GuCN buffer GuHCl buffer 
Guanadine isothiocyante 10g  
Guanadine hydrochloride  8.12g 
0.1M Tris/HCl pH 6.4 8.5ml 8.5ml 
0.2M EDTA pH 8 1.8ml 1.8ml 
Isopropanol (IPA) 10ml 10ml 
Guanadine molarity (buffer) 3.86 M 3.86 M 
Guanidine molarity (final) 3.05 M 3.05 M 
Table.1.15. Composition of the guanidine isothiocyante and guanidine hydrochloride based lysis 
buffers  
 
Fig.1.6. The average time to amplification in the GC GroEL LAMP assay from nucleic acid extracted 
from a suspension of N. gonorrhoeae (1 x 105 CFU/ml) in urine, using the various lysis methods. Error 
bars represent the range of 5 replicates. 
The time to amplification in the LAMP assay from nucleic acid extracted using the different lysis 
methods remained constant, with an average time to amplification of 21.9, 22.4 and 21.6 minutes 
when nucleic acid extracted using the guanidine isothiocyanate buffer, guanidine hydrochloride 
buffer, and guanidine hydrochloride buffer with a pre-heating step, respectively (Fig.1.6). The range 
between the replicates was smaller for the reactions carried out on extractions using the guanidine 
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isothiocyante buffer (20.9 – 23.3 minutes), than those using the guanidine hydrochloride buffer 
(24.9 – 19 minutes) or the guanidine hydrochloride buffer with heating step (19.1 – 24.3 minutes). 
 
1.3.4. Effect of guanidine hydrochloride lysis buffer and thermal lysis on a range of dilutions of N. 
gonorrhoeae cell suspensions in urine 
 
One question regarding the use of thermal lysis that would need to be addressed is whether it is 
necessary to heat the sample in the presence of the lysis buffer, or whether it is optimal to heat the 
sample before the sample and lysis buffer are mixed. 
 
Fig.1.7. The effect of lysis method used during nucleic acid extraction from various concentrations of 
N. gonorrhoeae cell suspension on the subsequent time to amplification in the GC GroEL LAMP 
assay. 
 
The shortest average time to amplification in the GroEL LAMP assay for each concentration of cell 
suspension was generated from nucleic acid extracted using the guanidine hydrochloride buffer and 
a pre mixing heat treatment (Fig.1.7). Compared to the use of guanidine isothiocyanate based 
buffer, the average times to amplification were 8.7, 5.6, 2.1 and 2.4 minutes shorter for the 
extractions containing 10, 1 x 102, 1 x 103, and 1 x 104 cells per reaction, respectively. The percentage 
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time difference between the use of the guanidine hydrochloride lysis buffer with pre heating, 
compared with the use of guanidine isothiocyanate lysis buffer and guanidine hydrochloride buffer 
with simultaneous heating are shown in Tables 1.15 and 1.16, respectively. 
 
Organism load (per 
200µl) 
Average time to amplification in GroEL LAMP 
assay (Minutes) 
Time difference (%) 
GuHCl - Heated 
sample 
GuCN 
10,000 17.5 19.9 +13.7 
1,000 21.7 23.8 +9.7 
100 23.1 28.7 +24.2 
10 22.6 31.3 +38.5 
Table 1.16. Comparison of the average time to amplification in the GroEL LAMP assay using N. 
gonorrhoeae nucleic acid extracted using a guanidine hydrochloride lysis buffer and 95oC pre 
heating step, and nucleic acid extracted using a guanidine isothiocyante lysis buffer. 
 
Organism load (per 
200µl) 
Average time to amplification in GroEL LAMP 
assay (Minutes) 
Time difference (%) 
GuHCl - Heated 
sample 
GuHCl - heated sample 
+ Buffer 
10,000 17.5 25.9 +48 
1,000 21.7 31.5 +45.2 
100 23.1 43.3 +87.4 
10 22.6 39.9 +76.5 
Table 1.17. Comparison of the average time to amplification in the GroEL LAMP assay using N. 
gonorrhoeae nucleic acid extracted using a guanidine hydrochloride lysis buffer and 95oC pre 
heating step, and nucleic acid extracted using the same lysis buffer with a simultaneous heating 
step. 
 
Compared with the use of the guanidine hydrochloride buffer and pre heating, amplification 
occurred 48.1% and 37.5% later when a simultaneous heating step or guanidine isothiocyanate lysis 
buffer were used, respectively (Table 1.16, Table 1.17). When extracting from the samples with the 
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lowest organism load tested, the difference in performance was more pronounced, with the pre 
heating method leading to an average amplification time of 22.6 minutes, compared with 39.85 
minutes (a 76.32% increase in time to amplification) and 31.3 minutes (a 38.4% increase) when using 
a simultaneous heating step or guanidine isothiocyanate lysis buffer, respectively. 
The extractions carried out utilising the heating of sample and guanidine hydrochloride buffer 
together generated the longest time to amplification during the LAMP assay, for all N. gonorrhoeae 
concentrations tested. This is indicative of either a reduced yield of nucleic acid from the extraction, 
or a reduction in the quality of nucleic acid obtained, caused by the degradation of the DNA or RNA. 
It is unlikely that the delay in time to amplification could be attributed to the insufficient removal of 
inhibitory compounds, as the efficiency of the wash steps is the critical parameter in the removal of 
impurities, rather than the lysis method.  
 
1.3.5. Effect of the duration of the 95oC heating step during lysis on the yield of nucleic acid and 
LAMP amplification time 
During the thermal lysis protocol, the sample is heated to 95oC before entering the lysis buffer. The 
duration of this heating step requires optimisation, to ensure that the sample is not heated for 
longer than is necessary. An increased duration of heating will increase the time needed to carry out 
the extraction, the power requirements of the test, and the likelihood that thermal degradation will 
occur to the DNA and RNA present in the sample. 
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Fig.1.8. The effect of the duration of heat treatment during lysis on the concentration of nucleic acid 
extracted, and the time to amplification in the resulting GC GroEL LAMP assays.  
 
The LAMP assay generated a detectable amplification from the nucleic acid extracted without a heat 
treatment after 16.6 minutes. A heat treatment of 10 and 20 seconds resulted in a decrease in this 
time to 15.2 and 15.9 seconds respectively (Fig.1.8).  An increase of the heating duration to 30 
seconds corresponded with a reduction in the time to amplification from 15.9 seconds to 14 
seconds. Further heating after this point had no effect on the time to amplification. 
The concentration of nucleic acid purified from the sample without heating was 21.9ng/µl, which 
increased as the heating duration increased, to 23.3ng/µl after 20 seconds and 25.9ng/µl after 50 
seconds (Fig.1.8). 
 
1.3.6. Effect of GuHCl concentration on concentration and quality of extracted DNA 
 
A key element of the lysis buffer requiring optimisation is the concentration of guanidine 
hydrochloride. Guanidine hydrochloride concentration is likely to have a sizeable effect on adequate 
prevent of degradation by endogenous nuclease enzymes, and also the binding of DNA and RNA to 
the magnetic silica particles responsible for the capture and concentration of nucleic acids.  
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Fig.1.9. The effect of the final guanidine hydrochloride concentration in the lysis buffer and sample 
on the concentration and purity of eluted nucleic acid, extracted from a suspension of N. 
gonorrhoeae (1 x 106 CFU/ml). Error bars indicate the range of three replicates. 
The guanidine hydrochloride concentration had an effect on both the yield and purity of the nucleic 
acid obtained (Fig.1.9). A final guanidine hydrochloride concentration of 3.15M to 3.55M, resulting 
from a buffer concentration of 4M to 4.5M produced the highest yield of nucleic acid, 20.2 and 
20.1ng/µl respectively. The only lower concentration tested, a final concentration of 2.76M, yielded 
15.6ng/µl. An increase in final concentration to levels above 3.55M corresponded with a reduction in 
yields, with final guanidine hydrochloride concentrations of 3.95, 4.35 and 4.74, resulting in yields of 
18ng/µl, 16.1ng/µl, and 17.5ng/µl respectively. The A260/A280 ratio, used as an indicator of nucleic 
acid purity, was highest for the nucleic acid extracted using a final guanidine hydrochloride 
concentration of 3.55M, at 1.7. Increasing the final guanidine hydrochloride concentration to 4.35M 
and above resulted in a sizeable decrease in the A260/A280 ratio, which reduced to 1.59. 
 
1.3.7. Buffer component concentrations  
  
The lysis buffer contains a volume of both 0.2M EDTA, and 0.1M Tris/HCl, primarily in order to 
regulate the acidity and osmotic concentration of the lysed sample.  A reduction in the 
concentration of these components would cause a minor decrease in the cost of production of the 
buffer, and would enable a reduction in the buffer volume required. 
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Fig. 1.10. The effect of the volume of 0.2M EDTA in the lysis buffer on the concentration and purity 
of eluted nucleic acid, extracted from a suspension of N. gonorrhoeae (1 x 106 CFU/ml). Error bars 
indicate the range of three replicates. 
The concentration of extracted nucleic acid showed little variation when the volume of 0.2M EDTA 
was varied between 0% and 100% of the standard volume, with a concentration range of 20.3ng/µl 
to 21.6ng/µl obtained over all EDTA volumes tested (Fig.1.10).  The 260/280 ratio also stayed 
relatively constant, ranging between 1.75 and 1.79 for all EDTA volumes tested. One replicate of the 
nucleic acid extracted with 25% of the standard EDTA volume contained a low concentration of 
nucleic acid (17.02ng/µl), and had a corresponding low 260/280 ratio of 1.69, however the 
remaining replicates at this concentration were markedly higher in concentration (22.33ng/µl, 
21.85ng/µl) and 260nm/280nm ratio (1.8, 1.76).  
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Fig.1.11. The effect of the volume of 0.1M Tris/HCl in the lysis buffer on the concentration and purity 
of eluted nucleic acid, extracted from a suspension of N. gonorrhoeae (1 x 106 CFU/ml). Error bars 
indicate the range of three replicates 
 
The variation of the Tris/HCl volume in the lysis buffer from 100% to 0% of its original concentration 
had negligible effect on nucleic acid yield, with the concentration of extracted nucleic acid ranging 
from 20.6 to 18.9 across all Tris/HCl volumes tested (Fig.1.11).  The average 260/280 ratio was seen 
to slightly decrease as the volume of Tris/HCl was decreased, with the 100% volume resulting in a 
260nm/280nm ratio of 1.76, compared with the 260nm/280nm ratio of 1.71 for nucleic acid 
extracted with the buffer containing 0% Tris/HCl.   
 
1.3.8. Comparison of 1x and 2x lysis buffer for total nucleic acid recovery from clinical C. 
trachomatis samples, using a silica based total nucleic extraction method. 
 
Typically, with regards to sample management in a microfluidic device, a reduction in fluid volume 
results in a reduction in the time taken to process the sample (Kent et al., 2010). A smaller volume is 
able to be manoeuvred through channels and between compartments at a faster rate, and smaller 
volumes can also be heated and cooled more rapidly, speeding up these components of the 
extraction process. A 2x concentrated lysis buffer would enable a 50% reduction in lysis buffer 
volume, whilst retaining the concentration of active buffer components, and therefore buffer 
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activity. In order to examine any impact an increase in concentration would have on lysis buffer 
efficiency, extractions were carried out on three clinical samples using both the standard 1x buffer 
and a 2x concentrated buffer. Higher concentrations of buffer proved unfeasible, as the components 
would not solubilise in the reduced volumes. 
Nucleic acid extractions were carried out on 4 clinical C. trachomatis samples supplied by Public 
Health England South West (2 positive urine samples, 1 positive endocervical swab sample, 1 
negative urine sample), using the silica based total nucleic acid extraction method with both the 
standard 1x lysis buffer, and a 2x concentrated buffer. All extractions were tested for the presence 
of C. trachomatis nucleic acid with the CT-0332 LAMP assay. 
 
 
Fig.1.12. LAMP reaction amplification plot showing a comparison of the use of 1x and 2x 
concentrated lysis buffer during the nucleic acid extraction process. DNA extractions using both 
buffers were carried out with 2 clinical C. trachomatis positive urine samples (S 1 & S 2) and 1 
endocervical swab sample (S 3). Extractions were then tested for the presence of C. trachomatis 
nucleic acid using the CT-0332 assay. A C. trachomatis negative clinical urine sample was used as a 
negative control. 
For each clinical sample the use of both 1x and 2x lysis buffer during the extraction process yielded 
identical amplification times during the LAMP reaction (Fig.1.12). The fluorescence intensity and 
curve exhibited during the LAMP reaction of nucleic acid extracted from samples 1 and 2 were 
identical when either lysis buffer was used. For sample 3, an increase in fluorescence intensity was 
92 
 
detected during the LAMP reaction when the 1x buffer was used, although this is likely to have been 
caused by reasons other than nucleic acid concentration or purity, such as a pipetting error 
introducing an increased volume of reaction mix, and therefore fluorophore. 
 
1.3.9. Robustness of nucleic acid extraction method in the presence of inhibitory compounds 
 
Clinical samples contain a number of potential inhibitors of nucleic acid amplification, which need to 
be adequately removed during the extraction process in order to avoid any negative effects on the 
amplification reaction. Whilst LAMP is known to have a higher tolerance to a range of inhibitors than 
PCR, the exact tolerances are unknown. Also, the majority of studies have used end-point LAMP to 
investigate whether the LAMP reaction can generate a positive amplification in the presence of an 
inhibitor, and not determined any effect on amplification using real-time monitoring.  
Nucleic acid extractions were carried out on 200µl aliquots of a suspension of N. gonorrhoeae cells in 
urine (1 x 105 CFU/ml), which were spiked with varying concentrations of whole blood (Table 1.18), 
E. coli culture (Table 1.19), or bovine serum albumin (BSA) (Table 1.20). 
Clinical urine samples can contain whole blood, originating from bacterial infection of the genital 
tract. Additionally, high vaginal or endocervical swab samples can contain significant levels of blood 
during menstruation, which would enter in the nucleic acid extraction system and require removal 
before amplification. Lysed red blood cells contain a number of proteins that can interfere with PCR 
amplification, and therefore potentially LAMP amplification, principally haemoglobin and lactoferrin. 
Blood plasma also contains inhibitory proteins.  
Extractions were carried out containing varying dilutions of whole defibrinated horse blood, and the 
red blood cells per ml were  quantified. A range of between 5.5x107 (representing a 50:50 dilution of 
whole blood and culture) and 5.5x103 red blood cells per extraction were investigated. 
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Sample RBC count Result 
Time to amplification 
(mins) 
RBC 1 5.5x107 POSITIVE 12.6 
RBC 2 5.5x106 POSITIVE 11.6 
RBC 3 5.5x105 POSITIVE      11 
RBC 4 5.5x104 POSITIVE                   11.3 
RBC 5 5.5x103 POSITIVE                  11.6 
Positive 0 POSITIVE 11.3 
Negative 0 NEGATIVE - 
Table 1.18. Time to amplification in the GC GroEL LAMP assay from nucleic acid extracted from N. 
gonorrhoeae cell suspension (1 x 105 CFU/ml), in combination with varying concentrations of whole 
defibrinated horse blood. 
 
The LAMP assay was able to detect the N. gonorrhoeae target from nucleic acid extracted from 
samples containing all of the concentrations of whole blood tested (a 50:50 sample:whole blood 
mix). This level is far higher than would be expected in any urine or genital swab sample. There was 
no effect on the LAMP amplification caused by the presence of 5.5x103 to 5.5x106 RBC’s per ml, with 
all samples generating an amplification within +/- 0.3 minutes of the positive control extraction 
containing no blood component. The sample containing 5.5x107 RBC’s per ml, generated a signal 1 
minute later than the positive control. (Table 1.18).  
An additional consideration when evaluating the performance of the extraction method in the 
presence of various inhibitors, is the effect that excess non-target cells, and particularly non-target 
DNA will have on the yield and purity of target DNA acquired. Swab and urine samples are both likely 
to contain a proportion of human cells, commensal bacteria, and possibly very high concentrations 
of pathogenic bacteria, in the case that a urethral infection with these organisms has resulted in the 
test for a sexually transmitted infection.  Excess non target nucleic acid will passively compete with 
target nucleic acid for binding space on the silica surface of the magnetic beads, and an excess of 
non target nucleic acid in the LAMP reaction could reduce the likelihood of the initial priming event 
necessary to instigate LAMP amplification. 
Extractions were carried out on a 50:50 mixed sample of N. gonorrhoeae (1 x 105 CFU/ml), and E. coli 
culture of varying concentrations. 
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Sample E. coli count (CFU) Result 
Time to amplification 
(mins) 
E. coli 1 1x108 POSITIVE 13.3 
E. coli 2 1x107 POSITIVE 11.3 
E. coli 3 1x106 POSITIVE     12 
E. coli 4 1x105 POSITIVE                   13 
Positive 0 POSITIVE 12.3 
Negative 0 NEGATIVE - 
Table 1.19. Time to amplification in the GC GroEL LAMP assay from nucleic acid extracted from N. 
gonorrhoeae cell suspension (1 x 105 CFU/ml), in combination with varying concentrations of E. coli. 
 
Amplification was generated in each positive LAMP reaction, irrespective of the accompanying 
concentration of E. coli (Table 1.19). A slight delay in amplification occurred in the reaction 
containing 1x108 CFU of E. coli, which was generated at 13.3 minutes, 2 minutes later than the 
positive control reaction. It is worth noting that the reaction containing 1x107 CFU generated 
amplification 1 minute sooner than the positive control, meaning that the small changes in 
amplification time could be due to variations in reaction speed rather than inhibition. 
In healthy individuals, the protein content in urine should be minimal (<0.1 mg/ml). However, 
proteinuria, the excretion of excess serum proteins in the urine, can be caused by a number of 
pathological conditions, including diabetes, HIV infection and kidney disease.  In extreme cases of 
proteinuria, concentrations as high as 2mg/ml of serum proteins, mostly made up of serum albumin, 
are encountered. It is unknown whether the presence of such concentrations in the pre-extraction 
sample will have an impact on the yield of nucleic acid obtained, or the amplification during the 
LAMP process. 
Nucleic acid extractions were carried out from samples containing varying concentrations of BSA, 
ranging from 10mg/ml to 0.1mg/ml.  
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Sample 
BSA concentration 
(mg/ml)  
Result 
Time to amplification 
(mins) 
BSA 1 10 POSITIVE 23 
BSA 2 2 POSITIVE 26.3 
BSA 3 1 POSITIVE                   25.3 
BSA 4 0.5 POSITIVE 24.3 
BSA 5 0.1 POSITIVE 24 
Positive 0 POSITIVE 26.3 
Negative 0 NEGATIVE - 
Table 1.20. Time to amplification in the GC GroEL LAMP assay from nucleic acid extracted from N. 
gonorrhoeae cell suspension (1 x 105 CFU/ml), in combination with varying concentrations of BSA. 
 
The GC GroEL LAMP assay was able to amplify the N. gonorrhoeae target sequence from nucleic acid 
extracted in the presence of all of the concentrations of BSA tested. The range of time to 
amplification was 3.3 minutes for all concentrations tested (23 minutes – 26.3 minutes), and there 
was no correlation between BSA concentration and the amplification time (Table 1.20). 
 
1.3.9. Effect of lysis buffer lyophilisation on nucleic acid extraction. 
 
Lyophilisation, or freeze drying, is a dehydration process in which water is removed from a frozen 
substance by a process of sublimation. This versatile and well used process has been utilised for 
many applications, including food production and pharmaceutical manufacture. Lyophilising a 
substance significantly reduces its mass, and also allows it to be stored at ambient temperatures, 
reducing shipping and storage costs. The substance can then be rehydrated at the time of use, and 
will recover the chemical structure and properties of the substance prior to the lyophilisation 
process (Slater et al., 2003). The lyophilisation of the lysis buffer component in a microfluidic chip 
based device would reduce fluid volume in the chip itself, enable a faster processing of the clinical 
sample, which is a primary concern for a point of care microfluidic platform. It would also simplify 
the manufacture process, as a dried reagent is typically easier to integrate into chips during 
manufacture than liquid reagents. Chip shelf live could also be lengthened; an important 
consideration of any diagnostic test destined for clinical use. 
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Fig.1.13. LAMP amplification plot showing effect of lysis buffer lyophilisation on nucleic acid 
extraction efficiency. Nucleic acid extractions were carried out using lyophilised (L) and standard 
buffers (S), from a N. gonorrhoeae cell suspension, in duplicate. Extractions were then tested for the 
presence of N. gonorrhoeae nucleic acid using the GC GroEL LAMP assay. Uninoculated culture 
media was used as a negative control. 
 
Nucleic acid from both of the extractions carried out using lyophilised 2x lysis buffer was successfully 
amplified during the GC GroEL LAMP assay. There was no difference in the time to amplification (Ta) 
generated using DNA extracted with either the rehydrated lyophilised buffer, or the standard liquid 
buffer (Fig.1.13). This shows that the freeze drying process had no negative effect on the 
performance of the lysis buffer in this experiment. 
 
1.3.10. Tablet Manufacture 
 
During manufacture, the freeze dried buffer will need to be added into the correct partition of the 
microfluidic LabDisk, along with reagents for the LAMP reaction mix, and primer sets. In its freeze 
dried powdered form the lysis buffer would need to be weighed out individually for each disk, 
adding complication and time needed for the manufacturing process. Also, if the lysis buffer is 
supplied as free powder, there is the risk that it could disperse from the chamber during transfer, 
and find it sway into fluid channels on the LabDisk. In order to address this problem, the feasibility of 
the manufacture of tablets made from the lysis buffer was examined. The process involves 
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compressing the freeze dried lysis buffer powder into a cast, producing a solid tablet than can be 
more easily handled. As well as producing tablets containing 100% active ingredient, it is possible to 
improve the properties of the final tablet via the inclusion of excipients. These excipients include 
lubricating agents, which improve the efficiency of the tabletting process; disintegrants which assist 
in the break up of the tablet and release of the active ingredient; and bulking agents, which can 
improve the flow of the powder through the tabletting machine, and the solidity of the final product.  
 
 
Fig. 1.14. Lysis tablet 1 
 
Two tablets were produced; tablet 1 (Fig.1.14), containing 516mg of 100% active ingredient, and 
measuring 12mm in diameter; and tablet 2, containing 516mg of a 50:50 ratio of excipients and the 
active buffer components. 
 
1.3.11. Initial test of tablet performance 
 
Although it has been confirmed that freeze drying the lysis buffer does not lead to a degradation in 
performance (Fig.1.13), It is important that the lysis tablets produced also do not have any negative 
effect on the time to amplification of the LAMP reactions taking place using the extracted nucleic 
acid.  
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Fig.1.15. Amplification plots generated by the GC GroEL LAMP assay from nucleic acid extracted 
from a N. gonorrhoeae urine suspension (2 x 106 per ml), using lysis tablet 1, lysis tablet 2, 
lyophilised powdered lysis buffer and standard “wet” lysis buffer.  
 
The two LAMP reactions containing DNA extracted using tablet 1 generated detectable amplification 
after 16.6 and 17.6 minutes. The extractions carried out using lyophilised lysis buffer and standard 
“wet” lysis buffer generated an amplification after 15.6 and 16.6 minutes respectively (Fig.1.15). 
These amplifications were fairly closely grouped within a 2 minute period. The use of tablet 2 during 
the extraction process caused a delay in the downstream LAMP assay of ~4.5 minutes, with a 
detectable amplification generated after 20 minutes and 21.3 minutes in these reactions. 
The negative control reaction generated a late amplification of signal, with a curve more gradual 
than those generated in the true positive reactions. The signal generated equalled those of the true 
positives (1000 RFU), but appeared like an extension of the gradually increasing baseline 
fluorescence rather than a positive reaction.  This experiment was the first carried out with a new 
formulation of reaction mix provided by Mast Group Ltd, and it was thought that this may be 
responsible. A total of eight negative reactions were carried out with a range of LAMP primer sets, 
and all exhibited this gradual late amplification. Due to the difference in amplification curve and 
time, and the occurrence of this phenomenon with a range of primer sets, it is assumed that there is 
no contamination of the reagents that would influence the positive reactions. 
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Tablet 2 also did not fully dissolve in the urine and IPA; the tablet took longer to fully break up, 
despite the included disintegrants, and was not fully soluble. Whilst tablet 2 was the same weight as 
tablet 1, it contained 50% of the active compounds, and two tablets were required per reaction, 
increasing the material present in the extraction. As the performance of tablet 2 was inferior during 
this test, would create problems due to the increased material, and were less cost effective to make, 
their use was discontinues in further experiments. 
 
 
Fig.1.16. Amplification plots generated by the GC GroEL LAMP assay from nucleic acid extracted 
from a N. gonorrhoeae urine suspension (2 x 102 per ml), using lysis tablet 1, lyophilised powdered 
lysis buffer and standard “wet” lysis buffer.  
 
The performance of the lysis tablet 1, lyophilised buffer, and standard “wet” lysis buffer during the 
extraction of nucleic acid from a low density N. gonorrhoeae urine suspension (2 x 102 per ml) was 
equivalent, with a Ta of 20.5 minutes achieved during LAMP amplification of nucleic acid extracted 
using each method (Fig.1.16). 
 
1.3.12. Lysis buffer pellets 
 
Due to difficulties encountered during the tabletting process, caused by the freeze dried lysis buffer 
damaging the steel tooling of the machine, the use of freeze dried lysis buffer pellets was examined. 
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Liquid lysis buffer was frozen overnight at -80oC in 790µl aliquots in plastic circular moulds (2.7cm 
diameter). These moulds were then placed in the cold chamber of a freeze drier, and subjected to 
lyophilisation for 24 hours.  
 
 
Fig.1.17. Time to amplification of the GC GroEL LAMP assay using nucleic acid extracted from various 
concentrations of N. gonorrhoeae cell suspension using the 790µl lysis pellet and liquid 2x lysis 
buffer  
 
The effect of the use of the lysis pellets compared with the use of lysis buffer is shown in Fig.1.17. 
Overall, the use of the lysis pellets resulted in an average reduction in amplification time of 3.1 
minutes for all cell concentrations tested. This ranged from a 2.7 minute reduction for the lowest cell 
concentration (1 x 102), to a 4 minute reduction for the lowest cell concentration (1x 105). 
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1.3.13. Lyoprotectants 
 
In order to improve the consistency of the freeze dried lysis buffer pellets, the effect of the inclusion 
of a number of lyoprotectants was investigated. These lyoprotectants were added to the lysis buffer 
at a range of concentrations before the freeze drying process was initiated. Lyoprotectant 
compounds add stability to lyophilised products, and can improve consistency of the finished 
product, maintaining a more solid structure which can be more easily manipulated.  
Final concentrations of polyvinylpyrrolidone (PVP) of 1%, 2%, 4%, 8% and 10% were tested, as PVP is 
a well known lyoprotectant at these concentrations. PVP is a water soluble polymer, used as an 
amorphous bulking agent during the lyophilisation of pharmaceuticals, in order to provide a more 
robust cake. 
Two proprietary buffers from Mast were also included in the study; Lyo B and Lyo D. The exact 
formulation of these buffers was not disclosed, only that they include a concentration of 
poly(ethylene glycol) (PEG) 8000, and a variety of buffering compounds and ions. These buffers were 
designed to protect LAMP reaction mix, bst polymerase and reverse transcriptase enzymes, and 
primers, during the freeze drying process. These buffers also provide a solid freeze dried cake, which 
can be handled in one piece, which is an essential property of the lysis pellets. The concentrations 
found to work best for the reaction mix was 10%, so the concentrations of 5%, 10% and 15% were 
tested. 
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Fig. 1.18. A photograph showing the integrity of lysis pellets including varying concentrations of PVP 
(A), and a photograph demonstrating the appearance of the lysis tablets in the molds, after the 
freeze drying process (B). 
 
A PVP concentration of 1% - 8% was found to increase the integrity of the pellet, in comparison to 
pellets formed without the inclusion of a lyoprotectants (Fig. 1.18). The inclusion of 10% PVP lead to 
the pellets becoming heavily stuck to the mold, and difficult to retrieve without breaking. 
 
PVP 
concentration 
(%) 
Time to amplification (Minutes) 
Replicate 1 Replicate 2 Replicate 3 Average 
Difference 
from 0% 
Negative 
Control 
0 18.0 18.4 18.7 18.4 0.0 NA 
1 21.8 21.6 24.0 22.5 4.1 NA 
2 22.2 22.2 25.2 23.2 5.0 NA 
4 23.4 23.0 24.4 23.6 5.2 NA 
8 25.6 25.2 26.0 25.6 7.2 NA 
10 29.1 - - 29.1 10.7 NA 
Table.1.21. GC GroEL amplification times from nucleic acid extracted from aliquots of N. gonorrhoea 
culture (2 x 105 cells per ml), using lysis buffer pellets containing various concentration of PVP   
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The inclusion of PVP in the lysis pellet inhibited the LAMP reaction, with an increase in PVP 
concentration correlating with an increase in the Ta (Table 1.21). A PVP concentration of 1% resulted 
in an average delay of 4.1 minutes compared with the pellets prepared without PVP. This delay 
increased to 10.7 minutes when pellets containing 10% PVP were used. Amplification was not 
generated in the negative control reactions, irrespective of the absence or inclusion of PVP, at any 
concentration. 
 
                      
Fig. 1.19. A photograph showing the integrity of lysis pellets including varying concentrations of Lyo 
B (A), and a photograph demonstrating the appearance of the lysis tablets in the molds, after the 
freeze drying process (B). 
 
The inclusion of the Lyo B buffer at a 5% v/v concentration caused incomplete lyophilisation of the 
lysis buffer in two out of three replicates, whilst one of the three replicates failed to lyophilise when 
Lyo B was included at 5% or 15% concentrations (Fig.1.19 B). The pellets were difficult to remove 
from the molds, and stuck to the plastic surface, making retrieval problematic (Fig.1.19. A).  
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Lyo B 
concentration 
(%) 
Time to amplification (Minutes) 
Replicate 1 Replicate 2 Replicate 3 Average 
Difference 
from 0% 
Negative 
Control 
0 18.0 18.4 18.7 18.4 0.0 NA 
5 18.3 17.8 19.0 18.4 0.0 NA 
10 23.1 25.0 26.1 24.7 6.3 NA 
15 18.2 17.9 23.5 19.9 1.5 NA 
Table.1.22. GC GroEL amplification times from nucleic acid extracted from aliquots of N. gonorrhoea 
culture (2 x 105 cells per ml), using lysis buffer pellets containing various concentration of Lyo B. 
 
A Lyo B concentration of 5% had no inhibitory effect on subsequent LAMP assays, causing no change 
in the average amplification time (Table 1.22). However, the presence of 10% and 15% Lyo B caused 
an average delay in amplification of 6.3 minutes and 1.5 minutes respectively. No false-positive 
amplification was generated in any of the negative control reactions. 
 
 
Fig. 1.20. A photograph showing the integrity of lysis pellets including varying concentrations of Lyo 
D (A), and a photograph demonstrating the appearance of the lysis tablets in the molds, after the 
freeze drying process (B). 
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The inclusion of the Lyo D buffer at a concentration of 15% resulted in the formation of solid pellets, 
that were easily removed from the molds intact (Fig.1.20 A). At concentrations of 10% and 5% the 
integrity of the pellets were affected, and the fragility was increased in comparison with the pellets 
without a lyoprotectants (Fig. 20 B). 
 
Lyo D 
concentration 
(%) 
Time to amplification (Minutes) 
Replicate 1 Replicate 2 Replicate 3 Average 
Difference 
from 0% 
Negative 
Control 
0 18.0 18.4 18.7 18.4 0.0 NA 
5 17.5 19.0 18.8 18.4 0.0 NA 
10 18.2 18.7 18.5 18.5 0.1 NA 
15 18.3 18.1 18.1 18.2 -0.2 NA 
Table.1.23. GC GroEL amplification times from nucleic acid extracted from identical aliquots of N. 
gonorrhoea culture (2 x 105 cells per ml), using lysis buffer pellets containing various concentration 
of Lyo D. 
 
Lysis pellets containing 5%, 10%, or 15% Lyo D had no effect on the amplification time of the GroEL 
LAMP assay, compared to lysis pellets containing no lyoprotectants (Table 1.23). The negative 
control reactions did not generate amplification, in the presence or absence of Lyo D. 
 
1.3.14. Lyoprotectants: PEG 
 
The absence of any negative effect on the LAMP assay arising from the presence of Lyo D in the lysis 
pellet prompted further investigation of its constituents. As the exact formulation was undisclosed, 
the concentrations of the reagents were unknown. As the buffer was primarily designed to maintain 
the stability of the enzymes during lyophilisation of the reaction mix, a number of the reagents, 
particularly pH buffers and salts, are not applicable to improving the composition of the cake 
obtained by freeze drying the lysis buffer. Lyo D contains an unknown quantity of PEG 8000, which is 
responsible for producing a solid, consistent, product.  
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PEG 8000 
concentration 
(%) 
Time to amplification (Minutes) 
Replicate 1 Replicate 2 Replicate 3 Average 
Difference 
from 0% 
Negative 
control 
0.0 20.8 20.3 20.0 20.4 0.0 NA 
1.0 20.4 20.4 20.8 20.5 0.1 NA 
2.0 20.2 20.4 20.4 20.3 -0.1 NA 
4.0 20.1 20.4 19.6 20.0 -0.4 NA 
8.0 20.5 20.4 20.4 20.4 0.1 NA 
10.0 21.3 20.5 20.4 20.7 0.3 NA 
Table.1.24. GC GroEL amplification times from nucleic acid extracted from identical aliquots of N. 
gonorrhoea culture (2 x 105 cells per ml), using lysis buffer pellets containing various concentration 
of PEG. 
 
The inclusion of PEG at any concentration between 1% and 10% had negligible effect on the time to 
amplification of the LAMP reactions carried out from the extracted nucleic acid (Table 1.24). The 
average amplification times using each concentration of PEG tested were within 0.5 minutes of the 
average amplification times when pellets not containing a lyoprotectants compound were used. 
 
1.3.15. Scanning electron microscopy analysis of lysis pellets 
 
Scanning electron microscopy (SEM) was used in order to image the surface of the lysis pellet cake, 
produced with and without 2% PEG, to examine for topological features characteristic of a properly 
formed cake. A key element of a well formed cake is the presence of micropores, which provide 
routes for water to vapour to escape the cake during the drying cycle. Insufficient frequency or 
complete absence of these pores prevents the escape of the water vapour, leading to a larger 
volume of water being retained in the final product. As guanidine hydrochloride is highly 
hygroscopic, any retained water is likely to draw the molecule back into solution, ruining the 
consistency of the pellet. 
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Fig. 1.21. SEM image of the surface of the lysis pellet (2% PEG) at 1000x mag. 
 
Fig.1.22. SEM image of the surface of the lysis pellet (2% PEG) at 3084x mag. 
108 
 
 
Fig.1.23. SEM image of the surface of the lysis pellet produced with buffer without PEG, at 1375x 
mag. 
 
Micropore structures were clearly visible on the surface of the lysis pellets containing 2% PEG, 
indicating the presence of escape routes for water vapour sublimated during the freeze drying 
process (Fig. 1.21; 1.22). This is evidence that there is likely to be very low residual water content 
retained in the pellets, which is essential for their performance. The surface of the pellet formed 
from without the inclusion of 2% PEG did not have any observable micropore structures (Fig.1.23). 
 
1.3.16. Swab performance 
 
As the test will be required to be able to process swab samples, in addition to urine samples, it was 
necessary to determine the most suitable swab type for inclusion with the test. The recovery rate of 
the swab, which is the ability of the swab to retrieve cells, and then also subsequently elute the cells 
into a sterile media, will be an important factor in the overall sensitivity of the test.  
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Three swabs were tested; Copan flocked swabs, Sterilin cotton swabs, and Copan cotton swabs. The 
swabs were used to collect cells from 1ml aliquots of N. gonorrhoeae cell suspensions of varying 
concentrations, and then elute the cells into transport media. Total viable counts using the initial 
suspension, and inoculated transport media, were then carried out in order to work out the overall 
percentage recovery rate.  
 
 
Fig.1.24. The recovery rate of bacteria from various concentrations of N. gonorrhoeae cell 
suspension, using Copan flocked swabs, Copan cotton swabs and Sterilin cotton swabs 
 
The recovery rate using each swab for various cell suspension concentrations are shown in Fig.1.24. 
The highest recovery rate was seen using the Copan flocked swab, which enabled an average 
recovery of 17.6% over all concentrations tested. The Copan cotton swab and Sterilin cotton swab 
had overall recovery rates of 9.7% and 10.7% respectively, across all the concentrations of cell 
suspension. The Copan flocked swab performed best with more concentrated cell suspensions, 
recovery 24.4% of cells from the 3 x 107 dilution, compared with 15.2% from the 3 x 103 dilution. 
 
1.3.17. Effect of Vortexing speed on swab recovery 
 
Due to the low recovery rates achieved with all swab types in previous experiments, where no 
mechanical force was used to assist during the elution of cells, the effect of vortexing during this 
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process was examined. It was hoped that the force exerted during elution would improve the 
removal of cells from the swab into the transport media, by forcefully dislodging the cells from the 
swab. 
A five second period of vortexing was carried out during the elution of the swab into transport 
media, at speeds of 0rpm, 500rpm, or 1000rpm. 
 
 
Fig.1.25. The effect of vortexing on the recovery rate of N. gonorrhoeae from Copan flocked swabs 
 
Without vortexing, a recovery rate of ~24% was achieved, showing good agreement with the data 
shown in Fig. 1.24. The use of vortexing significantly increased recovery rate, with a speed of 500rpm 
increasing the recovery rate to ~45% (range 37% - 52%), and a speed of 1000rpm bringing it up to 
~78% (range 68% - 84%) (Fig.1.25). 
 
1.3.18. Swab buffer performance 
 
In order to determine the optimum transport media for use with the Copan flocked swabs, an 
experiment was carried out to determine the effect of three transport media on the organism 
recovery rate from N. gonorrhoea suspensions of varying cell concentration. The three transport 
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media tested were Copan UTM, PBS and PBS Tween (0.02% Tween). The Copan UTM medium is 
frequently used in conjunction with Copan swabs for the collection of genital swab samples, with 
which it is frequently provided alongside. It is designed for the collection and transport of swabs 
containing Chlamydiae, Mycoplasma or Ureaplasma, but is also widely used for collection of N. 
gonorrhoeae. PBS and PBS Tween (0.02% Tween) are alternative commonly used transport media, 
which are simpler and less expensive than commercially available transport media such as the Copan 
UTM. 
 
N. 
gonorrhoeae 
CFU/ml 
Average PBS 
recovery 
(CFU/ml) 
Average 
PBS 
recovery 
overall (%) 
Average PBS 
Tween 
recovery  
(CFU/ml) 
Average PBS 
Tween 
overall  
recovery (%) 
Average 
Copan TM 
recovery 
(CFU/ml) 
Average 
Copan TM 
overall 
recovery 
(%) 
8,500,000 1,400,000 16 1,500,000 18 1,700,000 20 
850,000 155,000 18 135,000 16 180,000 21 
85,000 18,500 22 12,500 15 19,000 22 
8,500 1,500 18 1,500 18 1,700 20 
Table.1.25. Comparison of the effect of various transport media on the recovery rate of N. 
gonorrhoeae cells from Copan flocked swabs. 
 
The percentage recovery of each buffer remained relatively stable for each starting concentration of 
cells in the suspension (PBS range 16 – 22%; PBS Tween range 15% - 18%; Copan TM range 20 – 
22%). The average recovery across all concentrations of the PBS, PBS Tween and Copan UTM were 
18.5%, 16.75%, and 20.75%, respectively (Table.1.25.).   
 
1.3.19. Evaluation of the use of lysis buffer as swab transport media 
 
In a clinical setting, after a swab is used to collect a sample from a patient it is then placed into a 
transport media, into which the cells are eluted. For NAAT testing, nucleic acid is then extracted 
from cells in this eluate. As previous experiments (Fig.1.25) have shown, the recovery rate from the 
swab is less than 100%, with only 24% recovered without vortexing, and a recovery rate of 78% 
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achieved with a 1000rpm vortex. Therefore, it is possible that a higher yield of nucleic acid could be 
achieved by lysing the cells at this point, whilst still on the swab, mitigating any loss from cells 
remaining on the swab. The replacement of the transport media with 1x GuHCl lysis buffer was 
tested in order to determine the subsequent effect on the time to amplification in the down-stream 
LAMP assays. This would provide an indication of the yield and quality of nucleic acid obtained from 
the sample.  
 
 Time to amplification (Minutes) 
1 x 106 Ng per ml 1 x 105 Ng per ml 1 x 104 Ng per ml 
TM LB Difference TM LB Difference TM LB Difference 
1 19.3 18.8 -0.5 21.3 19.8 -1.5 26.3 22.7 -3.6 
2 17.7 17.8 0.1 22.4 18.9 -3.5 24.8 20.6 -4.2 
3 20.1 20.6 0.5 22.5 21.8 -0.7 28.7 25.9 -2.8 
Average 19.3 19.7 0.4 22.1 20.2 -1.9 26.6 23.1 -3.6 
Table.1.26. Comparison of the effect of the use of Copan transport media and 1x GuHCl lysis buffer 
during the elution of N. gonorrhoeae from Copan flocked swabs on the time to amplification in 
subsequent GC GroEL LAMP assays. Assays that generated more rapid amplification when lysis 
buffer was used are highlighted green. 
 
At the higher cell concentration, 1 x 106 CFU per ml, there was minimal difference in time to 
amplification, with the samples placed in transport media generating amplification 0.4 minutes 
quicker than the samples placed in lysis buffer (Table.1.26). However, at the lower starting 
concentration of 1 x 104 CFU/ml, the use of lysis buffer rather than transport media lead to an 
average decrease of 1.9 minutes in time to amplification. This difference was greater for the lowest 
concentration, 1 x 104 CFU/ml, where an average decrease of 3.5 minutes was acheived using the 
lysis buffer. 
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1.3.20. Comparison of the effect of swab incubation time in lysis buffer and Copan transport 
media 
An important function of the transport buffer provided with the swab is the protection of the target 
nucleic acid in the sample. In the transport media this is accomplished by ensuring the cells remain 
intact, and do not release their nucleic acid into the extracellular environment, where it may be 
degraded by DNase or RNase enzymes present in the sample. The lysis buffer protects the released 
nucleic acid, after lysis has taken place, via the strong reducing action of the chaotropic salt, which 
deactivates these nucleases.  
Swabs were incubated for 0, 10, 20, and 30 minutes in either lysis buffer or Copan transport media. 
Nucleic acid extractions were subsequently carried out, and the GroEL LAMP assay was used to test 
the extracted nucleic acid. Real time monitoring was carried out in order to determine whether 
there was a delay in signal due to lengthier incubation. The experiment was repeated using the lysis 
buffer, with the time period extended to 1 hour, as this was thought to be the maximum length of 
pre assay incubation for the POC system.  
 
 
Fig.1.26. Comparison of the effect of the length of swab incubation in Copan TM and lysis buffer on 
the time to amplification in downstream GC GroEL LAMP assays. Error bars indicate a range of three 
replicates.  
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The incubation in lysis buffer had little effect on the time to amplification achieved in the 
subsequent LAMP assays, irrespective of time spent. The length of time that buffers were incubated 
in the Copan media prior to extraction also had little effect on the time to amplification of 
downstream LAMP assays. Similar time to amplification occurred when transport media or lysis 
buffer was used, which was also seen in previous experiments when using this cell concentration 
(Table.1.26) 
 
Fig.1.27. The effect of the duration of swab incubation in 1x GuHCl lysis buffer on the time to 
amplification in downstream GroEL LAMP assays. Error bars indicate a range of three replicates.  
 
The experiment was repeated on another occasion solely using the lysis buffer, for an hour, in order 
to determine whether any degradation of the nucleic acid content of the sample occurred in the one 
hour duration with this buffer (Fig.1.27). There was no increase in the time to amplification seen as a 
result of an hourly incubation, indicating the stability of the released nucleic acid in the lysis buffer 
solution. 
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1.4. Discussion  
1.4.1. Total nucleic acid extraction from E. coli culture using a magnetic silica based total nucleic 
acid extraction method 
 
The image of the agarose gel electrophoresis of total nucleic acid extracted from E. coli culture in 
Fig.1.4 shows the various nucleic acid fractions successfully extracted using this method. The 
extracted genomic DNA is visible as a high weight band (>10kb) in all three samples, and shows no 
smearing. This indicates the extraction of unfragmented genomic DNA from the sample, showing 
that the DNA is preserved during the reaction process. This is important, as the extraction of 
unfragmented DNA from the sample will ensure that the DNA target sequence of the LAMP primers 
remains intact, and viable for the annealing of the primers and subsequent amplification. 
The 23s rRNA (2904bp) and 16s rRNA (1541bp) bands are also clearly visible as sharp bands on the 
gel. There is a small degree of smearing, which could indicate minor degradation of the RNA, or be 
indicative of the varied mRNA population. The optimum intensity ration between the 23s rRNA band 
and 16s rRNA band should be around 2:1. This is because that although there is an identical number 
of 16s and 23s RNA transcripts in each cell, and each should degrade at the same rate, the 
fluorescence seen is a function of how many ethidium bromide molecules can bind to each nucleic 
acid strand. This depends on the number of bases available, so as the 23s rRNA contains roughly 
twice as many bases as the 16s rRNA, a 2:1 ratio should be seen. The ratio between the bands in 
Fig.1.4. is closer to 1:1, possibly indicating some degradation of the RNA during extraction. 
A bright band was also present in each of the sample loading wells on the gel. This is likely to be 
fragments of cellular proteins released by the lysed cells during the extraction, which have survived 
the extraction process and been eluted into the final nucleic acid sample. These proteins are unable 
to pass through the agarose gel due to their large size. Positively charged proteins could bind to the 
negatively charged DNA, which would in turn bind to ethidium bromide molecules in the gel. As the 
extraction does not include a proteinase digestion step, typically found in most kit based extraction 
methods, it relies solely on the wash buffers to remove any contaminating proteins. This is an 
important step to remove any proteins inhibitory to PCR, such as haemoglobulin, and also 
ribonucleases, which could degrade RNA in the sample once free of the denaturing guanidine 
isothiocyanate present in the lysis buffer.  
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If LAMP amplification from samples processed by this extraction method is inhibited due to the 
carry-over of these proteins, it may be necessary to include a Proteinase K digestion during the 
process, or improve the efficiency of the wash procedure. 
 
1.4.2. A comparison of thermal and chemical lysis methods for total nucleic acid extraction from E. 
coli culture 
 
The use of a 30 second 95oC heat treatment to lyse the E. coli cells during the nucleic acid extraction 
process resulted in a higher concentration of both DNA and RNA during elution compared to 
extraction carried out using a 10 minute lysis buffer incubation (Fig.1.5). This is possibly due to a 
decreased exposure of the nucleic acids to ribonucleases before the first wash step removes protein 
contaminants, the heat assisting in ribonuclease inactivation, or an increase in the percentage of 
cells fully lysed. Importantly, the heat treatment did not result in thermal degradation of the nucleic 
acid.  
The sample lysed by a 1 minute incubation in lysis buffer also yielded a similar concentration of 
nucleic acid when compared to the sample lysed by a 10 minute incubation step, indicating that the 
10 minute incubation is excessive and does not significantly increase nucleic acid yields. The 
performance of both the 1 minute buffer mediated lysis, and the 1 minute thermal lysis procedure, 
show that this part of the extraction process can easily be carried out within these time scales 
without any detrimental effect on the quality or quantity of nucleic acid retrieved. 
 
1.4.3. Initial evaluation of the effect of chaotropic salt on lysis buffer performance 
 
Although guanidine isothiocyanate (GuCN) is a more potent reducer of proteins than guanidine 
hydrochloride (GuHCl) (Rajeshwara and Prakash, 1994) and is also a more potent lytic agent, it 
carries safety risks associated with its use. Although both chemicals are classified in the same risk 
brackets in their respective MSDS (Health, 2; fire, 1; Reactivity, 0; personal protection, E), GuCN 
reacts with bleach to produce hydrogen cyanide gas, complicating the cleaning process in case of 
spillage. The inclusion of GuCN in the extraction method may lead to more stringent safety 
precautions surrounding the use of the test, and may lead to a reduced uptake of the platform once 
commercialised.  
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The initial test of the viability of a GuHCl based lysis buffer showed that there was negligible 
difference in the average LAMP amplification time between nucleic acid extracted using the GuCN 
buffer, or GuHCl buffer, with or without a heating step. A greater range of amplification time was 
seen across the five replicates for extractions carried out with the GuCHl buffer, suggesting a greater 
variability in extraction performance using this method. It was surprising that there was no 
difference in amplification time seen when the lysis process was aided by a heat step, as previous 
results have suggested that a greater yield of nucleic acid would be obtained in this manner. 
However, those experiments were carried out using E. coli as a model organism, and at higher 
concentrations than those used in this experiment, which may have affected the results. 
 
 1.4.4. Effect of guanidine hydrochloride lysis buffer and thermal lysis on a range of dilutions of N. 
gonorrhoeae cell suspension in urine 
 
The tests that were carried out to examine the performance of the GuHCl lysis buffer, compared 
with the GuCN buffer, over a range of N. gonorrhoeae concentrations, showed that the GuHCl 
buffer, in conjunction with a prior 95oC heating step of the sample, resulted in a faster LAMP 
reaction. The difference in amplification time was particularly pronounced for the extractions carried 
out on low density suspensions, which suggests that the use of this method may improve 
sensitivities of the assay, when dealing with samples containing at organism loads close to the limits 
of detection.  
A critical parameter in the use of a thermal lysis procedure was the timing of the heating step; if the 
heating step was carried out after the mixing of the sample and buffer, a large increase in the time 
to amplification occurred. The reasons for this are unclear; by lysing the cells in the presence of 
GuHCl it was thought that a greater deal of protection would be from nucleases present in the urine, 
as when heating is carried out prior to buffer mixing, the released nucleic acid is at risk from this 
enzymatic degradation until it encounters the lysis buffer. One possible explanation is that by 
heating the lysis buffer along with the sample a proportion of the IPA was lost via evaporation. The 
IPA component is necessary for the efficient binding of the nucleic acid to the silica beads, and a 
reduction in concentration could possibly result in a reduction on the nucleic acid yield. 
Due to this degradation, it is imperative that the application of heat to the sample in the LabDisk 
occurs prior to the mixing of the sample and buffer. This will actually simplify the process, as the 
volume at this stage will be at the lowest point throughout the process, and there will be no issue of 
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heating in the presence of IPA, which could cause evaporation, moving IPA vapour into other 
compartments of the system. 
 
1.4.5. Effect of the duration of the 95oC heating step during lysis on the yield of nucleic acid and 
LAMP amplification time 
 
The duration of the 95oC heating step during lysis effected the time to amplification of the LAMP 
reactions; an increased heating duration improved the speed of the LAMP reaction, up to a 30 
seconds duration, at which time the amplification time reached a plateau and did not increase any 
further. This reason for this is likely that 30 seconds at 95oC is enough to ensure complete lysis of all 
cells present in the sample, while a reduced heating duration leads to incomplete lysis and a 
reduction in nucleic acid release. The concentration of the purified nucleic acid did increase as the 
duration of heating was extended, although the gain was minimal, increasing from 21.94ng/µl to 
24.16ng/µl from 0 to 30 seconds of heating. 
Whilst thermal lysis is capable of lysing cells in the sample at a fast rate, it also risks degrading the 
nucleic acid in the sample, which could reduce intact target sequence for the LAMP assay, reducing 
assay sensitivity. It is important that the duration of heating is enough to lyse the cells, but 
insufficient to cause damage to the released nucleic acid. It has been demonstrated that a 5 minute 
100oC heat treatment during the extraction of DNA from M. tuberculoisis does not degrade DNA 
(Bemer-Melchior and Drugeon, 1999), although studies have shown that by increasing the 
incubation at this temperature to 30 minutes results in the significant shearing of the DNA (Zwadyk 
et al., 1994). Heat shocks of 95oC for 30 seconds have been found to lyse over 90% of viable Gram-
negative bacteria in a microfiuidic chip (Privorotskaya et al., 2010). The use of thermal lysis in a 
microfluidic device has also been shown to produce DNA with the same integrity as that extracted 
using sonication, which is considered the safest lysis method for maintaining DNA integrity (Baek et 
al., 2010). The extraction of RNA using thermal lysis has also been demonstrated, and been found to 
result in comparable yields and purity to RNA extracted using commercial kit lysis buffer s (Baek et 
al., 2010).  
As the use of a 95oC heat step decreased the Ta, and agarose gel electrophoresis of nucleic acid 
extracted in this manner did not reveal any evidence of degradation (Fig. 1.5), this lysis methodology 
seems well suited to use on the LabDisk. 
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1.4.6. Effect of GuHCl concentration on concentration and quality of extracted DNA 
 
The concentration of GuHCl is an important parameter of the lysis buffer composition; the reversible 
absorption of nucleic acid to the surface of the silica microparticles is driven by the presence of this 
chaotropic salt, and will vary depending on its concentration (Vandeventer et al., 2012). The 
chaotropic activity of GuHCL disrupts the lattice of water molecules in the sample solution, which 
combined with the high ionic strength of the solution, due to the presence of both GuHCl and NaCl 
from the lysis buffer, enable the formation of salt bridges between the negatively charged silica 
surface, and negatively charged oxygen atoms in the phosphate backbone of DNA or RNA molecules 
(Tan and Yiap, 2009). At high salt concentrations, as provided by the lysis buffer, the sodium ions 
break the bonds between the negatively charged oxygen ions in the silica matrix, and hydrogen 
atoms in water molecules in the solution, enabling the formation of the salt bridge (Tan and Yiap, 
2009). GuHCl is also a potent reducer of proteins, and has been shown to denature RNase A at 
concentrations >3M (Ahmad, 1984). This protects the released nucleic acid during the lysis process 
from the action of endonucleases in the sample, maintaining the integrity of the nucleic acid prior to 
the amplification step. A final GuHCl concentration of between 2M (Kim and Morrison, 2009) and 
5M (Shaw et al., 2009) has been shown to be effective for SPE of nucleic acid using a silica matrix, 
although concentrations as high as 7M have been used in buffers lacking additional salts (Mathot et 
al., 2013). Minimising the amount of GuHCL in the lysis buffer, to the lowest effective level, will be 
an important part of the buffer optimisation, as this will help to reduce costs during manufacture. It 
will also reduce difficulties in ensuring the GuHCl is fully dissolved in solution, as concentrations over 
~5M require heating in order to be completely soluble in water. 
The lysis buffer containing the lowest concentration of GuHCL tested, 3.5M, which resulted in a final 
concentration of 2.76M, resulted in the lowest yield of nucleic acid, 15.6ng/µl. This concentration is 
below the ~3M required to denature endonucleases (Ahmad, 1984), and it may be the absence of 
protection from these enzymes that has reduced the yield obtained using this buffer. 
The highest concentration of extracted nucleic acid, and 260nm/280nm ratio was obtained using the 
buffer containing 4.5M GuHCl, which results in a final concentration of 3.55M. Buffers containing 
higher concentrations of GuHCl than this generated a reduction in both yield and 260nm/280nm 
ratio. This was slightly unexpected, as buffers containing these concentrations and above have been 
demonstrated in the literature as being effective for silica SPE (Mathot et al., 2013). The difference 
in yield between the concentrations was fairly low, with a decrease from 20.1ng/µl to 17.5ng/µl 
recorded between the 4.5M and 6M buffers. Additionally, the values for the nucleic acid yield 
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obtained using the 5.5M and 6M had a comparatively large inter-replicate variance of 6.1ng/µl and 
5.7ng/µl, respectively, so a lack of experimental reproducibility could factor in these results.  
 
1.4.7. Buffer component concentrations 
 
Another component of the lysis buffer that requires optimisation is EDTA. This was tested as 
percentage reductions of the initial 0.2M EDTA volume, which was 1.8ml per 20.3ml of buffer. EDTA 
is included in the lysis buffer as a chelating agent, with the purpose of binding 2+ ions, and 
preventing their involvement in any reaction processes. Certain DNase enzymes require Mg2+ for 
functionality, and the presence of EDTA will reduce their activity, protecting DNA from degradation 
(Guéroult et al., 2010). It is important that the EDTA is sufficiently removed before the amplification 
process, as EDTA can inhibit polymerase enzymes, by sequestering the Mg2+ ions required for 
enzyme activity (Huggett et al., 2008), although the concentration of EDTA required for inhibition of 
the LAMP reaction appears to be higher than those used in the lysis buffer (Francois et al., 2011). 
The difference in nucleic acid yield for buffers containing 100% to 0% of the volume of EDTA present 
in the standard lysis buffers was minimal. This was to be expected, as the main benefit of EDTA in 
this system is the reduction in nuclease activity, which is already effectively prevented by the 
presence of GuHCl. The volume of EDTA added is comparatively low, at around 9% of the total buffer 
volume, and EDTA is cheap and simple to make, so the presence at these volumes will not have a 
great impact on the price of manufacture. This experiment shows that the EDTA component could 
likely be removed, without any negative effect on assay performance. 
The volume of 0.1M Tris/HCl pH 6.4 in the lysis buffer is greater than that of EDTA, comprising 42% 
of the total fluid volume.  The purpose of the Tris/HCL component is to provide a level of control 
over the pH of the lysate and lysis buffer, to ensure optimal binding conditions. The formation of salt 
bridges between the phosphate backbone of the nucleic acid molecules and the silica beads will only 
form at <pH 7 (Tan and Yiap, 2009), and the Tris/HCL buffer will maintain these conditions. 
The presence of Tris/HCl had little effect on the nucleic acid yield obtained in the experiment, with 
the 100% volume generating a yield of 19.8ng/µl, compared with a yield of 18.9ng/µl for the buffer 
not containing any Tris/HCl. A possible explanation for this is that as guanidine hydrochloride is 
acidic in solution, and although urine pH is highly variable, it is typically ~pH 6 (+/- 0.8) (Welch et al., 
2008), the combination of the lysis buffer and sample were unlikely to exceed the pH of 7 necessary 
for the binding of the nucleic acid to the silica beads. However, urine samples with a pH of up to 7.7 
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are encountered clinically, and the test needs to be able to process samples in this range (Proudfoot 
et al., 2004).  
 
1.4.8. Comparison of 1x and 2x lysis buffer for total nucleic acid recovery from clinical C. 
trachomatis samples, using a silica based total nucleic extraction method. 
 
The use of a 2x concentrated lysis buffer during the extraction of nucleic acid from clinical samples 
had no effect on the amplification time of the CT-0332 LAMP assay, with nucleic acid extracted using 
the standard 1x GuHCl buffer generating an amplification at the same time-point. This result was 
expected, as the 2x concentrated buffer delivers an identical final concentration of GuHCl and IPA, 
the two components chiefly responsible for the yield and quality of the purified nucleic acid. The 
LAMP amplification curves generated by nucleic acid extracted using the two different buffers start 
at identical timepoints, showing a high level of reproducibility between extractions from the same 
sample. 
 
1.4.9. Robustness of nucleic acid extraction method in the presence of inhibitory compounds 
 
One of the primary objectives of the extraction system is the removal of compounds inhibitory to 
the LAMP assay from the clinical specimen.  Inhibition of amplification can manifest as a failure of 
the reaction to produce any detectable product, a reduction in product produced, or an increase in 
the time to amplification in comparison to an uninhibited reaction (Huggett et al., 2008). 
Diagnostically this leads to an increase in the likelihood of false-negative results and a reduction in 
assay sensitivity (Chernesky et al., 1997). A large scale study investigating the presence of PCR 
inhibitors in STI samples using the COBAS AMPLICOR C. trachomatis test found that PCR inhibition 
occurred in 7% of cervical swabs, 45% of urethral swabs, and 1.1% of urine samples (Toye et al., 
1998). Urine samples contain a number of compounds known to interfere with PCR amplification, 
including urea, and protein components in cases of proteinuria. Significant concentrations of red 
blood cells can be rarely found in urine samples, especially samples from patients with urethral or 
kidney infections, which have symptoms that can overlap those of STD infection, leading to testing. 
Traces of blood are more commonly found in swab samples (Toye et al., 1998), and are particularly 
prevalent in vaginal swab samples, with concentrations varying during the menstrual cycle. Blood 
contains haemoglobin and lactoferrin, which are both inhibitory to PCR (Al-Soud and Radstrom, 
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2001), and therefore may also be inhibitory to LAMP. The anticoagulant molecule heparin, a 
glycosaminoglycan present in blood plasma, can also inhibit PCR at physiological concentrations 
(García et al., 2002).The robustness of the combination of the nucleic acid extraction system and 
LAMP assay was demonstrated by the lack of inhibition in the LAMP reaction, despite the presence 
of whole blood in the pre extraction sample in concentrations of up to 5.5x107 RBC’s per ml, 
equating to a 50:50 dilution of whole blood and N. gonorrhoeae cell suspension. This is a much 
higher level concentration of whole blood in the extraction system than would be encountered 
when sampling for sexually transmitted disease. Studies have defined haematuria as RBC counts 
over 1.1 x 103 (Hyodo et al., 1997), and the assay system was able to process samples containing a 
greater than 1000-fold increase of this concentration. The LAMP reaction itself is known to be more 
tolerant than PCR to inhibitory compounds present in blood (Francois et al., 2011), and the direct 
detection of pathogenic DNA sequences from un-processed whole blood has been demonstrated 
(Ebbinghaus et al., 2012). Despite the fact that inhibition of the LAMP reaction itself by low 
concentrations inhibitory compounds carried through the extraction process is unlikely, it is 
important that the presence of blood does not interfere with the lysis of the sample, or the binding 
of nucleic acid to the silica particles during lysis. 
There is a significant overlap between the symptoms of a number of STI’s, and urinary tract infection 
(UTI) caused by bacteria that are not sexually transmissable. Additionally, co-infection between STI 
and UTI caused by organisms such as E. coli and Klebsiella pneumoniae can occur. The result of this is 
that both negative and positive samples submitted for STI testing can contain high densities of non-
target bacterial species. This potential overabundance of nucleic acid could potentially compete for 
binding space on the silica bead surface with target nucleic acid, reducing the concentration 
available for amplification in the eluate. Lysed cells will also release their contents into the lysis 
buffer, increasing the concentration of RNAses leading to a greater likelihood of RNA degradation in 
the case of incomplete protection by the chaotropic salt. The absence of a reduction in amplification 
time in the LAMP reactions containing up to 1 x 107 E. coli cells shows that no inhibitory effect was 
found from the presence of bacteria at these levels. There was a small increase in the amplification 
time in the reaction containing 1 x 108 E. coli cells, 1.15 minutes more than the average of the 
reactions containing fewer E. coli cells. This could indicate that this is the threshold at which the 
concentration of non-target cells has an inhibitory effect on the extraction process, or it could be 
variance between reaction speed.      
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1.4.10. Effect of lysis buffer lyophilisation on nucleic acid extraction. 
 
The use of a rehydrated lyophilised lysis buffer during the extraction of nucleic acid from a N. 
gonorrhoeae cell suspension had no effect on the time to amplification in the LAMP reaction, 
compared with the use of standard liquid lysis buffer. This shows that the freeze drying process has 
not impacted on the chemical properties of the guanidine hydrochloride; the identical amplification 
curves obtained show that the nucleic acid yield has not been reduced either by nuclease activity or 
reduced binding to the silica particles. This result is important as it shows that there is no loss of 
performance when freeze drying the buffer, and rehydrating it back to the original concentrations. 
This suggests that the storage of the lysis buffer in the microfluidic system will be able to occur as in 
a freeze dried form. This will have two major benefits; firstly the storage of liquid reagents is 
problematic, due to difficulties in applying them to the disk during manufacture, evaporation and 
leakage. Secondly, freeze drying the lysis buffer allows for the possibility of rehydrating using the 
sample itself, decreasing fluid volumes in the system and allowing for faster processing. This will also 
reduce the buffer concentration of the reagents necessary to generate the optimum final reagent 
concentration in the sample, reducing the cost of the buffer preparation. The absence of false 
positive amplification in the LAMP reactions using negative extractions carried out with the freeze 
dried lysis buffer shows that the use of this buffer does not cause non-specific amplification events, 
and will not impact on the sensitivity of the assay. 
 
1.4.11. Tablet Manufacture 
 
Tablet 1, produced using 100% freeze dried guanidine hydrochloride lysis buffer, formed solid 
tablets which were easily handled without breaking. They also dissolved completely in urine and IPA, 
with minimal agitation. The major benefit of these tablets is that just a single 516mg tablet is 
required per extraction, whereas the use of tablet 2 requires two tablets per extraction. 
It was thought that tablet 2, containing 50% freeze dried lysis buffer, and a 50% mix of excipients, 
would break up more readily in solution, and have an improved consistency when compared with 
tablet 1. However, it was found that the consistency was actually less optimal, as the tablets easily 
crumbled and tended to disintegrate during contact. The tablets did not fully dissolve into solution; 
the rehydrated guanidine forms an almost saturated solution, leading to the lactose, which has a 
poor solubility in water and IPA, forming a suspension. The saturation of the solution could prevent 
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the active buffer components from dissolving into solution, and reduce the concentration in the lysis 
reaction down from the optimum level.  Additionally, due to the 516mg tablets only containing 50% 
of the necessary active buffer component, two tablets are required per reaction, increasing the 
amount of materials required for the disk, and complicating the extraction process. Due to these 
reasons, tablet 2 was deemed unsuitable for use on the disk, unless the performance in the 
extraction was improved by using this tablet. 
 
1.4.12. Initial test of tablet performance 
 
The performance of tablet 1 during the lysis process was equal to the performance of the liquid lysis 
buffer, with the LAMP reactions from nucleic extracted from the high density (2 x 106 per ml) cell 
suspension of N. gonorrhoeae using these lysis buffers all generating an amplification between 16.6 
and 17.6 minutes. The extractions carried out on the low density cell suspension (2 x 102 per ml) 
using tablet 1, lyophilised buffer, and liquid lysis buffer, all generated identical amplification curves 
after 20.5 minutes in the subsequent LAMP assay, demonstrating an equal yield and relative purity 
produced by the various buffers. Although the fact that freeze drying and subsequent rehydration 
does not diminish the performance of the lysis buffer during the extraction process has been 
demonstrated, this experiment shows that the same is true for the freeze dried buffer when 
compressed into tablets.  
Extractions using tablet 2 were only carried out on the high density cell suspensions, due to the small 
volume of tablets produced, and their poor performance in this, and previous tests. The use of tablet 
2 caused a delay of ~4.5 minutes compared with the use of tablet 1 or liquid lysis buffer. This could 
be due to carry over of the excipients present into the tablet into the eluted nucleic acid, inhibiting 
the LAMP reaction. Alternatively, the presence of the excipient compounds could interfere with the 
binding of the nucleic acid to the silica beads, reducing the starting copy number in the LAMP 
reaction. The increase in the time to amplification of the LAMP assay caused by the use of tablet 2, 
in combination with the need for two tablets to achieve the correct concentration, and the poor 
tablet consistency means that the tablet 2 formula is inappropriate for the extraction system. 
Despite the encouraging performance of the lysis tablets, some problems with their manufacture 
arose during development. The buffer components had a strong oxidising effect on the stainless 
steel molding and punch, causing a rust build up and discolouration, which was then transferred to 
the tablets. This also appeared to cause the tablets to dissolve slightly, becoming wet and sticky. 
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Additionally, although tablet 1 performed well in the tests, due to the lack of a bulking agent and 
lubricant, the “flow” of the powder was poor. This is acceptable when manually producing the 
tablets, but would have caused major difficulties when the process was scaled up for automation. In 
light of this, it was decided to investigate freeze drying the buffer in individual molds. 
 
1.4.13. Lysis buffer pellets 
 
The use of lysis pellets resulted in an average reduction of the time to amplification in the LAMP 
assay, with an overall average reduction of 3.1minutes being recorded. This is likely to be due to the 
increased sample volume afforded by the use of tablets compared to the use of liquid lysis buffer. 
The extractions were carried out using the KingFisher ml extraction platform, in order to ensure 
reproducibility, and the fact that an unacceptable proportion of the beads are lost when attempting 
to manually carry out the liquid handling steps using a magnet. As the system can process only 1ml 
of sample in total, a 1ml portion of the mixture of tablet, 1ml of sample, and 0.5ml of IPA was used. 
This reduces the volume of sample processed to around 66% of the total that will be processed on 
the disk. This 660µl volume is larger than the 200µl volume of sample used during the standard 
extraction method with liquid reagents, and provides a higher concentration of target for the LAMP 
assay, reducing amplification times. 
 
1.4.14. Lyoprotectants 
 
The inclusion of PVP in the lysis pellets at concentrations of 1% to 8% produced a well formed cake, 
with good consistency. Unfortunately, even the lowest concentration of PVP tested, 1%, had a 
marked inhibitory effect on the subsequent LAMP amplification of extracted nucleic acid. The 
inhibitory effect was proportional to the PVP concentration; the higher the PVP concentration used, 
the greater the delay in amplification during the LAMP assay. The inclusion of 1% PVP resulted in an 
average delay of 4.1 minutes, and the inclusion of 2%, 4% and 8% PVP resulted in delays of 5 
minutes, 5.2 minutes and 7.2 minutes, respectively. Target nucleic acid was only detectable in 
extractions carried out using pellets containing 10% PVP in one of the three triplicates, and the 
amplification was 10.7 minutes later than the average amplification using nucleic acid extracted 
using the 0% PVP pellets. 
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The reasons for this inhibitory effect are unclear; PVP is not a known inhibitor of PCR at low 
concentrations, and is used at concentrations of 0.5%-2% in PCR reactions to prevent inhibition 
arising from polyphenolic inhibitors, particularly from plant tissues (Koonjul et al., 1999), although 
PCR inhibition has been noted at concentrations in excess of 2% (Koonjul et al., 1999). Even so, 
LAMP is known to have a markedly higher tolerance than PCR to inhibitors, including those found in 
blood or stool (Francois et al., 2011), and it would be surprising if the LAMP reaction was less 
tolerant to PVP than PCR. An inhibitory effect was noticed with a 1% concentration of PVP in the 
pellet, which would correlate to a 0.66% concentration in the lysis buffer. A possible explanation 
would be that the PVP is being co-purified in this system alongside the nucleic acid, by binding to the 
silica beads. This could either exert an inhibitory effect by interfering with the final LAMP reaction, 
or by competing for binding space on the silica beads, and reducing the yields of nucleic acid 
obtained.  
The presence of polyvinylpolypyrrolidone (PVPP), a highly crossed linked version of PVP, has been 
shown to reduce the yield of DNA extracted using a sodium dodecyl sulphate (SDS) based extraction 
method (Zhou et al., 1996), so there does exist evidence in the literature of PVP based compounds 
negatively impacting on DNA purification.  The negative effect of PVP on the LAMP reaction has also 
been encountered by Mast Group Ltd during their development of the LAMP reaction buffer, so it is 
not a phenomenon peculiar to our laboratory.  
 
1.4.15. Lyoprotectants: PEG 8000  
 
Lyo B and Lyo D solutions were both developed by Mast as lyoprotectant solutions for the LAMP 
reaction buffer and enzyme during freeze drying. The full list of components was not disclosed, apart 
from the fact that the primary lyoprotectant compound was polyethylene glycol (PEG).  The pellets 
produced containing the Lyo B solution were not suitable, due to the incomplete freeze drying of the 
product that occurred.  
However, as the Lyo D buffer produced a solid stable cake at concentrations of 5%-15%, whilst 
having no negative effects on amplification time during LAMP amplification of the extracted nucleic 
acid (table 3), the use of the primary lyoprotectant in Lyo D, PEG 8000, was evaluated. Although the 
precise concentration of PEG 8000 in the Lyo D buffer was undisclosed, it corresponded to a final 
concentration of between 2% and 10%, so this range of concentrations was tested. 
127 
 
The optimal consistency of the pellet was achieved with a PEG 8000 concentration of 2%-8%. The 
pellet readily dissolved in urine and IPA within seconds, yet the cake was solid and easy to handle. 
The inclusion of PEG had a negligible effect on the amplification time in the LAMP assay at any 
concentration tested, with the largest average differences being a less than 30 seconds increase or 
decrease in amplification time. 
The use of PEG 8000 as a lyoprotectants has been previously noted as creating a well formed cake 
(Amin et al., 2004), in comparison with lower molecular weight PEG compounds. PEG 8000 has also 
been used in PCR reaction mix in microfluidic chips in order to prevent surface interactions, without 
compromising amplification efficiency (Panaro et al., 2004), evidence that PEG 8000 carry over into 
the LAMP reaction is unlikely to have inhibitory effects. In fact, it has been demonstrated that the 
inclusion of PEG 8000 or PEG 20000 in the LAMP reaction mix can actually increase the speed of the 
reaction (Nose et al., 2013). 
 
1.4.16. Scanning electron microscopy analysis of lysis pellets 
 
SEM analysis of the surface of the lyophilised lysis buffer pellets revealed the structural differences 
resulting from the inclusion of 2% PEG in the buffer prior to lyophilisation. The pellets containing 
PEG possessed clearly visible pore structures, 2µm - 5µm in size, that are indicative of a well formed 
product. These pores provide a route for water vapour to escape the dry later, ensuring a low 
residual water content, which is paramount when dealing with highly hygroscopic materials such as 
GuHCl, and also reducing drying time (Wang, 2000). 
There was no evidence of any pore structure on the surface of the lysis pellets produced without a 
lyoprotectants. This could explain the poor consistency of these pellets, as it is possible that 
incomplete sublimation had resulted in a higher residual water content than in the pellets containing 
PEG. 
 
1.4.17. Swab performance 
 
An important factor determining the overall sensitivity of the testing process on the LabDisk will be 
the collection of cells during sampling. The design and composition of the swabs used during swab 
sampling can have a large bearing on the organism recovery rate. It is essential that the swab 
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collects as many pathogenic cells from the anatomical site as possible, and that as high a proportion 
as possible are eluted in the transport media in order to be applied for the disk, ultimately providing 
as high a starting copy number as possible in the LAMP assay. 
The use of Copan flocked swabs enabled the highest recovery rate of N. gonorrhoeae from aliquots 
of culture media; an average recovery of 17.6% over all concentrations tested compared with overall 
recovery rates of 9.7% and 10.7% achieved by the Copan cotton swabs and Sterilin cotton swabs, 
respectively. This increase was expected; nylon flocked swabs have been shown as providing a 
greater recovery rate during bacterial sampling, providing an increase of up to 45% total recovery 
efficiency when compared with cotton swabs (Probst et al., 2010). Additionally, previous studies 
have found that the elution of trapped cells occurs more readily from nylon flocked swabs, further 
enhancing the recovery rate, by up to 6-fold (Benschop et al., 2010).  
However, the recovery rates were much lower than those expected. Recovery rates achieved from 
bacterial cultures using flocked swabs have been determined to be between 56% and ~100% by 
various studies (Dube et al., 2013; Harry and Madhusudhan, 2014; Tan et al., 2014), considerably 
higher than the rates obtained by our tests. One difference in the methodologies employed by our 
test, compared with those detailed in the literature, is the absence of a vortexing step to aid in 
elution in our methods. This absence of a vortexing step was decided on by Mast, as there was a 
concern that a vortxing step prior to sample application would constitute a complication of the 
single-step sample handling that is stipulated by the terms of the TSB project. The lack of vortexing 
could be hindering the elution of cells from the swab, due to the absence of any mechanical 
agitation. Vortexing has been shown to increase swab recovery, with one study finding the use of 
vortexing increased the recovery rate from 17.7% to 43.7% (Rose et al., 2004).  
It is worth noting that the swabs were only tested using N. gonorrhoeae, rather than the full set of 
target organisms. These swabs have been tested extensively in the literature, and have been shown 
to provide improved capture rates for a large range of microbial species  (Probst et al., 2010; 
Benschop et al., 2010) Once confirmed experimentally in our laboratory using N. gonorrhoeae, it was 
felt that this was sufficient evidence to support the data in the literature. 
 
1.4.18. Effect of Vortexing speed on swab recovery 
 
The use of a vortex period yielded a sizeable increase in recovery rate, with a 30 second 1000rpm 
vortex increasing the average recovery rate from 24% to 78%. This shows that lower than expected 
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recovery rates achieved using the Copan swabs in the previous study was due to incomplete elution 
of captured cells from the swabs, rather than the swab failing to retrieve the majority of the cells. 
The increase in recovery seen with vortexing was dependent on the strength of the agitation, 
illustrating that the greater the force applied, the less likely the cells are to remain caught in the 
fibres of the swab. The increased gained by using the vortex could be essential in ensuring as high a 
sensitivity as possible for the LabDisk test, especially for samples containing low cell numbers. For 
example, whilst the average organism load from a C. trachomatis positive high vaginal swab sample 
is 7728 cells per ml, the range includes samples with 10 – 100 cells per ml (Michel et al., 2007). With 
organism loads at this low level, a high recovery rate becomes imperative in enabling the test to 
determine the sample as positive. 
 
1.4.19. Swab buffer performance 
 
There was minimal difference in the recovery rate from the Copan flocked swabs between the use of 
any of the buffers tested. The Copan universal transport media provided the highest average 
recovery rate (21%) across all concentrations tested, compared with the PBS buffer and PBS Tween 
buffer, which retrieved an average of 19% and 17% of the cells, respectively. These experiments 
were carried out without the use of a vortexing step, hence the low recovery rates encountered. A 
large scale study examining the effect of the elution buffer on organism recovery rate from wipes 
found that PBS and PBS-Tween (0.04%) enabled optimum recovery rates, which could be enhanced 
by a vortexing period  (Downey et al., 2012). 
 
 
1.4.20. Evaluation of the use of lysis buffer as swab transport media 
 
The replacement of a swab transport media with lysis buffer was able to increase the concentration 
of nucleic acid retrieved during the extraction process, particularly at low sample concentrations, 
evidenced by the decrease in the time to amplification of subsequent LAMP assays. Lysing the cells 
on the swab alleviates the low swab recovery rates caused by the incomplete elution of cells from 
the swab, by ensuring that all nucleic acid is released from cells that have been picked up during 
sampling. This would also remove the need for a vortexing step to be carried out prior to the 
application of the sample. 
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The practical application of the use of lysis buffer rather than a transport media is not without 
difficulty; the use of the lysis pellets requires a liquid sample in order to rehydrate the buffer. The 
pellets would not be soluble in a lysis buffer already containing a ~3M concentration of guanidine 
hydrochloride. If lysis was to take place off disk, and then the lysed sample applied and processed, 
the urine samples would also have to be lysed off disk. If a liquid buffer was to be used, this would 
dilute the sample, potentially impacting on the analytical sensitivity of the system. A possible 
solution to this problem would be to lyse the urine off disk with a lysis tablet, and apply the entire 
sample to the disk, whilst doing the same for swab samples with the liquid media. 
 
1.4.21. Comparison of the effect of swab incubation time in lysis buffer and Copan transport 
media 
 
The pre extraction incubation of the sample in either lysis buffer or Copan UTM transport media had 
no effect on the time to amplification in the LAMP assay, demonstrating that there was a negligible 
level of nucleic acid degradation over the hour tested. Whilst the lysis buffer causes the release of 
nucleic acid into the extracellular environment during lysis, the reducing activity of the guanidine salt 
protects the nucleic acid from degradation by denaturing nuclease enzymes. The Copan UTM works 
by maintaining cell viability and cell integrity, ensuring that the intracellular nucleic acid remains 
protected within the cell, and is not degraded. The initial test was only carried out for one hour, as it 
is unlikely that a sample will be left unprocessed for longer than this in a point of care setting. 
 
 
 
 
 
 
 
 
131 
 
1.4.22. Evaluation and recommendations 
 
The design of a suitable nucleic acid extraction system, and sampling handling methodology, for the 
proposed POC assay required the optimisation of each step of the process. The utilisation of the 
LabDisk as the microfluidic processing unit for the assay, with liquid movements controlled via 
centrifugation, resulted in the initial testing of a magnetic silica based extraction system. A variant of 
this method has been successfully used on centrifugally operated disk platforms previously, it 
enables the rapid concentration of nucleic acids from clinical samples, concentrates both RNA and 
DNA, and can be modelled using the KingFisher Ml extraction robot, which was available in our 
laboratory.  
The assay would need to be able to process both urine samples, and vaginal/endocervical swab 
samples. The urine samples will simply be collected as is standard practice at the point of operation. 
A 1ml volume of this sample will then be applied to the LabDisk using a fixed volume pipette. Swab 
samples would be collected, placed in a transport media, and then a 1ml volume of this transport 
media would be applied to the LabDisk using the same fixed volume pipette. For the swab samples it 
was necessary to determine the optimum swab type, and also transport media required. It was 
found that out of the swab types under consideration, the Copan flocked swabs outperformed the 
Copan and Sterilin cotton swabs (Fig.1.24), and provided the highest recovery rate. This swab type 
was therefore recommended for use.  
The use of lysis buffer as the transport medium for swab samples, rather than a classic transport 
medium, resulted in an increase in assay speed, presumably due to an increase in the quality or 
quantity of nucleic acid being presented to the subsequent LAMP assays (Table 1.26).  This was 
particularly evident when extracting from samples containing low concentrations (1 x 104 cells per 
ml). However, the use of lysis buffer in the transport media would require the use of two separate 
disks; one for urine samples with on-chip lysis, and another for swabs with in-tube lysis. This would 
complicate manufacture of the LabDisks, and could make the test less attractive to consumers. If 
lysis buffer was not used, it was found that Copan TM, which can be supplied alongside the Copan 
flocked swabs which have been chosen for use with this system, enabled a slight increase in the 
percentage of eluted cells when compared with other PBS based buffers tested (Table 1.25).  
It was found that the absence of mechanical agitation during the elution of cells from the swabs 
resulted in poor recovery rates, which could be greatly increased by a vortexing step. A five second 
vortex at 1000rpm, of the swab in transport media, increased the recovery rate from ~24% to 78% 
(Fig.1.25). This is a highly significant increase in the recovery rate and its inclusion could lead to a 
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sizeable increase in clinical sensitivity. It has been suggested that a vortex is sold alongside the POC 
system, in order to be able to provide this agitation step. 
Once the samples, either transport media from a swab, or a urine sample, are applied to the LabDisk 
they will undergo a lysis step. A 95oC heat step at this stage was shown to increase the nucleic acid 
yield obtained (Fig.1.7), reducing the time to amplification of downstream LAMP assays (Fig.4.), and 
also reduce the time needed for complete sample lysis. It is imperative that this heat step occurs 
before the sample contacts the lysis pellet, silica beads, and IPA, in order to have this positive effect 
on amplification time (Fig.1.7). The optimum duration of the heat treatment was found to be 30 
seconds, as this was the minimum time that generated the full benefits of the thermal lysis step 
(Fig.1.8). 
After the thermal lysis step, the sample should be channelled into the extraction chamber, where it 
would be mixed with 0.5ml of IPA, and rehydrate the 15µl of dried MagnaSil beads (Thermo), and 
790µl 2x lysis buffer pellet. Rehydrated freeze dried buffer was equally effective as liquid lysis buffer 
(Fig.1.13). The use of a freeze dried lysis buffer pellet was shown to decrease assay amplification 
time (Fig.1.17.), by enabling a larger volume of sample to be processed. It also removes the need for 
storage of liquid lysis buffer on the LabDisk, which reduces issues of evaporation and spillage, and 
the need for the expensive blister packs required for the IPA and wash buffers. The inclusion of PEG 
8000 in the lysis buffer at a concentration of 2% assisted in the formation of a solid, easily handled 
cake, whilst having no negative effect on the extraction process or downstream LAMP assays 
(Table.1.24.). A 30 second incubation involving the beads, sample, and lysis reagents, was sufficient 
to enable binding of the nucleic acids to the silica beads (Fig.1.5). 
After the lysis procedure is completed, the beads are captured via an external magnet, whilst the 
disk is moved around their position, bringing them through the three wash buffers; wash A, wash B, 
and wash C. A total of 30 seconds is spent in each buffer. The beads are then placed over a heat pad, 
in a procedure designed by IMTEK, to ensure residual 75% v/v ethanol is evaporated before the 
elution stage. The nucleic acid is then eluted in molecular grade water, and used to rehydrate the 
LAMP reaction mix. This mixture is then divided between the LAMP assay wells, where it rehydrates 
the freeze dried primers, and undergoes amplification and fluorescence detection. 
An overview of the suggested sample handling and extraction process, based on the findings of the 
experimental work detailed in this chapter, is shown in Fig.1.28. 
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Fig.1.28. An overview of the recommended sample handling and extraction process, showing 
suggested processes. The figures referred to show supporting experimental data. 
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2.1. Introduction 
 
Neisseria gonorrhoeae is a species of Gram-negative, aerobic, fastidious bacteria, and the causative 
agent of the disease gonorrhoea, the second most common human sexually transmitted infection in 
the developed world (Newman et al., 2007). An estimated 106 million incidences of gonorrhoea 
infection are reported yearly worldwide (World Health Organisation, 2012), representing a 
significant global health burden. Gonorrhoea is transmitted by sexual contact; colonisation usually 
occurs as a localised infection in the genital or cervical mucosa. Infection of the pharynx, anorectum 
and disseminated infections are also encountered (Sherrard, 2005), including endocarditis (Butterly 
et al., 2011) and arthritis (Dalla Vestra et al., 2008).  
90% to 95% of urethral infections in men are symptomatic, compared with only 20% of genital 
infections in women and 5% to 10% of pharyngeal infections (CDC, 2010). In men, symptoms include 
mucopurulent urethral discharge and pain upon urination. If left untreated infection can lead to 
epididymititis with associated testicular pain, swelling and fever (Little, 2006). In women, symptoms, 
if present, tend to be milder. They include pain upon urination, vaginal bleeding and discharge. 
Pelvic inflammatory disease (PID) also occurs in 10% to 20% of untreated women, which can lead to 
infertility and ectopic pregnancy, with symptoms including chronic abdominal pain, fever and 
cervical motion tenderness (Pearson et al., 2004). 
 
2.1.1 Pathogenesis 
 
Transmission of N. gonorrhoeae occurs via sexual contact with an infected partner, although 
transmission to a child during pregnancy can also occur (Brocklehurst, 2002). In heterosexual sex, 
transmission is thought to occur more readily from an infected man to an uninfected woman (50 – 
70% probability per exposure), than vice-versa (20 – 35% per exposure) (Edwards and Apicella, 
2004). Infection is initiated by adherence to host epithelia, which is mediated by a number of N. 
gonorrhoeae surface proteins and pili. N. gonorrhoeae possesses type IV pili, which enable twitching 
motility, providing a means for the N. gonorrhoeae cells to move through the mucosal epithelia 
during colonisation (Plant and Jonsson, 2006). Type IV pili also play a key role in the adherence of the 
gonococcus to the host epithelial surface, via the presence of a number of pili-associated adhesins. 
PilC, a pilus associated 110-kDa protein, is expressed in the tip of the pilus, and cell membrane, and 
is essential for adherence to epithelial cells (Wolfgang et al., 1998). N. gonorrhoeae mutants lacking 
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PilC are unable to adhere to epithelia (Wolfgang et al., 1998), and purified PilC conjugated to latex 
beads enables bead binding to epithelial cells (Rudel et al., 1995), demonstrating the function of PilC 
as an essential adhesion. Additionally, PilE, the major pilus subunit, has been determined as having 
binding affinity to epithelial cells itself, and antigenic variants of this protein modulate epithelial 
adherence (Winther-Larsen et al., 2001; Plant and Jonsson, 2006). The fibre subunit PilV has also 
been demonstrated to have a key role in pili mediated adherence, by promoting the functional 
display of the PilC adhesin on the pilus fibre itself (Winther-Larsen et al., 2001). Interaction between 
the pili and the host cell membrane has been shown to result in cyto-skeletal rearrangement in of 
the host cell, activating microvilli which promote the engulfment of the bacterial cells, enhancing 
invasion(Griffiss et al., 1999). This pili-host membrane interaction also instigates the redistribution of 
membrane associated proteins such as actin, ezrin and CD46, a membrane cofactor receptor that 
has been demonstrated to act as a receptor for PilC in some cell lines (Merz and So, 1997; Edwards 
and Apicella, 2004). 
After this initial pili-mediated attachment, the intimate attachment and subsequent invasion of N. 
gonorrhoeae is chiefly mediated by Opacity (Opa) proteins; a family of outer membrane proteins 
that modulate attachment, tissue tropism, and the avoidance of the immune response. A strain of N. 
gonorrhoeae may harbour up to 12 variants of the Opa gene, the expression of which is constantly 
varied. These proteins can be grouped into two classes dependent on their binding targets; OpaHS 
proteins target host cell heparin sulphate proteoglycans (HSPG) (Grant et al., 1999), whilst OpaCEA 
proteins bind to members of the carcinoembryonic related cell adhesion molecule (CEACAM) family 
(Sadarangani et al., 2011). Binding of OpaHS proteins to surface HSPG is mediated by bridging 
molecules such as vitronectin or fibronectin, in a process resulting in host cell invasion caused by a 
cytoskeletal rearrangement that facilitates the endocytosis of the membrane associated bacterial 
cell (Gomez-Duarte et al., 1997; van Putten et al., 1998). Binding of OpaCEA to CEACAM proteins, also 
results in endocytosis of the gonococcus following cytoskeletal activity, in a process resulting from 
the activation of host cell Src tyrosine kinases, and subsequent activation of Rac GTPase (Hauck et 
al., 1998). 
N. gonorrhoeae porins have also been implicated in having a number of roles in N. gonorrhoeae 
pathogenesis. Porins form hydrophilic ion and water channels in the gonoccocal membrane, where 
they are abundantly expressed. N. gonorrhoeae possesses two porins, PIA and PIB, expressed by the 
PoR and PorB genes, respectively (Olesky et al., 2006). The porins of pathogenic Neisseria are unique 
in their ability to insert into the cell membranes of eukaryotic cells that they are in close contact 
with, to form gated ion channels (Ayala et al., 2002), which has been shown to impede neutrophil 
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activity and macrophage maturation (Lorenzen et al., 2000). Porin IB has been shown to activate NF-
KappaB in human urethral epithelial cells in vitro, which results in the increased expression of a 
number of anti-apoptotic genes such as cox-2, bfl-1 and c-IAP-2 (Binnicker et al., 2004). It is thought 
that the prevention of apoptosis allows the gonococcus to evade the host immune response, and 
multiply intracellularly, enhancing the likelihood of successful colonisation (Binnicker et al., 2003). 
A primary mechanism of inflammation encountered during the course of N. gonorrhoeae infection 
occurs via the release of peptidoglycan monomers, which instigate the release of host pro-
inflammatory cytokines, damage ciliated epithelia, and activates the Nod signalling cascade, 
ultimately increasing production of Interleukin-8 (Cloud-Hansen et al., 2008). One peptidoglycan 
monomer released by N. gonorrhoeae is tracheal cytotoxin (TCT), a 921 dalton glycopeptide, shown 
to be cytopathogenic to vaginal and fallopian ciliated epithelia (Swaminathan et al., 2006; Melly et 
al., 1984). The damage and subsequent sloughing of ciliated epithelia seen in pelvic inflammatory 
disease occurring from persistent infection may be a result of this peptidoglycan-host cell interaction 
(Cloud-Hansen et al., 2008); purified peptidoglycan fragments released by N. gonorrhoeae cause 
sloughing of ciliated fallopian tube cells in the absence of N. gonorrhoeae cells (Melly et al., 1984). 
 
2.1.2. Epidemiology and clinical presentation 
 
In 2008 there were an estimated 106.1 million new cases of N. gonorrhoeae infection worldwide, 
with an estimated 36.4 million people infected at any one time (WHO, 2012). This represents an 
estimated 21% increase in incidence compared to the 2005 WHO figures (WHO, 2008), illustrating 
the increasing spread of this disease. It is worth noting, however, that this sharp increase could be 
explained by the increased use of sensitive NAAT based diagnostics, especially in resource poor 
settings, increasing the likelihood of diagnosis, and inflating the number of cases reported. The 
incidence of gonoccocal infection is higher in developing countries, such as those found in South East 
Asia, the Western Pacific region, and Africa (Table 1), due in part to lower levels of safe-sex 
education, reduced condom use, and lack of access to testing facilities (Mayaud and Mabey, 2004). 
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WHO Region 
Incidence (per 1000) Prevalence (%) 
Female Male Female Male 
Africa 49.7 60.3 2.3 2.0 
The Americas 18.5 27.6 0.8 0.7 
South East Asia 16.2 37.0 0.8 1.2 
European 8.3 7.0 0.3 0.2 
Eastern 
Mediterranean 
8.1 11.6 0.3 0.3 
Western Pacific 34.9 49.9 1.5 1.3 
Table 2.1. Global incidence and prevalence of N. gonorrhoeae infection, according to 2008 WHO 
estimates. Data taken from WHO (2012). 
 
In England the incidence of gonorrhoea is increasing; 25,525 cases were diagnosed in 2012, a 21.4% 
increase since 2011 (Health Protection Agency, 2012) and a 51.6% increase since 2010 (Health 
Protection Agency, 2011). As with the increase seen in the WHO figures, the increase may partially 
be down to an increase in test sensitivity driven by increased NAAT use, however it is thought that 
these figures do indicate a genuine increase in gonorrhoea incidence in the UK (Savage et al., 2012). 
In the UK, around half of all diagnosed cases are found in men who have sex with men (MSM), and 
the incidence in this group rose 61% from 2010 to 2011, making this group the target of particular 
attention from public health bodies in the UK (Savage et al., 2012). A large scale study in the US 
screened MSMs at an STD clinic (n=5539) and at a gay men’s community health centre (n=895) and 
found an overall prevalence of 6%, 6.9% and 9.2% of detectable gonoccocal infection at urethral, 
rectal, and pharyngeal sites, respectively (Kent et al., 2005). A total of 64% of the infections were at 
non-urethral sites, and it is imperative that extra-urethral testing is offered to MSM in order provide 
effective testing to this population. 
Infections in males are frequently symptomatic, with urethral infections causing symptoms in 90 – 
95% of cases. Symptoms occur 2-5 days post-exposure, with urethral discharge and dysuria present 
in >80% and >50% of infections, respectively (BASHH, 2011 guidelines). Pharyngeal infections are 
frequently asymptomatic, with symptoms occurring in 5% - 10% of cases, and include tonsillitis and 
pharyngitis. Anal N. gonorrhoeae infection, particularly prevalent in MSM, is also rarely 
symptomatic, with symptoms such as proctitis and discharge occurring in <15% of cases (Hamlyn and 
Taylor, 2006). N. gonorrhoeae infection in males has also been documented as causing epididymitis 
(Trojian et al., 2009) and prostatitis (Zhou et al., 2003). 
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N. gonorrhoeae infections in females can occur in multiple anatomical sites, including the 
endocervix, urethra, anus and pharynx. Endocervical infections are asymptomatic in 80% of cases 
(CDC, 2010); possible symptoms, if present, include increased or altered vaginal discharge, lower 
abdominal pain, and rarely, intermenstrual bleeding (BASHH, 2012). Untreated endocervical 
infection, which is a possibility due to its asymptomatic nature, is thought to progress to PID in 10%-
20% of cases. This serious ascending infection leads to uterine and tubal scarring, which causes 
infertility, chronic pelvic pain, and ectopic pregnancy in 20%, 18% and 9% of PID sufferers, 
respectively (Walker, 2011). Rectal infection in women presents in a similar fashion to those found in 
males, and often occurs via transmucosal spread of genital secretions to the anus, rather than by 
anal intercourse (BASHH, 2012). Occurrences of gonococcal infection during pregnancy can lead to 
transmission to the neonate during childbirth, with the likelihood thought to be around 50% 
(Hammerschlag, 2011). Neonatal infection can occur as conjunctivitis, arthritis or sepsis (Walker, 
2011). Disseminated gonoccocal infections can occur in either sex, with N. gonorrhoeae cells 
migrating from the primary site of infection via the circulatory system (Sherrard, 2005), which can 
lead to arthritis (Dalla Vestra et al., 2008), endocarditis (Butterly et al., 2011), or even sepsis (Walker, 
2011). 
 
2.1.3. Relationship with other pathogens 
 
Co-infection of N. gonorrhoeae and C. trachomatis is common, with a large UK based study involving 
1239 women and 1141 men with gonorrhoea, chlamydia, or both, finding the 24% of heterosexual 
men and 38.5% of heterosexual women who had gonorrhoea were simultaneously infected with C. 
trachomatis (Creighton et al., 2003). Of patients with C. trachomatis infection, 18.8% of men and 
13% of females were also concurrently infected with N. gonorrhoeae. A large study in the US youth 
detention system, involving over 100,000 samples found that of patients with N. gonorrhoeae 
infection, C. trachomatis co-infection was present in 51% of males and 54% of females (Kahn et al., 
2005). Co-infection with sexually transmitted pathogens is not uncommon, as the methods of 
transmission, and high-risk populations are the same. Also, the frequent asymptomatic nature of 
STIs increases the likelihood that an infection will go undetected, allowing the patient to become 
exposed to another pathogen prior to treatment. The presence of an STI can also damage the genital 
epithelia, increasing the likelihood of the transmission of other pathogens across this surface. The 
high prevalence of C. trachomatis co-infection in patients diagnosed as harbouring N. gonorrhoeae 
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infection has lead the CDC in the US, and PHE in the UK, to recommend that C. trachomatis is treated 
for concurrently with antibiotic therapy for N. gonorrhoeae (CDC, 2012; GRASP, 2012). 
Infection with N. gonorrhoeae has been identified as a risk factor for increased HIV-1 transmission, 
with a study in Zaire finding women were 3.8 times as likely to become infected with HIV-1 whilst 
infected with N. gonorrhoeae (Laga et al., 1993). One study examining 431 initially HIV negative 
heterosexual women, of which 9.8% seroconverted over the two year study period, found that HIV 
infection was 4.8 times more likely in women with gonoccocal infections (Laga et al., 1993). Anal N. 
gonorrhoeae infection has been associated with increased risk of HIV acquisition in MSMs in 
Australia (Jin et al., 2010) and America (Bernstein et al., 2010). 
N. gonorrhoeae releases extracellular heptose during a growth, which has been shown to induce 
HIV-1 expression in CD4+ lymphocytes in an NF-κB dependent manner, driving viral production 
(Malott et al., 2013). This increases viral shedding, and therefore the infectivity of the patient, 
providing a direct link between N. gonorrhoeae infection and increased HIV transmission. 
Additionally, the human defensins 5 and 6 (HD5 and HD6), released as a response to N. gonorrhoeae 
infection, have been found to increase HIV transmission, by facilitating viral entry (Klotman et al., 
2008). These defensins, and human beta defensins (HBDs) which are also released during gonococcal 
infection,  can also up regulate inflammation via a range of interleukins and pro-inflammatory 
cytokines, which act to recruit HIV target cells, providing a larger pool of potential host cells for 
initial HIV infection and replication(Jarvis and Chang, 2012). HD5 and HD6 have also been shown to 
prevent the anti-HIV activity of polyanionic microbicides, and HIV entry and fusion inhibitors in vitro 
(Jarvis and Chang, 2012). It has also been demonstrated that N. gonorrhoeae can enhance the 
susceptibility of primary CD4+ cells to HIV-1 infection, via the activation of toll-like receptor 2 (TLR2) 
(Ding et al., 2010). These mechanisms contribute to the increased risk of HIV-1 acquisition in people 
who are already harbouring a N. gonorrhoeae infection. Control of N. gonorrhoeae, along with other 
sexually transmitted pathogens implicated in increased HIV transmission risk, is an important aspect 
of the control of HIV worldwide. 
 
2.1.4. Diagnosis 
 
Traditionally, diagnosis of gonorrhoea has been carried out via microscopy and culture of the 
organism on selective media. Microscopy of Gram stained genital specimens enables detection of 
the coffee bean shaped diplococcus, and offers acceptable sensitivities of 90-95% in symptomatic 
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men. The sensitivity of this method for the diagnosis of asymptomatic men or females is 
considerably lower; 50% - 75% and 20% - 50% respectively (BASHH, 2011). Microscopy from urethral 
exudates of symptomatic men is sensitive and specific enough to be utilised diagnostically, and has 
the added advantage of being fast enough to be carried out at the point of care (POC), enabling 
immediate treatment (Tapsall, 2001).  
Culture from clinical specimens is carried out using a non-selective agar, typically chocolate agar, in 
conjunction with a selective media such as Thayer martin agar in order to remove commensal 
microorganisms frequently picked up by genital sampling (Ng and Martin, 2005). Plates are 
incubated at 35oC to 37oC, supplemented by 5% CO2, for 24 hours and then inspected for growth. 
The recovery of Gram negative diplococcus from N. gonorrhoeae selective media, testing oxidase 
positive, is considered a positive diagnosis. Ideally, specimens should be inoculated onto culture 
media and incubated immediately after acquisition in order to maintain maximum viability of the 
organisms. Realistically this is only possible if there is a dedicated microbial diagnostics laboratory at 
the site of testing. If this is not the case, the sample is added to a transport media designed to 
maintain viability prior to culture, or the plates are inoculated and held in a 5% CO2 enriched 
atmosphere in a candle jar or incubator during transit. The more sophisticated of these transport 
media’s include mechanisms to provide a CO2 enriched atmosphere, such as the InTray GC system 
(BioMed Diagnostics, USA), which relies on a CO2 tablet to provide conditions conducive to growth of 
the gonococcus. Various studies have demonstrated the sensitivity of culture for N. gonorrhoeae to 
be 69.8%, 66.7%, 47.4% and 72.2% for endocervical swabs (Van Dyck et al., 2001), rectal swabs 
(Bachmann et al., 2010), pharyngeal swabs (Shafer et al., 2002) and male urethral swabs (Buimer et 
al., 1996), respectively. 
Nucleic acid amplification testing (NAAT) for gonorrhoea is becoming more widespread, and in the 
developed world is commonly used, often in conjunction with culture, to provide a diagnosis in 
suspected cases of gonorrhoea. Commonly used NAATs include those based on the polymerase 
chain reaction (PCR), ligase chain reaction (LCR) and novel amplification assays such as APTIMA GC 
(Gen-Probe) assays, which utilise transcription mediated amplification technology, and the BD 
ProbeTec (PT) energy transfer amplified DNA assay (Chernesky et al., 2005). NAATs offer 
unparalleled specificities and sensitivities, with PCR assays typically boasting sensitivities and 
specificities of >95% and 100% respectively, compared with sensitivities of ~68% obtained via culture 
(Luijt et al., 2005). NAAT provides a more rapid diagnosis than culture, due to the removal of the 
need for lengthy incubation periods.  
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The first NAAT s to be described for N. gonorrhoeae, as with most organisms, were home-brew PCR 
assays, published in the literature. PCR assays have been described for amplification of a number of 
conserved gene targets, including cppB (Ho et al., 1992) and the glnA gene (Chaudhry and Saluja, 
2002). An abundance of commercial PCR, and real-time PCR assays have been released, to accord for 
the high levels of testing occurring for N. gonorrhoeae infection, owing to the high prevalence of 
infection, and overlap of symptoms with other prevalent infections such as those caused by C. 
trachomatis and T. vaginalis.  
The Cobas CT/NG test, is a commercially available and FDA approved NAAT, processed on the c4800 
platform (Roche Cobas, US), providing a fully automated testing system for the diagnosis of C. 
trachomatis and N. gonorrhoeae infection. An automated magnetic silica based nucleic acid 
extraction system purifies nucleic acid from the sample, which then undergoes real-time PCR 
amplification using two primer sets, specific to the highly conserved DR-9 repeat region (Van Der Pol 
et al., 2012). The sensitivity of the assay has been determined to be between 95.6% and 100%, with 
a specificity of >99.8% (Van Der Pol et al., 2012). 
Another available FDA approved NAAT for the combined detection of N. gonorrhoeae and C. 
trachomatis is the CT/NG GeneXpert assay (Cepheid, US). This assay uses disposable single use assay 
cartridges, which enable automated sample processing and rapid real-time PCR based detection, 
which removes the need for liquid handling by the operator. The test takes 90 minutes to complete, 
from the application of the patient sample to the retrieval of the results, enabling same day testing. 
A comparison with the APTIMA Combo 2 assay (Hologic GenProbe, US) and the BD ProbeTec BDPT 
assay (Becton Dickinson, US) demonstrated that the GeneXpert assay had sensitivities of 100%, 
100% and 95.6%, and 98% when processing endocervical, vaginal, female urine, and male urine 
samples, respectively (Gaydos et al., 2013). Specificities were over 99.8% with all sample types. 
Simple point of care (POC) tests have been developed for the detection of N. gonorrhoeae, but have 
not found widespread use, due to low analytical sensitivities. Leukocyte esterase (LE) dipstick tests, 
which detect the presence of leucocytes present due to inflammation caused by infection of the 
urthera, have been used to screen for gonoccocal infections. These tests are simple to carry out, and 
typically take no longer than two minutes to provide a result, enabling their use at the POC (Watchirs 
Smith et al., 2013). A systematic review of evaluations of a number of LE tests for N. gonorrhoeae 
detection found an overall sensitivity of 71%, and a specificity of 70% (Watchirs Smith et al., 2013). 
These tests only identify the presence of inflammation caused by infection, and are therefore non-
specific for gonorrhoeae, but can indicate the need for antibiotic therapy, or for more specific 
testing. The application of these tests is limited by this un-specific nature, and their low sensitivities, 
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but they remain a viable option for screening of populations unlikely to return for follow up (Olshen 
and Shrier, 2005). Rapid immunochromatographic assays, for the detection of N. gonorrhoeae 
specific antigen, are also available, and well suited to POC testing.  An evaluation of the 
immunochromatographic NOW Gonorrhoea test using a sample of 58 male patients (34 positive) 
found that the assay sensitivity and specificity to be 94.1% and 95.8%, respectively (Suzuki et al., 
2004). A comparative study of three POC immunographic assays found a median sensitivity and 
specifity of 70% and 96% (Watchirs Smith et al., 2013). The authors did note that the sensitivity 
could have been overestimated, due to the predominance of samples from symptomatic patients 
used in the study, who will typically have a higher organism load, and therefore antigen 
concentration in the sample. These immunochromatographic POC tests are relatively expensive, and 
the lower analytical sensitivity of around 1 x 104 N. gonorrhoeae cells per ml, a 100 fold decrease in 
sensitivity compared with modern NAAT technologies such as the AC2 assay (Harkins and Munson, 
2011), means that they are not regularly used clinically. 
Rapid isothermal amplification technologies are beginning to be applied to the detection of this 
pathogen. A multiplex helicase-dependent amplification end-point assay has been described for the 
simultaneous detection of C. trachomatis and N. gonorrhoeae (Doseeva et al., 2011). Also, an on-
chip recombinase polymerase amplification assay capable of detecting 100 N. gonorrhoeae CFU has 
been developed (Kersting et al., 2014). To the best of our knowledge, there has not yet been a loop 
mediated isothermal amplification assay designed for the detection of N. gonorrhoeae. A N. 
gonorrhoeae specific LAMP assay would enable rapid molecular testing, without the need for 
expensive real-time PCR technology, and with a greater tolerance to amplification inhibition, which 
may allow for the direct detection from urine samples. 
 
2.1.5. Treatment and Resistance 
 
Treatment for gonorrhoea infection consists of appropriate antimicrobial therapy, with azithromycin 
(1g orally) in conjunction with ceftriaxone (500mg intramuscularly) currently administered in the UK 
and US (GRASP report, 2011; CDC MMWR, 2010). The primary anti-gonoccocal agent in this dual 
therapy is the cephalosporin ceftriaxone, which has excellent efficacy against N. gonorrhoeae. The 
supplementation of ceftriaxone with azithromycin was instigated as a response to growing 
resistance rates in N. gonorrhoeae to third generation cephalosporins, and the high incidence of co-
infcetion with C. trachomatis (CDC, 2010). Doxycycline has also been administered for this purpose, 
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in place of azithromycin, but is regarded as less preferable, as isolates possessing resistance to third 
generation cephalosporins frequently also display decreased tetracycline susceptibility (MMWR 
Morb Mortal Wkly Rep, 2010). 
Antimicrobial resistance in N. gonorrhoeae isolates is extremely widespread, with resistance to most 
classes of antibiotic, including penicillins, macrolides, tetracyclins, quinolones (Whiley et al., 2012) 
and most recently cephalosporins (Ross and Lewis, 2012), documented in clinical isolates. Wide 
spread resistance to previously extensively used therapies, such as penicillins, tetracyclins,and 
macrolides, has rendered their use ineffective, leaving expensive third generation cephalosporins as 
the only remaining drugs with high efficacy available. The recent emergence of isolates with 
decreased susceptibility to extended spectrum cephalosprins (ESC), such as cefixime and ceftriaxone 
(Ohnishi et al., 2011), which are considered to be the “last line” treatment options, indicate the 
potential future difficulties facing the treatment of N. gonorrhoeae infection, and raise the 
possibility of untreatable gonoccocal infection (Bolan et al., 2012). The loss of effective treatment for 
this disease would significantly raise the morbidity and mortality associated with gonoccocal 
infection, and has lead the World Health Organisation to produce a global action plan to control the 
spread and impact of antimicrobial resistance in Neisseria gonorrhoeae (WHO, 2012). Treatment 
failures with 500mg ceftriaxone in infections caused by the multi drug resistant NG-MAST genotype 
1407 clone have been described in Sweden (Golparian et al., 2014a). This strain has also been 
recorded in Japan as causing a treatment failure with 2g azithromcyin (Morita-Ishihara et al., 2014), 
and has been responsible for multiple cefixime treatment failures since 2010; in the UK (Ison et al., 
2011), Austria (Unemo et al., 2011) Norway (Unemo et al., 2010), and the US (Hess et al., 2012) 
which have lead to cefixime being removed from recommended treatment lists by leading public 
health bodies worldwide (CDC, 2010; WHO, 2012; BASHH, 2012). 
Since the beginning of the antibiotic era, N. gonorrhoeae has demonstrated the ability to rapidly 
generate and maintain antibiotic resistance, via the acquisition of chromosomal and plasmid-
mediated resistance genes. N. gonorrhoeae is known to be highly transformable, and has the unique 
ability to take up double stranded DNA sequence harbouring specific 10bp sequence elements, 
termed DNA uptake sequences (DUS), present in the N. gonorrhoeae genome and those of related 
species, in a highly efficient manner (Elkins et al., 1991). This process has been shown to rely on the 
expression of genes required for the production of type IV pili, in combination with three associated 
proteins; ComP, PilT, and ComE (Aas et al., 2002). N. gonorrhoeae is also capable of taking up double 
stranded DNA lacking this particular recognition sequence, bus does so with much less efficiency. 
Absorbed DNA is then incorporated into the homologous area of the receiving cells genome in a 
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process of recombination, providing the gonococcus with a mechanism for genetic diversification, 
and potential route for the acquisition of resistance genes from closely related species or other N. 
gonorrhoeae cells (Aas et al., 2002). This mechanism is thought to be responsible for the transfer of 
antimicrobial resistance genes from commensal Neisseria species, which are likely to be exposed to 
antimicrobials more frequently than the transient pathogenic gonococcus (Unemo and Shafer, 
2011). N. gonorrhoeae also displays a high frequency of internal recombination and mutation 
(O'Rourke and Stevens, 1993), increasing the likelihood of mutations leading to antimicrobial 
resistance arising as a response to exposure to antimicrobial drugs. A feature of N. gonorrhoeae 
antimicrobial resistance is the ability of N. gonorrhoeae to maintain its resistant phenotype, even 
after extended periods without the selection pressure of the drugs in question. For example, a high 
proportion of N. gonorrhoeae isolates in areas where the application of tetracyclins, quinolones and 
penicillins for the treatment of gonorrhoea has long been discontinued still exhibit high level 
plasmid-mediated resistance to these drugs (WHO, 2012). 
A primary route to ESC resistance is mutation of the penA gene, which encodes the protein target of 
ESCs, the PBP2 transpeptidase(Unemo and Nicholas, 2012). Mosaic alleles of penA, and non-mosaic 
alleles containing a base substitution at A501, have been shown to lead to a reduced ESC 
susceptibility phenotype (Golparian et al., 2010; Ohnishi et al., 2010; Huang et al., 2010). Mosaic 
PBP2 mediated resistance tends to lead to decreased susceptibility to cefixime in comparison with 
ceftriaxone (Zhao et al., 2009; Unemo and Nicholas, 2012), and this may be one of the reasons that 
decreased susceptibility to cefixime ha been detected more readily than to ceftriaxone in clinical 
isolates. Resistance arising from single base substitutions at A501 tend to equate to increased 
ceftriaxone resistance, and is less commonly encountered. This particular mutation has not been 
discovered in any species other than N. gonorrhoeae, and is therefore thought to have arisen via 
mutation in these species rather than via the acquisition of genetic elements from alternate species 
of Neisseria (Unemo and Nicholas, 2012). 
One mechanism of ESC resistance that has been demonstrated in ESC resistant clinical isolates is the 
overexpression of the MtrC-MtrD-MtrE efflux pump, which increases the rate of the removal of ESC 
drugs from the intracellular environment (Zhao et al., 2009; Folster et al., 2009). Overexpression of 
the two other pump systems known to remove antimicrobial compounds in this organism, MacA-
MacB and NorM, is also thought to contribute to ESC resistance, but to a lesser degree (Golparian et 
al., 2014b). The demonstration that the inactivation of these efflux pumps absolves the resistance 
phenotype from ESC resistant isolates, reducing MICs to clinically susceptible breakpoints, has lead 
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to the suggestion that efflux pump inhibitors could have a part to play in the future treatment of 
resistant N. gonorrhoeae (Golparian et al., 2014b). 
One difficulty facing the monitoring of global resistance profiles in N. gonorrhoeae is the increased 
reliance on molecular detection methods for gonorrhoea diagnosis. NAATs are typically carried out 
from nucleic acid extracted directly from samples, precluding the need for prior culturing (WHO, 
2012). Compounding this, transport buffers for samples destined for NAAT are designed to protect 
nucleic acid integrity rather than organism viability, making the retrieval of viable organisms difficult. 
The development of methods for detecting antimicrobial resistance in N. gonorrhoeae directly from 
nucleic acid faces difficulties due to the genetic complexity behind the resistant phenotypes, with 
multiple variations in large numbers of genes all potentially involved in any isolate(Golparian et al., 
2014b). Therefore, culture of the organism from clinical isolates and subsequent determination of 
MIC’s of relevant antimicrobial compounds is an essential process for the monitoring of global AMR 
in N. gonorrhoeae. 
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Aims 
 To maintain the culture of N. gonorrhoeae, in order to provide a source of N. gonorrhoeae 
DNA to ourselves and also Public Health England 
 To provide confirmation of the suitability of the magnetic silica based extraction system for 
the purification of nucleic acids from N. gonorrhoeae. 
 To determine the limits of detection of the GroEL LAMP assay designed by PHE. 
 To design both a LAMP assay and PCR assay for a suitable N. gonorrhoeae target sequence, 
and compare the sensitivity of both methods. 
 To compare the performance of the designed LAMP assay with PHE designed LAMP assays 
for alternative targets. 
 To determine the tolerance of the N. gonorrhoeae LAMP assay to the presence of 
amplification inhibitors in urine, such as urea and blood. 
 To explore the use of the LAMP assay for the direct detection of N. gonorrhoeae from urine 
samples, using a visual detection method. 
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2.2. Materials and Methods  
 
2.2.1. Culture of N. gonorrhoeae 
 
N. gonorrhoeae (ATCC 19424) was cultured on chocolate agar (blood agar base, Sigma Aldrich, UK; 
defibrinated horse blood, TCS, UK) at 37oC at 5% CO2. Broth cultures were maintained under the 
same conditions, in brain heart infusion broth (Oxoid, UK). 
 
2.2.2. Culture of Escherichia coli 
 
E. coli K-12 (lab strain) was cultured on nutrient agar (Oxoid, UK) incubated at 37oC. Broth cultures 
were maintained under the same conditions in nutrient broth (Oxoid, UK). 
 
2.2.3. Use of human urine  
 
For each experiment were human urine was used, the urine was a mix of urine taken from one 
individual over a 12 hour period. Urine was stored at 6oC and used no later than 24 hours after 
excretion. 
 
2.2.4. PCR primer design 
 
PCR primers were designed for ORF1 of the glutamine synthetase (glnA) gene of N. gonorrhoeae. 
The target sequence was first downloaded from the NCBI GenBank database (Accession number 
M84113), and primers were designed using Primer3 (http://frodo.wi.mit.edu/). ORF1 PCR primer 
sequences are shown in Table 1. Primer specificities were checked using BLAST 
(http://blast.ncbi.nlm.nih.gov/).  
 
 
166 
 
Primer Sequence Length (bp) Product size 
(bp) 
Annealing 
Temp (oC) 
N. gonorrhoeae 
ORF1 FWD 
GACGTATTTCATATCTTGGG 20 
139 47 
N. gonorrhoeae 
ORF1 RVS 
GGTGAACATTTTGGAAG 17 
Table 2.2. ORF1 PCR primer sequences 
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2.2.5. LAMP primer design 
 
In this study, LAMP primers were designed for ORF1 of the glnA gene of N. gonorrhoeae. The target 
sequence was first downloaded from the NCBI GenBank database (Accession number M84113). 
LAMP primers were designed using PrimerExplorer Version 4 (http://primerexplorer.jp/e/). The 
additional optional Loop primers were not included. ORF1 LAMP primer sequences are shown in 
Table 2.3. Primer specificities were checked using BLAST (http://blast.ncbi.nlm.nih.gov/). Both PCR 
and LAMP primers were synthesised commercially (Eurofins, Germany). 
 
LAMP Primer Sequence Length (bp) 
N. gonorrhoeae 
ORF1 S1 F3 
GGGAAACGCGCTTCGATG 
18 
N. gonorrhoeae 
ORF1 S1 B3 
ACCGCGCTCTACTACATCG 19 
N. gonorrhoeae 
ORF1 S1 FiP 
GGCCTATTCCGCCAAAAACCGTGCCTTGCTGCTGTTCACA 40 
N. gonorrhoeae 
ORF1 S1 BiP 
ACGAGGCGTTTGTAGGAGTTGGCAAACACGCCAAAGCCCT 40 
N. gonorrhoeae 
ORF1 S2 F3 
TGGTCGGTGCTTCAAAGTG 19 
N. gonorrhoeae 
ORF1 S2 B3 
GCACGTCCACCAATCCATT 19 
N. gonorrhoeae 
ORF1 S2 FiP  
CAAACACGCCAAAGCCCTGAACGCACGAGGCGTTTGTAGG 40 
N. gonorrhoeae 
ORF1 S2 Bip  
TGTAGTAGAGCGCGGTATCGGACGGTCAAAACCTGTTCGCA 41 
Table 2.3. Sequences of the N. gonorrhoeae ORF1 S1 and ORF1 S2 LAMP primer sets. 
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2.2.6. Public Health England (PHE) N. gonorrhoeae LAMP primer sets 
 
Sequences were provided by PHE for N. gonorrhoeae LAMP primer sets, specific to the 
GroEL and PorA genes. The primer sequences are shown in table 2.4 and 2.5. 
LAMP Primer Sequence Length (bp) 
N. gonorrhoeae 
GroEL F3 
ACTTTATCAACGACGCGGAA 
18 
N. gonorrhoeae 
GroEL B3 
ACGGTTTTCAGGATGCCG 19 
N. gonorrhoeae 
GroEL FiP 
AGGTCGCGGATGTTGCTGATTTAAATCGCCGGTCTGGACA 40 
N. gonorrhoeae 
GroEL BiP 
TGGAACAAGTGGCGAAAGCCAGACCAAAGTCGCCAAGGC 40 
N. gonorrhoeae 
GroEL Loop F3 
GTCGAACAGCAAAACAAACGG 21 
N. gonorrhoeae 
GroEL Loop B2 
CCCGCTGTTGATTATCGCTGAAG 23 
Table 2.4. Sequences of the N. gonorrhoeae GroEL LAMP primer sets, designed by PHE. 
 
LAMP Primer Sequence Length (bp) 
N. gonorrhoeae 
PorA F3 
ACCAAAAACAGTACGACCGA 19 
N. gonorrhoeae 
PorA B3 
AAGTGCGCTTGGAAAAATCG 19 
N. gonorrhoeae 
PorA FiP  
ATGGGCATAGCTGATGCGCGAATTGCCGCCACTGCTTC 40 
N. gonorrhoeae 
PorA Bip  
TCGACTTTGTCGAACGCAGTCAAATCGACACCGGCGATGA 41 
N. gonorrhoeae 
PorA Loop F3 
GCGAACATACCAGCTATGATCAA 23 
Table 2.5. Sequences of the N. gonorrhoeae PorA LAMP primer sets, designed by PHE.  
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2.2.7. DNA extraction 
 
DNA extractions were carried out using a QIAmp DNA mini kit (QIAGEN Inc., USA), following the 
protocol for bacterial cells. RNase A (New England Biolabs, UK) was used during the RNA digestion 
step. DNA was eluted in a single 60µl volume of molecular grade water. DNA quantification was 
carried out using a Spectrostar plate reader in conjunction with an LVIS plate (BMG Labtech, UK). 
The corresponding genome copy number was calculated from the weight of the N. gonorrhoeae 
genome, which is 2.45fg (2.2 × 106 bp × 665 Da/bp × 1.67 × 10−24 g/Da) (Geraats-Peters et al., 2005a). 
Where indicated, total nucleic acid extractions were also carried out using the KingFisher ML 
automated extraction system (See chapter 1.2.7.). 
 
2.2.8. ORF1 PCR Reactions 
 
PCR reactions were set up as follows; 25µl RedTaq reaction mix (Sigma Aldrich, UK), 0.5pmol forward 
primer, 0.5pmol reverse primer, 5µl DNA sample. Reactions were then made up to 50µl with water. 
Reaction conditions were as follows; 94oC for 5 minutes initial denaturation; 35 cycles of 94oC for 30 
seconds, 47oC for 30 seconds and 72oC for 30 seconds; 72oC for 5 minutes final extension. Reactions 
were controlled using an ABI 2720 thermocycler (Applied Biosystems, UK). 
 
2.2.9. LAMP Reactions 
 
LAMP reactions were set up using reagents from a Mast Isoplex DNA amplification kit (Mast Group 
Ltd, UK), as follows; 5µl five times LAMP reaction buffer, 12µl molecular grade water, 1µl 
intercalating dye (propriety dye, emission in FAM channel), 1µl of 8U/µl Bst polymerase (New 
England Biolabs, USA), 1µl of primer mix containing 40pmol of FiP and BiP primers, and 5pmol of F3 
and B3 primers. Loop primers, if present, were included at a 25pmol/µl concentration in the primer 
mix. Finally 5µl of DNA sample or water was added to the reaction. Reactions were carried out in a 
ESEQuant Tube Scanner (Qiagen Inc., CA), at 63oC for 60 minutes. Reactions were terminated by 
heating to 80oC for 1 minute in order to denature the Bst polymerase. 
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2.2.10. Reaction Product Detection 
 
Detection of reaction products from the PCR and LAMP reactions was carried out primarily by 
electrophoresis, using 1.5% w/v agarose gels with transillumination and photography provided by a 
BioRad Gel/Chem Doc system (Bio-Rad Inc, UK).  
LAMP reactions were also monitored in real-time using the ESEQuant Tube Scanner (Qiagen Inc, UK), 
through the FAM channel. The “Tube Scanner Studio” software package was used to analyse the real 
time data and produce a manually set threshold line for the purposes of determining time to 
amplification.  
End point visual detection was also carried out on the reactions assaying raw urine samples. In these 
reactions the 1µl intercalating dye was replaced with 1µl of calcein (fluorescent detection reagent; 
Eiken Chemical Co., Japan). A colour change from orange to green was seen in the positive reactions, 
easily visible in natural light. The negative reactions remained orange. Visual detection of 
fluorescence in the positive reactions was also possible, by placing reactions on a 365nm UV light 
source.  
 
2.2.11. Limits of detection of the N. gonorrhoeae GroEL LAMP assay. 
 
 A 1ml aliquot of overnight culture of N. gonorrhoeae was taken, and cells were concentrated by 
centrifugation at 5000 x g for 1 minute. The cells were then resuspended in urine, and a series of 
1:10 dilutions were carried out in urine. Total viable counts were then carried out, with 50µl of each 
dilution being spread over chocolate agar plates, in triplicate. The colonies on each plate were 
counted after 48 hours of incubation at 37oC and 5% CO2, to quantify the cells in the suspension.  
Nucleic acid was then extracted from a 200µl aliquot of each suspension using the KingFisher ML 
automated extraction system. LAMP reactions using the GroEL primer set were then carried out, and 
monitored in real time using the Qiagen ESEquant Tubescanner. Nuceic acid extracted from a 200µl 
aliquot of Escherichia coli culture was used as a negative control. 
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2.2.12. Initial testing of the ORF1 primer sets 
 
LAMP reactions containing 0.1µg of N. gonorrhoeae DNA were carried out using the ORF1 S1, ORF1 
S2, GroEL and PorA primer sets. The DNA was extracted using a Qiagen genomic DNA kit (Qiagen), 
and quantified using a Spectrostar plate reader (BMG), with LVIS attachment. Negative control 
reactions were carried out simultaneously for each primer set, with the DNA replaced by molecular 
grade water. The reactions were carried out in duplicate, and monitored in real time. The products 
of the positive reactions from both duplicates, and a single negative control, were analysed by 
agarose gel electrophoresis (1.5%). 
 
2.2.13. Relative sensitivity of the GroEL and ORF1 S2 primer sets 
 
Nucleic acid extractions were carried out on N. gonorrhoeae cell suspensions in urine containing 
5000, 500, 50 and 5 cells per 200µl aliquot. The extracted DNA was then tested using the GroEL and 
ORF1 S2 LAMP assays, and the reactions were monitored in real-time using the Qiagen ESEquant 
Tubescanner. 
 
2.2.14. Specificities of ORF1 PCR and LAMP assays 
 
DNA was extracted from the following organisms; N. gonorrhoeae (ATCC 19424), C. trachomatis (lab 
strain, serovar L2), Trichomonas vaginalis (ATCC 30001) and Pseudomonas aeruginosa (ATCC 15692). 
The DNA was diluted to 20ng/µl and 5µl of each DNA sample (0.1µg) was used as a template in both 
ORF1 PCR and ORF1 LAMP reaction.  
 
2.2.15. Sensitivities of ORF1 PCR and LAMP assays 
 
DNA was extracted from a 200µl sample of an overnight culture of N. gonorrhoeae and quantified 
after RNA digestion. Copy number was determined, and the DNA sample was diluted to a 
concentration of 4 x 104 copies/µl using molecular grade water.  1:10 serial dilutions of the DNA 
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stock were carried out, down to a concentration of 0.4 copies/µl. ORF1 PCR and ORF1 LAMP 
reactions were carried out using 5µl of each dilution of DNA.  
 
2.2.16. Urea tolerance of ORF1 PCR and LAMP assays 
 
ORF1 PCR and ORF1 LAMP reactions, including 0.1µg of N .gonorrhoeae DNA, were spiked to include 
the following concentrations of urea; 1mM, 10mM, 100mM, 1M, 2M. Additional duplicate ORF1 
LAMP reactions were spiked to include the following urea concentrations; 1M, 1.2M, 1.4M, 1.6M, 
1.8M, 2M.  
 
2.2.17. Direct detection from urine samples 
 
ORF1 LAMP reactions were carried out on 5µl samples of both molecular grade water and human 
urine spiked with 2x103 copies, 2x102 copies, 20 copies, and 0 copies of the N. gonorrhoeae genome. 
The reactions contained 1µl of calcein to enable visual detection. Real-time detection of the 
intercalating dye was not possible due to the interference exerted by urine on the signal.  
 
2.2.18. Tolerance of the ORF1 LAMP assay to the presence of blood 
 
ORF1 LAMP reactions containing 0.1µg of N. gonorrhoeae DNA were spiked to include the following 
concentrations of defibrinated whole horse blood (TCS); 5%, 10%, 20%, 30%, 40%, 50%. The volume 
of blood used replaced the same volume of molecular grade water in the reaction. A reaction 
containing N. gonorrhoeae DNA, without blood was used as the positive control, whilst negative 
controls contained molecular grade water, or 10% blood, without N. gonorrhoeae DNA. 
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2.3. Results 
 
2.3.1 Limits of detection of the N. gonorrhoeae GroEL LAMP assay 
 
The limit of detection of the GroEL LAMP assay for the detection of N. gonorrhoeae was determined 
by carrying out GroEL LAMP assays on total nucleic acid extracted from varying concentrations of N. 
gonorrhoeae cells suspended in urine, using the silica based extraction method 
 
 
Fig.2.1. LAMP amplification plot showing the limit of detection of the GroEL LAMP assay. Nucleic acid 
extractions were carried out on 1/10 serial dilutions of a quantified N. gonorrhoeae suspension. The 
cell count of each sample is shown in Table 2.6. Extractions were then tested for the presence of N. 
gonorrhoeae nucleic acid using the GroEL D2 assay. Molecular grade water (Neg control 1) and 0.1µg 
of E. coli DNA (Neg control 2) was used as a negative control. 
 
The GroEL LAMP assay, in conjunction with the silica based extraction method, was able to detect 
the presence of N. gonorrhoeae nucleic acid from a 200µl aliquot containing a minimum of 100 N. 
gonorrhoea cells, equating to 6.7 cells worth of nucleic acid per reaction (Table 2.6.). The assay was 
able to generate a positive result from all cell suspensions containing a greater number of cells. 
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There was no detectable signal generated in the reactions containing 0.67 or 0.067 N. gonorrhoeae 
cells, or in the negative controls containing non-target DNA or molecular grade water (Fig.2.1) 
The time to amplification was dependent on the concentration of N. gonorrhoeae cells in the 
sample, with the reactions containing DNA equivalent to that from 6,700, 670, 67 and 6.7 cells 
generating an amplification after 15.3, 20.3, 22 and 28.6 minutes respectively (Fig.2.1).  
 
Sample GC cell 
count (per 
ml) 
Volume used 
in extraction 
Cells used in 
extraction 
Elution 
Volume 
Volume 
amplified 
Equivalent 
number of 
cells 
Results 
1 500,000 200µl 100,000 75µl 5µl 6700 POS 
2 50,000 200µl 10,000 75µl 5µl 670 POS 
3 5,000 200µl 1,000 75µl 5µl 67 POS 
4 500 200µl 100 75µl 5µl 6.7 POS 
5 50 200µl 10 75µl 5µl 0.67 NEG 
6 5 200µl 0.2 75µl 5µl 0 NEG 
Negative 0 200µl 0 75µl 5µl 0 NEG 
Negative 0 200µl 0 75µl 5µl 0 NEG 
Table 2.6. The concentration of N. gonorrhoeae cells in samples used for the determination of the 
detection limits of the GroEL LAMP assay, and equivalent number of cells entering the LAMP 
reactions. 
 
2.3.2. Initial testing of the ORF1 primer sets 
 
The two primer sets specific to ORF1 of the glnA gene, ORF1 S1 and ORF1 S2, required initial testing 
in order to determine the best primer pair, and their performance with previously designed and 
optimised assays to the GroEL and PorA genes was also compared. Real-time monitoring of the 
reactions gave some evidence as to the superior primer set from a reaction speed perspective, which 
can also inform as to the likely comparative sensitivity. The comparison of the ORF1 sets, and their 
glnA target, with the GroEL and PorA LAMP assays compared these primer sets in terms of reaction 
speed with the primer sets designed by Public Health England Southwest, to determine whether it 
would be beneficial to fully test them clinically, potentially with a view to adopting this set for the 
LabDisk. 
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Fig.2.2. Amplification curves produced by real-time monitoring of the ORF1 S1, ORF1 S2, GroEL and 
PorA LAMP reactions. 0.1µg of N. gonorrhoeae DNA was used as the positive control reactions. 
Molecular grade water was used in place of the DNA in the negative reactions. 
 
The shortest time to amplification occurred using the ORF1 S2 primer set, which generated a 
positive amplification after 15.3 minutes (Fig.2.2). This was ~10 minutes sooner than the ORF1 S2, 
GroEL and Por A primer sets, which produced amplification after 26.6, 26 and 26 minutes, 
respectively. The ORF1 S2 and PorA positive reactions both generated a gradual increase in 
fluorescence starting from the initiation of the reaction, through to the point of amplification. When 
the negative control reactions using these primer sets were analysed using gel electrophoresis, there 
was no visible product, barring the presence of a low weight (<100bp) band representing the primers 
(Fig.2.4). It could be that an element of primer dimerisation was occurring with these primer sets, 
resulting in a gradual increase in fluorescence but falling short of (and not preventing) a true 
exponential amplification. This gradual increase in signal was also encountered in the ORF1 S2 
negative, but not the PorA negative reaction. 
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Fig.2.3. Amplification curves produced by real-time monitoring of the ORF1 S1, ORF1 S2, GroEL and 
PorA LAMP reactions; a repeat of the experiment detailed in Fig.2.2. 0.1µg of N. gonorrhoeae DNA 
was used as the positive control reactions. Molecular grade water was used in place of the DNA in 
the negative reactions. 
 
A repeat of the experiment again found the ORF1 S2 primer set to result in the fastest reaction, 
generating an amplified signal at 22.3 minutes, compared with 25.3 minutes in the GroEL assay, and 
30 minutes in the PorA assay (Fig.2.3). The gradual increase in fluorescence was again encountered 
in the ORF1 S2 positive and negative reactions, but not the PorA positive, as in the previous 
experiment (Fig.2.2). The ORF1 S1 positive reaction failed to generate a detectable amplification 
curve, although an increase in signal did occur between 52 and 60 minutes. 
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Fig.2.4. Comparison of the reaction products of LAMP reactions using ORF1 primer sets 1 (A) and 2 
(B), with the GroEL (C) and PorA (D) primer sets. The positive control reactions were carried out in 
duplicate (1, 2), and a reaction containing molecular grade water was used as the negative control 
(3). 
Agarose gel electrophoresis of the reaction products from Fig.2.2, Fig. 2.3. (Fig.2.4) showed the 
characteristic profile of LAMP reaction product, in each of the positive reaction duplicates for each 
primer set. The positive reaction from the second ORF1 S1 duplicate was markedly fainter on the gel, 
which was to be expected after the late amplification that was recorded in that reaction (Fig.2.3). 
There was no evidence of any amplified product in any of the negative control lanes. 
 
2.3.3. Relative sensitivity of the GroEL and ORF1 S2 primer sets 
 
The ORF1 S2 primer set was found to enable a faster reaction speed than the ORF1 S1 primer set in 
both of the initial tests of performance (Fig.2.2, Fig.2.3). For this reason the ORF1 S2 set was chosen 
for all further investigation, and will be referred to as the ORF1 primer set from here on. 
A1    A2     A3       B1     B2    B3       C1    C2     C3      D1     D2                 D3 
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1000bp - 
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As the ORF1 primer set enabled a more rapid reaction than the GroEL and PorA assays, when tested 
with a quantity of 0.1µg of N. gonorrhoeae genomic DNA, it is possible that this increase in speed 
would also be seen at lower concentrations of DNA. A faster LAMP reaction can be indicative of an 
increase in starting copy number, which would result in an improved sensitivity, or it can be down to 
the compatibility and sequence identity of the primer sets themselves, leading to a faster reaction 
but not an improvement in sensitivity. 
 
 
Fig.2.5. Comparative sensitivity and reaction speed of the GroEL and ORF1 LAMP assays. GroEL and 
ORF1 LAMP reactions containing nucleic acid extracted from 200µl aliquots containing 5000 (1), 500 
(2), 50 (3) and 5 (4) N. gonorrhoeae cells were monitored in real-time. 
 
The ORF1 LAMP assay generated faster amplification than the GroEL assay for each dilution tested, 
with the reactions containing 5000, 500 and 50 N. gonorrhoeae cells amplifying at  14.6, 17, 29.3 
minutes, respectively (Fig.2.5). The corresponding reactions utilising the GroEL primer sets 
generated detectable amplification at 22, 22.6 and 33.3 minutes. 
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2.3.4. Specificities of ORF1 PCR and LAMP assays 
 
The ORF1 LAMP reaction will be required to detect N. gonorrhoeae nucleic acid from samples 
presented for STI testing. As such, it is essential that the assay can accurately distinguish the N. 
gonorrhoeae DNA from that of other non-target organisms that may be encountered in the samples. 
The small scale specificity test included the organisms T. vaginalis and C. trachomatis; both sexually 
transmitted pathogens of the human genital tract that are sampled for in the same manner as N. 
gonorrhoeae, and cause overlapping symptoms. The commensal organism, and opportunistic 
pathogen, Pseudomonas aeruginosa was also included as it is frequently encountered in urine 
samples. 
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Fig.2.6. Specificity of N. gonorrhoeae ORF1 PCR  and LAMP assay; agarose gel electrophoresis of (A) 
PCR and (B) LAMP reaction products from reactions containing 0.1µg of N. gonorrhoeae (lanes 1, 2), 
C. trachomatis (lanes 3, 4), T. vaginalis (lanes 5, 6), P. aeruginosa (lanes 7, 8) DNA. Water was used 
as a negative control (lanes 9, 10). 
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The ORF1 PCR assay produced a 139bp fragment from N. gonorrhoeae DNA, as expected. No non-
specific amplification or primer dimerization could be detected from the gel (Fig.2.6.A). The ORF1 
LAMP assay generated a successful amplification from N. gonorrhoeae DNA, evidenced by the 
presence of various sized DNA fragments in a characteristic ladder pattern seen on the gel 
(Fig.2.6.B). No amplification was seen for any non-target organism tested when using either the PCR 
or LAMP assay.  
 
2.3.5. Sensitivities of ORF1 PCR and LAMP assays 
 
The analytical sensitivities of LAMP assays are typically greater than, or at least equal to, standard 
PCR reactions for the same target. In order to determine whether this LAMP primer set was as 
sensitive as a PCR for the same target gene, the limits of detection of each assay were determined 
using N. gonorrhoeae genomic  DNA 
The ORF1 PCR assay was able to detect a minimum level of 20 copies of the N. gonorrhoeae genome 
per reaction (Fig.2.7). However, even after 35 cycles the amount of product generated was very low, 
demonstrated by the faintness of the band seen on the gel. A stronger signal was seen for reactions 
containing >200 copies. 
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Fig.2.7. Sensitivity of ORF1 PCR and LAMP assays; agarose gel electrophoresis of ORF1 PCR (lanes A1-
A6) and ORF1 LAMP reactions (lanes B1-B6) containing 2x105 (lanes A1, B1), 2x104(lanes A2, B2), 
2x103(lanes A3, B3), 2x102(lanes A4, B4), 20 (lanes A5, B5)and 2 copies (lanes A6, B6)of the N. 
gonorrhoeae genome. PCR (lane C1) and LAMP (C2) reactions containing 5µl of water instead of DNA 
were used as a negative control. 
 
The ORF1 LAMP reaction was able to detect a minimum of 20 copies of the N. gonorrhoeae genome 
(Fig.2.7). Real-time analysis of the amplifications using the ESEQuant Tube Scanner (QIAGEN, CA.) 
showed that the time to amplification was shorter with an increased starting concentration of 
template, with the reaction containing 2x105 copies showing the earliest amplification, crossing the 
manually set threshold line at 17 minutes (Table 2.7). The latest time to amplification, 27.3 minutes, 
was seen in the reaction containing 20 copies. 
 
 
A1   A2       A3       A4      A5      A6                B1      B2       B3      B4      B5     B6      C1      C2 
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N. gonorrhoeae genome copy number Time to amplification (minutes) 
2x105 17 
2x104 18.6 
2x103 20.6 
2x102 25 
20 27.3 
2 No amplification 
0 No amplification 
Table.2.7. Sensitivity of ORF1 LAMP assay; Average time to amplification of ORF1 LAMP reactions 
containing 2x105, 2x104, 2x103, 2x102, 20 and 2 copies of the N. gonorrhoeae genome. Time to 
amplification was taken as the time point that the fluorescent signal exceeded a manually set 
threshold line on the Tube Scanner Studio software package (Qiagen). A LAMP reaction containing 
5µl of water instead of DNA was used as a negative control. 
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2.3.6. Urea Tolerance 
 
In order to examine the suitability of the ORF1 LAMP assay for the direct detection of N. 
gonorrhoeae from urine, the tolerance of the LAMP assay to urea, the primary amplification inhibitor 
in urine, was determined. This was compared with PCR, as the most commonly used amplification 
technology, and one ill suited for use with urine samples, without a prior nucleic acid purification 
step.  
 
 
Fig.2.8.A.Tolerance of the ORF1 PCR assay and ORF1 LAMP assay to urea; agarose gel 
electrophoresis  of ORF1 PCR (lanes A1-A5) and LAMP (lanes B1 – B5) reaction products from 
reactions spiked with urea concentrations of 1mM (lanes A1, B1), 10mM (lanes A2, B2), 100Mm 
(lanes A3, B3), 1M (lanes A4, B4), 2M (A5, B5). Positive reactions contained 0.1µg of N. gonorrhoeae 
DNA.  PCR (lane C3) and LAMP (lane C4) reactions containing no urea were carried out as positive 
controls. PCR (lane C1) and LAMP (lane C2) reactions containing 5µl of water instead of DNA was 
used as a negative control. 
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Fig.2.8.B. Agarose gel electrophoresis of reaction products from LAMP reactions spiked with urea 
concentrations of 1M (lane A1), 1.2M (lane A2), 1.4M (lane A3), 1.6M (lane A4), 1.8M (lane A5), 2M 
(lane A6). Positive reactions contained 0.1µg of N. gonorrhoeae DNA. A LAMP reaction (B1) 
containing 5µl of water instead of DNA was used as a negative control. A LAMP reaction containing 
no urea was carried out as a positive control. 
The ORF1 PCR reaction was able to tolerate a urea concentration of 10mM, whereas a concentration 
of 100mM proved inhibitory (Fig.2.8.A). The LAMP reaction was totally inhibited by a urea 
concentration of 2M. At concentrations of 1.8M and below, no inhibitory effects, such as a reduction 
in product or increase in time to amplification, were seen (2.8.B). 
 
2.3.7. Detection of N. gonorrhoeae directly from urine samples 
 
The simplest option available for positive reaction determination using the LAMP assay is direct 
amplification detection, using an intercalating dye or indicator dye to provide a visually detectable 
colour change. One of the detection dyes most frequently used in conjunction with the LAMP assay 
is calcein, a fluorescent dye with excitation and emission wavelengths of 495nm/515nm. During 
LAMP amplification, pyrophosphate is released, which removes manganese ions bound to calcein, 
which are replaced with magnesium ions, resulting in fluorescence.  
A1       A2       A3       A4       A5       A6       A7        B1      B2  
 
A1       A2       A3       A4       A5       A6       A7        B1      B2  
200bp – 
 
200bp – 
B) 
 
B) 
Urea 
Concentration 
 
Urea 
Concentration 
400bp - 
 
400bp - 
200bp - 
 
200bp - 
100bp - 
 
100bp - 
186 
 
 
 
 
Fig. 2.9. Comparison of calcein-mediated end point detection of positive N. gonorrhoeae ORF1 LAMP 
reactions, using either urine (i) or water (ii) spiked with N. gonorrhoeae DNA. Detection was carried 
out by observing the amplification dependent color change in daylight (A) or with excitation of the 
fluorophore via a UV transilluminator (B).  The LAMP reactions contained 2x103 copies (1), 2x102 
copies (2), 20 copies (3), and 0 copies (4) of the N. gonorrhoeae genome. 
The inclusion of calcein in the LAMP reaction, in place of the intercalating dye, resulted in an easily 
distinguishable colour difference between the positive and negative reactions (Fig.2.9.). Under 
ambient light the positive reactions appear green, whilst the negative reactions appear yellow (A). 
The presence of urine in the reaction (ii) did not affect this. Under UV light (365nm) the positive 
reactions emitted bright green fluorescence irrespective of the presence of urine (B). The water-
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containing negative emitted a faint green fluorescence, whilst the urine-containing negative emitted 
a slightly brighter blue/green fluorescence. 
 
2.3.8. Tolerance of the ORF1 LAMP assay to the presence of blood 
 
The tolerance of the ORF1 LAMP assay to the presence of blood, another potential source of 
amplification inhibition that could be found in a clinical sample taken for STI testing, was 
characterised.  
 
 
Fig.2.10. Agarose gel electrophoresis of reaction products of ORF1 LAMP reactions containing 0.1µg 
of N. gonorrhoeae DNA and the following concentrations of whole blood; 5% (A1), 10% (A2), 20% 
(A3), 30% (A4), 40% (A5), 50% (A6). The positive control reaction contained containing 0.1µg of N. 
gonorrhoeae DNA, without blood (B1). Negative reactions contained no N. gonorrhoeae DNA, with 
water (B3) or blood (B4). Well B2 was empty.  
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The ORF1 LAMP assay was able to tolerate up to a 20% volume of whole blood present in the 
reaction, equating to 5µl of the 25µl reaction, the standard sample volume (Fig.2.10). This shows 
that whole blood would be an acceptable sample type for the ORF1 LAMP assay, and would not 
cause inhibition in an end-point LAMP assay. At concentrations of 30% and 40%, and to a lesser 
extent 50%, there was a low level of the typical ladder-like pattern of LAMP reaction fragments 
present on the gel, indicating that the reaction was not completely inhibited, even at these high 
concentrations of whole blood. 
The negative control, containing 5% whole blood without template, did not generate any product, 
showing that the presence of blood at this concentration does not cause non-specific amplification. 
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2.4. Discussion 
 
2.4.1 Limits of detection of the N. gonorrhoeae GroEL LAMP assay 
 
The GroEL LAMP assay, in conjunction with the magnetic silica based extraction method, was 
capable of detecting a minimum of 100 N. gonorrhoeae cells per extraction. This was the equivalent 
to 6.7 cells worth of nucleic acid per LAMP reaction. As the extraction was carried out using a 200µl 
sample, this equates to 500 N. gonorrhoeae cells per ml. The range of N. gonorrhoeae cells present 
in clinical samples depends greatly on the sample type, and stage of infection of the patient. One 
study found that the organism load in male first void urine (FVU) during symptomatic N. 
gonorrhoeae infection ranged from 3.7 x 104 to 2.6 x 107, with an average of 6.1 x 106 (Isbey et al., 
1997). FVU Samples taken during early stage infection (21 – 48 hours post inoculation) yielded an 
average of 1.8 x 103 CFU/ml (Isbey et al., 1997). The organism load in vaginal or cervical swab 
samples is likely to be higher than these levels, as evidenced by the improved assay sensitivity 
obtained from these sample types (Fang et al., 2008). The limit of detection of the GroEL LAMP 
assay, as determined in this set of experiments, lies below the range of organism loads given in this 
study, and is also lower than the ID50 (Infectious dose 50; the number of cells required to generate 
an infection in 50% of exposures) of 1.8 x 103 to 1 x 105, depending on the strain, as determined by 
human inoculation experiments (Hobbs et al., 2011). The ability of the assay to detect the organism 
at levels below that typically encountered in clinical samples is a good predictor that the test will 
have a high clinical sensitivity; the assay will be unlikely to generate false negative results due the 
presence of an organism load lower than the limits of detection of the assay. However, care must be 
taken when equating this information to clinical samples; clinical samples are likely to contain a 
range of inhibitory compounds absent from a cell suspension in urine, such as blood and mucous. 
The LAMP assay, in combination with the magnetic silica based extraction process, has been shown 
to be tolerant of inhibitory compounds at supra-physiological levels (Fig. 2.8.B), so the impact of 
these inhibitors should be limited. A larger problem will be the decay of nucleic acid during the 
sampling process; it will be imperative that the degradation of nucleic acid during the period 
between sampling and the initiation of the assay is minimised. In order to accurately determine the 
performance of this assay, a clinical trial will be required, in order to assess the sensitivity and 
specificity of the assay when dealing with clinical samples. This work will be carried out by Public 
health England Southwest, at a later date. 
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2.4.2. Initial testing of the ORF1 primer sets 
 
The initial test of the performance of the ORF1 primer sets showed that the ORF1 S2 primer set 
enabled a faster time to detection than the ORF1 S1, GroEL and PorA primer sets, generating a 
positive signal 10.7 minutes earlier than the next fastest set. Whilst in the duplicate run of this 
experiment the difference was smaller, the ORF1 primer set generated a detectable amplification 3 
minutes sooner than the other primer sets. 
 The fact that the ORF1 S2 set generated an amplification 11.3 minutes earlier than the ORF1 S1 set 
was surprising, as the primers target the same gene, with the 5’ F3 positions only lying 93bp apart on 
the N. gonorrhoeae genome, and will have the same starting copy number. This suggests that the 
increase in reaction speed is more a symptom of the actual primer sequences involved, and their 
compatibility with each other.  The late amplification generated by the ORF1 S1 primer set in the 
duplicate experiment suggests that this primer set is sub-optimal, and this may have resulted in the 
slower reaction speed also seen in the first experiment. 
The steady gradual increase in fluorescence that occurred in the ORF1 S2 negative reaction could be 
due to primer dimerisation or self-priming events. The gradual increase was maintained for ~15 
minutes in the first experiment, and ~20 minutes in the second experiment, before reaching a 
plateau and maintaining this level. This could be at the point that all of the copies of the primer had 
formed dimers or self-primed. The examination of the products of the negative reaction revealed an 
absence of any LAMP reaction products, but the presence of a bright band around 50bp in size. This 
was approximately the same size as the primer sequences, but was brighter than in the negative 
reactions carried out with the alternate primer sets, indicating the generation of a greater quantity 
of DNA. The formation of primer dimers can have a deleterious effect on the amplification reaction, 
as the amplification of the dimer by the polymerase enzyme can lead to premature exhaustion of 
the PCR reagents, such as dNTP’s and primer. Agarose gel electrophoresis of the LAMP products 
showed that the ORF1 S2 primer set generated an increased concentration of product compared to 
the other primer sets, indicating that the reaction was not limited by a shortage of components. The 
LAMP reaction mix contains a greater concentration of both primers and dNTP’s than the 
recommended concentrations for PCR, and this could act to alleviate the impact of primer dimer 
formation. In these initial tests, the ORF1 S2 primer set provided the fastest reaction, and highest 
amount of product, whilst generating no false positive amplification. Therefore it was selected for 
further testing, in order to further characterise its performance and sensitivity. 
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2.4.3. Relative sensitivity of the GroEL and ORF1 S2 primer sets 
 
The ORF1 primer set generated a faster amplification than the GroEL primer set from each dilution 
tested. Despite this there was no difference in the limit of detection of the two assays. The faster 
assay speed afforded by the ORF1 primer set would enable a more rapid diagnosis to be made, and 
allow an earlier cut-off point to be used for the assay without affecting the sensitivity. Although the 
N. gonorrhoeae glnA gene include a ~130bp hypervariable region, the ORF1 region of glnA is highly 
conserved, and has little variation (Vidovic et al., 2011). This is in contrast to the PorA gene, as PorA 
mutants are now more frequently encountered, and have previously been determined as the cause 
of a range of sequence related false-negative results in clinical samples (Whiley et al., 2011). 
Mutations in other genes commonly used as the targets of in-house PCR assays for this organism 
such as cppB and opa have also been identified as the cause of false negative results in a diagnostic 
setting (Geraats-Peters et al., 2005b; Bruisten et al., 2004).  
 
2.4.4. Specificities of ORF1 PCR and LAMP assays 
 
The ORF1 PCR assay produced a 139bp fragment from N. gonorrhoeae DNA, as expected. No non-
specific amplification or primer dimerization could be detected from the gel (Fig.2.6.A). 
The ORF1 LAMP assay was able to detect N. gonorrhoeae DNA, with a positive reaction 
demonstrated separating the amplified products using agarose gel electrophoresis (Fig.2.6.B), in 
order to visualise the characteristic ladder effect caused by the various sized concatemers of double 
stranded DNA formed during the LAMP reaction (Notomi et al., 2000). No amplification was seen for 
any non-target organism tested when using either the PCR or LAMP assay. This experimentally 
confirmed the high levels of primer specificity previously determined using BLAST. The non-target 
organisms tested were all common urinary pathogens, and like N. gonorrhoeae, potential causes of 
urethritis, so it is essential that these organisms are not incorrectly identified by a diagnostic test. 
The correct identification of the pathogen in question when diagnosing sexually transmitted disease 
is important, due to the recommendation of different antimicrobial treatment programmes for each 
of these infections (Health Protection Agency, 2011).  
LAMP assay specificities are typically higher than PCR assays targeted to the same sequence, due to 
the use of 4 primers specific to 6 regions of target DNA, rather than the use of 2 primers specific to 
two targets as used in PCR (Notomi et al., 2000). The high specificity of LAMP assays has been 
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demonstrated by the development of species-specific malaria LAMP assays (Iseki et al., 2010), and 
LAMP assays capable of identifying specific subtypes of virus (Zhou et al., 2011). 
 
2.4.5. Sensitivities of ORF1 PCR and LAMP assays 
 
The ORF1 LAMP assay was able to detect a minimal level of 20 copies of the N. gonorrhoeae 
genome. The more sensitive diagnostic LAMP assays presented in the literature have typically been 
shown to have limits of detection ranging from 20 to 5 copies per reaction (Shan et al., 2012; Kim et 
al., 2011; Nakao et al., 2010). However, limits of detection ranging from 100 copies (Iseki et al., 
2010; Uemura et al., 2008), to single copy detection (Zhou et al., 2011) have been reported. As the 
ORF1 LAMP assay was chosen to examine the inhibitory effects of urine on LAMP assays in general, it 
was important that the ORF1 assay was representative of a sensitive LAMP assay. Monitoring the 
reactions in real time using the ESEQuant TS showed that amplification occurred after 17 minutes for 
the reactions containing the highest copy number (2 x105 per reaction) and 27.3 minutes for the 
lowest (20 per reaction). The time to amplification was similar (within 2 minutes) during all 3 
replications of the experiment. The assay ran for 60 minutes, but the cut off time could be reduced 
by up to 30 minutes without affecting the results. 
 
2.4.6. Urea Tolerance 
 
Urine is a complex, and highly variable sample. Composition varies between individuals and depends 
on the diet, hydration and disease state of the patient. Urine consists primarily of water, and soluble 
excreted compounds, including sodium chloride, urea, and ionic potassium, calcium and sulphate 
(Lind, 2001). The primary compound found in urine responsible for PCR inhibition is urea (Khan et 
al., 1991), present in urine as an excreted by-product of the metabolism of nitrogen containing 
compounds, primarily proteins (Brosnan and Brosnan, 2010).  
The inhibition of PCR via compounds present in urine has been shown to have a detrimental effect 
on assays for the detection of bacterial (George JA, 2003) and viral pathogens (A. Behzadbehbahani, 
1997). A study on the evaluation of the performance of an internal positive DNA control for a PCR 
assay for the detection of C. trachomatis found that 23% of 100 clinical urine samples tested were 
inhibitory to PCR unless a pre-assay DNA extraction was carried out (Betsou et al., 2003). If a 
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potential false negative result due to inhibition of the reaction has been identified through the use 
of an internal control, the dilution of the sample 1:10 has been reported as a likely solution (Mahony 
et al., 1998). This dilutes the concentration of inhibitory compounds sufficiently to allow 
amplification to take place. However, this practice will reduce overall assay sensitivity by reducing 
the target nucleic acid concentration in the sample by 90%, which will prevent the positive 
identification of samples with a starting organism load close to the assay detection limits. A recent 
evaluation of a direct urine PCR test for N. gonorrhoeae, which relied on a pre-assay dilution step, 
reported a sensitivity of 83% when compared with a commercial PCR test (Rahimi et al., 2013). 
The urea tolerance of the ORF1 PCR reaction was shown to be <100mM, which is in agreement with 
previous research, which has variously determined the minimum inhibitory concentration to be 
>50mM (Khan et al., 1991) and >20mM (A. Behzadbehbahani, 1997). The average concentration of 
urea in adult urine is ~300mM, above the determined minimum inhibitory threshold for PCR. This 
means that simple DNA extraction procedures, such as chelex based methods, or the use of a lysate 
are not suitable for PCR when dealing with urine samples.  
The LAMP assay was able to detect N. gonorrhoeae DNA at urea concentrations of 1.8M and below 
and urea concentration had no effect on time to amplification (data not shown), or a noticeable 
effect on the amount of product generated when visualised on an agarose gel. This minimum 
inhibitory urea concentration of 2M represents a 20 fold increase of the minimum concentration 
inhibitory to the ORF1 PCR, demonstrating the increased robustness of the LAMP assay to urea 
mediated inhibition, when compared to PCR. A urea concentration of >1.8M is higher than the 
maximum urea concentrations found in samples of human urine, and this high tolerance for urea 
makes the LAMP assay more suitable for use with unextracted samples than PCR assays.    
PCR inhibition by urea is mediated by interference in non-covalent bonding between the polymerase 
enzyme and template, and also the annealing primer and template (Hedman and Radstrom, 2013) . 
The reasons for the lack of inhibition of the LAMP assay to urea is currently undetermined, but could 
involve the stability of the Bst enzyme itself, or the isothermal nature of the reaction maintaining 
constant favourable conditions for annealing of the primers and template. 
The ability of the LAMP reaction to withstand higher levels of urea than those found in human urine, 
and therefore enable the detection of target nucleic acid from urine samples that have either not 
undergone a nucleic extraction process, or undergone a very simple process such as a heat 
treatment, has implications for the use of LAMP assays to diagnose sexually transmitted infections in 
a resource poor setting. The removal of the need for a nucleic acid purification/extraction 
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procedure, coupled with the lack of specialist equipment needed to process the reactions, and 
detect the outcomes, mean that LAMP technology is well suited for use in laboratories without the 
equipment or staff necessary to perform conventional PCR based testing. 
2.4.7. Detection of N. gonorrhoeae directly from urine samples 
 
In order to demonstrate the suitability of the LAMP assay for use with unprocessed urine samples, 
ORF1 LAMP reactions were carried out on both urine and water samples spiked with  2x104 copies, 
2x103 copies, 2x102 copies, and 0 copies of the N. gonorrhoeae genome. Real-time detection using 
V13-01184 dye monitored by the ESEQuant fluorometer proved difficult, as the presence of urine 
increased the baseline fluorescence via an unknown mechanism, making it difficult to differentiate 
between the positive and negative reactions. This was not seen for the LAMP reactions containing 
any concentration of urea, so must occur due to another component of the urine. The urine would 
be expected to contain a component of endogenous DNA, but the amount was too low to measure, 
and would not be sufficient to cause the size of increase in fluorescent intensity that occurred. 
As an alternative, and in order to demonstrate a more rapid and cost effective method of detection, 
end point detection using the fluorescent dye calcein was carried out. The inclusion of an indicator 
or dye, such as calcein, enables visual end point detection and removes the need for real-time 
analyzers, which although provide the fastest result, are costly. It also enables detection without any 
further post-reaction steps, such as separating reaction products on an agarose gel, which 
necessitate opening the reaction tubes and introducing high levels of contaminating amplicon into 
the laboratory environment. Several dyes and fluorophores have been used in conjunction with 
LAMP for this purpose, including SYBR green (Tao et al., 2011), hydroxy napthol blue (Goto et al., 
2009), and calcein (Tomita et al., 2008).  
Calcein is added to the reaction, along with manganous ions (Mn2+), which bind to the calcein 
molecule and act as a quencher, preventing fluorescence. The rapid synthesis of large quantities of 
double stranded DNA during the LAMP reaction generates high concentrations of pyrophosphate as 
a by-product, which displaces manganous ions from the calcein molecules, resulting in a colour 
change from orange to green, and fluorescence when exposed to UV light (Tomita et al., 2008). 
Additionally, magnesium ions (Mg2+) are then able to bind to calcein, which enhances the intensity of 
fluorescence (LaBarre et al., 2011).  
The end point detection of positive LAMP reactions was equally accurate for both the spiked urine 
and water samples, with positive reactions undergoing an orange to green colour change. This 
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colour change was obvious in daylight. The negative reactions remained orange, whether urine or 
water was used. A minor colour difference was seen between the urine negative and water negative 
under UV, with the urine negative exhibiting a low blue fluorescence. This assisted in distinguishing 
between the positive and negative results when un-processed urine was used. However, the colour 
chance was unambiguous in ambient light, meaning that the only equipment needed once the 
reactions had been set up was a method of heating to a constant temperature of 63oC, such as a 
water bath. 
 
2.4.8. Tolerance of the ORF1 LAMP assay to the presence of blood 
 
The ability of the ORF1 LAMP assay to successfully generate an amplified product with up to 20% of 
the reaction volume taken up by whole blood demonstrates the greatly increased robustness of 
LAMP when compared with PCR. The 20% volume is also significant; this equates to 5µl of the 25µl 
reaction, which is the suggested sample volume for the LAMP reaction. This shows that whole blood 
could be used as the sample for the LAMP reaction, without a purification or extraction step. This 
would enable sensitive NAAT testing of blood borne disease, such as malaria or hepatitis B, without 
the need for complicated and expensive extraction methodologies. LAMP assays for the direct 
detection of malaria (Ebbinghaus et al., 2012; Poon et al., 2006) Methecilin-resistant Staphylococcus 
aureus (Hanaki et al., 2011) and BK virus (Bista et al., 2007) from blood samples demonstrate this. 
PCR is inhibited by a number of compounds in urine, including immunoglobulins, haemoglobin, and 
lactoferrin (Al-Soud and Radstrom, 2001), and PCR is not capable of the detection of pathogenic DNA 
directly from blood samples without prior purification. However, the use of mutant variations of taq 
polymerase, in combination with a PCR enhancer cocktail including heparin and other 
anticoagulants, has been shown to enable PCR amplification in the presence of up to 25% whole 
blood  (Zhang et al., 2010).  
The ability of the ORF1 LAMP reaction to detect N. gonorrhoeae DNA from whole blood, containing 
higher levels of blood-borne amplification inhibitors than will be found in urine or swab samples, 
show that inhibition by these compounds would not be a problem when using this assay to test for 
N. gonorrhoeae. 
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3.1. Introduction 
 
Mycoplasma genitalium is a sexually transmissible, pathogenic bacterium, belonging to the class 
Molicutes, and genus Mycoplasma (Sethi et al., 2012). M. genitalium carries one of the smallest 
genomes of any self-replicating prokaryote, consisting of a ~580kb genome containing ~480 protein 
coding regions (Suthers et al., 2009), and is considered to have close to the minimal gene 
complement of a living cell that can be grown in pure culture (Glass et al., 2006). M. genitalium was 
first isolated from two patients presenting with non-gonococcal urethritis (NGU) at the sexually 
transmitted disease clinic of St. Marys’s Hospital, London, UK in 1980. In the previous decade it had 
been noticed that tetracycline therapy was shown to have success in some instances of NGU, despite 
the absence of bacteria in the urethra, and it was hypothesised that an as yet unknown bacterium 
was responsible for the infections (Tully et al., 1981). Samples were taken from a number of patients 
and sent to the National Institute of Health, MD, USA, where two different strains of a mycoplasma 
were isolated from the samples, that differed serologically from all previously encountered 
mycoplasma. These two strains, G-37 and M-30, were then classified as a new organism, M. 
genitalium (Taylor-Robinson and Jensen, 2011). 
 
3.1.1 Pathogenesis 
 
Morphologically, M. genitalium is a 0.2µm – 0.3µm, flask shaped cell, with a defined tip known as 
the adhesion organelle, which is used for adhesion and invasion of host cells (Cazanave et al., 2012). 
Adhesion has been demonstrated on a number of cell types, including a variety of genital epithelial 
cells, spermatozoa, erythroyctes, and also non biological surfaces such as glass and plastic (Taylor-
Robinson and Jensen, 2011). In cell culture, adhesion to vaginal and cervical epithelial cells has been 
shown to occur within two hours of infection, with invasion occurring at 3 hours post infection 
(McGowin et al., 2009). It is thought that only subsets of M. genitalium cells actually internalise 
during an infection (Ueno et al., 2008), and also that not all host cells are susceptible to this 
internalisation (Taylor-Robinson and Jensen, 2011). During the infection of Vero cells in tissue 
culture, only around 10% of cells will harbour internalised mycoplasma (Jensen, 1994). M .genitalium 
is considered a facultative intracellular pathogen; unlike obligate intracellular pathogens such as 
Chlamydia trachomatis, it is able to remain viable and reproduce either intracellularly or 
extracellularly (Jensen, 2006). During colonisation of lung fibroblasts in vitro, M. genitalium invades 
the cells, and migrates through the intracellular environment to the nucleus. Intranuclear replication 
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then occurs, followed by lysis of the host cell and the release of infectious mycoplasma into the 
extracellular environment, which can then further infect surrounding cells(Mernaugh et al., 1993). 
This process results in the lysis of the cells in 96 hours. Contrastingly, a study on the colonistaion of 
HEp-2 epithelial cells found that the internalisation of M. genitalium resulted in the long term 
colonisation and persistence of intracellular infection, without host cell lysis (Dallo and Baseman, 
2000). M. genitalium replication was found to be slower intracellularly than extracellularly, and this 
gives rise to the possibility that cell invasion is used as a survival strategy, to maintain a state of low 
growth maintenance whilst evading the host immune system. 
Adhesion to the host cell is mediated by the localisation of a number of surface exposed adhesion 
proteins, linked to the internal cytoskeleton apparatus of the adhesion organelle (Burgos et al., 
2006). The primary adhesion proteins are MgPa, also referred to as P140 or MG191, and P110, also 
known as MG192. These adhesins, in combination with a number of cytoskeletal accessory proteins, 
are required for adhesion to the host cell, and therefore colonisation (Pich et al., 2008). The binding 
of M. genitalium to host cells can be blocked by either removing the surface exposed binding 
proteins with trypsin, or by binding MgPa to a monoclonal antibody in order to prevent any cell 
surface interactions (Baczynska et al., 2007), illustrating their importance to this process. Gene 
knockouts of MgPa or P110 result in reduced haemadsorption, reduced expression of associated 
cytoskeletal proteins such as MG386 and Dnak, and also the incomplete formation of the adhesion 
organelle itself (Burgos et al., 2006).  
 
3.1.2. Epidemiology and clinical presentation 
 
Epidemiological studies have estimated the overall prevalence of M. genitalium infection to be 2% 
and 7.3% for low and high risk populations, respectively (McGowin and Anderson-Smits, 2011). A 
large UK study of 2378 sexually active female students found the prevalence of M. genitalium 
infection in this population to be 3.3% (Oakeshott et al., 2010). Similar, smaller scale studies on 
female populations in Denmark (Andersen et al., 2007) and Japan (Hamasuna et al., 2008) found 
comparable levels of infection. A large scale study in the US tested 1714 female and 1218 male urine 
samples from adolescents and young adults for a range of sexually transmitted infections, and found 
a prevalence of 1.0%, 0.4%, 4.2%, and 2.3% for M. genitalium, Neisseria gonorrhoeae, C. trachomatis 
and Trichomonas vaginalis respectively. Some European studies have found the prevalence of M. 
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genitalium infection to be greater than that of C. trachomatis infection (Anagrius et al., 2013), whilst 
other similar studies have found the prevalence to be less (Oakeshott et al., 2010).  
M. genitalium is now known to be a prominent cause of urethritis in males, and is thought to be 
responsible for approximately 20% - 35% of the NGU cases in men that are not caused by C. 
trachomatis infection (McGowin and Anderson-Smits, 2011). M. genitalium infection of the male 
urethra is more frequently symptomatic than asymptomatic (Falk et al., 2004) with symptoms 
present in between 61% and 73% of patients (Anagrius et al., 2005; Falk et al., 2004), and the 
likelihood of discharge is higher than with NGU caused by other infectious agents (Wetmore et al., 
2011). M. genitalium infection is also strongly correlated with chronic NGU, often resulting from 
doxycycline and azithromycin treatment failures (Taylor-Robinson et al., 2004). M. genitalium is not 
thought to be a significant cause of prostatitis (Taylor-Robinson, 2002), however studies have found 
M. genitalium in both prostate biopsy specimens  (Krieger et al., 1996), and in semen of men with 
chronic prostatitis (Mandar et al., 2005). In vitro studies have found that chronic exposure of human 
prostate cells to M. genitalium can lead to a malignant phenotype (Namiki et al., 2009), although 
further work is required to establish whether M. genitalium infection is a risk factor in human 
prostate cancer. Urethral to rectal transmission of this organism has been demonstrated in men who 
have sex with men (MSM) (Edlund et al., 2012) and a screening of 438 MSM in the UK found an 
overall prevalence of rectal positivity of 4.4% (Soni et al., 2010).  
M. genitalium infection in female patients is associated with cervicitis (Mobley et al., 2012), pelvic 
inflammatory disease (Haggerty et al., 2006) and endometriosis (Cohen et al., 2002). The vaginal 
inoculation of mice results in the ascendance of the organism through the urethral tract, to the 
cervix, uterus, fallopian tubes and ovaries (McGowin et al., 2010). In humans, M. genitalium has 
been isolated in tissues of the cervix, uterus and fallopian tubes, demonstrating this model of 
ascending infection (McGowin et al., 2010). There has been no causal link found between M. 
genitalium infection and miscarriage or ectopic pregnancy (Manhart et al., 2011; Oakeshott et al., 
2004), although the available studies are of small populations, and are difficult to draw conclusive 
observations from. Infection in women is often asymptomatic (Falk et al., 2005), which increases the 
likelihood of the infection lying undetected and causing more serious sequelae. The instigation of a 
routine M. genitalium screening programme, as is carried out for C. trachomatis in the UK and US, 
has been suggested, partially because of this reason (Ross et al., 2009). 
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3.1.3. Relationship with other pathogens 
 
Co-infection of M. genitalium with a number of other sexually transmitted bacterial, viral and 
protozoan pathogens has been noted by a number of screening studies, as both the mode of 
transmission, and behavioural risk factors are the same for these infections (Andersen et al., 2007), a 
level of co-infection is to be expected. A study on a population of 390 N. gonorrhoeae culture 
positive men in Japan found the rate of M. genitalium co-infection to be 4.1% (Yokoi et al., 2007). A 
large study of 1182 symptomatic men in Australia found an overall M. genitalium prevalence of 
8.1%, with 14.6% also infected with C. trachomatis and 3.1% with N. gonorrhoeae (Mezzini et al., 
2013).  
M. genitalium infection has been associated with an increased risk of HIV infection (Mavedzenge et 
al., 2012), with some studies recording a greater than two-fold increase in risk of HIV acquisition 
(Mavedzenge et al., 2012). A study on a high risk population in Kenya found that HIV positive 
patients were more likely to also be coinfected with M. genitalium than HIV negative patients 
(Cohen et al., 2007), which is likely to reflect high risk behaviour, or HIV mediated 
immunosupression, facilitating M. genitalium colonisation (Manhart et al., 2008). Infection by M. 
genitalium in HIV positive patients has been linked to an increase in viral shedding from the cervix, 
but only in patients with a high M. genitalium organism load (Manhart et al., 2008). A high organism 
load is typically indicative of a recent infection, with lower organism loads occurring once specific 
immunity is generated, and the infection cleared to some degree (Manhart et al., 2008). This 
increase in viral shedding makes transmission more likely (Anderson and Cu-Uvin, 2008), and is 
another mechanism by which the prevalence of M. genitalium in a population can affect the 
prevalence of HIV. Experiments in mice have shown that for effective antibiotic treatment of M. 
genitalium a functioning immune system is also required (Taylor-Robinson and Furr, 2000), although 
it is yet to be established whether immunocompromised human patients have the same difficulties 
in clearing mycoplasma infections during antimicrobial therapy (Taylor-Robinson, 2008). 
 
3.1.4. Treatment 
 
Currently, the primary antibiotic used in treatment of M. genitalium infections, is azithromycin (Skov 
Jensen, 2009). Azithromycin is a macrolide antibiotic, which exerts its antimicrobial effects by 
competing for [14C]erythromycin ribosome binding sites, and preventing the translation of mRNA 
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needed for protein synthesis (Retsema et al., 1987). A single 1g dose of azithromycin has been 
shown to eradicate ~87% of M. genitalium infections (Mena et al., 2009), whilst an extended dosage 
of 500mg on day one, followed by a 250mg dose for a subsequent 4 days has been shown to 
improve outcomes, clearing >95% of infections (Björnelius et al., 2008). At least one study however, 
has found no difference in cure rates between these two programmes of azithromycin therapy 
(Jernberg et al., 2008). Cases of NGU in which the aetiological agent has not been identified are 
often treated with either azithromycin, or doxycycline. Doxycycline has been shown to be effective 
in treating around 17% to 37% of M. genitalium infections (Björnelius et al., 2008), and is therefore 
not recommended once M. genitalium has been identified as the cause of the symptoms. It is partly 
for this reason that recent guidelines for NGU recommend an azithromycin regimen (Workowski and 
Berman, 2010). Treatment failures after single dose azithromycin therapy have been associated with 
the generation of resistance, with follow up extended azithromycin treatment failing in up to 66% of 
patients (Jernberg et al., 2008). This resistant phenotype has been linked to point mutations at 
positions 2058 and 2059 in region V of the 23S rRNA gene (Jensen et al., 2008), which have 
previously been linked to macrolide resistance in other organisms including Staphylococcus aureus 
and Helicobacter pylori (Vester and Douthwaite, 2001). A recent study in the UK (Pond et al., 2014) 
diagnosed M. genitalium in 16.7% of 217 men with asymptomatic urethritis, and found of this group 
that 41% (95% confidence interval: 20%-62%) were infected with strains possessing genotypic 
macrolide resistance. 
In cases of treatment failure, patients are treated with moxifloxacin, which is given at 400mg daily 
for seven to ten days, and is not known to have been unsuccessful in clearing M. genitalium infection 
(Manhart et al., 2011). Moxifloxacin, like all quinolones, exert their antimicrobial effect by inhibiting 
the activity of type II topoisomerases, DNA gyrase, and topoisomerase IV (Hooper, 1999). Despite 
the lack of clinical resistance encountered, point mutations in the quinolone resistance determining 
region (QRDR) of the parC gene, encoding a subunit of topoisomerase IV, have been discovered in 
clinical isolates, which could indicate the emergence of quinolone resistance (Shimada et al., 2010). 
Studies have found the prevalence of these mutations to currently be between occurring in 10% to 
15% of isolates encountered clinically (Tagg et al., 2013; Shimada et al., 2010). QRDRs also exist in 
the M. genitalium gryA, gyrB, and parE genes, and mutations in these genes causing a 
fluoroquinolone resistant phenotype have been detected in clinical isolates (Hamasuna et al., 2011; 
Shimada et al., 2010). In vitro data suggests alternative quinolone therapies utilised for the 
treatment of both NGU and cervicitis, including levofloxacin, ofloxacin and ciprofloxacin, have 
limited effectiveness against M. genitalium (Renaudin et al., 1992).  
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A considerable obstacle in the susceptibility testing of M. genitalium is the extreme difficulty in 
obtaining a pure culture from a clinical specimen. Conventional broth dilution, or agar dilution 
susceptibility testing can be carried out once an axenic culture is obtained from the clinical specimen 
(Taylor-Robinson and Bebear, 1997). However, some strains are incapable of adaptation to axenic 
culture, and can therefore not be tested in this manner (Hamasuna et al., 2005). A method based on 
real-time PCR has been developed, which uses a primer set specific to the single copy mgpB gene, to 
detect M. genitalium DNA levels in co-culture with Vero cells (Hamasuna et al., 2005). This removes 
the need for the generation of an axenic culture, and allows for much earlier susceptibility testing. In 
one evaluation, the MICs obtained for macrolides using this method were slightly higher than those 
obtained using the broth diffusion method (Hamasuna et al., 2008), whilst the MICs for 
flouroquinolones and tetracyclines showed good agreement. Due to the extremely high macrolide 
MICs seen for macrolide resistant strains, this difference would not be clinically relevant.  
 
3.1.5. Diagnosis 
 
The laboratory diagnosis of M. genitalium infection is almost exclusively carried out using nucleic 
acid amplification tests (NAATS), usually in the form of either commercially available or “in house” 
PCR assays (Cazanave et al., 2012; Shipitsyna et al., 2009). The culture of M. genitalium is difficult 
and extremely time consuming, requiring incubation periods in excess of a month to provide a 
maximally sensitive culture protocol (Hamasuna et al., 2005). Obtaining an axenic culture from a 
clinical specimen can take over 6 months using standard culture methods, and around 5 weeks using 
the Vero cell method (Hamasuna et al., 2005), making traditional culture based antibiotic 
susceptibility very difficult. Culture by the Vero cell method involves the propagation of the 
mycoplasma in Vero cells, before broth cultures are attempted, and then finally the growth of the 
organism on solid media (Jensen et al., 1996; Jensen, 2004). The high failure rate and lengthy 
incubation times mean that culture of M. genitalium is very rarely attempted using clinical samples, 
especially now alternative molecular diagnostics methods are available (Waites et al., 2012). The 
development of serological diagnostic assays has also proven difficult, due to the cross reactivity 
between M. genitalium and the closely related, and antigenically similar, M. pneumoniae(Lind et al., 
1984). This cross reactivity has been overcome with some success by targeting lipid associated 
membrane proteins (LAMPs) as antigens, due to the lack of response that antibodies to M. 
genitalium LAMPs show towards the corresponding proteins of M. pneumoniae (Wang et al., 1997). 
In one of the few published evaluations of serological tests for M. genitalium, an enzyme linked 
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immunosorbent (ELISA) assay developed using recombinant fragments of the MgPa adhesin protein 
(rMgPa) was shown to have a sensitivity and specificity of 59% and 81% respectively, when 
compared with a polymerase chain reaction (PCR) assay specific to the mgpB locus (Svenstrup et al., 
2006). The lack of availability of commercial ELISA tests for M. genitalium in the UK or USA (Waites 
et al., 2012), the difficulty of their design, and their poor performance when compared to NAAT tests 
such as PCR, means that serology based diagnostics are infrequently used in the clinical diagnosis of 
this organism. 
M. genitalium specific PCR and rtPCR assays have been designed for a number of targets, including 
the 16S rRNA region (Jensen et al., 2003), and genes in the MgPa operon (Jensen et al., 2004). The 
16S rRNA gene of M. genitalium shares 98% sequence homology with its counterpart in M. 
pneumoniae, complicating the selection of suitable primer binding sites (Jensen et al., 2003a). The 
use of probe based real-time assays has helped in this regard, due to the added specificity provided 
by the internal probe sequence (Yoshida et al., 2002). Despite the high level of sequence homology, 
several published 16S rRNA PCR assays have been demonstrated to have no cross reactivity with M. 
pneumoniae DNA (Eastick et al., 2003), and assay sensitivities of ~10 gene copies per reaction have 
been reported (Yoshida et al., 2002). 
The MgPa operon includes the mgpA, mgpB and mgpC genes, which encode the highly expressed 
MgPa adhesin protein. Over 4.7% of the entire M. genitalium genome is composed of the MgPa 
operon, and repeated elements known as MgPars, which show significant homology to MgPa, and 
are interspersed at nine chromosomal locations (Ma et al., 2012). These regions are attractive 
targets for NAATs, as the repeated sequences afford a high starting copy number per cell, enabling 
improved assay sensitivities. However, extensive variance has been shown between strains in the 
MgPar regions, demonstrated to be caused by recombination between the mgpB and mgpC genes 
and MgPar sequences (Iverson-Cabral et al., 2007). This recombination results in MgPa antigenic 
variance of the mycoplasma during the course of infection, assisting the organism in evading the 
host immune response. Samples taken from a patient persistently infected with a single strain of M. 
genitalium yielded 17 mgpB variants when sequenced, illustrating this phenomenon (Iverson-Cabral 
et al., 2007). The reported variability of these sequences has led to concern over their reliability as 
targets for NAAT assays, and has encouraged researchers to turn to more highly conserved, single 
copy targets, despite the reduction in sensitivity. Examples of these single copy targets include the 
gap housekeeping gene, which encodes a glyceraldehydes-3-phosphate dehydrogenase (Svenstrup 
et al., 2005); the pdhD gene, encoding a dihydrolipoamide dehydrogenase (Muller et al., 2012); and 
the 115-kDa gene (Dupin et al., 2003). 
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In addition to “in house” assays detailed in the literature, a range of commercial rt-PCR assays are 
available for diagnostic use in the UK. These include singleplex assays such as the EuroClone (Pero, 
Italy) Duplica RealTime Mycoplasma Genitalium kit, which uses the Mgp-r2 repetitive element as a 
target, and Tib MolBiol (Berlin, Germany) LightMix Kits, for use on the Roche Lightcycler, which 
detect the M. genitalium gap gene. Multiplex assays capable of detecting a panel of sexually 
transmitted infections including M. genitalium are also on the market. Examples include the Bio-Rad 
(Hercules, US) CT/NG/MG assay for simultaneous detection of C. trachomatis, N. gonorrhoeae and 
M. genitalium in urogenital samples; The Amplex Biosytems (Giessen, Germany) Hyplex STD 
Mycoplasma kit for the detection of pathogenic mycoplasma species including Mycoplasma hominis, 
M. genitalium, Ureaplasma urealyticum and Ureaplasma parvum; and the Seegene (Seoul, South 
Korea) SeeplexTM STD detection kit, which enables the user to choose from a range of 12 sexually 
transmitted pathogens including M. genitalium, and simultaneously detect between 4 and 6 
different infections per test. 
The application of novel isothermal amplification methods to M. genitalium detection has been 
limited. Gen-Probe (San Diego, US) has developed a transcription mediated amplification (TMA) 
assay for M. genitalium detection, for research use. TMA is an isothermal method of amplifying a 
target DNA or RNA sequence using a pair of target specific primers, and driven by reverse 
transcriptase and RNA polymerase enzymes (Wroblewski et al., 2006). The reverse transcriptase 
catalyses the formation of a double stranded DNA template from single stranded RNA target 
sequences, and the RNA polymerase make copies of the single stranded complementary RNA 
sequence, providing more template for the reaction. In this exponential manner, TMA is capable of 
producing over a billion copies of amplicon in 30 minutes, per starting RNA or DNA target copy. The 
generated amplicon is detected by DNA probes, and fluorescently monitored. A comparison of the 
assay with a multi target rt-PCR assay, involving the screening of 607 clinical samples (101 positive), 
found the TMA assay to have both a sensitivity and specificity of 98.1%. The multi target rt-PCR assay 
had a sensitivity and specificity of 91.8% and 99.5% respectively (Hardick et al., 2006).  
To our knowledge, no loop mediated isothermal amplification (LAMP) assay has been designed for 
M. genitalium. Recent reviews of the diagnostic options available for M. genitalium detection do not 
identify any LAMP assays, or indeed alternative isothermal assays, bar the Gen-Probe TMA assay 
previously mentioned (Waites et al., 2012). A LAMP assay has been published for the detection of M. 
pneumoniae (Saito et al., 2005), which is closely related to M. genitalium. An M. genitalium LAMP 
assay would provide another assay to the limited number of diagnostic options for M. genitalium 
diagnosis, the vast majority of which are based on standard PCR. LAMP has several advantages over 
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PCR, including the potential for increased specificity (Notomi et al., 2000), higher tolerance to 
inhibitors (Francois et al., 2011), and speed. LAMP reactions also offer a number of different 
detection strategies, including the real time monitoring of the reaction via the incorporation of a 
fluorescent intercalating dye, or the end point detection of amplification using calcein (Tomita et al., 
2008). The use of calcein mediated end point detection requires no additional equipment, and 
enables the use of sensitive NAAT diagnostics in a resource poor environment. This would enable 
rapid, sensitve testing for M. genitalium infection in laboratories without either expensive real-time 
PCR platforms, or thermocycling equipment. 
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Aims 
 
 To maintain the culture of M. genitalium, in order to provide a source of M. genitalium DNA 
to ourselves and also Public Health England. 
 To provide confirmation of the suitability of the magnetic silica based extraction system for 
the purification of nucleic acids from M. genitalium. 
 To design a PCR assay for the detection of M. genitalium, in order to provide a tool for the 
determination of the successful culture of this organism. 
 To determine the analytical sensitivity of PHE designed 16S rRNA LAMP primer sets for M. 
genitalium. 
 To design a LAMP assay for a suitable gene target to enable the sensitive detection of M. 
genitalium. 
 To determine the limit of detection and analytical specificity of the assay comparing this 
with gold standard PCR assays for the detection of this organism. 
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3.2. Materials and Methods 
 
3.2.1. PCR primer design 
 
The sequences of both the M. genitalium G37 strain 16S rRNA gene (NCBI Reference Sequence: 
NC_000908.2, Gene ID: 875400), and M. genitalium G37 strain MgPa gene (NCBI Reference 
Sequence: NC_000908.2, Gene ID: 875543) were retrieved from GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/). The design of target specific primers was carried out using 
Primer-BLAST (http://www.blast.ncbi.nlm.nih.gov/) (Ye et al., 2012). Two sets were designed for the 
mgpB gene, designated M. genitalium mgpB 1, and M. genitalium mgpB 2. One set was designed for 
the 16S rRNA sequence. The primer sequences and predicted product sizes are shown in Table 3.1. 
 
Primer Sequence Length (bp) Product size (bp) Annealing Temp 
(oC) 
M. genitalium mgpB 
1 F 
CTGCACTTACCCTTGGG
GTT 
20 
666 57 
M. genitalium mgpB 
1 R 
ACCTTTGGGTGGGGTT
GAAG 
20 
M. genitalium mgpB 
2 F 
AGCAGGGTATCGCGTT
CAAA 
20 
243 58 
M. genitalium mgpB 
2 R 
AGCAACAGTTGATTGC
GCTG 
20 
M. genitalium 16S 
rRNA 1 F 
TGCCCCTTATGTCTAGG
GCT 
20 
270 58 
M. genitalium 16S 
rRNA 1 R 
ATCCTTGACATGCGCTT
CCA 
20 
Table 3.1. M. genitalium PCR primer sequences 
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3.2.2. LAMP primer Design 
 
LAMP primer sets were designed for the pdhD gene of M. genitalium. Available pdhD gene 
sequences were retrieved from GenBank (http://www.ncbi.nlm.nih.gov/genbank/), from the 
following M.genitalium strains; G37, M2288, M2300, M2321, M2341. Sequences were aligned using 
ClustalX (Chenna et al., 2003).  LAMP primers were designed using PrimerExplorer Version 4 
(http://www.primerexplorer.jp/e/), with the primer binding sites compared to the alignment data to 
ensure compatibility. The additional optional loop primers were not designed. Primer specificities 
were checked using BLAST (http://www.blast.ncbi.nlm.nih.gov/). LAMP primers were synthesised 
commercially (Eurofins, Germany). LAMP primer sequences are shown in Table 3.2. 
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Primer Sequence Length (bp) 
M. genitalium pdhD 
1 LAMP F3 
ACTACAAACATCAACTACAAACA 23 
M. genitalium pdhD 
1 LAMP B3 
ACAAAAGCAACTTCAGGATT 
20 
M. genitalium pdhD 
1 LAMP FiP 
TGCCCTGTTGGTAAGCGTAGCTATCTAATAGGTGATGTTAACACG 
45 
M. genitalium pdhD 
1 LAMP BiP 
TGCTGTTGATCAAATTTTGAACCATGTAAATACAAGCAGGACACTT 
46 
M. genitalium pdhD 
2 LAMP F3 
TCTGAACTGATAAGTAAAACCTT 
23 
M. genitalium pdhD 
2 LAMP B3 
TGTTTGTAGTTGATGTTTGTAGT 
23 
M. genitalium pdhD 
2 LAMP FiP 
GACTGTTCAACTCCATTAACTGTGTGAGTTCAGATTATTACCAATGCT 
48 
M. genitalium pdhD 
2 LAMP BiP 
TAGGAAGAATTGCTAACACAGAGTGTTTTGTTGTTATGGTCACG 
45 
M. genitalium pdhD 
3 LAMP F3 
ACAACACAACTTACACCACTA 
21 
M. genitalium pdhD 
3 LAMP B3 
TGGTCACTTCACTCCCTAA 
19 
M. genitalium pdhD 
3 LAMP FiP 
GTGCTTTTTCAAACCCTGGTAAAGTACAACATTATTGTTGCAACCG 
46 
M. genitalium pdhD 
3 LAMP Bip 
CATTGACTCAACCCAAGCTTTGGACTCAACCCCAATCACAC 
41 
Table 3.2. M. genitalium pdhD LAMP primer sequences.  
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3.2.3. Public Health England M. genitalium 16S rRNA LAMP primer sets 
Sequences were provided by Public Health England for their M. genitalium 16S rRNA LAMP primer 
set. The primer sequences are shown in Table 3.3. 
 
Primer Sequence Length (bp) 
M. genitalium 16S 
F3 
CGTGAACGATGAAGGTCTT 
20 
M. genitalium 16S 
B3 
ACCACACTCTAGACTGATAGTT 
22 
M. genitalium 16S 
FiP 
GCGACTGCTGGCACATAGTAATGACTCTAGCAGGCAATG 
39 
M. genitalium 16S 
BiP 
ACATAGGTCGCAAGCGTTATCCCTGCCTTTAACACCAGACTT 
42 
M. genitalium 16S 
LoopF 
TGGTACAGTCAAACTCCAGC 
20 
M. genitalium 16S 
LoopB 
GGATTTATTGGGCGTAAAGCAA 
22 
Table 3.3. Sequences of the Public Health England M. genitalium 16S rRNA LAMP primer sets 
 
3.2.4. Culture 
 
M.genitalium (NCTC 10195) was cultured on Mycoplasma Agar Base (Oxoid, UK), containing 20% 
Mycoplasma Supplement G (Oxoid, UK). Plates were inoculated aerobically in a moist environment 
at 37oC. Colonies were typically detectable using a dissecting microscope at a 60x magnification after 
a period of 2 to 3 weeks. 
Broth cultures were also used, from the initial freeze dried culture. 100µl of rehydrated M. 
genitalium cell suspension was added to 100ml of mycoplasma broth base, containing 20% 
mycoplasma supplement G (Oxoid, UK). Cultures were incubated aerobically in a moist environment 
at 37oC. DNA was extracted from 200µl of the culture, and tested using M. genitalium mgpB and 16S 
rRNA PCR assays for the presence of M. genitalium. 
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3.2.5. DNA extraction 
 
M. genitalium cells were harvested from solid media plates after a 3 week period post inoculation, 
when colonies were visible with the aid of a dissecting microscope. As much material was removed 
from the plates as possible, using a cotton swab, and transferred to a 1ml aliquot of molecular grade 
water. Alternatively, if broth cultures were used, a 100µl volume of culture was removed from the 
vessel. The cells were then concentrated by centrifugation at 30,000 x g for 15 minutes at 4oC. DNA 
extractions were carried out using a QIAmp DNA mini kit (QIAGEN Inc., USA), following the protocol 
for bacterial cells. RNase A (New England Biolabs, UK) was used during the RNA digestion step. 
Alternatively, in section 3.2.11, extractions were carried out on the centrifuged cells using the total 
nucleic acid extraction methodology (1.2.7). DNA was quantified spectrophotometrically using 
Spectrostar plate reader in conjunction with an LVIS plate (BMG Labtech, UK). Genome copy number 
was worked out from the size of the M. genitalium genome (580kb), and the following equation; 5.8 
× 105 bp × 665 Da/bp × 1.67 × 10−24 g/Da). 
 
3.2.6. LAMP Reactions 
 
LAMP reactions were set up using reagents from a Mast Isoplex DNA amplification kit (Mast Group 
Ltd, UK), as follows; 5µl five times LAMP reaction buffer, 1µl intercalating dye (propriety dye, 
emission in FAM channel), 1µl of 8U/µl Bst polymerase (New England Biolabs, USA), 1µl of primer 
mix containing 40pmol of FiP and BiP primers, and 5pmol of F3 and B3 primers, 12µl molecular grade 
water. Finally 5µl of DNA sample or water was added to the reaction. Reactions were carried out in 
an ESEQuant Tube Scanner (Qiagen Inc., CA), at 63oC for 60 minutes. Reactions were terminated by 
heating to 80oC for 1 minute in order to denature the Bst polymerase. The ESEQuant Tube Scanner 
allows for real-time monitoring of the LAMP reactions, via optical detection of the fluorescent 
intercalating dye through the FAM channel. The “Tube Scanner Studio” software package was used 
to analyse the real time data and produce a manually set threshold line for the purposes of 
determining time to amplification (Ta). 
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3.2.7. PCR Reactions 
 
PCR reactions were set up as follows; 25µl RedTaq reaction mix (Sigma Aldrich, UK), 0.5pmol 
Forward primer, 0.5pmol reverse primer. Reactions were then made up to 45µl with water, and 5µl 
DNA (or water as a no template control) was added. Reaction conditions were as follows; 94oC for 5 
minutes initial denaturation; 35 cycles of 94oC for 30 seconds, the correct primer annealing 
temperature (specific to each primer set) for 30 seconds and 72oC for 30 seconds; 72oC for 5 minutes 
final extension. Reactions were heated using an ABI 2720 thermocycler (Applied Biosystems, UK). 
PCR reaction products were separated on 2% % w/v agarose gels, with transillumination and 
photography provided by a BioRad Gel/Chem Doc system (Bio-Rad Inc, UK). 
 
3.2.8. Detection of M. genitalium in broth culture by PCR 
 
A 100µl aliquot of the rehydrated freeze dried M. genitalium cell suspension purchased from NTCC 
had been reserved in order to provide a positive control, and a source of DNA in case culture proved 
impossible. DNA was extracted from both the original inoculum, and also from 100µl of the first 
attempt at a broth culture, that had been incubating for a period of 1 week. PCR reactions were then 
carried out with both extracted DNA samples, using the M. genitalium specific primer sets mgpB 1, 
mgpB 2 and 16S rRNA 1. For each primer set, a reaction was carried out with molecular grade water 
in place of the DNA sample, as a negative control. PCR products were then separated using agarose 
gel electrophoresis (2% w/v gel), and visualised. 
 
3.2.9. Detection of M. genitalium from culture on solid media by PCR 
 
Cells were harvested, and DNA extracted, from an agar plate of M.genitalium culture as described 
above. The plates were harvested at 3 weeks post inoculation. PCR reactions were then carried out 
with the extracted DNA sample, using the M. genitalium specific primer sets mgpB 1, mgpB 2 and 
16S rRNA 1. For each primer set, a reaction was carried out with molecular grade water in place of 
the DNA sample, as a negative control, and a reaction with DNA extracted from the initial freeze 
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dried cell suspension, as a positive control. PCR products were then separated using agarose gel 
electrophoresis (2% w/v gel), and visualised. 
 
 
3.2.10. Sensitivities of the M. genitalium 16S rRNA PCR and mgpB 2 PCR assays 
 
DNA was extracted from M. genitalium cultured on solid media. The DNA was quantified 
spectrophotometrically, and the sample was diluted to 2ng/µl. As 5µl of DNA is used in each assay, 
this equates to 0.1µg per individual reaction. This stock DNA was then sequentially diluted 1:10 in 
molecular grade water to a level of 0.2fg/µl. PCR reactions were then carried out using the M. 
genitalium 16S rRNA and mgpB 2 PCR assays for each dilution of DNA from 20pg/µl to 0.2fg/µl.  
Molecular grade water was used as a negative control for each assay. PCR products were then 
separated using agarose gel electrophoresis (2% w/v gel), and visualised. 
 
3.2.11. Sensitivity of the 16S rRNA LAMP assay 
 
DNA was extracted from M. genitalium cultured on solid media, using the total nucleic acid 
extraction protocol. The DNA concentration was measured spectrophotometrically, and the sample 
was diluted to 2ng/µl. As 5µl of DNA is used in each assay, this equates to 0.1µg per individual 
reaction. This stock DNA was then sequentially diluted 1:10 in molecular grade water to a level of 
0.2fg/µl. PCR reactions were then carried out using the M. genitalium 16S rRNA PCR assay for each 
DNA dilution from 20pg/µl to 0.2fg/µl. LAMP reactions using the 16s rRNA primer set were then also 
carried out for each DNA dilution. Molecular grade water was used in lace of DNA as a negative 
control for both assays. Reaction products PCR reactions were then separated using agarose gel 
electrophoresis (2% w/v gel), and visualised. LAMP reactions were monitored in real-time using the 
ESEQuant tube scanner. 
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3.2.12. Initial testing of pdhD LAMP primer sets 
 
DNA was extracted from M. genitalium colonies as described in section 2.1.4. The DNA 
concentration was measured, and the sample was diluted to 2ng/µl. A single positive reaction, 
containing the extracted DNA, and a single negative reaction, containing molecular grade water was 
carried out for each of the 3 pdhD primer sets (sequences shown in Table.2.). 
 
3.2.13. Comparison of pdhD LAMP reactions with pdhD PCR, and notable M. genitalium PCR assays 
from the literature 
 
DNA was extracted from M. genitalium colonies as described in section 2.1.4. The DNA 
concentration was measured, and the sample was diluted to 2ng/µl. As 5µl of DNA extract is used in 
each assay, this equates to 0.1µg per individual reaction. This stock DNA was then sequentially 
diluted 1:10 in molecular grade water to a level of 0.2fg/µl. Each dilution from 20pg/µl to 0.2fg/µl 
was then used as the template for a LAMP reaction using the pdhD 1 and pdhD 3 LAMP sets. PCR 
reactions were also carried out on the same DNA dilutions using the F3 and B3 primers from the 
pdhD 1 and pdhD 3 LAMP sets, and the annealing temperature and predicted product size is shown 
in Table 3.4. 
 
Primer Sequence Length (bp) Product size (bp) Annealing Temp 
(oC) 
M. genitalium 
pdhD 1 LAMP F3 
ACTACAAACATCAACTA
CAAACA 
23 
183 52 
M. genitalium 
pdhD 1 LAMP B3 
ACAAAAGCAACTTCAGG
ATT 
20 
M. genitalium 
pdhD 3 LAMP F3 
ACAACACAACTTACACC
ACTA 
21 
225 51 
M. genitalium 
pdhD 3 LAMP B3 
TGGTCACTTCACTCCCTA
A 
19 
Table 3.4. Primer sequences and properties of the pdhD 1 and pdhD 2 F3 and B3 PCR reactions. 
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The same dilutions of extracted M. genitalium DNA were tested using two prominent PCR assays 
from the literature, a 16S rRNA PCR assay (Jensen et al., 2003), and a MgPa assay (Jensen et al., 
2004). The primer sequences, annealing temperatures and expected product sizes are detailed in 
Table 3.5. 
 
Primer Sequence Length (bp) Product size (bp) Annealing Temp 
(oC) 
MgPa-355F GAGAAATACCTTGATGGTCAG
CAA 
24 
78 62 
MgPa-432R GTTAATATCATATAAAGCTCT
ACCGTTGTTATC 
33 
MG16-45F TACATGCAAGTCGATCGGAA
GTAGC 
25 
425 60 
MG16-447R AAACTCCAGCCATTGCCTGCT
AG 
23 
Table 3.5. Primer sequences and properties of the 16s rRNA PCR assay from Jensen et al. (2003), and 
MgPa PCR assay detailed in Jensen et al. (2004). 
 
The reaction conditions for the 16S rRNA assay were as described in Jensen et al (2003), with the 
exception that Redtaq reaction mix (Sigma, UK) was used in place of the separate reaction 
components and enzyme previously detailed. The reaction contained 0.4µM of each primer.  A 
touchdown PCR methodology is used in order to promote higher specificity. After an initial 94oC 
denaturing step for 2 minutes, 10 cycles of the following steps were carried out;  denaturation at 
94oC for 15 seconds; annealing at 72oC to 62oC for 30 seconds, with a 1 degree decrease per cycle; 
extension at 72oC for 15 seconds. A further 30 cycles were performed with the following steps; 
denaturation at 92oC for 15 seconds; annealing at 62oC for 30 seconds; extension at 72oC for 30 
seconds.  
The reaction conditions for the MgPa PCR assay were as described in Jensen et al. (2004), with a 
number of modifications. As the primer set was being used for conventional PCR, rather than real 
time PCR, for which the assay was designed, the inclusion of a an intercalating dye was not 
necessary. Also, the reactions could be performed in a standard thermocycler (ABI 2720), rather 
than the Smartcycler (Cepheid) used in the original study. Redtaq reaction mix (Sigma) was used in 
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place of the separate components and Hot Gold Star taq polymerase used in the original study, 
which necessitated an increase in reaction volume to 50µl. The reaction contained a 1µM 
concentration of each primer.  A touchdown PCR methodology is used in order to promote higher 
specificity. After an initial 94oC denaturing step for 2 minutes, 1 cycle of the following steps were 
carried out;  denaturation at 94oC for 15 seconds; annealing at 64oC for 30 seconds; extension at 
72oC for 30 seconds. The next cycle was performed with the following steps; denaturation at 94oC 
for 15 seconds; annealing at 64oC for 30 seconds; extension at 72oC for 30 seconds. A further 48 
cycles were performed with the following steps; denaturation at 95oC for 15 seconds; annealing at 
60oC for 30 seconds; extension at 72oC for 30 seconds.  
 
3.2.13. Specificity of the pdhD 1 LAMP assay 
 
DNA was extracted from the following organisms using a QIAmp DNA mini kit (QIAGEN Inc., USA), 
following the protocol for bacterial cells; N. gonorrhoeae (ATCC 19424), C. trachomatis (lab strain, 
serovar L2), T. vaginalis (ATCC 30001) Pseudomonas aeruginosa (ATCC 15692), and Escherichia coli 
(lab strain). M. pneumoniae (NCTC 010119) genomic DNA was purchased commercially from 
Minerva Biolabs Gmbh (Germany). 
DNA extractions from two clinical cervical swab samples which had been confirmed positive for 
Ureaplasma urealyticum and Ureaplasma parvum DNA using the PCR assays detailed in Cultrela et 
al. (2006), and negative for M. genitalium DNA using the 16S rRNA PCR assay (12) were used as a 
source of U. urealyticum and U. parvum DNA. A clinical cervical swab sample which had tested 
positive for M. genitalium DNA by 16S rRNA PCR was used as a clinical M. genitalium specimen. All 
clinical samples were negative for C. trachomatis and N. gonorrhoeae DNA, as determined by the 
APTIMA COMBI 2 assay (GenProbe, US). 
 Each DNA sample was diluted to 20ng/µl and 5µl of each DNA sample (0.1µg) was used as a 
template in the pdhD LAMP reaction, to test the specificity of the primers when in contact with non-
target DNA, from organisms commonly found in samples from patients with urethritis. 
 
 
 
229 
 
3.3. Results 
 
3.3.1. Detection of M. genitalium in broth culture by PCR 
 
Due to the difficulty in visually detecting M. genitalium growth using liquid or solid media, order to 
determine the success of the initial culture of M. genitalium from the purchased cell stock, it was 
necessary to design a PCR assay capable of amplifying M. genitalium genomic DNA. Although 
standard endpoint PCR assays were developed, by comparing the brightness of the amplified 
product on an agarose electrophoresis gel, a comparison of relative product abundance, and hence 
starting copy number, can be made.  PCR reactions were carried out on DNA extracted from both the 
rehydrated freeze dried inoculum (+) and first attempted broth culture, 1 week post inoculation (1). 
PCR reactions containing the mgpB 1, mgpB 2 and 16S rRNA primer sets were used. PCR products 
were then separated using agarose gel electrophoresis (2% w/v gel), and visualised (Fig.3.1). 
 
Fig.3.1. Agarose gel electrophoresis (2%) of reaction products from mgpB 1 (A), mgpB 2 (B) and 16S 
rRNA (C) PCR reactions, from DNA extracted from the rehydrated freeze dried inoculums (1), 1 week 
post inoculation broth culture (2), and molecular grade water (3). 
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The mgpB 1, mgpB 2, and 16S rRNA PCR assays all generated a product of the expected size from the 
positive control DNA; 666bp, 243bp, and 270bp, respectively (Fig.3.1). Additionally, no amplification 
was generated by any assay from the no template control, indicating a lack of baseline non-specific 
amplification. The mgpB 1 and 16S rRNA assay both failed to generate any product from the DNA 
extracted from the broth culture, indicating a failure of the culture to generate any biomass. The 
mgpB 2 assay did manage to generate a low level of product, faintly visible on the agarose gel at 
243bp. This is likely to have been amplified from DNA present in the initial inoculum, indicating that 
the mgpB 2 assay is potentially the most sensitive PCR assay of the three tested. 
 
3.3.2 Detection of M. genitalium from culture on solid media by PCR 
 
The PCR assays used to test liquid culture (section 3.3.1) were also used to investigate whether the 
culture of M. genitalium on solid media had been successful. 
PCR reactions were carried out on DNA extracted from both the rehydrated freeze dried inoculum 
(+) and M. genitalium cultured on solid media, 3 weeks post inoculation (1). PCR reactions containing 
the mgpB 1, mgpB 2 and 16S rRNA primer sets were used. PCR products were then separated using 
agarose gel electrophoresis (2% w/v gel), and visualised (Fig.3.2). 
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Fig.3.2. Agarose gel electrophoresis (2%) of reaction products from mgpB 1 (A), mgpB 2 (B) and 16S 
rRNA (C) PCR reactions, from DNA extracted from the rehydrated freeze dried inoculums (1), M. 
genitalium cultured on solid media (3), and molecular grade water (2). 
 
As in Fig.3.1, all three PCR assays generated an amplified product from the positive control DNA, 
whilst failing to generate a product from the no template control (Fig.3.2). The mgpB 1, mgpB 2, and 
16S rRNA assay all generated a product of the expected size from the DNA extracted from harvested 
cells from solid media, indicating the successful growth of M. genitalium cells by this method. The 
increased brightness and size of the amplified products from the cultured cells compared to the 
initial cell stock, when visualised using agarose gel electrophoresis, shows that the copy number, and 
hence cell mass, has increased. 
 
3.3.3. Sensitivities of the M. genitalium 16S rRNA PCR and mgpB 2 PCR assays 
 
In order to provide a comparison with the M. genitalium LAMP assays in development, and also be 
able to use the PCR assays to give an indication of copy number, the limits of detection of the 16S 
rRNA PCR and mgpB 2 PCR assays were determined. The mgpB 1 assay was not included in the study 
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as it appeared less sensitive than the mgpB 2 assay (Fig.3.1), and the excessive product size (666bp) 
is likely to strain the PCR reaction and prove disadvantageous. 
PCR reactions were carried out on a dilution series of M. genitalium DNA, using the mgpB 2 and 16S 
rRNA primer sets. Final amounts of DNA per reaction of 0.1ng, 10pg, 1pg, 0.1pg, 10fg, 1fg. Molecular 
grade water was used as a negative control. PCR products were then separated using agarose gel 
electrophoresis (2% w/v gel), and visualised (Fig.3.3).  
 
 
Fig.3.3. Agarose gel electrophoresis of reaction products of PCR reactions using primer sets mgpB 2 
(A) and 16S rRNA (B). Final amounts of M. genitalium DNA per reaction were 0.1ng (A1, B1), 10pg 
(A2, B2), 1pg (A3, B3), 0.1pg (A4, B4), 10fg (A5, B5), 1fg (A6, B6). Molecular grade water was used in 
place of DNA as a negative control (A7, B7). 
 
The 16S rRNA PCR reaction was able to detect a minimum of 1pg of purified M. genitalium DNA. The 
mgpb 2 assay was able to detect 0.1pg of M. genitalium DNA and above; a 10-fold increase in 
sensitivity when compared to the 16S rRNA assay. When visualised using agarose gel 
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electrophoresis, the size and brightness of the 243bp (mgpB 2) and 270bp (16S rRNA) products 
proportionally increased with an increase in starting DNA concentration. 
 
3.3.4. Sensitivity of the 16S rRNA LAMP assay 
 
In order to determine the sensitivity of the M. genitalium 16S rRNA LAMP assay it was necessary to 
identify the minimal concentration of M. genitalium genomic DNA detectable by the assay. As M. 
genitalium cells are too small to perform cell counts in broth culture, and the colonies are too small 
to perform plate counts, starting copy number was worked out from the concentration of genomic 
DNA in order to quantify the number of M. genitalium genomes present. DNA was extracted using 
the total nucleic acid extraction methodology, to ensure the capatability of this process with M. 
genitalium cells. 
PCR reactions were carried out on a dilution series of M. genitalium DNA, using the 16S rRNA primer 
set. Final amounts of DNA per reaction were of 0.1ng, 10pg, 1pg, 0.1pg, 10fg, 1fg. LAMP reactions 
were carried out with the same diluted DNA samples, using the 16S rRNA LAMP primers provided by 
Public Health England. The reaction products from both the LAMP and PCR assays were separated 
using agarose gel electrophoresis (2% w/v gel), and visualised (Fig.3.4). The LAMP reactions were 
monitored in real-time using the ESEQuant tube scanner (Fig.3.5). 
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Fig.3.4. Sensitivity of the 16S rRNA LAMP reaction compared with the 16S rRNA PCR assay. Reaction 
products of the 16S rRNA PCR (A) and 16S rRNA LAMP (B) reactions were separated by agarose gel 
electrophoresis. Final amounts of M. genitalium DNA per reaction were 0.1ng (A1, B1), 10pg (A2, 
B2), 1pg (A3, B3), 0.1pg (A4, B4), 10fg (A5, B5), 1fg (A6, B6). Molecular grade water was used in place 
of DNA as a negative control (A7, B7).  
 
The 16S rRNA PCR assay was able to detect a minimum concentration of 1pg of M. genitalium 
genomic DNA, evidenced by the presence of a visible 270bp product after agarose gel 
electrophoresis of the reaction products (Fig.3.4). The 16S rRNA LAMP assay was able to generate an 
amplified product from 1fg of M. genitalium DNA. Agarose gel electrophoresis of the reaction 
products enabled visualisation of the characteristic ladder like LAMP reaction products, formed by a 
range of DNA concatamers of varying size. The amount of product produced in the reaction 
containing 1fg was noticeably lower than in the other reactions, indicating the low starting copy 
number. 
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Fig.3.5. Real-time amplification curves of M. genitalium 16S rRNA LAMP reactions, showing assay 
sensitivity. LAMP reactions were carried out on a dilution series of DNA, with final amounts of M. 
genitalium DNA per reaction of 0.1ng, 10pg, 1pg, 0.1pg, 10fg, 1fg. The separation of these reaction 
products by agarose gel electrophoresis is shown in Fig.3.4. 
 
Real time monitoring of the 16S rRNA LAMP reactions showed that the fastest time to amplification 
(ta) was seen in the reaction containing the largest amount of DNA, 0.1ng (Fig.3.5; Table 3.6), which 
generated a detectable amplification at 23 minutes.  The reactions containing 10pg, 1pg and 0.1pg 
generated detectable amplification at 25.9, 27.3 and 35.1 minutes respectively. There was then a 
delay of 20.5 minutes before amplification was generated in the reactions containing 10fg and 1fg, 
at 55.8 and 55.6 minutes respectively. In this test, both the positive and negative reactions showed a 
gradual baseline increase. This was not due to amplification of the target sequence, as it occurred in 
the negative reaction, and agarose electrophoresis of the reaction showed a lack of product. Also, an 
amplification would produce a typical amplification curve. It is possible that the caps of the tubes in 
this run were not tight, enabling evaporation of the liquid, which would act to concentrate the 
fluorophore in the reaction, increasing the baseline fluorescence. 
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Amount of DNA per reaction Time to amplification (Minutes) 
0.1ng 23 
10pg 25.9 
1pg 27.3 
0.1pg 35.1 
10fg 55.8 
1fg 55.6 
Negative 1 58 
Negative 2 n/a 
Table.3.6. Time to amplification values of M. genitalium 16S rRNA LAMP assay calculated from 
amplification curves shown in Fig.3.5, using the Tube Scanner Studio software package. 
 
3.3.5. Initial testing of pdhD primer sets 
 
Three LAMP assays specific to the pdhD gene of M. genitalium were designed, and an initial 
evaluation was carried out in order to determine whether the primer sets would be able to amplify a 
product from M. genitalium DNA, and also whether they generated non-specific amplification in the 
absence of a template. LAMP assays for the same target can vary considerably in their speed and 
specificity, due to variations in primer sequences and the position of the loop sequences. Real time 
monitoring would provide a comparison of the reaction speed of all of the primer sets. 
A single positive reaction, containing 0.1µg of M. genitalium DNA, and a single negative reaction 
containing molecular grade water was carried out using the pdhD 1, pdhD 2 and pdhD 3 LAMP 
primer sets. The reactions were monitored in real time to compare the reaction efficiency of each 
primer set. 
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Fig.3.6. The initial screening of pdhD LAMP primer sets 1, 2 and 3. A single positive and negative 
reaction were carried out using each primer set and monitored in real time. 
Real time monitoring of the LAMP reactions containing various pdhD primer sets showed that the 
pdhD 3 primer set had the shortest ta, generating a detectable signal at 12.3 minutes (Fig.3.6). The 
pdhD 3 set also generated an amplification in the negative control reaction, which contained no DNA 
template. This amplification occurred at 51 minutes, and so was likely to be a non-specific 
amplification, rather than the result of any contamination of DNA in the reaction. The pdhD 1 and 
pdhD 2 sets had a Ta of 13.8 and 22.9 minutes, respectively, and did not generate an amplification in 
the negative control. The sizeable delay in amplification when using the pdhD 2 set is indicative of a 
less efficient LAMP primer set. 
 
3.3.6. Comparison of pdhD LAMP reactions with pdhD PCR, and notable M. genitalium PCR assays 
from the literature 
 
In order to determine the sensitivity of the pdhD LAMP reactions, the minimum concentration of M. 
genitalium genomic DNA detectable by the pdhD 1 and pdhD 3 LAMP assays was determined. The 
pdhD 2 LAMP assay was not included in the tests due to its poor performance in previous tests 
(Fig.3.6). Using the same dilutions of DNA, the detection limits of the pdhD PCR assay and two 
prominent PCR assays from the literature, one targeting the 16S rRNA sequence (Jensen et al., 
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2003), and one targeting the mgpB gene (Jensen et al., 2004). These assays use multi copy targets, in 
order to maximise sensitivity, and are the two most common non-commercial PCR tests. This was 
done in order to provide a relative comparison of analytical sensitivity.  
The limit of detection of the following assays were determined; the pdhD 1 and pdhD 3 LAMP assays, 
PCR assays using the F3 and B3 primers of the pdhD 1 and pdhD 3 LAMP sets, the 16S rRNA PCR 
assay (Jensen et al., 2003), and the mgpB PCR assay (Jensen et al., 2004). Reactions were carried out 
using each assay, on a dilution series of M. genitalium DNA. Final amounts of DNA per reaction were 
0.1ng, 10pg, 1pg, 0.1pg, 10fg, 1fg. The experiments were all carried out on the same DNA samples, 
over a period of 2 days. DNA samples were stored at -80oC when not in use. 
 
    
Fig.3.7. Agarose gel electrophoresis of PCR products showing the limits of detection of the 16S rRNA 
PCR assay from Jensen et al. (2003) (A), and the MgPa PCR assay detailed in Jensen et al. (2004) (B). 
PCR reactions with each primer set, containing the following concentrations of DNA were carried 
out; 0.1ng (1), 10pg (2), 1pg (3), 0.1pg (4), 10fg (5), 1fg (6). The expected fragment sizes were 425bp 
for the 16S rRNA assay (A), and 78bp for the MgPa assay (B). 
 
The 16S rRNA PCR assay (Jensen et al., 2003) was able to generate a 425bp product from a minimum 
of 0.1pg of M. genitalium DNA (Fig.3.7. A). The MgPa PCR assay (Jensen et al., 2004) was able to 
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detect 10fg of DNA, a further 1:10 dilution. When visualised via agarose gel electrophoresis, the 
product from the MgPa assay was less bright than that of the 16S rRNA assay, due to the small 
product size of 78bp reducing the number of ethidium bromide molecules able to bind, and 
therefore produce fluorescence. 
 
 
Fig.3.8. Amplification curves showing sensitivity of the pdhD 1 LAMP assay. LAMP reactions were 
carried out on a dilution series of DNA, with final amounts of M. genitalium DNA per reaction of 
0.1ng, 10pg, 1pg, 0.1pg, 10fg, 1fg, 0.1fg. Molecular grade water was used as a negative control (NC). 
The pdhD 1 LAMP assay was able to detect a minimum amount of 10fg of M. genitalium genomic 
DNA (Fig.3.8). Real time monitoring of the reactions showed that the amplification time for the 
reactions containing 0.1ng, 10pg, 1pg, 0.1pg, 10fg was 16.3, 17.5, 21.6, 28.8, and 32.7 minutes, 
respectively (Table 2). There was no amplification generated in the negative control reaction, or the 
reaction containing 1fg of M. genitalium DNA. 
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Fig.3.9. Amplification curves showing sensitivity of the pdhD 3 LAMP assay. LAMP reactions were 
carried out on a dilution series of DNA, with final amounts of M. genitalium DNA per reaction of 
0.1ng, 1pg, 0.1pg, 10fg, 1fg, 0.1fg. Molecular grade water was used as a negative control (NC). 
 
The pdhD 3 LAMP assay was able to detect a minimum amount of 10fg of M. genitalium genomic 
DNA (Fig.3.9), within the first 30 minutes of the reaction. Real time monitoring of the reactions 
showed that the amplification time for the reactions containing 0.1ng, 10pg, 1pg, 0.1pg, 10fg was 
10.3, 12.8, 13.7, 15.6, and 25.9 minutes, respectively (Table 3.7). The Ta for these amplifications 
were lower than those of the pdhD 1 assay containing the same amount of DNA, by an average of 
7.7 minutes. However, the reactions containing 1fg of M. genitalium DNA, and also both of the 
negative control reactions, generated a positive amplification between 44.3 and 52.6 minutes. 
Amplification in the negative control was also seen during the initial test of the primer set (Fig.3.6.). 
This is likely to be caused by complementary regions in the primer sequence leading to non-specific 
amplification events, making this primer set unsuitable for use diagnostically. 
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Assay 
DNA per reaction Water 
Negative 0.1ng 10pg 1pg 0.1pg 10fg 1fg 
pdhD 1 LAMP + 
16.3 m 
+ 
17.5 m 
+ 
21.6 m 
+ 
28.8 m 
+ 
32.7 m 
- - 
pdhD 3 LAMP + 
10.3 m 
+ 
12.8 m 
+ 
13.7 m 
+ 
15.6 m 
+ 
25.9 m 
+ 
52.6 m 
+ 
44.3/44.8 m 
pdhD 1 PCR + + - - - - - 
pdhD 3 PCR + + - - - - - 
16S rRNA PCR 
(Jensen, 2003) 
+ + + + + - - 
mgpB PCR (Jensen, 
2004) 
+ + + + + - - 
Table 3.7. A Comparison of assay sensitivity. A “+” is indicative of a positive result, a “-” indicates a 
negative. Time to amplification is given for each LAMP assay in minutes (m), and was calculated 
using a manually set threshold value in the Tube Scanner Studio software.  
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3.3.7. Specificity of the pdhD 1 LAMP assay 
 
In order to determine the analytical specificity of the pdhD LAMP assay it was necessary to challenge 
the assay with genomic DNA from a range of non-target organisms. The organisms chosen were all 
potential causes of urethritis, or could be encountered whilst sampling for M. genitalium; U. parvum, 
U. urealyticum, C. trachomatis, N. gonorrhoeae, T. vaginalis, P. aeruginosa, E. coli. Additionally, the 
ability of the assay to function in the presence of M. pneumonia DNA was tested, due to the genetic 
similarity between the organisms. 
 
Species Source pdhD LAMP result 
M. genitalium NCTC 10195 + 
M. genitalium Clinical sample + 
M.  pneumoniae NCTC 010119 - 
U. parvum Clinical sample - 
U. urealyticum Clinical sample - 
C. trachomatis Lab strain (serovar L2) - 
N. gonorrhoeae ATCC 19424 - 
T. vaginalis ATCC 30001 - 
P. aeruginosa ATCC 15692 - 
E. coli Lab strain - 
Table 3.8. Specificity of the pdhD LAMP assay. (NCTC, National Collection of Type Cultures, Public 
Health England, UK; ATCC, American Type Culture Collection, MD, USA; Clinical samples were 
collected from an STI clinic environment and provided by the Public Health Laboratory Bristol, Public 
Health England). 
 
The pdhD 1 LAMP assay correctly identified both the M. genitalium type strain, and also the M. 
genitalium clinical isolate. The presence of genomic DNA of any of the non-target organisms did not 
result in a detectable amplification (Table 3.8). 
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3.4. Discussion 
 
3.4.1. Detection of M. genitalium in broth culture by PCR 
 
PCR reactions containing all three primer sets successfully amplified the predicted sized product 
from the control DNA (Fig.3.1). The faintest band, indicating a comparative reduction in DNA 
produced, and therefore starting copy number, was seen from the reaction containing the 16S rRNA 
primer set. This was expected, as the mgpB sequence used as a target for the mgpB 1 and mgpB 2 
primer sets is also present in the MgPar repeat sequences, which together with the MgPa operon 
make up ~4.7% of the M. genitalium genome (Ma et al., 2010). The mgpB 2 primer set yielded a 
slightly larger band on the gel, which could have been due to an increase in product formed. This 
could possibly have been due to the smaller product size (243bp compared with 666bp), which 
would place less stress on the PCR reaction, and would be less likely to exhaust surplus DNTPs (Cha 
and Thilly, 1993). The reactions containing molecular grade water instead of the positive control 
DNA contained no identifiable product when separated on the gel, indicating there was no non-
specific amplification in the reactions.  
The mgpB 1 and 16S rRNA PCR reactions containing DNA extracted from the M. genitalium broth 
cultures showed no amplified product. This suggests that the culture of the organism has failed, as 
after 1 week there should be a level of biomass detectable by PCR. A very faint band could be seen 
for the mgpB 2 PCR reaction containing this DNA sample. This primer set appeared to produce the 
largest yield of product from the positive control, and therefore could be assumed to be the most 
sensitive. The broth itself would contain M. genitalium DNA from the initial inoculum, whether there 
had been any growth or not, and it could be this low concentration of M. genitalium cells that the 
reaction has detected. 
 
3.4.2. Detection of M. genitalium from culture on solid media by PCR 
 
As in (Fig.3.1), the positive control DNA was amplified successfully by each primer set, whilst the 
negative control yielded no product (Fig.3.2). The DNA extracted from the M. genitalium cultured on 
solid media was successfully amplified by each PCR primer set. The bands, in each case, were 
brighter than those from the positive control DNA, indicating an increase in DNA concentration, and 
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therefore the starting copy number. This indicated the successful growth of the organism on this 
media type. All subsequent M. genitalium culture was carried out using this solid media 
(mycoplasma agar, 20% supplement G). 
 
3.4.3. Sensitivities of the M. genitalium 16S rRNA PCR and mgpB 2 PCR assays 
 
The 16S rRNA primer set was able to detect M. genitalium DNA at a concentration of 1pg per 
reaction, and above. The mgpB 2 primer set was able to detect a further 1:10 dilution of template 
DNA, at a level of ≥0.1pg per reaction. The increased sensitivity was expected, due to the brighter 
bands seen when using this primer set in previous PCR assays (Fig.3.3, Fig.3.2). The increased 
sensitivity is due to the increased copy number of the mgpB sequence, due to its replication in the 
MgPar repeats found in nine chromosomal locations throughout the M. genitalium genome (Ma et 
al., 2012). Although this assay has performed with a higher sensitivity than the 16S rRNA assay with 
the exact M. genitalium G37 strain from which the primers were designed, the assay would be 
potentially less suitable for use as a diagnostic assay with modern clinical strains. Analysis of the 
primer set using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) showed two 
predicted products from the M. genitalium G37 strain genome, a 243bp fragment of the mgpB gene 
(Accession number EF458038) , and also a 240bp fragment of the MgPar 9 region (Accession number 
DQ248104). Analysis of products from alternate M. genitalium strains (M2288, M6320, M6282), 
showed no exact matches, with a minimum of five base mismatches per primer set present for any 
predicted product. Analysis of the 16S rRNA primer set however, shows that it would produce a 
270bp fragment from all the M. genitalium strains with sequences available on GenBank (G37, 
M2288, M6282, M6320). The drawback of using the 16S rRNA target in a diagnostic setting is that 
the M. genitalium 16S rRNA sequence shares 98% homology with the equivalent gene in M. 
pneumoniae (Jensen et al., 2003). This is apparent in analysis of the 16S rRNA primer set, as there is 
only a single base mismatch in the reverse primer preventing 100% sequence complementarity for a 
268bp fragment in the M. pneumonia 16S rRNA sequence. In order to adequately determine the 
sensitivity of this primer set they would need to be screened against M. pneumonia DNA to test for 
non-specific amplification, which with only a single 3’ mismatch on the reverse primer, is a 
possibility. 
 
245 
 
3.4.4. Sensitivity of the 16S rRNA LAMP assay 
 
The 16S rRNA LAMP assay, designed by Public Health England South West Virology Lab, was able to 
successfully amplify M. genitalium DNA at concentrations of 1fg per reaction, and above. This was a 
1000-fold greater sensitivity than the 16S rRNA PCR reaction, and 100-fold greater than the mgpB 2 
PCR assay (Fig.3.4). The number of M. genitalium genome copies equating to 1fg of DNA is around 
1.6, indicating the high level of sensitivity of the assay. Real-time monitoring of the amplification 
(Fig.3.5) found the Ta for the most highly concentrated sample to be 23 minutes, followed by 25.9 
minutes and then 27.3 minutes for subsequent DNA dilutions (Table.3.6). There was a delay until the 
onset of detectable amplification in the reaction containing 0.1pg, which occurred at 35.1 minutes. 
The reactions containing 10fg and 1fg of M. genitalium DNA demonstrated detectable amplification 
after a period of 55.6 minutes and 55.8 minutes respectively. Amplification at this point is extremely 
late, and would not be detected on the final LabDisk platform, as the reaction will be proceeding for 
a period of 50 minutes. The sizeable delay between the amplification in the reaction containing 
0.1pg and the reactions at lower concentrations suggest that the signal detected in these reactions 
may have resulted from non-specific amplification. The fact that a similar late amplification was seen 
in negative control 1 (NC 1, Fig.3.5), suggests that this may be the case, and that the actual detection 
limit could be considered to lie between 0.1pg and 10fg. This would equate to a detection limit of 
between 160 and 16 genome copies.    
 
3.4.5. Initial testing of pdhD primer sets 
 
The pdhD 3 primer set generated the earliest amplification from the positive reactions, with the 
reaction crossing the set threshold at 13.1 minutes (Fig.3.6). This was a faster amplification than 
seen when using the M. genitalium 16S rRNA set with the same concentration of DNA (Fig.3.5). This 
increase in time could be explained by an increase in copy number, as the pdhD gene is present as a 
single copy per M. genitalium genome, and the same concentration of M. genitalium genomic DNA 
was used in both reactions. LAMP primer sequences can affect the reaction efficiency in a number of 
ways, including influencing the likelihood of the initial binding event of any of the four primers to the 
target sequence, and the formation of the stem loop from the dumbbell structure at the beginning 
of the LAMP cycle (Fakruddin et al., 2013). The pdhD 3 negative reaction, containing molecular grade 
water instead of a DNA template, generated detectable amplification at 52.3 minutes. This late false 
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positive result would be missed by the LabDisk assay, which runs for 50 minutes. However, it does 
indicate the possibility that this primer set has the ability to generate non-specific amplification, 
possibly due to complementary regions between the primers themselves.  
The pdhD 1 primer set generated detectable amplification after 15.1 minutes, a 1.7 minute delay 
compared to the pdhD 3 positive reaction. The pdhD 1 negative reaction did not amplify during the 
60 minute monitoring period, meaning that despite the slight delay in amplification in the positive 
reaction, this set may be more suitable than pdhD 3 set, due to the lack of non-specific amplification 
seen. 
The pdhD 2 primer set generated detectable amplification after a period of 24.1 minutes in the 
positive reaction, a delay of 10.2 minutes when compared to the pdhD set 3 positive. This was a 
sizeable increase in the time to amplification (Ta), and represents a significant reduction in reaction 
efficiency when compared to the two other sets. It was on the basis of this difference in Ta that this 
primer set was disregarded for all subsequent experiments. 
 
3.4.6. Comparison of pdhD LAMP reactions with notable M. genitalium PCR assays from the 
literature 
 
The pdhD 1 and pdhD 3 LAMP assays were able to detect a minimal level of 1fg of M. genitalium 
DNA per reaction. This is equivalent to approximately 16 genome copies of M. genitalium DNA 
(Fig.3.8, Fig.3.9).  
The pdhD S1 primer set showed no non-specific amplification in the water negative reactions, whilst 
the pdhD S3 primer set generated a false positive result in both of the water negative results. This 
was possibly due to complementary areas within the primer sequences resulting in self-priming, and 
subsequent amplification. BLAST analysis of the specificity of the F3 and B3 primers revealed no 
alternative templates. Also, PCR reactions using the F3 and B3 primers resulted in successful 
amplification at concentrations of 1pg and above, and no amplification in the negative control. The 
generation of amplification in the negative control, leading to a false positive result makes this 
primer set unusable in an M. genitalium LAMP assay. The extremely rapid amplification seen using 
the pdhD 3 set could be due to the comparative ease with which these primer sequences bind, 
which is also leading to self-priming, or non-specific primer binding, and causing non-specific 
amplification. 
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The MgPa PCR assay, described in (Jensen et al., 2004), is one of the most frequently cited M. 
genitalium PCR assays in the literature (Twin et al., 2011). The primers, incorporated into a Taqman 
real-time PCR assay, have a limit of detection of 5 copies of the M. genitalium genome (Jensen et al., 
2004). A clinical study found the real time MgPa assay using this primer set to be more sensitive 
than a real time PCR assay based on the single copy gap gene, and the conventional 16S rRNA PCR 
assay from Jensen et al. (2003) (Svenstrup et al., 2005). This result was replicated in a separate study 
(Edberg et al., 2008). In the current study the assay was able to detect 1fg of M. genitalium DNA, but 
not 0.1fg (Fig.3.7). This equates to ~16 genome copies, and is in agreement with the limit of 5 copies 
presented in the literature. The fact a conventional PCR assay was used instead of a real time assay 
should not affect the sensitivity, with previous studies demonstrating a higher sensitivity for 
conventional PCR compared to real-time PCR, when using the same M. genitalium 16S rRNA primer 
sets (Jurstrand et al., 2005).  
The 16S rRNA PCR assay was also able to detect 10fg of M. genitalium DNA (16 genome copies) 
(Fig.3.7), however the band seen on the gel was very faint. A brighter band was seen for reactions 
containing 0.1pg of M. genitalium DNA. 16S rRNA PCR assays in the literature have been shown to 
have a detection limit of 10 copies per reaction (Yoshida et al., 2002). Multiple studies have shown 
the MgPa PCR assays to be more sensitive than PCR assays relying on the 16S rRNA sequence as 
target (Edberg et al., 2008), however the 16S rRNA gene is more highly conserved than the MgPa 
sequence, which may be the site of random recombination events (Iverson-Cabral et al., 2007), and 
so is considered by some to be the more desirable target for NAATs. 
The pdhD LAMP assays, and MgPa PCR assay, and 16S rRNA assay were able to detect a minimum 
level of 10fg M. genitalium DNA per reaction. The lower dilution tested was 1fg, or 1.6 genome 
copies, which none of the assays were able to detect. There would possibly be some difference 
between the assays at detecting DNA levels between these two values. The pdhD 1 LAMP assay was 
equally sensitive as the two widely used PCR assays, whilst enabling more rapid detection of target 
DNA. Monitoring of the reactions in real-time enabled detection of M. genitalium DNA in between 
16.3 (0.1ng) and 32.7 (10fg) minutes. As well as offering a more rapid diagnosis than PCR, this assay 
also has the intrinsic benefits of a LAMP reaction, including higher tolerance to contaminating 
inhibitors (Francois et al., 2011), the lack of need for thermocycling (Notomi et al., 2000), and 
improved reagent stability (Thekisoe et al., 2009). 
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3.4.7. Specificity of the pdhD 1 LAMP assay 
 
Sampling for M. genitalium takes place using genital swabbing (urethral, cervical or vulvovaginal), or 
urine samples, all of which will potentially contain a range of commensal bacteria from the skin or 
genital mucosa, and any non-target pathogenic species present. In light of this it is essential that any 
diagnostic assay using these samples is only able to generate a positive result from its target 
organism. The pdhD gene, the target of the pdhD LAMP assay, is highly conserved in M. genitalium, 
and has a unique sequence in this organism. BLAST analysis of the primer sequences and target 
amplicon show that there are no identical, or highly similar sequences, in any alternative organism, 
including the genetically similar M. pneumonia. However, it important to confirm this predicted high 
level of specificity experimentally. The pdhD 1 LAMP assay did not generate a positive result when 
challenged with DNA from any of the non-target organisms tested, which included a number of 
sexually transmitted pathogens, and causes of urethritis. 
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Chapter 4 
Chlamydia trachomatis 
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4.1. Introduction 
 
Chlamydia trachomatis is an obligate intracellular bacterium and a prevalent and highly clinically 
significant pathogen in humans, responsible for ocular and respiratory tract infections, in addition to 
being the most widespread sexually transmitted disease in developed countries (Bavoil et al., 2000) 
Over 18 serovars of C. trachomatis have been identified, based on variations in the antigenically 
diverse major outer membrane protein (MOMP) (Gomes et al., 2005). Serovars A-C are the causative 
agents of trachoma; infection of the cunjuctival follicles or lymphoid germinal centres of the eye. 
Serovars D-K are responsible for uritogenital tract infections, and serovars L1-L3 cause 
lymphogranuloma venereum (Borges et al., 2010), and are found to a lesser extent in ano-rectal 
infections (Geisler et al., 2002). Progression of the infection from the lower to upper genital tract is 
associated with an increase in the severity of the disease, frequently leading to epididymitis in men 
and pelvic inflammatory disease (PID) in women (Ostaszewska et al., 2000; Paavonen and Eggert-
Kruse, 1999). The inflammation seen in these conditions, and scarring seen in PID, can have a serious 
impact on the reproductive health of an individual and cause infertility or ectopic pregnancy. 
 
4.1.1. Pathogenesis 
 
C. trachomatis has a biphasic developmental cycle, which comprises of two stages. In its extracellular 
stage, C. trachomatis exists as a metabolically inactive elementary body (EB), a small coccus, around 
0.3µm in diameter (Fig.4.1). This is the infectious stage of C. trachomatis, which can be passed 
between hosts via sexual contact. This occurs when EBs present in the penile urethra or vagina of 
the infected party, having been shed via infected epithelial cells, are passed to their sexual partner. 
The EBs are then internalised into the epithelial cells of the new host via receptor mediated 
endocytosis, of which only a small percentage are lost via fusion with host cell lysosomes. At this 
point the EBs inside the vacuoles differentiate into the next stage of the developmental cycle, the 
non-infectious and metabolically active reticulate body (RB) (Moulder, 1991), of around 1µm in 
diameter in size. 
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Fig.4.1. Diagram of the life cycle of C. trachomatis, showing: a) Extracellular EB, b) Entry of EB into 
host cell via phagocytosis, c) Primary differentiation of EB into RB, d) Rbs multiply by binary fission 
inside inclusion body, e) Secondary differentiation of RBs into EBs, f) Host cell lysis, release of EBs. 
 
The initial stage of infection with C. trachomatis is the binding event between the infectious 
elementary body, and the cells of the host genital epithelia. This initial adhesion is a complex 
process, mediated by a number of C. trachomatis surface proteins and their corresponding ligands 
on the epithelial surface. The major outer membrane protein (MOMP) of C. trachomatis is known to 
act as a cytoadhesin, binding to heparin sulphate proteoglycans on the outer membrane of the 
epithelial cell (Su et al., 1996). Additionally, the OmcB outer membrane peptide has been shown to 
have a major involvement in the binding of the EBs to epithelial cells, with the retardation of these 
proteins resulting in a 70% reduction in infectivity (Fadel and Eley, 2007). OmcB binds to 
glycosaminoglycan (GAG) like receptors on the host cell surface, in a similar fashion to the MOMP 
(Fadel and Eley, 2007). Bacterial membrane associated GAG proteins also contribute during the 
binding process, with a range of host cell receptors, including heparan sulfate, mannose receptor 
and estrogen receptor, facilitating these interactions (Cocchiaro and Valdivia, 2009). The presence of 
functional protein disulphide isomerase (PDI), a multifunctional peptide located on the surface of 
epithelial cells, is necessary for the binding and internalisation of EBs (Conant and Stephens, 2007). 
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This protein is not thought to act as a specific receptor for EB attachment, but is necessary for the 
correct structural arrangement of such receptors. After the initial binding between the EB and host 
cell, the enzymatic activity of PDI is a requirement of EB internalisation (Abromaitis and Stephens, 
2009). Cell lines with defective PDI expression are inherently resistant to C. trachomatis infection, 
underlining the importance of this protein in pathogenesis (Conant and Stephens, 2007).  
C. trachomatis also takes advantage of the host fibroblast growth factor 2 (FGF2) pathway to 
enhance its infectivity, by binding to FGF2, and interacting with the fibroblast growth factor receptor 
(FGFR) on the epithelial surface. This interaction results in FGFR activation at the location of the 
FGF2 bound-chlamydial EBs, resulting in the increased uptake of EBs into the cell (Kim et al., 2011). 
The production of FGF2 is also upregulated in epithelial cells infected with C. trachomatis, and the 
extracellular release of this molecule during the lysis of the cell acts to promote further infection by 
extracellular EBs (Kim et al., 2011). 
The uptake of surface-bound Chlamydia EBs into the intracellular environment is facilitated by the 
reorganisation of the actin cytoskeleton to form microvillus like structures, which engulf the 
bacterial cells (Cocchiaro and Valdivia, 2009). This process is instigated by the translocation of an 
actin recruiting protein (translocated actin recruiting phosphoprotein; TARP) into the host cell 
membrane (Engel, 2004). This protein is activated by phosphorylation via the host membrane 
associate Src and Ab1 kinases, which results in the recruitment of guanine exchange factors Sos1 and 
Vav2, and subsequent activation of the Rac1 GTPase. Rac1 activates the Arp2/3 complex, which 
instigates actin reorganisation, via the activation of WAVE2 and Abi-1 (Carabeo et al., 2007). These 
relationships have been visualised by imaging studies showing Rac1, WAVE2 and a number of actin-
associated cytoskeletal proteins migrating to the invasion point, and co-localising with EBs during 
invasion (Carabeo et al., 2004). This modulation of the actin cytoskeleton, and internalisation of C. 
trachomatis EBs is a fairly rapid process, taking ~90 seconds to occur, illustrating the rapid activation 
and suppression of the signalling molecules involved (Dautry-Varsat et al., 2005). RNA sequencing of 
the host transcriptome at these early stages of infection (1 hour post infection) reveals the 
differential expression of a wide variety of extracellular matrix associated proteins, including 
collagens, mucins and metalloproteinases, showing the significant effect that the infection has on 
the organisation and composition of the host cell structure (Humphrys et al., 2013). 
Once the EB has been internalised, it is held in a membrane-bound compartment, containing a high 
concentration of cholesterol and glycosphingolipid molecules, termed an inclusion (Dautry-Varsat et 
al., 2005). The involvement of clathrin mediated endocytosis in the uptake of C. trachomatis EBs is 
controversial; RNA interference and site-directed mutagenesis studies have given conflicting results, 
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with evidence presented that C. trachomatis internalisation is not inhibited by the production of 
non-functional clathrin (Dautry-Varsat et al., 2005), and also that clathrin and its accessory factors 
are required for C. trachomatis internalisation (Hybiske and Stephens, 2007). This vacuole is able to 
avoid becoming sequestered to the host cell endosome-lysosome pathway, preventing the 
lysosome-mediated degradation of its bacterial contents (Scidmore et al., 2003). The inclusion is 
then moved towards the endoplasmic reticulum (ER)/Golgi activity centre, via trafficking on 
cytoskeleton intermediate filaments, where gene expression dramatically shifts, and transcriptional 
and metabolic activity is upregulated, signalling the shift from the EB to RB form (Wyrick, 2010). 
During the growth and replication of the C. trachomatis RBs, components of the ER membrane are 
sequestered to the inclusion, enabling the inclusion to grow in size and accommodate the increasing 
biomass (Dumoux et al., 2012). Materials are obtained from the rough ER (rER) membrane in a 
process requiring direct contact between the inclusion and rER membrane, and also an alignment 
with bacterial type 3 signalling systems (T3SS) present on RBs in the inclusion. It is thought that this 
alignment acts as a portal for the transport of materials from the rER to the RBs (Dumoux et al., 
2012). C. trachomatis infection induces fragmentation of the Golgi apparatus via proteolytic cleavage 
of goglin-84, a key protein component of the Golgi matrix, enabling to inclusion to obtain vital lipids 
from the remnants of the organelle (Heuer et al., 2009). Vesicles are also intercepted from the host 
secretory pathway, and lipid droplets from the cytosol, providing the inclusion with a source of 
cholesterol and sphingolipids (Heuer et al., 2009; Cocchiaro and Valdivia, 2009).  
During infection, C. trachomatis prevents the recognition and killing of the infected cells by CD8+ 
cytotoxic T-lymphocytes by degrading intracellular transcription factors needed for the expression of 
the antigenic major histocompatability complex (Zhong et al., 2001). This is carried out by the 
release of chlamydial protease-lie activity factor (CPAF) into the cytosol from the bacterial cells 
within the inclusion. CPAF additionally cleaves a number of other intracellular substrates, including 
the pro-apoptotic B3-only proteins, preventing the infected cell from undergoing apoptosis. The 
generation of CPAF in uninfected epithelial cells has shown that this protease causes large scale 
morphology changes, and eventual cell death via non-apoptotic mechanisms, and is a major factor in 
C. trachomatis pathogenesis (Paschen et al., 2008). 
Infected epithelial cells are responsible for instigating the immune response associated with 
chlamydial infection, and release a range chemokines and pro-inflammatory cytokines, including IL-
8, GROα, GMCSF and IL-6, leading to inflammation of the infected epithelia (Rasmussen et al., 1997). 
The release of proteases, cytokines and tissue growth factors from infected epithelial cells, and also 
immune cells, leads to cellular damage in the location of the infection site (Darville and Hiltke, 2010). 
262 
 
Upon lysis of the infected cell, after the maturation of the inclusion, high concentrations of IL-1α are 
released into the extracellular environment, which aggravates the inflammatory response by 
stimulating enhanced cytokine production in neighbouring uninfected epithelial cells (Rasmussen et 
al., 1997). C. trachomatis has been shown to down regulate nectin-1, a cell adhesion 
immunoglobulin implicated in the maintenance of claudin-based tight junction complexes in 
epithelial monolayers (Sun et al., 2008). Infection also results in the breakdown of the N-cadherin/β-
catenin complex in epithelial cells, and subsequent sequestering of β-catenin within the C. 
trachomatis inclusion bodies (Prozialeck et al., 2002). These processes are thought to accelerate the 
release of infected epithelial cells from the monolayer, increasing infectivity, whilst increasing 
damage to the epithelial monolayer which is a key component of chlamydial pathogenesis. It is 
through these mechanisms of cytotoxicity, and the instigation of a robust inflammatory response, 
that the epithelial damage and scarring that occurs during long term Chlamydia infection occurs. 
C. trachomatis is a Gram negative bacterium and the EBs are found to entirely lack a peptideglycan 
layer, despite the existence of the genes required for peptidoglycan synthesis. However, antibiotics 
that act via disruption of peptidoglycan synthesis such a beta-lactams are found to be active against 
C. trachomatis and other members of the Chlamydiae genus. Treatment of C. trachomatis with these 
antibiotics results in morphologically aberrant RBs, preventing RB division and the differentiation 
into EBs (McCoy and Maurelli, 2006). This paradox is known as ‘the Chlamydia anomaly’. The most 
widely held opinion is that a cell wall is present, in the RBs but not the EBs of Chlamydiae, which do 
not require the protection against low external osmolarity provided by a cell wall due to the 
abundance of cysteine rich envelope proteins, linked by disulphide bridges, which offer the same 
level of protection (Everett and Hatch, 1995). These envelope protein, on the surface of the EBs act 
to strengthen the cell wall considerably by forming a disulphide cross-linked supramolecular 
complex with the major outer membrane protein (MOMP). This cysteine rich protein layer gives the 
EB substantial structural integrity, explaining the resistance seen to detergent solubilisation of the 
outer membrane complex under non-reducing conditions (Everett and Hatch, 1995). The reliance of 
C. trachomatis on these disulphide bonds for structural stability can be demonstrated by the onset 
of cellular lysis upon the introduction of reducing agents such as dithiothreitol (Hackstadt et al., 
1985). Transcriptional analysis of expression of the genes involved in peptidoglycan synthesis in C. 
trachomatis, murA, murB and pbp2, revealed the peak expression to lie between 2 and 6 hours post 
infection, which would indicate their involvement in the early stages of the transition from EBs to 
RBs (McCoy et al., 2003). Another study which carried out microarray analysis of the C. trachomatis 
genome found the highest peak in the expression of the same 3 genes to occur between 16 and 18 
hours post infection, indicating a role for the genes in RB cell division (Belland et al., 2003). 
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4.1.2. Epidemiology and clinical presentation 
 
 Worldwide prevalence and incidence data for 2008, published in 2012, estimate a worldwide 
incidence of 105.7 cases of C. trachomatis, with 100.4 million adults infected at any one time (World 
Health Organisation, 2012). Unusually amongst STI’s, the prevalence is higher in developed 
countries, such as those in Europe, compared with developing countries in Africa and Asia (Table 
4.1).  
 
WHO Region 
Incidence (per 1000) Prevalence (%) 
Female Male Female Male 
Africa 22.3 20.9 2.6 2.1 
The Americas 72.6 38.2 7.6 2.9 
South East Asia 9.2 6.2 1.1 0.6 
European 37.1 54.2 3.9 3.8 
Eastern 
Mediterranean 
9.8 10.9 1.1 0.9 
Western Pacific 38.4 42.5 4.3 3.4 
Table 4.1. Global incidence and prevalence of C. trachomatis infection, according to 2008 WHO 
estimates. Data taken from (World Health Organisation, 2012). 
 
The majority of C. trachomatis infections in women are asymptomatic, with symptoms occurring in 
5%-15% of cases (Detels et al., 2011). Due to its asymptomatic nature, C. trachomatis infections are 
liable to lie undetected, and therefore untreated, in patients unaware of the infection, although the 
instigation of screening programmes has helped to identify more of these infections. Untreated 
Chlamydia infection in women can lead to an ascending infection in the pelvis, causing PID in ~20% 
of cases (Paavonen and Eggert-Kruse, 1999). PID can lead to fallopian scaring, and lead to infertility 
and ectopic pregnancy. Chlamydia-mediated PID is the most prevalent preventable cause of 
infertility and adverse pregnancy outcome, making control of Chlamydia infection extremely 
important for public health bodies (Paavonen and Eggert-Kruse, 1999).     
Urethral infections in males cause symptoms in ~40% of cases, with the most common symptom 
being urethritis (Falk et al., 2005; Dixon et al., 2002). The infection can progress to epididymitis, 
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although this tends to be a less severe form compared with epididymitis arising from other means 
(Ostaszewska et al., 2000). It is thought prolonged untreated chlamdial infection can lead to chronic 
prostatitis (Shperling et al., 2011; Weidner et al., 2002), although unlike prostatitis caused by a 
number of other STIs, no association has yet been found with increased prostate cancer risk (Huang 
et al., 2013). 
 
4.1.3. Diagnosis 
 
Current detection methods in the UK are based around both molecular detection methods and 
culture, with samples being taken from different biological sites. Molecular methods include LCR, 
PCR, Gen-Probe and also enzyme immune-assay (EIA) (Watson et al., 2002). These methods tend to 
be time consuming, typically taking between 4 to 8 hours to obtain results from the raw sample. 
They also require skilled laboratory personnel and complex equipment to be carried out. Automated 
assays, featuring integrated sample preparation and nucleic acid amplification and detection are 
available, and widely used in the UK, but expensive. Many countries in the developed world, 
including the US and the UK, have instigated Chlamydia screening programmes, in order to identify 
the relatively large number of asymptomatic infections in the population. As a disease, chlamydia 
infection has many aspects of a disease that will typically benefit from screening as a mechanism of 
disease control; it is highly prevalent, frequently asymptomatic, associated with significant 
morbidity, and is easily diagnosed and treated (Paavonen and Eggert-Kruse, 1999). 
Direct cytological inspection of urethral exudates, in conjunction with Giemsa staining, has been 
used in the past for diagnosing chlamydia infection, but is insensitive, and rarely used clinically 
(Chernesky, 2005). Culture of chlamydia from clinical samples is more sensitive, and has the added 
advantage of being the only diagnostic method that will detect live organisms. The clinical sample 
can be centrifuged over an animal cell monolayer, possibly after dilution to reduce toxicity(Yong and 
Paul, 1986). Cell lines commonly used for C. trachomatis propogation include McCoy cells, Hep-2, 
HeLa and Buffalo green monkey (BGM) cells (Krech et al., 1989; Chernesky, 2005), which are often 
treated with cycloheximide in order to prevent cell division and provide a stable monolayer during 
infection. Chlamydia cells are cultured for 48 – 72 hours, after which the monolayer is examined for 
the presence of inclusion bodies indicative of infection, using microscopy aided by either Geimsa 
staining, or fluorescent microscopy aided by fluorescently conjugated C. trachomatis specific 
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antibodies.  The culture of the organism is time consuming, requires animal cell culture capabilities, 
and skilled technical staff, and is difficult to carry out with a high throughput. 
Enzyme immunoassays (EIA) for C. trachomatis are commercially available, and are used as a 
diagnostic, despite suffering from poor sensitivities compared with molecular tests. EIAs rely on the 
detection of C. trachomatis LPS using an enzyme labelled monoclonal or polyclonal antibody (CDC, 
2002). Upon binding of the LPS, the enzyme then catalyses a colorimetric reaction, which can be 
read visually, or by using a spectrophotometer. One study found the sensitivity of a commonly used 
EIA test, the MicroTrak (Trinity Biotech, Ireland) to be 42% compared with that of LCR (Van Dyck et 
al., 2001). Other studies have found the sensitivity to range between 65% and 75% (Chernesky, 
2005). The specificity of these assays is also sub-optimal, due to the tendency of these assays to 
generate false positive results in the presence of LPS from non-target organisms (CDC, 2002). To 
alleviate this issue, confirmatory testing of positive samples is recommended, which increases 
specificity from ~97% to ~99.5% (Moncada et al., 1990). Enzyme linked immunosorbant assays 
(ELISA) are also commercially available for detection of Chlamydia, and are used more frequently 
than EIAs due to the improved sensitivity, and decreased hands on time afforded by this technique 
(Witkin et al., 1997).  
Direct fluorescent antibody (DFA) tests have been applied to detecting C. trachomatis EBs directly 
from specimen material applied to a slide. Fluorescent antibodies specific to either C. trachomatis 
LPS or MOMP are then used to stain the slide, which is then examined using fluorescent microscopy 
(Phillips et al., 1987). The sensitivity of this technique is ~70% compared with culture, and lower still 
when compared with NAATs (Phillips et al., 1987; Chernesky, 2005). However, it is fast to carry out, 
and can be performed on-site to provide same day results. 
The use of NAAT technologies for the detection of C. trachomatis is highly widespread. The first 
NAAT tests to find use in the laboratory diagnosis of Chlamydia were in-house PCR assays, which 
enabled a marked increase in assay sensitivity compared with culture based methods. Commercial 
PCR kits were also quickly made available, providing molecular diagnostics to laboratories without 
the need for lengthy assay development (Smith et al., 1993). Common targets for C. trachomatis 
specific PCR assays are MOMP (Naidu et al., 1997), and the multi copy 16S rRNA gene (Claas et al., 
1990) and cryptic plasmid (Jaton et al., 2006), which are all highly conserved and offer high 
specificity. 
 One of the most widely used early PCR assays was the AMPLICOR PCR test (Roche, US), which one 
large scale evaluation found provided sensitivities of 88% from male urines, and 86% from 
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endocervical swab samples, compared with sensitivities of 50.7% and 67.3% when culture was used 
from the same sample types (Quinn et al., 1996). Early PCR assays required post assay analysis, 
either via the separation of reaction products using agarose gel electrophoresis, or in the case of the 
AMPLICOR PCR test, DNA hybridisation (Quinn et al., 1996). This increases the time taken to process 
each sample and achieve a diagnosis, and also increases the likelihood of amplicon contamination in 
the laboratory (Eickhoff et al., 2003). The development of real-time PCR assays removed the need 
for post assay analysis, as detection is carried out in real-time during the amplification process, via 
the optical detection of fluorescence. Real-time PCR assays based on Taqman probe technology have 
been developed, with one assay specific to the C. trachomatis cryptic plasmid providing sensitivity 
and specificity of 95.7% and 100%, respectively (Jaton et al., 2006).  
The instigation of C. trachomatis screening programmes in developed countries has lead to an 
increased volume of C. trachomatis testing, which has necessitated the development of high 
throughput, automated molecular diagnostics platforms (Van der pol et al., 2000). The COBAS 
AMPLICOR analyzer (Roche, US), is an automated platform for processing AMPLICOR PCR and 
subsequent DNA hybridisation steps, reducing hands-on time, and enabling same-day diagnosis 
(Jaton et al., 2006). The automation of this assay has been shown to provide a slightly increased 
sensitivity in comparison to the manual assay (Livengood and Wrenn, 2001). More recent diagnostics 
platforms have incorporated the automation of not only the amplification and detection processes, 
but also the sample preparation and nucleic acid extraction steps, leading to a sample in-answer out 
system.  
One such test is the Aptima Combo 2 test (Gen-Probe), a transcription mediated amplification (TMA) 
based test that utilizes target capture for the qualitative detection of C. trachomatis (via the 23S 
rRNA sequence) and N. gonorrhoeae from clinical swab or urine samples, which is run on the Gen-
Probe Tigris or Panther platform. Package insert specificity for C. trachomatis detection is given as 
98.9%, which has been replicated experimentally (Levett et al., 2008). The limit of detection of the 
Aptima assay has been recorded as low as 0.008 EB’s per assay, making it the most sensitive 
commercial diagnostic test for C.trachomatis (Lowe et al., 2006).  
A comparison between three of the most frequently used, FDA approved, automated molecular 
platforms for C. trachomatis detection over a large volume of female and male samples (n=3,832) at 
diverse geographical sites, found the sensitivity of the Abbot Realtime CT/NG assay (Abbot, US), the 
Aptima Combo 2 assay (Hologic Genprobe, US), and the ProbeTec ET assay (Becton Dickinson, US), to 
be 92.4%, 94.5%, and 90.3%, respectively (Gaydos et al., 2010). The specificity of the Abbot realtime 
was 99.2%, the Aptima combo 2 was 99%, and the ProbeTec ET was 99.5%. 
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Point of care testing for Chlamydia infection is currently available, in the form of rapid immunoassay 
test kits. Whilst these kits are very simple to use, and provide a rapid time to result (as low as 15 
minutes), they typically have much lower sensitivities than nucleic acid amplification assays 
(Mahilum-Tapay et al., 2007). The most widely used rapid immunoassay in the UK, the Clearview 
Chlamydia MF test (Clearview, Inverness Medical, Bedford, UK), has been shown to have a sensitivity 
as low as 32.8% with vaginal swab samples, and 49.7% with endocervical swabs (Yin et al., 2006), 
although previous studies had shown higher sensitivities, of 60.4% from male samples and 62% from 
female samples (Kluytmans et al., 1993). A comparison of three POC tests widely available for home 
use, and available on the internet or in pharmacies, found assay sensitivities to be extremely low in 
comparison with NAATs. The study involved 772 female samples (11% positive), and the sensitivity 
of the Biorapid Chlamydia Ag test (Biokit, Spain), Quickvue chlamydia test (Quidel corporation, US), 
and Handi-lab C test (Zonda, US) were 17%, 27% and 12%, respectively (van Dommelen et al., 2010). 
This low level of sensitivity seriously undermines the effectiveness of these assays, and despite their 
speed and ease of use, this group of tests is unlikely be able to provide the solution to the lack of 
sensitive POC Chlamydia test available to clinicians. 
The current goal of POC technology is to provide simple, easy to use, rapid testing at the point of 
care, with equal sensitivity to laboratory based NAAT systems. Currently there is an FDA approved 
assay for simultaneous detection of C. trachomatis and N. gonorrhoeae available on the GeneXpert 
platform (Cepheid, US), which enables POC NAAT. This platform utilises a fully automated nucleic 
acid extraction process, and real-time PCR based target amplification and detection, taking place on 
a disposable cartridge. The test provides results within 90 minutes, which enables same day 
diagnosis and treatment, and can be used as a POC diagnostic, provided that the patient can remain 
for that period of time on site. When compared with modern NAAT tests such as the Aptima Combo 
2 assay (Genprobe, US), the GeneXpert CT/GC test has been shown to have a sensitivity of 97.4%, 
98.7%, 97.6% and 97.5%, when dealing with endocervival swabs, vaginal swabs, female urines and 
male urines, respectively (Gaydos et al., 2013). Specificity values for all sample types were over 
99.4%. 
A cost/benefit analysis of the implementation of POC NAAT in UK GUM clinics found that POC testing 
could reduce spending, and improve patient experience, mostly due to the prevention of 
presumptive treatment resulting in patients receiving antibiotics unnecessarily (Turner et al., 2014). 
A similar study undertaken in the US also found that POC testing was likely to be more cost effective, 
and also identify more infections before they progress to PID (Huang et al., 2013). 
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4.1.4. Treatment 
 
The current recommendation for treatment of genital chlamydial infection from the UK PHE, and US 
CDC is 1g oral azithromycin, or a one week course of 100mg doxycyline twice a day, in case of 
contra-indications (CDC, X; PHE, X). Azithromycin is considered preferable, in part due to the 
improved compliance encountered when dealing with a single dose therapeutic (Taylor and 
Haggerty, 2011). 
As an obligate intracellular pathogen, the MIC of an antibiotic is determined as the minimum 
concentration required to prevent intracellular proliferation. C. trachomatis also displays heterotypic 
resistance, in which only a sub-population of the C. trachomatis cells will be phenotypically resistant 
(Somani et al., 2000), complicating MIC determination. Strains displaying homotypic resistance have 
not been encountered (Wang et al., 2005). Due to the relative complexity in determining MIC values 
for this organism, MIC testing is not routinely carried out; in general only isolates that have caused 
clinical treatment failures will be tested.  
Although C. trachomatis is able to evolve antimrocrobial resistance in vitro, reports of isolates with 
antimicrobial resistance are rare, and these isolates have not maintained their resistance once 
propagated in vitro (Sandoz and Rockey, 2010). In vitro studies have shown that C. trachomatis cells 
can enter a persistent state when challenged with sub-lethal concentrations of antibiotics, in which 
cell division is halted, but protein synthesis and DNA replication continue, and the instigation of this 
state of persistence can result in treatment failures (Hogan et al., 2004). It is unknown whether this 
is significant in vivo, but it is possible that a certain proportion of treatment failures, or refractory 
infections, are occurring due to persistent C. trachomatis cells, which are inherently more resilient in 
the face of an antimicrobial challenge.  
A small number of multi-drug resistant isolates of C. trachomatis have been previously described, 
although the infections have responded to an increased antibiotic dosage. isolates displaying 
resistance to azithromycin and ofloxacin have been reported as causing treatment failures, although 
the infections either resolved spontaneously or after the administration of an increased dosage, and 
the resistant isolates did not maintain their resistance in vitro (Somani et al., 2000). 
Macrolide antibiotics such as azithromycin exert their effects by binding to the 50S subunit of the 
bacterial ribosomes, inhibiting protein synthesis, leading to the death of the cell (Retsema et al., 
1987). Mutations in the 23S rRNA gene have also been shown to confer macrolide resistance in a 
number of other clinically significant bacterial species, such as Pseudomonas aeruginosa (Marvig et 
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al., 2012) and N. gonorrhoeae (Chisholm et al., 2010), and mutations in the 23S rRNA gene of C. 
trachomatis are associated with a macrolide resistant phenotype, particularly mutations in the 
peptidyl transferase region (Misyurina et al., 2004). Antimicrobial resistance surveillance of genital C. 
trachomatis isolates after mass azithromycin distributions in Ethiopia due to endemic trachoma 
detected no change in susceptibility, despite the obvious selection pressure (Hong et al., 2009), 
demonstrating the relative slow generation of resistance in this organism.  Indeed, it is thought that 
the majority of treatment failures are due to lack of treatment compliance, or re-infection from an 
infected partner (Lanjouw et al., 2010). 
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Aims 
 
 To maintain the culture of C. trachomatis, in order to provide a source of C. trachomatis DNA 
to ourselves and also Public Health England. 
 To provide confirmation of the suitability of the magnetic silica based extraction system for 
the purification of nucleic acids from N. gonorrhoeae. 
 To determine the limits of detection of the C. trachomatis 16S rRNA LAMP assay designed by 
PHE. 
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4.2. Methods 
 
4.2.1. Growth and maintenance of McCoy cells 
 
 Monolayers of McCoy cells were cultured in 75cm3 flasks in Eagles MEM (Invitrogen Life 
Technologies), supplemented with 10% foetal calf serum (PAA Laboratories), 1% 
streptomycin/vancomycin (Sigma) and 1% glutamine (Invitrogen Life Technologies). Monolayers 
were initially seeded with 12ml of cell suspension at a concentration of 3.5 x 105 cells per ml, and 
incubated at 35oC with 5% CO2. Once the monolayers were observed to have grown to 90% 
confluence they could be infected with C. trachomatis, or passaged. During passage, cells were 
washed twice with PBS, trypsinised with 0.25% trypsin solution for 5 minutes at 35oC, before 
resuspending in 10ml of growth medium. Cells were then counted using an improved Neubauer 
counting chamber, and an appropriate volume was then added to a sterile 75cm3 culture flask for 
each fresh culture required, along with fresh growth media, ensuring a final concentration of 3.5 x 
105 cells per ml. After 72 hours the cells could then be passaged again if >90% confluence was 
reached, or the media was removed, and fresh growth media was added.   
 
4.2.2. Chlamydia trachomatis culture 
 
Monolayers of McCoy cells produced as described. Once the monolayers were observed to have 
grown to 90% confluence, the media was replaced, and 1ml inoculums of harvested C.trachomatis 
elementary bodies were added. The culture flasks were then centrifuged at 1,000 x g for 30 minutes, 
to enhance the rate of inclusion formation. The infected cultures were then incubated at 35oC and 
5% CO2 for 72 hours, to insure inclusions predominantly contained elementary bodies. The 
supernatant was removed and stored. The monolayer was then trypsinised with 0.25% trypsin 
solution for 5 minutes at 35oC. The trypsin was deactivated by the addition of 6ml of growth media, 
and the cell suspension was removed and added to the previously collected supernatant. The 
recovered cells and supernatant where mixed, sonicated for 30 seconds at 30kHz, and separated 
into 1ml aliquots. These aliquots were then stored at -80oC, in order to provide infectious material to 
initiate future cultures or provide a positive sample for assays.  
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4.2.3. Confirmation of successful C. trachomatis infection of McCoy cells using fluorescence 
microscopy 
 
Infected McCoy cell monolayers were harvested at 48 hours post infection, when inclusions should 
have formed, but cell lysis not yet occurred. Cells were trypsinised with 0.25% trypsin solution for 5 
minutes at 35oC, before resuspending in 10ml of growth medium. A 2.5µl aliquot of the cell 
suspension was taken and incubated with 2.5µl of bacterial LIVE/DEAD baclight stain (Invitrogen), 
formulated according to the manufacturer’s instructions, in the dark for 10 minutes, on a glass slide. 
After the incubation, a coverslip was placed over the slide and the slide was visualised using an 
Olympus (Model) fluorescence microscope, using the x60 lens. An excitation wavelength of 480nm 
was applied, and emissions were collected via the green (500nm) and red (630nm) wavelengths. 
 
4.2.4. Purification of C. trachomatis Elementary Bodies via gradient centrifugation 
 
Chlamydia cells were harvested from an infected McCoy cell monolayer at 70 hours post infection, 
as described in Appendix 2. Any intact McCoy cells were then lysed via sonication for 1 30 second 
burst at 30kHz. The suspension was then centrifuged at 250 g for 5 minutes, in order to remove 
mammalian cell debris. The osmolality of the suspension was then increased by the addition of an 
equal volume of PBS containing 0.4M sucrose. A density barrier solution was made containing 180ml 
OptiPrep solution, 210ml H2O, and 210ml of solution A (0.13 M NaCl, 3 mM KCL, 0.3mM CaNa2EDTA, 
5 mM Tris-HCL, pH 7.2) (modified from Everson et al., 2002). 15ml of the C. trachomatis cell 
suspension was layered over 10ml of the barrier solution in 30ml centrifuge tubes. The tubes were 
then centrifuged at 30,000g for 1 hour in a swinging bucket rotor. A sterile syringe was then used to 
harvest the visible grey fraction at the interface, typically yielding a ~1.5ml suspension of purified 
EB’s. The presence of C.trachomatis was confirmed using a PCR reaction, with primers specific to the 
C.trachomatis 16s rRNA region, as described below. Purified C.trachomatis elementary bodies (EB’s) 
were then quantified using a GeneSig C. trachomatis absolute quantification qPCR kit (PrimerDesign 
Ltd., UK). 
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4.2.5. C. trachomatis PCR reaction 
 
PCR reactions were set up as follows; 25µl RedTaq reaction mix (Sigma Aldrich, UK), 0.5pmol 
Forward primer, 0.5pmol reverse primer. Reactions were then made up to 45µl with water, and 5µl 
DNA (or water as a no template control) was added. Reaction conditions were as follows; 94oC for 5 
minutes initial denaturation; 35 cycles of 94oC for 30 seconds, the correct primer annealing 
temperature (specific to each primer set) for 30 seconds and 72oC for 30 seconds; 72oC for 5 minutes 
final extension. Reactions were heated using an ABI 2720 thermocycler (Applied Biosystems, UK). 
PCR reaction products were separated on 2% % w/v agarose gels, with transillumination and 
photography provided by a BioRad Gel/Chem Doc system (Bio-Rad Inc, UK). 
 
4.2.6. PCR primer design 
 
Primers were designed to the C. trachomatis 16S rRNA gene (NCBI reference sequence: 
NC_020967.1) using Primer-BLAST (http://www.blast.ncbi.nlm.nih.gov/) (Ye et al., 2012). The primer 
sequences are shown in Table 4.2. 
Primer Sequence Length (bp) Product 
size (bp) 
Annealing 
temperature 
(oC) 
C. trachomatis 16S 
rRNA Forward 
CGGTTGGAAACGGCCGCTAAT 
21 
449 63 
C. trachomatis 16S 
rRNA Reverse 
CCTACACGCCCTTTACGCCC 
20 
Table.4.2. C. trachomatis 16S rRNA PCR primer sequences 
 
4.2.7. LAMP Reactions 
 
LAMP reactions were set up using reagents from a Mast Isoplex DNA amplification kit (Mast Group 
Ltd, UK), as follows; 5µl five times LAMP reaction buffer, 1µl intercalating dye (propriety dye, 
emission in FAM channel), 1µl of 8U/µl Bst polymerase (New England Biolabs, USA), 1µl of primer 
mix containing 40pmol of FiP and BiP primers, and 5pmol of F3 and B3 primers, 12µl molecular grade 
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water. Finally 5µl of DNA sample or water was added to the reaction. Reactions were carried out in 
an ESEQuant Tube Scanner (Qiagen Inc., CA), at 63oC for 60 minutes. Reactions were terminated by 
heating to 80oC for 1 minute in order to denature the Bst polymerase. The ESEQuant Tube Scanner 
allows for real-time monitoring of the LAMP reactions, via optical detection of the fluorescent 
intercalating dye through the FAM channel. The “Tube Scanner Studio” software package was used 
to analyse the real time data and produce a manually set threshold line for the purposes of 
determining time to amplification (Ta). The CT-0332 primer set, designed by Public Health England, 
South West Laboratory, was used in all C. trachomatis LAMP reactions. 
 
4.2.8. Public Health England C. trachomatis 0332 LAMP primer set 
 
Sequences were provided by Public Health England for their C. trachomatis 0332 primer set. The 
primer sequences are shown in Table 4.3. 
 
Primer Sequence Length (bp) 
C. trachomatis 0332 
F3 
AAATGGAAAGACGGGGAG 
18 
C. trachomatis 0332 
B3 
AAAAAAAACGCAAGGCTCT 
19 
C. trachomatis 0332 
FiP 
CATGCCTAACCGCTCAGTGACTCAAAGACCGCCCAGTA 
38 
C. trachomatis 0332 
BiP 
CTGCTTGGGGCTACAGAGATCCAAAAAATAGGTTAGACGGAA 
42 
Table.4.3. Sequences of the Public Health England C. trachomatis 0332 primer sets 
 
4.2.9. Detection of C.  trachomatis nucleic acid from C. trachomatis infected McCoy cell culture 
using the CT-0332 LAMP assay. 
 
Cells were harvested from C. trachomatis infected McCoy cell culture, as described in 2.2. Nucleic 
acid was extracted from the mix of McCoy cells and elementary bodies using the total nucleic acid 
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extraction method. Extractions were also carried out on uninfected McCoy cells as a negative 
control. Four LAMP reactions were carried out using the nucleic acid from the uninfected and 
infected McCoy cells. 
 
4.2.10. Detection of C.trachomatis in clinical samples using the 0332 LAMP assay in conjunction 
with the magnetic silica based extraction method. 
 
Nucleic acid extractions were carried out on a C. trachomatis positive urine and endocervical swab 
sample (from different patients) in duplicate, using the magnetic silica based total nucleic acid 
extraction method. Extractions were carried out on a C. trachomatis negative urine swab in order to 
provide a negative control. The samples provided were un-extracted excess transport media, from 
Aptima CT/GC assay tubes (Hologic Genprobe, US), provided by PHE South West. The positivity of 
each sample had been previously been determined by the Aptima assay, the current gold standard 
for the detection of this organism. Eluted nucleic acid from all extractions was then tested for the 
presence of C. trachomatis nucleic acid using the CT-0332 LAMP assay. 
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4.2.11. The determination of the limits of detection (LOD) of the 0332 LAMP assay, 16S rRNA 
taqman qPCR assay, and Genprobe Aptima Combi 2 assay for the detection of C. trachomatis 
 
Purified C.trachomatis elementary bodies (EB’s) were quantified using a GeneSig C. trachomatis 
absolute quantification qPCR kit (PrimerDesign Ltd., UK). The stock was diluted to 2 x 105 EB per ml. 
2.9ml of purified EB stock was added to 2.9ml of transport media in an Aptima assay tube 
(Genprobe, US). After adequate mixing, 800µl of media was removed, leaving a 5ml volume.  A total 
of 6 tenfold serial dilutions were then carried out into additional Aptima assay tubes containing 
transport media. The final EB concentration of each tube is shown in Table 4.4. 
 
Sample Tube EB concentration (per ml) 
1 100,000 
2 10,000 
3 1,000 
4 100 
5 10 
6 1 
7 0 
Table.4.4. Concentration of C. trachomatis elementary bodies in each Aptima sample tube. 
 
Total nucleic acid was then extracted from 200µl of each sample using the silica based total nucleic 
acid extraction method (chapter 1.2.7). The sample tubes then underwent the Aptima Combi 2 
CT/GC assay (Hologic Genprobe, US), carried out using a Tigris (Hologic, Genprobe US) automated 
NAAT system. The nucleic acid extractions were then tested for the presence of C.trachomatis 
nucleic acid via the 16SrRNA qPCR assay (an in-house diagnostic assay at the Public Health England 
South West Laboratory), carried out on an ABI 7500, and also the CT 0332 LAMP assay, carried out 
using the Qiagen ESEquant. 
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4.3. Results 
 
4.3.1. Confirmation of successful C. trachomatis infection of McCoy cells using fluorescence 
microscopy 
 
LIVE/DEAD staining of McCoy cells infected with C. trachomatis was used in order to visually identify, 
via fluorescence microscopy, whether the infection was successful.   
 
 
Fig.4.2. Image of McCoy cells (stained red; nuclei bright red) infected with C. trachomatis (stained 
green), acquired using fluorescence microscopy. Staining carried out using LIVE/DEAD backlight cell 
viability kit (Invitrogen, US). 
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The McCoy cells are visible (Fig.4.2.), the cytoplasm stained dark red, whilst the nuclei are a brigher 
red, having taken up a larger concentration of propidium iodide. The C. trachomatis inclusion can be 
seen as a green area surrounding the nuclei of the cells. 
 
4.3.2. Detection of C. trachomatis nucleic acid from C. trachomatis infected McCoy cell culture 
using the CT-0332 LAMP assay. 
 
An experiment was carried out In order to determine whether the CT-0332 LAMP assay, in 
conjunction with the total nucleic acid extraction method, was capable of detecting the presence of 
C. trachomatis in infected McCoy cell culture. This was carried out to demonstrate primer specificity 
and confirm the particular C. trachomatis strain that we are working with is detectable with the 
primer sets, and also show the ability of the extraction method to extract nucleic acid from this 
organism. 
 
 
Fig.4.3. LAMP reaction amplification plot of nucleic acid extracted from McCoy cells infected with C. 
trachomatis (Ext 1-4). Nucleic acid extracted from uninfected McCoy cells was used as a negative 
control.  
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Fig.4.4. 1.5% agarose gel electrophoresis of LAMP reaction products from fig.3.1. Extractions 1-4 in 
well A1-A4, negative control 1-4 in wells B1-B4 
 
Amplification occurred in all of the LAMP reactions containing nucleic acid extracted from C. 
trachomatis elementary bodies, as expected (Fig.4.3). No amplification was seen in the negative 
control reactions. Amplification in all 4 of the positive reactions was detectable after 11-12 minutes, 
with uniform grouping of the amplification curves. The level of fluorescence intensity generated was 
similar between all positive reactions (340 – 370 RFUs). 
The agarose gel electrophoresis of the end point reaction products (Fig 4.4) shows the characteristic 
ladder formation of LAMP reaction products (Notomi et al., 2000), formed by a high concentration of 
nucleic acid concatamers of certain undefined lengths, between 600bp and ~100bp. The negative 
reactions showed no amplified nucleic acid, only low molecular weight bands representing the 4 
primers used in the reaction. 
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4.3.3. Detection of C. trachomatis in clinical samples using the 0332 LAMP assay in conjunction 
with the magnetic silica based extraction method. 
 
An experiment was carried out in order to determine whether the CT- 0332 LAMP assay, in 
conjunction with the magnetic silica based extraction method, was capable of detecting C. 
trachomatis DNA from clinical endocervical swab and urine samples. 
Nucleic acid extractions were carried out on a C. trachomatis positive urine and endocervical swab 
sample in duplicate, using the magnetic silica based total nucleic acid extraction method. Extractions 
were carried out on a C. trachomatis negative urine swab in order to provide a negative control.  
Eluted nucleic acid from all extractions was then tested for the presence of C. trachomatis nucleic 
acid using the CT-0332 LAMP assay. 
 
 
Fig.4.5. CT-0332 LAMP reaction amplification plot of nucleic acid extractions carried out using the 
silica bead based method, from C. trachomatis positive clinical endocervical swab sample (Swab +), 
and positive urine sample (Urine +). A C. trachomatis negative clinical urine sample was used as a 
negative control (Urine -). 
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The CT-0332 LAMP assay was able to identify C. trachomatis DNA in the positive urine and swab 
sample, in both duplicate extractions. The LAMP assay generated no detectable amplification from 
the samples determined as negative by the Aptima assay. The swab sample generated the earliest 
amplification, with both duplicates showing good agreement of amplification time, crossing the 
manually set Ct value at ~18 minutes (Fig.4.5). The urine sample generated a later amplification, 
indicating a lower gene copy number, and hence organism load, in this sample. There was a larger 
difference in time to amplification between the duplicates of the extractions from the positive urine 
samples, which crossed the threshold line at 29 minutes and 34 minutes, respectively.  
 
4.3.4. The Determination of the limits of detection (LOD) of the CT-0332 LAMP assay, 16s rRNA 
taqman qPCR assay, and Genprobe Aptima Combi 2 assay for the detection of C. trachomatis.  
 
The limit of detection (LOD) of an assay is the minimum concentration of analyte, in this case C. 
trachomatis cells, which the assay is capable of detecting. This is an important factor to determine, 
as the detection limit will directly impact on the assay sensitivity. It is important that the limit of 
detection is not greater than the minimum concentration seen in positive clinical sample, as this will 
lead to false-negative results when used as a diagnostic test. It is important that the C. trachomatis 
LAMP assay performs as well as other NAAT methods, as these are the benchmarks of sensitivity 
that the assay will be judged against. 
The lowest number of C. trachomatis elementary bodies detectable by three nucleic acid 
amplification tests (NAATs) for the detection of C. trachomatis; 16S rRNA taqman qPCR assay, 0332 
LAMP assay, and the Aptima assay (Genprobe), were determined. 
Purified C. trachomatis EB stock was added to transport media in an Aptima assay tube (Genprobe), 
to a final concentration of 100,000 EB per ml. A total of 6 1:10 serial dilutions were then carried out 
into additional Aptima assay tubes containing transport media. The EB concentration of each tube is 
shown in Table 4.5. 
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 Table.4.5.Concentration of C. trachomatis EBs in each sample tube 
 
Total genomic nucleic acid was then extracted from 200µl of each sample, using the KIngFisher Ml 
automated RNA extraction system, in conjunction with standard extraction buffers. The sample 
tubes then underwent the Aptima Combi 2 CT/GC assay, ran using a Genprobe Tigris automated 
NAAT system. The RNA extractions were then tested for the presence of C. trachomatis nucleic acid 
via the 16SrRNA qPCR assay, carried out on an ABI 7500, and also the CT 0332 LAMP assay, carried 
out on a Qiagen ESEquant. 
 
 
 
 
 
Sample Tube EB concentration (per ml) 
1 100,000 
2 10,000 
3 1,000 
4 100 
5 10 
6 1 
7 0 
283 
 
 
Fig.4.6. LAMP amplification plot showing the limit of detection of the CT-0332 LAMP assay. Nucleic 
acid extractions were carried out on 1/10 serial dilutions of a quantified C. trachomatis elementary 
body suspension (100,000 EB’s per ml).  Extractions were then tested for the presence of C. 
trachomatis nucleic acid using the CT-0332 assay. A C. trachomatis negative clinical swab sample was 
used as a negative control. 
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Fig.4.7. Amplification plot showing limits of detection of C. trachomatis 16s Taqman qPCR assay. 
Nucleic acid extractions were carried out on 1/10 serial dilutions of a quantified C. trachomatis 
elementary body suspension (100,000 EB’s per ml).  Extractions were then tested for the presence of 
C. trachomatis nucleic acid using the CT-0332 assay. A C. trachomatis negative clinical swab sample 
was used as a negative control. Line colour corresponding to sample identity shown via key. 
 
Sample 
1   
2   
3   
4   
      1      2         3       4 
 
      1      2         3       4 
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Sample EB count (per ml) Total RLU (000’s) Result 
CT Positive Control  1178 CT POS 
1 100,000 - - 
2 10,000 1301 CT POS 
3 1,000 1313 CT POS 
4 100 1261 CT POS 
5 10 669 CT POS 
6 1 59 CT EQUIV (NEG) 
7 0 27 CT NEG 
Negative Control 0 6 CT NEG 
 
Table 4.6. Table showing the limits of detection of the Genprobe Aptima C. trachomatis diagnostic 
assay, as run on a Genprobe Tigris instrument system. 1/10 serial dilutions of a quantified C. 
trachomatis elementary body suspension (100,000 EB’s per ml) were prepared and processed as 
samples. Sample 1 was not processed due to an excessive organism load, which can cause a false 
negative result. 
16S Taqman Assay  
Sample EB count 
(per ml) 
Volume 
used in 
extraction 
EB’s used 
in 
extraction 
Volume 
eluted 
Volume 
amplified 
Equivalent 
number of 
EBs  
Results 
1 100,000 200µl 20,000 75µl 5µl 1,333 POS 
2 10,000 200µl 2,000 75µl 5µl 133 POS 
3 1000 200µl 200 75µl 5µl 13 POS 
4 100 200µl 20 75µl 5µl 1.3 P/N 
5 10 200µl 2 75µl 5µl 0 NEG 
6 1 200µl 0 75µl 5µl 0 NEG 
7 0 200µl 0 75µl 5µl 0 NEG 
Negative 0 200µl 0 75µl 5µl 0 NEG 
 
Table 4.7. Tables showing the relation between the number of C. trachomatis Elementary bodies per 
extraction and per assay, and limit of detection for the 16s Taqman qPCR assay. 
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Genprobe Aptima  
Sample EB count 
(per ml) 
Volume 
used in 
extraction 
EB’s used 
in 
extraction 
Volume 
eluted 
Volume 
amplified 
Equivalent 
number of 
EBs 
Results 
1 100,000 1ml 100,000 1ml 1ml 100,000 - 
2 10,000 1ml 10,000 1ml 1ml 10,000 POS 
3 1000 1ml 1000 1ml 1ml 1000 POS 
4 100 1ml 100 1ml 1ml 100 POS 
5 10 1ml 10 1ml 1ml 10 POS 
6 1 1ml 1 1ml 1ml 1 POS 
7 0 1ml 0 1ml 1ml 0 NEG 
Negative 0 1ml 0 1ml 1ml 0 NEG 
 
Table 4.8. Tables showing the relation between the number of C. trachomatis Elementary bodies per 
extraction and per assay, and limit of detection for the Genprobe Aptima assay. 
 
CT 0332 LAMP Assay  
Sample EB count 
(per ml) 
Volume 
used in 
extraction 
EB’s used 
in 
extraction 
Volume 
eluted 
Volume 
amplified 
Equivalent 
number of 
EBs 
Results 
1 100,000 200µl 20,000 75µl 3µl 800 POS 
2 10,000 200µl 2,000 75µl 3µl 80 POS 
3 1000 200µl 200 75µl 3µl 8 POS 
4 100 200µl 20 75µl 3µl 0.8 NEG 
5 10 200µl 2 75µl 3µl 0 NEG 
6 1 200µl 0 75µl 3µl 0 NEG 
7 0 200µl 0 75µl 3µl 0 NEG 
Negative 0 200µl 0 75µl 3µl 0 NEG 
 
Table 4.9. Tables showing the relation between the number of C. trachomatis Elementary bodies per 
extraction and per assay, and limit of detection for CT 0332 LAMP assay.  
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The 16s Taqman qPCR assay was able to detect a level of 1000 EB per ml of sample in both duplicate 
reactions (Table 4.7). This equated to 200 EB’s used in the actual extraction, and an equivalent of 13 
EB’s quotient of nucleic acid in the actual assay tube. One of two duplicates was able to detect down 
to 100 EB per ml of sample, or 1.3 EB’s quotient of nucleic acid per reaction tube . 
The Genprobe Aptima assay was able to successfully detect 10 EBs per ml of sample (Table 4.8). The 
Aptima assay process involves the extraction of nucleic acid from the entire 1ml sample, increasing 
the chances of detection from samples with low organism loads. 
The CT-0332 LAMP assay was able to detect a minimum of 1000 EB per ml of sample (Table 4.9). This 
involved 200 EB’s being used in the actual extraction, equating to a total of 8 EB’s quotient of nucleic 
acid present in the assay itself. 
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4.4. Discussion 
4.4.1. Confirmation of successful C. trachomatis infection of McCoy cells using fluorescence 
microscopy 
 
Infected McCoy cells were stained using a LIVE/DEAD backlight cell viability kit (Invitrogen). This kit 
contains a mix of two dyes; Syto 9, which enters all bacterial cells, irrespective of cell membrane 
integrity, and produces a green fluorescence; and propidium iodide, which only crosses through 
permeable membranes, or non-viable cells, staining with a red fluorescence. This mixture of dyes 
has the effect of staining viable cells green, and non-viable cells red, giving an easily read 
visualisation of the viability of a culture. 
 The harvesting of the McCoy cells, including trypsinisation, centrifugation, and air drying, has 
impaired their membrane integrity, leading to the uptake of propidium iodide, but not Syto 9  
(Fig.4.2.). This provides a good contrast to enable the detection of C. trachomatis inclusion bodies 
surrounding the nuclei, which have taken up the Syto 9 dye, and are fluorescing green. The name 
“Chlamydia” is derived from the Greek word for cloak, after the observation that the inclusions are 
draped around the nuclei of infected cells, like a cloak (Kumaresan, 2005). The presence of these 
inclusions indicates that the infection of the McCoy cells was successful, and that replication of the C. 
trachomatis reticulate bodies has occurred. Being able to confirm this visually is very important; the 
alternative method, PCR, would also detect the original inoculum, and is unable to distinguish 
between dead or live cells. This is especially true of end-point PCR, which gives no quantifiable data 
on the level of DNA present.  By determining via fluorescence microscopy that the infection has 
been successful, confirmation is given that this sample will be suitable for lysing and using to reinfect 
further McCoy cell cultures to maintain the culture of C. trachomatis. 
 
4.4.2. Detection of C. trachomatis nucleic acid from C. trachomatis infected McCoy cell culture 
using CT-0332 LAMP assay. 
 
The CT-0332 LAMP assay was able to detect C. trachomatis nucleic acid in all four nucleic acid 
extractions from cultured C. trachomatis elementary bodies (Fig.4.3.). This showed the generation of 
amplifiable nucleic acid by the silica based total nucleic acid extraction method, and showed the 
methods compatibility with the LAMP assay. Amplification in all 4 of the positive reactions was 
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detectable after 11-12 minutes, with uniform grouping of the amplification curves. The level of 
fluorescence intensity generated was similar between all positive reactions (340 – 370 RFUs), 
indicating that either each LAMP reaction generated an equal concentration of amplified product, or 
the V13 dye in each reaction was saturated, and giving maximum output. 
The agarose gel electrophoresis of the end point reaction products (Fig 4.4) shows the characteristic 
ladder formation of LAMP reaction products, formed by a high concentration of nucleic acid 
concatamers of certain undefined lengths, between 600bp and ~100bp, containing multiple inverted 
repeats. Showing the presence of the characteristic bands in the LAMP reaction products via agarose 
gel electrophoresis confirms the reactions determined as positive by the ESEQuant are genuine 
positive reactions, and the amplification seen was not a product of non-specific amplification, or a 
false positive reaction.  The negative reactions showed no amplified nucleic acid, only low molecular 
weight bands representing the 4 primers used in the reaction. 
 
4.4.3. Detection of C. trachomatis in clinical samples using the 0332 LAMP assay in conjunction 
with the magnetic silica based extraction method. 
 
The ability of the silica based nucleic acid extraction system to extract amplifiable nucleic acid from 
clinical samples is paramount. As well as being representative of the type of samples that will be 
processed by the final assay, clinical samples represent a more complex sample than those created 
in the lab using C. trachomatis culture. For example, a urine sample can include human epithelial 
cells, variable numbers and species of non-target bacteria and yeast cells, a range of organic 
compounds including creatine, uric acid and urea, a range of peptides including hormones and 
mucins, and a number of positive and negatively charged ions, including K+, Na+, Cl-, Ca2+. 
Concentrations of several these components are typically elevated or depressed in particular disease 
states, leading to a highly variable sample. Therefore it is important to test the assay on human 
samples to determine the extent of the effect that these factors have on assay performance.  
The delay in amplification seen in extractions carried out from the urine swab sample (18, 18 
minutes) in comparison to the urine sample (29, 35 minutes) could have been down to a number of 
factors. One possibility is that the endocervical sample contained a higher number of C. trachomatis 
cells than the urine sample, which is likely, as the average organism load is known to be higher in 
endocervical swab samples than urines (Wiggins et al., 2009). A previous study (Wiggins et al., 2009) 
utilised qPCR to determine organism load at varying anatomical sites, and found swab samples to 
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contain a mean of 10,405 organisms per ml, compared to 503 per ml in first void urine specimens. 
However, the organism load in clinical specimens can be highly variable, with factors such as the 
length of duration of infection prior to sampling, urination prior to sampling, swabbing technique 
and antibiotic treatment all capable of having an effect. Both sample types potentially contain PCR 
inhibitors; excessive mucus in endocervical swab samples has been shown to have an inhibitory 
effect on downstream PCR assays for C. trachomatis detection (Tan and Chan, 2005), and urea, 
present in urine samples is a known inhibitor of PCR (Khan et al., 1991). The incomplete removal of 
these inhibitors during the extraction could also delay the amplification.  
Studies have shown nucleic acid diagnostic tests to have similar sensitivities and specificities for 
Chlamydia infection detection when endocervical swabs or urine samples were used. (Haugland et 
al., 2010) screened 603 women for infection, 80 of whom were positive for C. trachomatis.  They 
found the sensitivity and specificity of a PCR assay to be 90.2% and 98.3% respectively when a urine 
sample was used. The assay carried out using endocervical swab samples was determined to have a 
sensitivity and specificity of 89% and 99.2% respectively. This shows that both sample types are 
adequate samples for nucleic acid testing, and LAMP amplification should be possible from both 
types of common clinical samples. 
 
4.4.4. The Determination of the limits of detection (LOD) of the 0332 LAMP assay, 16s rRNA 
taqman qPCR assay, and Aptima Combo 2 (Genprobe) assay for the detection of C. trachomatis.  
 
The Aptima Combo 2 (Genprobe, US) test was found to have the lowest limit of detection, 
successfully detecting as few as 10 EB per ml (Table 4.8). However, due to the 1ml volume used in 
extraction, the extracted volume contains 5 times as much target nucleic acid tests than the 
extractions carried out using the Kingfisher Ml with the same samples. The Aptima Combo 2 Assay is 
a target amplification nucleic acid probe test that utilizes target capture for the qualitative detection 
of C. trachomatis (via the 23S rRNA sequence) and N. gonorrhoeae from clinical swab or urine 
samples. Package insert specificity for C. trachomatis detection is given as 98.9%, which has been 
replicated experimentally (Levett et al., 2008), making the assay one of the most sensitive 
commercially available diagnostic tests for C. trachomatis (Lowe et al., 2006). 
The limit of detection determined was slightly higher than seen in previous studies, which found it 
able to detect nucleic acids from concentrations as low as an equivalent of 0.008 EB per ml (Ikeda-
Dantsuji et al., 2005). This difference could be due to a higher number of dead cells present in the 
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purified EB stock, reducing RNA levels, or an initial overestimation of EBs in the stock. (Ikeda-
Dantsuji et al., 2005) used EB’s purified directly from cell culture, which would have significantly 
higher RNA levels, resulted in a higher concentration of nucleic acid target for the assay. 
The 16S Taqman assay was able to detect the sample 3 (1000 EB/ml) as positive (Fig.3.6.), which 
correlated to 13 EBs per assay (Table 4.7.). Of the two duplicate tests on sample 4 (100 EB/ml), one 
tested positive, one negative, indicating that the true LOD lies around this range. The assay is a qPCR 
assay, using primers targeted to the C. trachomatis 16S rRNA gene. The 16S rRNA genes of 
bacterium contain hypervariable sequences, which are typically species specific and are therefore a 
good target for amplification in diagnostic PCR assays. A Taqman probe provides the fluorescent 
signal, enabling real-time detection. Component concentrations of this assay were optimised by 
Bristol HPA, and the assay is used as a gold standard in their laboratory. 
The 0332 LAMP assay, like the 16S Taqman PCR, was able to detect sample 3 (1000 EB/ml) (Fig.3.5.). 
However due to the reduced volume of extracted nucleic acid used per test, this correlated to 8 EB’s 
per individual assay (Table 4.8.). This detection limit was found at a higher number of organisms 
than expected. Previous studies have reported detection limits of as low as 10 cells per ml, for 
organisms including Trypanosoma brucei rhodesiense (Njiru et al., 2008), and reports of detection 
limits in the range of 100 organisms per ml are common, for species such as mycobacterium 
tuberculosis (Bi et al., 2012), Pneumocystis jirovecii  (Uemura et al., 2008) and Salmonella (Chen et 
al., 2011).  
Blocker (Blocker et al., 2002), found EB levels in positive urine samples ranged from 32/ml to 
1,048,576/ml. An apparent bimodal distribution was displayed, with 37% of samples in a peak 
ranging from 32 to 1,015 EB/ml (median = 297 EB/ml), and 63% of samples in a grouping of higher 
concentrations, ranging from 1,086 to 218,670 EB/ml (median = 7,389 EB/ml). By scaling the LOD of 
the CT 0332 LAMP reaction up to a sample size of 1ml, 200 EBs would be the assays limit, relatively 
close to the minimum levels seen in Blocker et al., (2002) (Blocker et al., 2002). This could be 
improved further via optimisation of the primer concentration, reaction mix component 
concentration and extraction procedure. 
 
 
References 
 
292 
 
Abromaitis, S. & Stephens, R. S. (2009) Attachment and Entry of Chlamydia Have Distinct 
Requirements for Host Protein Disulfide Isomerase. PLoS Pathogens, 5(4), e1000357. 
Bavoil, P. M., Hsia, R. & Ojcius, D. M. (2000) Closing in on Chlamydia and its intracellular bag of tricks. 
Microbiology, 146 ( Pt 11), 2723-31. 
Belland, R. J., Zhong, G., Crane, D. D., Hogan, D., Sturdevant, D., Sharma, J., Beatty, W. L. & Caldwell, 
H. D. (2003) Genomic transcriptional profiling of the developmental cycle of Chlamydia 
trachomatis. Proceedings of the National Academy of Sciences, 100(14), 8478-8483. 
Bi, A., Nakajima, C., Fukushima, Y., Tamaru, A., Sugawara, I., Kimura, A., Kawahara, R., Hu, Z. & 
Suzuki, Y. (2012) A rapid loop-mediated isothermal amplification assay targeting hspX for the 
detection of Mycobacterium tuberculosis complex. Japanese Journal of Infectious Diseases, 
65(3), 247-51. 
Blocker, M. E., Krysiak, R. G., Behets, F., Cohen, M. S. & Hobbs, M. M. (2002) Quantification of 
Chlamydia trachomatis elementary bodies in urine by ligase chain reaction. Journal of 
Clinical Microbiology, 40(10), 3631-4. 
Borges, V., Ferreira, R., Nunes, A., Nogueira, P., Borrego, M. J. & Gomes, J. P. (2010) Normalization 
strategies for real-time expression data in Chlamydia trachomatis. Journal of Microbiological 
Methods, 82(3), 256-64. 
Carabeo, R. A., Dooley, C. A., Grieshaber, S. S. & Hackstadt, T. (2007) Rac interacts with Abi-1 and 
WAVE2 to promote an Arp2/3-dependent actin recruitment during chlamydial invasion. 
Cellular Microbiology, 9(9), 2278-2288. 
Carabeo, R. A., Grieshaber, S. S., Hasenkrug, A., Dooley, C. & Hackstadt, T. (2004) Requirement for 
the Rac GTPase in Chlamydia trachomatis invasion of non-phagocytic cells. Traffic, 5(6), 418-
25. 
CDC. (2002) Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections - 
2002. Infectious Diseases in Clinical Practice, 11(5), 315. 
Chen, S., Wang, F., Beaulieu, J. C., Stein, R. E. & Ge, B. (2011) Rapid Detection of Viable Salmonellae 
in Produce by Coupling Propidium Monoazide with Loop-Mediated Isothermal Amplification. 
Applied and Environmental Microbiology, 77(12), 4008-4016. 
Chernesky, M. A. (2005) The laboratory diagnosis of Chlamydia trachomatis infections. Canadian 
Journal of Infectious Diseases and Medical Microbiology, 16(1), 39-44. 
Chisholm, S. A., Dave, J. & Ison, C. A. (2010) High-level azithromycin resistance occurs in Neisseria 
gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrobial 
Agents and Chemotherapy, 54(9), 3812-6. 
293 
 
Claas, H. C., Melchers, W. J., de Bruijn, I. H., de Graaf, M., van Dijk, W. C., Lindeman, J. & Quint, W. G. 
(1990) Detection of Chlamydia trachomatis in clinical specimens by the polymerase chain 
reaction. European Journal of Clinical Microbiology and Infectious Diseases, 9(12), 864-8. 
Cocchiaro, J. L. & Valdivia, R. H. (2009) New insights into Chlamydia intracellular survival 
mechanisms. Cellular Microbiology, 11(11), 1571-1578. 
Conant, C. G. & Stephens, R. S. (2007) Chlamydia attachment to mammalian cells requires protein 
disulfide isomerase. Cellular Microbiology, 9(1), 222-32. 
Darville, T. & Hiltke, T. J. (2010) Pathogenesis of genital tract disease due to Chlamydia trachomatis. 
Journal of Infectious Diseases, 201 Suppl 2, S114-25. 
Dautry-Varsat, A., Subtil, A. & Hackstadt, T. (2005) Recent insights into the mechanisms of Chlamydia 
entry. Cellular Microbiology, 7(12), 1714-1722. 
Detels, R., Green, A. M., Klausner, J. D., Katzenstein, D., Gaydos, C., Handsfield, H., Pequegnat, W., 
Mayer, K., Hartwell, T. D. & Quinn, T. C. (2011) The incidence and correlates of symptomatic 
and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected 
populations in five countries. Sexually transmitted Diseases, 38(6), 503-9. 
Dixon, L., Pearson, S. & Clutterbuck, D. J. (2002) Chlamydia trachomatis infection and non-
gonococcal urethritis in homosexual and heterosexual men in Edinburgh. International 
Journal of STD and AIDs, 13(6), 425-6. 
Dumoux, M., Clare, D. K., Saibil, H. R. & Hayward, R. D. (2012) Chlamydiae assemble a pathogen 
synapse to hijack the host endoplasmic reticulum. Traffic, 13(12), 1612-27. 
Eickhoff, M., Laue, T., Ruckes, T., Cramer, S. O., Krupp, G. & Tiemann, C. (2003) Ultra-rapid detection 
of Chlamydia trachomatis by real-time PCR in the LightCycler using SYBR green technology or 
5'-nuclease probes. Clinical laboratory, 49(5-6), 217-25. 
Engel, J. (2004) Tarp and Arp: How Chlamydia induces its own entry. Proceedings of the National 
Academy of Sciences of the United States of America, 101(27), 9947-9948. 
Everett, K. D. & Hatch, T. P. (1995) Architecture of the cell envelope of Chlamydia psittaci 6BC. 
Journal of Bacteriology, 177(4), 877-82. 
Fadel, S. & Eley, A. (2007) Chlamydia trachomatis OmcB protein is a surface-exposed 
glycosaminoglycan-dependent adhesin. Journal of Medical Microbiology, 56(1), 15-22. 
Falk, L., Fredlund, H. & Jensen, J. S. (2005) Signs and symptoms of urethritis and cervicitis among 
women with or without Mycoplasma genitalium or Chlamydia trachomatis infection. 
Sexually Transmitted Infections, 81(1), 73-78. 
Gaydos, C. A., Cartwright, C. P., Colaninno, P., Welsch, J., Holden, J., Ho, S. Y., Webb, E. M., Anderson, 
C., Bertuzis, R., Zhang, L., Miller, T., Leckie, G., Abravaya, K. & Robinson, J. (2010) 
294 
 
Performance of the Abbott RealTime CT/NG for Detection of Chlamydia trachomatis and 
Neisseria gonorrhoeae. Journal of Clinical Microbiology, 48(9), 3236-3243. 
Gaydos, C. A., Van Der Pol, B., Jett-Goheen, M., Barnes, M., Quinn, N., Clark, C., Daniel, G. E., Dixon, 
P. B., Hook, E. W. & Group, T. C. N. S. (2013) Performance of the Cepheid CT/NG Xpert Rapid 
PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. Journal of 
Clinical Microbiology, 51(6), 1666-1672. 
Geisler, W. M., Whittington, W. L., Suchland, R. J. & Stamm, W. E. (2002) Epidemiology of anorectal 
chlamydial and gonococcal infections among men having sex with men in Seattle: utilizing 
serovar and auxotype strain typing. Sexually Transmitted Diseases, 29(4), 189-95. 
Gomes, J. P., Hsia, R. C., Mead, S., Borrego, M. J. & Dean, D. (2005) Immunoreactivity and differential 
developmental expression of known and putative Chlamydia trachomatis membrane 
proteins for biologically variant serovars representing distinct disease groups. Microbes and 
Infection, 7(3), 410-20. 
Hackstadt, T., Todd, W. J. & Caldwell, H. D. (1985) Disulfide-mediated interactions of the chlamydial 
major outer membrane protein: role in the differentiation of chlamydiae? Journal of 
Bacteriology, 161(1), 25-31. 
Haugland, S., Thune, T., Fosse, B., Wentzel-Larsen, T., Hjelmevoll, S. & Myrmel, H. (2010) Comparing 
urine samples and cervical swabs for Chlamydia testing in a female population by means of 
Strand Displacement Assay (SDA). BMC Women's Health, 10(1), 9. 
Heuer, D., Rejman Lipinski, A., Machuy, N., Karlas, A., Wehrens, A., Siedler, F., Brinkmann, V. & 
Meyer, T. F. (2009) Chlamydia causes fragmentation of the Golgi compartment to ensure 
reproduction. Nature, 457(7230), 731-5. 
Hogan, R. J., Mathews, S. A., Mukhopadhyay, S., Summersgill, J. T. & Timms, P. (2004) Chlamydial 
Persistence: beyond the Biphasic Paradigm. Infection and Immunity, 72(4), 1843-1855. 
Hong, K. C., Schachter, J., Moncada, J., Zhou, Z., House, J. & Lietman, T. M. (2009) Lack of macrolide 
resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. 
Emerging Infectious Diseases, 15(7), 1088-90. 
Huang, W., Gaydos, C. A., Barnes, M. R., Jett-Goheen, M. & Blake, D. R. (2013) Comparative 
effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among 
women in a clinical setting. Sexually Transmitted Infections, 89(2), 108-114. 
Humphrys, M. S., Creasy, T., Sun, Y., Shetty, A. C., Chibucos, M. C., Drabek, E. F., Fraser, C. M., 
Farooq, U., Sengamalay, N., Ott, S., Shou, H., Bavoil, P. M., Mahurkar, A. & Myers, G. S. A. 
(2013) Simultaneous Transcriptional Profiling of Bacteria and Their Host Cells. PLoS ONE, 
8(12), e80597. 
295 
 
Hybiske, K. & Stephens, R. S. (2007) Mechanisms of Chlamydia trachomatis Entry into Nonphagocytic 
Cells. Infection and Immunity, 75(8), 3925-3934. 
Ikeda-Dantsuji, Y., Konomi, I. & Nagayama, A. (2005) In vitro assessment of the APTIMA Combo 2 
assay for the detection of Chlamydia trachomatis using highly purified elementary bodies. J 
Med Microbiol, 54(Pt 4), 357-60. 
Jaton, K., Bille, J. & Greub, G. (2006) A novel real-time PCR to detect Chlamydia trachomatis in first-
void urine or genital swabs. Journal of Medical Microbiology, 55(12), 1667-1674. 
Khan, G., Kangro, H. O., Coates, P. J. & Heath, R. B. (1991) Inhibitory effects of urine on the 
polymerase chain reaction for cytomegalovirus DNA. Journal of Clinical Pathology, 44(5), 
360-5. 
Kim, J. H., Jiang, S., Elwell, C. A. & Engel, J. N. (2011) Chlamydia trachomatis Co-opts the FGF2 
Signaling Pathway to Enhance Infection. PLoS Pathogens, 7(10), e1002285. 
Kluytmans, J. A., Goessens, W. H., Mouton, J. W., van Rijsoort-Vos, J. H., Niesters, H. G., Quint, W. G., 
Habbema, L., Stolz, E. & Wagenvoort, J. H. (1993) Evaluation of Clearview and Magic Lite 
tests, polymerase chain reaction, and cell culture for detection of Chlamydia trachomatis in 
urogenital specimens. Journal of Clinical Microbiology, 31(12), 3204-10. 
Krech, T., Bleckmann, M. & Paatz, R. (1989) Comparison of buffalo green monkey cells and McCoy 
cells for isolation of Chlamydia trachomatis in a microtiter system. Journal of Clinical 
Microbiology, 27(10), 2364-5. 
Kumaresan, J. (2005) Can blinding trachoma be eliminated by 20//20? Eye, 19(10), 1067-1073. 
Lanjouw, E., Ossewaarde, J. M., Stary, A., Boag, F. & van der Meijden, W. I. (2010) 2010 European 
guideline for the management of Chlamydia trachomatis infections. International Journal of 
STD and AIDs, 21(11), 729-37. 
Levett, P. N., Brandt, K., Olenius, K., Brown, C., Montgomery, K. & Horsman, G. B. (2008) Evaluation 
of Three Automated Nucleic Acid Amplification Systems for Detection of Chlamydia 
trachomatis and Neisseria gonorrhoeae in First-Void Urine Specimens. Journal of Clinical 
Microbiology, 46(6), 2109-2111. 
Livengood, C. H. & Wrenn, J. W. (2001) Evaluation of COBAS AMPLICOR (Roche): Accuracy in 
Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by Coamplification of 
Endocervical Specimens. Journal of Clinical Microbiology, 39(8), 2928-2932. 
Lowe, P., O'Loughlin, P., Evans, K., White, M., Bartley, P. B. & Vohra, R. (2006) Comparison of the 
Gen-Probe APTIMA Combo 2 Assay to the AMPLICOR CT/NG Assay for Detection of 
Chlamydia trachomatis and Neisseria gonorrhoeae in Urine Samples from Australian Men 
and Women. Journal of Clinical Microbiology, 44(7), 2619-2621. 
296 
 
Mahilum-Tapay, L., Laitila, V., Wawrzyniak, J. J., Lee, H. H., Alexander, S., Ison, C., Swain, A., Barber, 
P., Ushiro-Lumb, I. & Goh, B. T. (2007) New point of care Chlamydia Rapid Test--bridging the 
gap between diagnosis and treatment: performance evaluation study. Bmj, 335(7631), 1190-
4. 
Marvig, R. L., Sondergaard, M. S., Damkiaer, S., Hoiby, N., Johansen, H. K., Molin, S. & Jelsbak, L. 
(2012) Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas 
aeruginosa. Antimicrobial Agents and Chemotherapy, 56(8), 4519-21. 
McCoy, A. J. & Maurelli, A. T. (2006) Building the invisible wall: updating the chlamydial 
peptidoglycan anomaly. Trends in Microbiology, 14(2), 70-7. 
McCoy, A. J., Sandlin, R. C. & Maurelli, A. T. (2003) In vitro and in vivo functional activity of 
Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in 
peptidoglycan synthesis and fosfomycin resistance. Journal of Bacteriology, 185(4), 1218-28. 
Misyurina, O. Y., Chipitsyna, E. V., Finashutina, Y. P., Lazarev, V. N., Akopian, T. A., Savicheva, A. M. & 
Govorun, V. M. (2004) Mutations in a 23S rRNA Gene of Chlamydia trachomatis Associated 
with Resistance to Macrolides. Antimicrobial Agents and Chemotherapy, 48(4), 1347-1349. 
Moncada, J., Schachter, J., Bolan, G., Engelman, J., Howard, L., Mushahwar, I., Ridgway, G., Mumtaz, 
G., Stamm, W. & Clark, A. (1990) Confirmatory assay increases specificity of the 
chlamydiazyme test for Chlamydia trachomatis infection of the cervix. Journal of Clinical 
Microbiology, 28(8), 1770-3. 
Moulder, J. W. (1991) Interaction of chlamydiae and host cells in vitro. Microbiology Reviews, 55(1), 
143-90. 
Naidu, B. R., Ngeow, Y.-F. & Pang, T. (1997) MOMP-based PCR reveals presence of Chlamydia 
pneumoniae DNA in respiratory and serum samples of patients with acute C. pneumoniae-
associated infections. Journal of Microbiological Methods, 28(1), 1-9. 
Njiru, Z. K., Mikosza, A. S. J., Armstrong, T., Enyaru, J. C., Ndung'u, J. M. & Thompson, A. R. C. (2008) 
Loop-Mediated Isothermal Amplification (LAMP) Method for Rapid Detection of 
Trypanosoma brucei rhodesiense. PLoS Neglected Tropical Diseases, 2(2), e147. 
Ostaszewska, I., Zdrodowska-Stefanow, B., Darewicz, B., Darewicz, J., Badyda, J., Pucilo, K., Bulhak, V. 
& Szczurzewski, M. (2000) Role of Chlamydia trachomatis in epididymitis. Part II: Clinical 
diagnosis. Medical Science Monitor, 6(6), 1119-21. 
Paavonen, J. & Eggert-Kruse, W. (1999) Chlamydia trachomatis: impact on human reproduction. 
Human Reproduction Update, 5(5), 433-47. 
297 
 
Paschen, S. A., Christian, J. G., Vier, J., Schmidt, F., Walch, A., Ojcius, D. M. & Häcker, G. (2008) 
Cytopathicity of Chlamydia is largely reproduced by expression of a single chlamydial 
protease. The Journal of Cell Biology, 182(1), 117-127. 
Phillips, R. S., Hanff, P. A., Kauffman, R. S. & Aronson, M. D. (1987) Use of a direct fluorescent 
antibody test for detecting Chlamydia trachomatis cervical infection in women seeking 
routine gynecologic care. Journal of Infectious Diseases, 156(4), 575-81. 
Prozialeck, W. C., Fay, M. J., Lamar, P. C., Pearson, C. A., Sigar, I. & Ramsey, K. H. (2002) Chlamydia 
trachomatis disrupts N-cadherin-dependent cell-cell junctions and sequesters beta-catenin 
in human cervical epithelial cells. Infection and Immunity, 70(5), 2605-13. 
Quinn, T. C., Welsh, L., Lentz, A., Crotchfelt, K., Zenilman, J., Newhall, J. & Gaydos, C. (1996) 
Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from 
women and men attending sexually transmitted disease clinics. Journal of Clinical 
Microbiology, 34(6), 1401-6. 
Rasmussen, S. J., Eckmann, L., Quayle, A. J., Shen, L., Zhang, Y. X., Anderson, D. J., Fierer, J., Stephens, 
R. S. & Kagnoff, M. F. (1997) Secretion of proinflammatory cytokines by epithelial cells in 
response to Chlamydia infection suggests a central role for epithelial cells in chlamydial 
pathogenesis. The Journal of Clinical Investigation, 99(1), 77-87. 
Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, 
L. & Mason, R. (1987) Spectrum and mode of action of azithromycin (CP-62,993), a new 15-
membered-ring macrolide with improved potency against gram-negative organisms. 
Antimicrobial Agents and Chemotherapy, 31(12), 1939-47. 
Sandoz, K. M. & Rockey, D. D. (2010) Antibiotic resistance in Chlamydiae. Future Microbiology, 5(9), 
1427-1442. 
Scidmore, M. A., Fischer, E. R. & Hackstadt, T. (2003) Restricted Fusion of Chlamydia trachomatis 
Vesicles with Endocytic Compartments during the Initial Stages of Infection. Infection and 
Immunity, 71(2), 973-984. 
Shperling, N. V., Vengerovskii, A. I., Shperling, I. A., Mironiuk, D. V., Bezmenova, M. A. & Kalaida, E. V. 
(2011) Treatment of chlamydial infection in chronic prostatitis. Urologiia, (4), 45, 47-9. 
Smith, I. W., Morrison, C. L., Patrizio, C. & McMillan, A. (1993) Use of a commercial PCR kit for 
detecting Chlamydia trachomatis. Journal of Clinical Pathology, 46(9), 822-5. 
Somani, J., Bhullar, V. B., Workowski, K. A., Farshy, C. E. & Black, C. M. (2000) Multiple drug-resistant 
Chlamydia trachomatis associated with clinical treatment failure. Journal of Infectious 
Diseases, 181(4), 1421-7. 
298 
 
Su, H., Raymond, L., Rockey, D. D., Fischer, E., Hackstadt, T. & Caldwell, H. D. (1996) A recombinant 
Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors 
on epithelial cells. Proceedings of the National Academy of Sciences, 93(20), 11143-8. 
Sun, J., Kintner, J. & Schoborg, R. V. (2008) The host adherens junction molecule nectin-1 is 
downregulated in Chlamydia trachomatis-infected genital epithelial cells. Microbiology, 
154(Pt 5), 1290-9. 
Tan, H. H. & Chan, R. (2005) Use of polymerase chain reaction on pooled cervical swabs to detect 
Chlamydia trachomatis infections in female sex workers in Singapore. Singapore Medical 
Journal, 46(5), 215-8. 
Taylor, B. D. & Haggerty, C. L. (2011) Management of Chlamydia trachomatis genital tract infection: 
screening and treatment challenges. Journal of Infection and Drug Resistance, 4, 19-29. 
Turner, K. M., Round, J., Horner, P., Macleod, J., Goldenberg, S., Deol, A. & Adams, E. J. (2014) An 
early evaluation of clinical and economic costs and benefits of implementing point of care 
NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine 
clinics in England. Sexually Transmitted Infections, 90(2), 104-11. 
Uemura, N., Makimura, K., Onozaki, M., Otsuka, Y., Shibuya, Y., Yazaki, H., Kikuchi, Y., Abe, S. & 
Kudoh, S. (2008) Development of a loop-mediated isothermal amplification method for 
diagnosing Pneumocystis pneumonia. J Med Microbiol, 57(Pt 1), 50-7. 
van Dommelen, L., van Tiel, F. H., Ouburg, S., Brouwers, E. E. H. G., Terporten, P. H. W., Savelkoul, P. 
H. M., Morré, S. A., Bruggeman, C. A. & Hoebe, C. J. P. A. (2010) Alarmingly poor 
performance in Chlamydia trachomatis point-of-care testing. Sexually Transmitted 
Infections, 86(5), 355-359. 
Van Dyck, E., Ieven, M., Pattyn, S., Van Damme, L. & Laga, M. (2001) Detection of Chlamydia 
trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic 
acid amplification tests. J Clin Microbiol, 39(5), 1751-6. 
Wang, S. A., Papp, J. R., Stamm, W. E., Peeling, R. W., Martin, D. H. & Holmes, K. K. (2005) Evaluation 
of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting 
report. Journal of Infectious Diseases, 191(6), 917-23. 
Watson, E. J., Templeton, A., Russell, I., Paavonen, J., Mardh, P. A., Stary, A. & Pederson, B. S. (2002) 
The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. 
Journal of Medical Microbiology, 51(12), 1021-31. 
Weidner, W., Diemer, T., Huwe, P., Rainer, H. & Ludwig, M. (2002) The role of Chlamydia 
trachomatis in prostatitis. International Journal of Antimicrobial Agents 19(6), 466-70. 
299 
 
Wiggins, R., Graf, S., Low, N., Horner, P. J. & Group, f. t. C. S. S. S. (2009) Real-Time Quantitative PCR 
To Determine Chlamydial Load in Men and Women in a Community Setting. Journal of 
Clinical Microbiology, 47(6), 1824-1829. 
Witkin, S. S., Bongiovanni, A. M. & Inglis, S. R. (1997) Detection of endocervical anti-Chlamydia 
trachomatis immunoglobulin A in pregnant women by a rapid, 6-minute enzyme-linked 
immunosorbent assay: comparison with PCR and chlamydial antigen detection methods. 
Journal of Clinical Microbiology, 35(7), 1781-3. 
World Health Organisation, (2012) Global incidence and prevalence of selected curable sexually 
transmitted infections – 2008. Geneva, Switzerland, World Health Organisation. 
Wyrick, P. B. (2010) Chlamydia trachomatis Persistence In Vitro: An Overview. Journal of Infectious 
Diseases, 201(Supplement 2), S88-S95. 
Yin, Y.-P., Peeling, R. W., Chen, X.-S., Gong, K.-L., Zhou, H., Gu, W.-M., Zheng, H.-P., Wang, Z.-S., Yong, 
G., Cao, W.-L., Shi, M.-Q., Wei, W.-H., Dai, X.-Q., Gao, X., Chen, Q. & Mabey, D. (2006) Clinic-
based evaluation of Clearview Chlamydia MF for detection of Chlamydia trachomatis in 
vaginal and cervical specimens from women at high risk in China. Sexually Transmitted 
Infections, 82(suppl 5), v33-v37. 
Yong, D. C. & Paul, N. R. (1986) Micro direct inoculation method for the isolation and identification 
of Chlamydia trachomatis. Journal of Clinical Microbiology, 23(3), 536-8. 
Zhong, G., Fan, P., Ji, H., Dong, F. & Huang, Y. (2001) Identification of a chlamydial protease-like 
activity factor responsible for the degradation of host transcription factors. The Journal of 
Experimental Medicine, 193(8), 935-42. 
 
 
 
 
 
Chapter 5 
Trichomonas vaginalis 
 
300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1. Introduction 
 
Trichomonas vaginalis is a flagellated protozoan parasite of the human genital tract and the cause of 
the most prevalent curable sexually transmitted disease globally, with an estimated 276.4 million 
cases per year, worldwide (World Health Organisation, 2012). Infections of the female genital tract 
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can cause a range of symptoms, including vaginitis and cervicitis (Heine and McGregor, 1993). 
Infections in males are generally asymptomatic, although mild urethritis or prostatitis can occur 
(Guenthner et al., 2005). During the last decade, the discovery that T. vaginalis infection is 
associated with a range of more serious conditions, such as prostate cancer, cervical cancer, adverse 
pregnancy outcomes, and an increased likelihood of HIV infection, has increased the efforts to 
diagnose and treat patients harbouring this parasite (Bachmann et al., 2011). 
 
5.1.1. Morphology 
 
T. vaginalis has no cystic stage in its life cycle, existing in axenic culture only as a tear drop shaped 
trophozoite, with an average length and width of 10µm and 7µm, respectively (Petrin et al., 1998). A 
total of four anterior flagella provide the parasite with its characteristic twitching motility, whilst a 
single posterior flagellum, which forms the outer edge of the undulating membrane, runs along the 
length of one side of the cell, assisting in motility and the movement of extracellular nutrients 
towards the cytosome of the cell. The cell also possesses an axostyl, a bundle of microtubules 
passing through the cell along its anterior-posterior axis into the extracellular environment (Lee et 
al., 2012), which has a function in cell attachment and mitosis (Ribeiro et al., 2000). During infection, 
whilst in contact with host epithelial cells, the morphology of the cell is markedly different; the 
flagella are internalised and the cell assumes an amoeboid conformation, and adheres to the 
epithelial surface (Fiori et al., 1999). The cytoplasm contains a single defined nucleus, and several 
hydrogenosomes; primitive redox organelles, evolved from mitochondria, which produce molecular 
hydrogen and ATP (Schneider et al., 2011).  
 
 
 
5.1.2. Pathogenesis 
 
 Transmission occurs almost exclusively via sexual contact, although transmission via fomites has 
been documented, but is rarely encountered and controversial (Schwebke and Burgess, 2004). 
Documented suspected non-sexual transmission routes include shared bathing water (Crucitti et al., 
2011; Burch et al., 1959), and bathing implements (Adu-sarkodie, 1995); routes that are theoretically 
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possible due to the ability of the parasite to survive for up to three hours in a moist environment 
(Krieger and Kimmig, 1995). However, these reports are difficult to definitively prove, as ruling out 
sexual contact relies on the reports of the individuals concerned, which may not always be reliable.  
During sexual intercourse, T. vaginalis cells in the genital tract of the infected partner are transferred 
to the uninfected partner, and come in to contact with the genital epithelia. When in contact with 
epithelial cells, the typically ovoid T. vaginalis cell morphologically adjusts, assuming an amoeboid 
conformation (Gould et al., 2013). The cells attach to the epithelial surface, with the amoeboid 
morphology enabling the parasite to increase the surface area contact, and interaction, with the 
epithelial cell. T. vaginalis adhesion is largely mediated by a range of iron-dependent surface 
adhesins (Munoz et al., 2012). There are five primary surface adhesins responsible for the 
attachment of the parasite to the host epithelia; AP120, AP65, AP51, AP33, AP23 (Garcia and 
Alderete, 2007). With the exception of AP51, the genes encoding these proteins are all 
transcriptionally upregulated by the presence of iron, which is an essential mediator of T. vaginalis 
growth, and a key factor in virulence (Ryu et al., 2001). Of these surface proteins, AP65 has been 
hypothesised as the most important;  anti AP65 serum IgG antibodies inhibit T. vaginalis 
cytoadherance, which does not occur when the same is carried out on other adhesins (Garcia et al., 
2003). Interestingly, it has been shown that AP65 does not have a covalent anchor motif, and is 
released extracellularly, where it binds to both the T. vaginalis and epithelial cell surface (Garcia and 
Alderete, 2007). The synthesis and transport of these adhesins to the outer membrane occurs in 
response to the contact of the parasite with vaginal epithelial cells, in tandem with a morphological 
shift to the amoeboid form. After adherence, the T. vaginalis cells recruit further parasites to the 
location, forming sizeable aggregates of ameboid cells on the epithelial surface (Arroyo et al., 1992). 
The other primary mediator of cytoadherance to the host epithelia is surface lipophosphoglycan, the 
most highly expressed protein on the T. vaginalis surface membrane (2 x 106 to 3 x 106 copies per 
parasite) (Fichorova et al., 2006), which binds to the galectin-1 protein located on the surface of 
human epithelial cells (Ryan et al., 2011). Site directed mutagenesis studies have shown that T. 
vaginalis cells expressing a lipophosphoglycan molecule with altered surface residues have a greatly 
reduced adherence and cytotoxicity to human vaginal epithelial cells, underlining the importance of 
this molecule for parasite attachment and virulence (Bastida-Corcuera et al., 2005). The 
glyceraldehyde-3-phosphate dehydrogenase, GAPDH, is another protein expressed on the surface of 
T. vaginalis that has been determined to be involved in cytoadherance (Lama et al., 2009). 
The adherence of T. vaginalis to the epithelial cell surface is a crucial factor in pathogenesis; 
adherence of the parasite is cytotoxic, and typically results in the lysis of the host cell, and erosion of 
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the epithelial monolayer. This process also instigates the inflammatory response, involving the 
release of chemokines such as IL-8 and the recruitment of neutrophils to infected tissues (Fichorova 
et al., 2006). Damage to the vaginal epithelial monolayer during infection is known to occur via a 
variety of mechanisms, and this contact dependent killing does not involve phagocytosis (Krieger et 
al., 1985). Adherence of T. vaginalis to epithelial cells causes a weakening of the junctional complex 
between individual cells in the epithelial monolayer. This weakening is a result of a decrease in trans-
epithelial electrical resistance, an increase in the gap between neighbouring cells, and also 
modification of the distribution of junction complex proteins, all resulting from the interaction with 
the parasite (Guenthner et al., 2005; da Costa et al., 2005).  
Damage to the host epithelia is also caused by parasite mediated apoptosis of epithelial cells, which 
is dependent on the release of CP30 cysteine proteases (Kummer et al., 2008). This group of 4 
cysteine proteases are also linked to adhesion and the passage of the parasite through the mucosal 
barrier, making them important factors in T. vaginalis pathogenesis. The release of polyamine 
compounds as metabolic end-products by T. vaginalis is another cause of the cytotoxicity caused 
during infection. T. vaginalis is incapable of producing spermine metabolically, and relies on the 
uptake of his molecule from the extracellular environment. This occurs via an antiporter system that 
requires the extracellular release of putrescine (Yarlett et al., 2000), which is detectable at high 
levels in the secretions of T. vaginalis infected women (Garcia et al., 2005). Putrescine has been 
shown to induce apoptosis of mammalian cells in vitro, via increased activity of caspase-3, a key 
regulator of the apoptosis process (Takao et al., 2006). The inhibition of polyamine metabolism has 
been shown to reduce contact dependent killing of vaginal epithelial cells by 90% in vitro, and also 
inhibit T. vaginalis growth (Garcia et al., 2005), demonstrating the importance of polyamine 
production in T. vaginalis pathogenesis. T. vaginalis is also capable of the in vitro phagocytosis of 
vaginal epithelial cells, leukocytes and erythroyctes, along with commensal bacteria (Rendon-
Maldonado et al., 1998) and yeasts (Pereira-Neves and Benchimol, 2007) of the genital tract. Two 
distinct mechanisms of phagocytosis have been observed during in vitro studies with yeasts; a classic 
form of phagocytosis involving extension of pseudopodia, which then engulf the target cell, and also 
a more passive form, where the target cell sinks into the T. vaginalis membrane (Pereira-Neves and 
Benchimol, 2007). Phagocytosis is followed by intracellular killing in lysosomes, and provides the T. 
vaginalis cell with a source of nutrients (Francioli et al., 1983). Phagoyctosis is also thought to be the 
primary route of horizontal gene transfer between bacteria and T. vaginalis, providing the parasite 
with an important mechanism of genetic diversification and adaptation (de Koning et al., 2000). The 
precise mechanisms by which the T. vaginalis cells recognise target cells appropriate for 
phagocytosis is poorly understood, although non-specific mannose receptors on the T. vaginalis 
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outer membrane have been implicated in the internalisation of yeast cells (Pereira-Neves and 
Benchimol, 2007). Mannose binding lectins have been shown to bind Gram positive and Gram 
negative bacteria, as well as yeasts, protozoa and even some viruses (Klein and Kilpatrick, 2004), 
showing the wide range of organisms identifiable by the presence of this ligand. Mannose is also 
present on the surface of epithelial cells (Hanada et al., 2014), leukocytes (Rodriguez-Ortega et al., 
1987), and erythroyctes (Lodish, 2000), so T. vaginalis mannose receptors may play a part in the 
recognition of these cell types during phagocytosis or lysis. T. vaginalis is known to be able to 
recognise erythrocytes, and is able to lyse erythrocytes both in vitro and in vivo, with haemolysis 
depending on adherence of the parasite (Fiori et al., 1993). This is thought to provide the parasite 
with a source of iron, an essential nutrient for T. vaginalis growth (Ryu et al., 2001).  
 
5.1.3. Epidemiology and clinical presentation 
 
The collection of meaningful epidemiological data on T.vaginalis infection is hampered by the fact 
that trichomoniasis is not currently a reportable infection, in developed or developing countries 
(Poole and McClelland, 2013). This means that global and local prevalence and infection rates have 
to be estimated from localised studies, due to the lack of case reporting data available. The most 
recent World Health Organisation (WHO) estimates from data collected in 2008 (World Health 
Organisation, 2012) indicate 276.4 million new cases per year, or 187 million adults infected at any 
one time. This represents a larger number of new infections than those of the next two most 
prevalent STI’s combined, with Chlamydia trachomatis and Neisseria gonorrhoeae infections 
estimated to number 105.7 million and 106.1 million, respectively (World Health Organisation, 
2012). The prevalence and incidence of T. vaginalis infection is geographically variable (Table 5.1), 
with the highest prevalence found in Africa (20.2% of females, 2% of males), and the Americas (22% 
of females, 2.2% of males). The prevalence in Europe is estimated as 5.8% of females and 0.6% of 
Males.  
WHO Region 
Incidence (per 1000) Prevalence (%) 
Female Male Female Male 
Africa 146.0 164.8 20.2 2 
The Americas 177.7 180.6 22.0 2.2 
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South East Asia 40.3 50.1 5.6 0.6 
European 51.7 48.4 5.8 0.6 
Eastern 
Mediterranean 
64.0 66.1 8.0 0.8 
Western Pacific 45.6 47 5.7 0.6 
Table 5.1. Global incidence and prevalence of T. vaginalis infection, according to 2012 WHO 
estimates. Data taken from World Health Organisation, 2012. 
 
The estimated incidence of T. vaginalis is fractionally higher in men than in women, with a male to 
female ratio of total cases globally of 1.14. There is an obvious discrepancy between this fairly equal 
relationship, and the sizeable difference in estimated prevalence rates between the sexes. The 
prevalence of T. vaginalis infection in women is around 10 times higher than in men, irrespective of 
geographic location. This is indicative of the self clearing nature of the infection in males, with the 
majority of persistent infections occurring in females (Van Der Pol, 2007). The higher likelihood of 
persistence in the female genital tract has been linked to the availability of iron, which increases 
during the menstrual cycle, providing the parasite with increased exposure to a major growth 
requirement (Beltrán et al., 2013). The expression of various adhesion proteins promoting 
cytoadherance is enhanced in response to increased iron concentration (Sehgal et al., 2012), and this 
is associated with increased virulence (Ryu et al., 2001). The prevalence of T. vaginalis infection has 
been seen to differ between ethnic populations in the same geographical area, with black females in 
the US having a higher prevalence (10.5%; 95% CI, 8.3-13.3%) than white females (1.1%; 95% CI, 0.8-
1.6%) (Miller et al., 2005). 
T. vaginalis infection in females is symptomatic in around 50% of cases, and around 30% of 
asymptomatic cases develop some symptoms in the 6 month period post infection (Rein, 1990). 
Common symptoms include itching and pain during intercourse, a frothy discharge, and vaginitis, 
which can range from mild to severe (Petrin et al., 1998). In acute cases, punctate hemorrhagic spots 
may be present on the vaginal and cervical mucosa, a pathology referred to as colpitis macularis, or 
“strawberry cervix” (Swygard et al., 2004). T. vaginalis infection has also been associated with 
cervicitis, urethritis and also more serious complications such as pelvic inflammatory disease (PID) 
(Heine and McGregor, 1993), cervical cancer (Zhang et al., 1995) and infertility (El-Shazly et al., 
2001). The effects of T. vaginalis infection during pregnancy, and on pregnancy outcomes, are well 
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documented. Infections with T. vaginalis at the mid gestation point of pregnancy increases the 
likelihood of a preterm delivery and low birth weight (Cotch et al., 1997). Interestingly, the 
successful treatment of T. vaginalis infection in pregnant women at the mid gestation point does not 
prevent this subsequent preterm delivery (Klebanoff et al., 2001). Neonatal genital and 
nasopharyngeal infections have been reported, with transmission thought to occur during birth 
(Smith et al., 2002).  
Infection of the male genitourinary tract is generally asymptomatic, although mild urethritis, 
epididymitis (Fisher and Morton, 1969), and prostatitis can occur (Guenthner et al., 2005). T. 
vaginalis colonisation of the prostate can lead to chronic infection, and is thought to be the cause of 
most persistent infections in males. Trichomonads have been detected in the prostatic urethra, and 
in the surrounding tissues of the prostate, including the glandula lumina, sub mucosa and stroma 
(Gardner et al., 1986). Until recently, T. vaginalis infection in males was considered a “nuisance 
infection”, without serious consequences (Van Der Pol, 2007). This view has been changed 
somewhat, with the realisation that colonisation of the prostate by T. vaginalis is a risk factor in the 
development of prostate cancer (Sutcliffe et al., 2006). A study involving 673 subjects with prostate 
cancer, and an equal number of control subjects, found a statistically significant association between 
those seropositive for T. vaginalis antibodies, and those with prostate malignancy (Stark et al., 
2009). The increase in risk in developing prostate cancer has been estimated to be between 23% and 
40% (Stark et al., 2009; Sutcliffe et al., 2006). One potential mechanism responsible for the increased 
likelihood of carcinogenesis seen during T. vaginalis infection is the host inflammatory response (Ryu 
et al., 2004), which involves the increase production of pro-inflammatory cytokines that have been 
implicated in prostate malignancy (Azevedo et al., 2011). T. vaginalis infection of has also been 
shown to increase the expression of the proto-oncogene PIM1 in cultured prostate epithelial cells 
(Sutcliffe et al., 2012). PIM1 is also known to induce the expression of another proto-oncogene, 
HMGA1, via the PIM1/c-MYC/HMG1 signalling cascade. Both c-MYC and HMG1 are frequently over 
expressed in malignant prostate cells, and their expression has been linked to increased proliferation 
and metastasis (Sutcliffe et al., 2012). Recent work has shown that T. vaginalis produces a novel 
protein, T. vaginalis macrophage migration inhibitory factor (TvMIF), which has 47% sequence 
agreement with the pro-inflammatory cytokine Human macrophage migration inhibitory factor 
(HuMIF) (Twu et al., 2014). TvMIF inhibits macrophage migration, causes inflammation, and 
activates ERK, Atk, and Bcl-2-associated death promoter phosphorylation, inhibiting with apoptosis 
and causing cellular proliferation. The same study demonstrates that exposure of benign and 
malignant prostate cells to TvMIF in vitro instigates growth and invasion (Twu et al., 2014). 
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5.1.4. Relationship with other microorganisms 
 
The presence of T. vaginalis in female patients can cause extensive changes in the vaginal 
microbiome, and trichomoniasis often occurs in tandem with bacterial vaginosis (BV) (Fichorova et 
al., 2013), a condition involving an imbalance in the bacterial flora of the vagina causing vaginal 
inflammation. This imbalance commonly manifests as a reduction in overall numbers of Lactobacillus 
sp., thought to be crucial for the maintenance of vaginal health, in combination with an increase in 
other commensal bacteria that are usually only present in lower levels, such as Gardnerella 
vaginalis, Mobiluncus curtisii, Megasphaera sp., Atopobium vaginae, and Leptotrichia sp. (Fredricks 
et al., 2007). The lactobacilii, predominant in women with a typical vaginal microbiota, contribute to 
vaginal health by releasing lactic acid, which maintains optimal vaginal pH. T. vaginalis grows 
optimally at a pH of 6 to 6.3 (Petrin et al., 1998), whilst the vaginal pH in women with a lactobacilli 
dominated vaginal environment ranges between 2.8 and 4.2 (O'Hanlon et al., 2011). The disruption 
of the lactobacilli community seen during trichomoniasis reduces the lactic acid released into the 
vaginal environment, increasing the pH, and creating more favourable conditions for T. vaginalis 
(Cudmore et al., 2004).  Lactobacilli also act against pathogenic organisms in the vaginal 
environment by out-competing them for nutrients, and also via the release of hydrogen peroxide, 
which is toxic to a number of potentially BV causing organisms such as Gardnerella vaginalis 
(Klebanoff et al., 1991), and the production of a range of antimicrobial peptides. These peptides 
include lactocin B, a bacteriocin which specifically inhibits the growth of a number of bacterial 
species associated with BV, whilst sparing organisms that form the healthy vaginal flora (Turovskiy et 
al., 2009). A variety of bacteriocins have been isolated from Lactobacillus strains, which have been 
characterised as having an antimicrobial effect on a wide range of Gram positive and Gram negative 
bacteria (Soylak et al., 2003). It is possible that some of these antimicrobial peptides could also have 
an antiprotozoal effect, and that the reduction of these organisms is conducive to the survival and 
growth of T. vaginalis. BV can have serious health implications, many of which overlap with 
trichomoniasis; increased risk of HIV transmission (Mirmonsef et al., 2012), ascending inflammatory 
infections and preterm birth/low birth weight pregnancy (Taylor et al., 2013). The combination of T. 
vaginalis and BV associated bacteria have been shown to amplify the host immune response, 
including an up-regulation of chemokines such as IL-8, and a down regulation of SLPI, an enzyme 
which protects epithelial cells from serine proteases (Fichorova et al., 2013). SLPI has virucidal 
effects, and the down-regulation of this enzyme, in combination with the damage caused to the 
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epithelial monolayer by T. vaginalis, could increased the likelihood of infection with sexually 
transmitted viral pathogens such as HIV and HPV. 
There is a growing body of evidence that suggests T. vaginalis infection increases the chance of the 
acquisition, and transmission of HIV (Mavedzenge et al., 2010).This is of particular concern as T. 
vaginalis is especially prevalent in regions where HIV is considered to be endemic, such as Sub-
Saharan Africa, where 32 million T. vaginalis infections occur each year (McClelland et al., 2007). 
Epidemiological studies have recorded an increase in the risk of HIV-1 acquisition of between 1.52 
and 2.74 fold in T. vaginalis positive women in Sub-Saharan African countries (McClelland et al., 
2007; Mavedzenge et al., 2010; Van Der Pol et al., 2008). A similarly sized increase in the risk of 
transmitting HIV to a serodiscordant partner has also been recorded in T. vaginalis positive women 
in these regions (Sorvillo et al., 2001). The fairly recent realisation of the impact that T. vaginalis 
prevalence has on HIV rates has hastened a greater public health response (McClelland et al., 2007), 
and it is now recognised that the control of T. vaginalis could have a sizeable impact on the 
reduction of HIV transmission in these populations. 
The exact mechanism by which T. vaginalis infection acts to increase the risk of contracting HIV is 
currently undetermined (Thurman and Doncel, 2011), although a number of theories have been 
suggested and tested. T. vaginalis infection instigates a robust mucosal immune response, involving 
localised inflammation and the recruitment of lymphocyctes and macrophages (Fichorova et al., 
2013). This increases the number of potential cells for the virus to invade and proliferate in, and 
would make transmission more likely in a HIV-negative individual.  Additionally, in a HIV-positive 
individual, the increase in cells infected with the virus localised in the genital tract would aid HIV 
shedding during sexual contact, exposing any partners to a higher level of viral particles, facilitating 
transmission (Shafir et al., 2009). HIV positive men with symptomatic urethritis caused by T. 
vaginalis have been shown to have a higher seminal viral load than those with either T. vaginalis 
negative, or with an asymptomatic (Hobbs et al., 1999). Those with symptoms of urethritis will 
necessarily have the greatest level of inflammation, and the greatest levels of CD4 lymphocytes and 
macrophages, increasing the targets for HIV invasion. Additionally, T. vaginalis causes damage to the 
urogenital epithelia, facilitating passage of HIV to deeper layers of the epithelium, and enhancing 
infection (Guenthner et al., 2005).  
One of the more novel intermicrobial relationships of T. vaginalis is the association of the parasite 
with Mycoplasma hominis. This symbiotic relationship, first reported by Nielsen (Nielsen, 1975) was 
the first described association of two obligate human parasites. Co-infection of T. vaginalis with a 
variety of bacterial strains is common, due to the change in vaginal milieu caused by T. vaginalis 
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infection, which leads to a favourable growth environment for a number of bacterial species not 
normally associated with the vaginal microbiota. In the case of M. hominis however, the 
mycoplasma has been found to actually enter T. vaginalis cells, surviving and even proliferating 
internally (Vancini and Benchimol, 2008). The presence of M. hominis alongside T. vaginalis has been 
shown to lead to an upregulation of inflammatory cytokines expression in host macrophages in vitro, 
which would potentially increase localised inflammation in vivo (Fiori et al., 2013). Initial concerns 
that infection with M. hominis could be related to metronidazole resistance in T. vaginalis appear 
unfounded (Butler et al., 2010). 
The relationship with M. hominis is not the only symbiotic relationship that occurs involving T. 
vaginalis. The majority of T. vaginalis strains encountered in human infections are infected with one 
or more of a family of four double stranded RNA viruses, from the genus Trichomonasvirus (TVV), 
family totiviridae (Parent et al., 2013). The presence of this virus has been shown to increase 
virulence of T. vaginalis (Parent et al., 2013), in a process hypothesised to involve the modulation of 
parasite gene expression (Goodman et al., 2011). T. vaginalis borne TVV is also recognised by the 
host immune system via its interaction with human toll-like receptor 3 (TLR3), which instigates a pro-
inflammatory cytokine cascade; a process previously linked to increased susceptibility to epithelial 
invasion by HIV (Fichorova et al., 2012). The presence of TVV during trichomoniasis can cause up to 
30 fold amplification of the immune response, increasing the severity of the infection, and risk of 
more serious complications such as PID (Fichorova et al., 2013). It has also been demonstrated that 
this effect is particularly pronounced during simultaneous bacterial vaginosis (Fichorova et al., 2013), 
highlighting that the interaction between the vaginal microbiome, protozoan parasite, associated 
endosimbiant TVV and human epithelial cells has a large bearing on the immune response and 
infection severity. 
 
 
 
5.1.5. Diagnosis in Female patients 
 
Trichomoniasis is the most common non-viral sexually transmitted infection (STI) worldwide, with a 
higher prevalence than C. trachomatis and N. gonorrhoeae infections combined (World Health 
Organisation, 2012). Despite this, there is no routine screening programme in place in the UK or US, 
apart from during pregnancy, as there is for C. trachomatis (Workowski and Berman, 2010; Ross, 
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2006). This is due in part to the higher incidence of PID and tubal infertility caused by C. trachomatis, 
and also the lower frequency of asymptomatic infection in female patients with trichomoniasis. 
Symptomatic patients in the UK are tested for T. vaginalis, with testing available in the majority of 
GUM clinics. 
The symptoms of T. vaginalis infection overlap significantly with those caused by a number of other 
sexually transmitted pathogens, such as N. gonorrhoea and Mycoplasma genitalium, and a diagnosis 
from clinical presentation alone is rarely possible. The specific symptoms of trichomoniasis, such as a 
the typical inflamed and speckled “strawberry cervix” , and frothy discharge, only occur in a minority 
of around 2% of cases (Fouts and Kraus, 1980), and so cannot be relied upon as a sole indicator of 
the infection. Accurate diagnosis of trichomoniasis is important for the subsequent treatment of 
infection, as antibiotics given for general urethritis treatment such as azithromycin or doxycycline 
are not effective treatments for trichomoniasis (Abdolrasouli et al., 2007).  
Diagnosis of trichomoniasis in female patients is frequently carried out microscopically, by the 
examination of a “wet mount” of vaginal or cervical exudates for motile parasites. This method is 
very simple to carry out, fast, and cost effective, when compared with alternative diagnostic options, 
including culture or molecular methods (Bachmann et al., 2011). Despite these advantages 
microscopic evaluation is not considered the optimal detection method, due to the low sensitivity 
afforded by this technique. Microscopy has been shown to have a sensitivity of around 60%, when 
compared with PCR based methods (Patil et al., 2012). Microscopy is unlikely to detect low level 
infections, in which the organism load in the sample may be under 104 cells/ml, and therefore will 
potentially not be included in the fields examined on the slide (Garber, 2005). The sensitivity of this 
method decreases rapidly if delays are present between sample acquisition and examination, with a 
reduction in sensitivity to 20% caused by a as little as a 10 minute delay reported (Kingston et al., 
2003). Due to this it has been suggested that any diagnostic service which cannot guarantee the 
ability to test samples within an hour of acquisition should use alternative methods (Stoner et al., 
2013). This is of particular concern for clinics that do not operate an on-site microscopy service, and 
rely on the transport of samples to remote centralised laboratories for examination. This loss of 
sensitivity occurs due to the reduction in parasite motility, making the trichomonads difficult to 
identify. Due to their similar size and shape, T. vaginalis cells can be hard to differentiate between 
lymphocytes when non motile (Garber, 2005).  
The culture of T. vaginalis from clinical samples has long been regarded as the gold standard for the 
diagnosis of this organism (Bachmann et al., 2011). Cultures are typically maintained in a broth 
medium, and inoculated with swab samples taken from the vaginal canal or cervix of female 
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patients, or urethral discharge from male patients. Cultures can also be inoculated from urine 
samples, although this is not the optimal sampling method, and reduces sensitivity. Growth can be 
apparent in as little as 48 hours, but cultures should be incubated for at least 7 days to enable the 
detection from low inocula (Garber, 2005). The most common media used are variants of Diamonds 
(TYM) medium (Diamond, 1957), which originally contained trypticase digest, yeast extract, maltose, 
cysteine, ascorbic acid and sheep serum. Possibly the most frequently used variant is Diamonds TYI-
S-33 medium, which also contains a source of iron, foetal bovine serum in place of sheep serum, and 
a vitamin 107-Tween 80 mixture (Diamond et al., 1978). T. vaginalis is incapable of synthesising a 
range of macromolecules necessary for survival and growth, including purines, pyrimidines and 
some lipids, and relies on nutrients acquired from secretions or phagocytosed human or bacterial 
cells in the host genital tract. This necessitates the presence of these molecules in any culture media, 
and serum especially is a key component to support axenic growth of this organism (Petrin et al., 
1998). 
The use of broth culture to diagnose T. vaginalis infection has a higher diagnostic sensitivity than 
wet mount microscopy. One study of 337 samples, including 97 positive samples, found microscopy 
and culture had sensitivities of 52% and 78% respectively (Wendel et al., 2002). However, the use of 
culture to diagnose trichomonas infection does have some significant disadvantages. The week long 
incubation required means that culture is the diagnostic option with the longest time between 
sample acquisition and result. Additionally, culture is less sensitive than molecular methods, such as 
PCR. The use of solid media to culture T. vaginalis has been reported in the literature (Stary et al., 
2002), although is rarely used in a clinical diagnostic setting. One study found a solid modified 
Columbia agar medium to be more sensitive (98.4%) than a commercially available Trichomonas 
medium (92.1%) (Stary et al., 2002). 
One commercially available culture based diagnostic test is the InPouch culture system (Biomed 
Diagnostics, USA). This system combines both culture and microscopy to provide a diagnostic 
solution that offers the advantages of both methods (Sood et al., 2007). It consists of a clear plastic 
pounch containing two conjoined chambers full of media, one of which is inoculated via a swab. The 
other chamber has thinner walls, and a viewing window enabling examination for any trichomonads 
using microscopy. This method has been shown to be more sensitive than wet-mount microscopy 
alone (Draper et al., 1993; Sood et al., 2007), and also removes the need for a pre culture transport 
medium, as the pouch is inoculated directly from the patient, which improves the likelihood of a 
successful culture (Schwebke et al., 1999). The fact that microscopic evaluation of the culture can be 
carried out without any fluid manipulation removes the possibility of contamination and reduces the 
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time taken during the examination. This method is more expensive than standard culture or 
microscopy based methods, however (Draper et al., 1993). 
Serological methods for diagnosing T. vaginalis from vaginal secretions have been developed, but 
are rarely used clinically. A monoclonal antibody based enzyme-linked immunosorbant assay (ELISA) 
test specific to T. vaginalis surface peptides has been shown to offer sensitivities and specificities of 
89% and 98% compared with broth culture (Lisi et al., 1988). A detection limit of 100 trichomonads 
per ml, and a greater sensitivity than wet mount microscopy, has been demonstrated using another 
ELISA assay (Watt et al., 1986). The Trichomonas Direct Enzyme Immunassay (California Integrated 
Diagnostics, US), was a commercially released ELISA test, which is no longer on the market. It relied 
on a mix of peroxidase labelled monoclonal antibodies to an assortment of T. vaginalis proteins, and 
was as sensitive as broth culture (Petrin et al., 1998). One immunoassay currently available 
commercially, and the only T. vaginalis immunoassay currently awarded FDA approval in the US, is 
the OSOM Trichomonas Rapid Test (Sekisui Diagnostics, US). The test is an immunochromatographic  
capillary flow dipstick test, and provides a result within 10 minutes, enabling it’s use at the point of 
care (POC). The OSOM test has a sensitivity and specificity of 82% and 97% respectively (Huppert et 
al., 2007), making it a more sensitive diagnostic test than wet-mount microscopy, culture, and 
standard ELISA methods, whilst being far quicker and simpler to carry out. 
Both commercial, and “in house” PCR based assays for T. vaginalis are available, and provide a more 
sensitive form of testing than the traditional methods of wet-mount microscopy and culture. 
Although PCR requires more highly trained staff and more expensive equipment and reagents, than 
alternative methods, the sizeable increase in sensitivity, coupled with a relatively short turnaround 
time,  makes PCR based assays the optimum diagnostic method in developed countries. A range of 
genes have been exploited as targets for T. vaginalis specific PCR tests. A standard PCR assay specific 
to a sequence of the beta-tubulin gene was found to have a sensitivity and specificity of 97% and 
98% respectively (Madico et al., 1998). The same study found the sensitivities of wet mount 
microscopy and culture to be 36% and 70% respectively, illustrating the improvement in sensitivity 
offered by PCR. A study comparing the sensitivity of two real-time fluorescence resonance energy 
transfer (FRET) hybridisation probe based PCR assays specific to the beta-tubulin gene and 18S rRNA 
gene found assay sensitivities of 96% and 100% respectively (Simpson et al., 2007). The T. vaginalis 
genome harbours a number of conserved repeated DNA sequences, and these are attractive targets 
for nucleic acid amplification tests (NAATs), as they provide a higher copy number per cell, and 
improve detection limits and sensitivities (Bandea et al., 2013). The sequencing of the ~160 Mb T. 
vaginalis genome identified 59 common repeat families that make up ~39 Mb of the complete 
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sequence (Carlton et al., 2007). The majority of the repeat sequences have a copy number of >100, 
with the average being 660 copies. Importantly, these repeats show a high level of homogeneity, 
with sequence variation identified between repeats of the same family in only 2.5% of repeats. This 
provides a stable, high copy number target for molecular assays. Single parasite detection has been 
demonstrated for PCR assays using these repeated sequences as targets (Kengne et al., 1994), and 
the improved sensitivity has enable testing from non-invasive urine samples, which typically contain 
a lower organism load than the swab samples more frequently used (Bandea et al., 2013). 
The majority of NAATs available for T. vaginalis identification are PCR based, however novel 
isothermal diagnostic methods have been applied to the detection of this organism. The 
commercially available APTIMA T. vaginalis assay (Hologic Gen-Probe, US), relies on transcription 
mediated amplification technology, in combination with a target capture specimen processing 
system, to provide a highly sensitive assay for T. vaginalis detection (Chapin and Andrea, 2011). The 
assay is designed to be used on one of the automation systems available from Gen-Probe, such as 
the TIGRIS. The assay is approved for use in the US by the Federal Drug Administration (FDA), and is 
approved for use in the UK. The approval only relates to the use of the assay with a number of 
sample types from female patients, including urine samples, endocervical swabs, and vaginal swabs. 
GenProbe also manufactures AMPTIMA assays for other sexually transmitted pathogens, including 
N. gonorrhoeae, human papillomavirus (HPV), and a combined C. trachomatis and N. gonorrhoeae 
assay (APTIMA COMBO 2 assay). A large scale study of 933 symptomatic and asymptomatic female 
patients attending an STI clinic found the APTIMA assay to have the following sensitivity and 
specificity, respectively, in the following samples types; 100% and 99.0% for vaginal swabs, 100% 
and 99.4% for endocervical swabs, and 95.2% and 98.9% in urine specimens (Schwebke et al., 2011). 
Another commercially available molecular diagnostic test for T. vaginalis infection is the Affirm VPIII 
Trichomonas vaginalis assay (Becton Dickinson, US), which relies on RNA probe hybridisation to 
detect target DNA.  The test has been shown to be more sensitive than wet mount microscopy 
(Brown et al., 2004), but lacks sensitivity compared to NAATs, as the target DNA is not amplified 
before detection, which results in a higher starting copy number being required in order to generate 
signal. One study compared the Affirm VPIII assay with the APTIMA assay, and found sensitivities of 
63.4% and 100% respectively (Chapin and Andrea, 2011). The test is fully automated, and takes 45 
minutes to run, including 2 minutes “hands on time”, potentially enabling point of care testing. The 
BD ProbeTec Qx (Becton Dickinson, US) is another NAAT for T. vaginalis with FDA approval, which 
uses strand displacement amplification in conjunction with a fluorescent detection system, targeting 
a portion of the T. vaginalis ap61-5 gene. This assay is processed on the BD Viper system, a fully 
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automated sample handling system capable of processing the sample through nucleic acid extraction 
and subsequent amplification.  An evaluation of the assay determined the assay performance as 
being similar to the Aptima T. vaginalis assay, with a sensitivity and specificity of 98.3% and 99.6% 
respectively, over the 838 samples tested (Van der Pol et al., 2014).  The planned release of a T. 
vaginalis test for the GeneXpert system (Cepheid, US) in the 2014-2015 product range has also been 
announced, potentially expanding the options for NAAT testing. The GeneXpert is a platform for 
processing real-time PCR based assays with fully automated sample preparation, amplification and 
detection on disposable assay-specific cartridges, providing results within 90 minutes in order to 
enable same-day testing and treatment (Helb et al., 2010). The automated liquid handling and 
extraction process minimise hands-on time, to less than five minutes per specimen (Marlowe et al., 
2011), and provides the high sensitivity and specificity of NAAT diagnostics without the need for 
highly trained laboratory staff.  
 POC testing for sexually transmitted infections, including trichomoniasis, could be of great benefit in 
the control of these diseases (Tucker et al., 2013). Testing at the POC enables consultation, testing, 
and the provision of appropriate treatment to all be carried out in the same day, at the same site. 
This removes the risk of patients neglecting to return for results and medication, and also reduces 
the possibility of transmission by sexual contact during the delay before treatment is instigated 
(Tucker et al., 2013). Currently, it is possible to carry out testing via wet mount microscopy at POC, 
although this is insensitive, low throughput, and effected by the experience and skill of the 
technician. Also, the immunochromatographic OSOM Trichomonas Rapid Test (Sekisui Diagnostics, 
US) is able to provide results within 10 minutes, is easy to use and read, and has higher sensitivity 
than non-molecular methods (82% compared with PCR), making it a very good option for providing a 
POC diagnostic (Huppert et al., 2007). The current goal of POC diagnostic research is to provide the 
sensitivity of NAAT diagnostics, whilst eliminating hands-on processing, and decreasing the time-to-
result, enabling maximally sensitive testing at the point of care (Craw and Balachandran, 2012). The 
majority of POC NAAT systems in development rely on an automated nucleic acid procedure, rapid 
target amplification, and detection of reaction products, typically by optical detection of 
fluorescence (Niemz et al., 2011). These processes are often carried out in a disposable single use 
cartridge or chip, preventing contamination of the machine during sample handling (Niemz et al., 
2011).  One such system currently in development is the Atlas Io PoC (Atlas Ltd, UK) platform, which 
is aiming to release a T. vaginalis test in 2014. The test involves automated nucleic acid extraction, 
followed by amplification of a multi-copy DNA repeat sequence target, and novel electrochemical 
endpoint detection. A small scale lab evaluation of the test, comparing its performance with that of 
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the APTIMA T. vaginalis test (Hologic Gen-Probe, USA), over 90 clinical samples, found that the 
sensitivity and specificity of the assay were 95.5% and 97.5% respectively (Pearce et al., 2013).  
The use of POC testing for trichomoniasis could be of particular benefit in sub-Saharan Africa, where 
both T. vaginalis and HIV infection are highly prevalent. The improved control of T. vaginalis could 
potentially reduce HIV transmission, and significantly impact on morbitity and mortality in the region 
(Johnston and Mabey, 2008). POC testing has been regarded as being particularly well suited to 
developing countries, as the automated POC systems reduce the need for skilled technicians, or well 
equipped centralised laboratories, which may not be widely available (Pai et al., 2012). Additionally, 
the ease of transport, and lack of additional equipment needed by these systems, enables the 
testing of remote communities, far removed from traditional hospital based healthcare. However, 
concerns remain over whether the expense of POC NAAT systems will prevent their widespread use 
in developing countries, with studies examining the prospective cost of implicating widespread POC 
NAAT testing in Africa highlighting the increased cost of diagnosis (Meyer-Rath et al., 2012).        
 
5.1.6. Diagnosis in male patients 
 
The diagnostic testing for T. vaginalis infection in male patients is rarely undertaken, for a number of 
reasons. T. vaginalis infection in men is rarely symptomatic, and male partners of women who have 
received a positive diagnosis are treated concurrently without any confirmatory testing (Schwebke 
and Lawing, 2002). Microscopy of urethral discharge, if present, has a poorer sensitivity with male 
samples than females. Culture can be undertaken from male samples, and the optimal sample type 
is considered to be a combination of urethral swabbing and collection of urine sediment, however, 
as with microscopy, sensitivity is poor (Krieger et al., 1993). The low organism loads encountered in 
male patients mean that sensitive, molecular methods are required in order to provide an 
acceptable level of sensitivity, if testing for T. vaginalis infection is going to be carried out. 
In the past T. vaginalis infection in males has often been considered to be a nuisance infection, due 
to the fact that the infection in males is self-limiting, typically clears without intervention, and the 
belief that infection in males rarely results in any serious sequelae (Van Der Pol, 2007). However, 
there is growing evidence to the contrary; that infection in males can lead to chronic colonisation 
(Lee et al., 2012), and that it may be a causative agent in prostate cancer (Sutcliffe et al., 2006). It 
has been shown conclusively that T. vaginalis increases the transmission of sexually transmitted 
viruses, including HIV (Sorvillo and Kerndt, 1998; Mavedzenge et al., 2010), which in itself makes the 
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control of this organism in males a non-trivial matter. The increasing realisation that this organism is 
associated with disease states with high morbidity in both men and women, and can have serious 
detrimental effects on reproductive health has lead to an increased interest for diagnosis and 
treatment of infections (Soper, 2004), and the treatment of males inevitably will play a part in this 
process. This is driving the need for sensitive, molecular based approaches for the detection of this 
organism. 
 
5.1.7. Treatment 
 
The standard treatment for T. vaginalis infection, in the UK and worldwide, is a single 2g oral dose of 
metronidazole or tinidazole (Muzny and Schwebke, 2013). These antibiotics from the 5-
nitroimidazole family exert their antimicrobial activity by disrupting the redox system of the parasite, 
with metabolic products of the drug binding to proteins in the thioredoxin mediated redox network 
and inhibiting thioredoxin reductase (Leitsch et al., 2009). The antimicrobial properties of these 
drugs rely on reduction at the nitro group, which occurs after passive diffusion of the drug into the 
hydrogenosome of the cell, generating nitroradical anions, and further reduced reactive 
intermediates (Dunne et al., 2003).Whilst in bacterial cells these nitroradicals would cause DNA 
damage, and cell death, the precise mechanism of by which they damage eukaryotic microorganisms 
is poorly understood (Kulda, 1999). 
Of the available 5-nitroimidazole drugs, metronidazole is most frequently admistered, part due to 
the low associated cost (Sherrard et al., 2014). This is despite tinidazole being considered the 
optimal antimicrobial agent, with numerous studies showing that tinidazole therapy has either an 
equal or lower failure rate than metronidazole therapy (Bachmann et al., 2011). Tinidazole therpay is 
also better tolerated, and has lower associated toxicity than metronidazole (Nailor and Sobel, 2007). 
A large scale study reviewing the outcomes of female patients receiving different therapies found 
the clinical failure rate of those taking metronidazole to be 14.8%, compared with a 3.7% failure rate 
for those receiving tinidazole (Bachmann et al., 2011). This is partly explained by the ~12.5 hour half-
life of tinidazole being ~70% longer than that of metronidazole, and its higher serum concentration 
(Bachmann et al., 2011), and tissue availability (Viitanen et al., 1985). The tissue availability of 
metronidazole also varies significantly between individuals, which is thought to account for a 
proportion of the treatment failures encountered (Holter et al., 1983; Kirkcaldy et al., 2012) 
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 A major cause of treatment failure in metronidazole therapy is metronidazole resistance; a study 
involving 175 women who had failed at least two standard treatments of metronidazole therapy 
found that 115 of the 175 isolates displayed metronidazole resistance in vitro (Bosserman et al., 
2011).  Resistance to metronidazole, the antimicrobial that has historically seen the greatest use in 
the treatment of this organism, is more frequently encountered than tinidazole resistance. Although 
increased metronidazole resistance is correlated with increased tinidazole resistance, in vitro testing 
has shown the minimum inhibitory concentrations (MICs) of metronidazole are significantly higher 
than those of tinidazole in metronidazole resistant isolates (Crowell et al., 2003). The overall 
prevalence of resistance is thought to be low; a study of 538 isolates from a number of clinical sites 
in the US found low level metronizadole resistance in 4.3% of isolates, and no resistance to 
tinidazole (Kirkcaldy et al., 2012). Another study, involving 467 high risk female adolescents 
attending STI clinics in the US found a high prevalence of T. vaginalis infection (14.4%), but a low 
prevalence of resistance to metronidazole (2.7%) and no tinidazole resistant isolates (Krashin et al., 
2010). The prevalence of 5-nitroimidazole resistance in developing countries does not appear to be 
any greater than in developed countries; studies in Africa have found the prevalence to be 6% 
(Rukasha et al., 2013). Although the prevalence of resistance is low, the number of resistant cases is 
still significant, due to the high incidence of T. vaginalis infection overall. Treatment failures due to 
metronidazole resistance increase the cost of therapy, due to the need for reassessment and 
additional treatment, and increase the risk of further transmission, if the patient resumes sexually 
activity in the belief that they are no longer infected.  
The in vitro determination of metronidazole MICs has been shown to be of value in determining 
therapeutic dose in female patients who have experienced treatment failure, with a higher cure rate 
obtained in women who had been treated in accordance with recommendations based on MIC 
testing (Bosserman et al., 2011). MIC testing for this organism has not been standardised, but is 
most commonly carried out by incubating a culture of the isolate in media containing varying 
concentrations of the antimicrobial for up to 48 hours, and then examining microscopically for 
motile trichomonads (Crowell et al., 2003; Wendel and Workowski, 2007). The MIC is given as the 
minimum concentration at which no motile parasites are detectable. For comprehensive 
susceptibility testing the incubations should be carried out under both aerobic and anaerobic 
conditions, as the mechanisms of anaerobic and aerobic resistance differ in this organism (Upcroft 
and Upcroft, 2001). Anaerobic resistance is very rarely clinically encountered; metronidazole 
resistant isolates are generally found to employ aerobic resistance mechanisms, making this the 
more clinically valuable condition to assess (Cudmore et al., 2004). Culture based MIC determination 
is time consuming, with incubation times of up to 48 hours, and also relies on visual identification of 
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motile trichomonads, which is insensitive (Patil et al., 2012; Garber et al., 2005). Whilst an aerobic 
metronidazole MIC of >200µg/ml is strongly associated with treatment failure, isolates with MICs of 
50 - 200µg/ml can vary significantly in their response to metronidazole in vivo, which when taken 
into account with the time consuming nature of susceptibility testing, has led to some clinicians 
questioning the usefulness of initial MIC determination of isolates, in absence of a suspected 
treatment failure (Sobel et al., 2001; Wendel and Workowski, 2007) 
Due to the lack of effective alternative antimicrobials for T. vaginalis infection, the only available 
approved treatment for metronizadole resistant infections is to increase the dosage, to a potentially 
toxic and side effect inducing level, or alternatively use tinidazole (Cudmore et al., 2004). In the case 
of repeated treatment failures with increased levels of nitroimidazole antimicrobials, the only 
alternative options are intravaginally administered antimicrobials such as paramomycin sulphate, 
furazolidone, clotrimazole or povidone iodine, which have all been used to successfully treat 
refractory cases of trichomoniasis (Bosserman et al., 2011; Dunne et al., 2003). Despite high efficacy 
in vitro, these treatments are associated with high failure rates, potentially due to the failure of the 
treatments to react extra-vaginal parasites, such as those residing in the urethra and Skene’s glands 
(Helms et al., 2008; Muzny et al., 2013; Nanda et al., 2006). These options are only available for 
female patients; there are no topical treatments available for treating males (Cudmore et al., 2004).  
Hypersensitivity to metronizadazole is encountered, and frequently occurs in tandem with tinidazole 
hypersensitivity, due to the structural similarity of the compounds (Helms et al., 2008). Documented 
adverse reactions to the administration of these drugs include fever, urticarial, angioedema and 
anaphylactic shock (Knowles et al., 1994; Asensio Sánchez et al., 2008). Nitroimidazole 
desensitization regimes, via either the oral or IV route, have been found to be effective in curing T. 
vaginalis infection in hypersensitive women. A study involving 15 hypersensitive women reported a 
100% success rate associated with desensitisation therapy, with 2 of the 15 individuals reporting 
manageable adverse symptoms (Helms et al., 2008). Desensitization therapy is not always possible in 
patients with a severe nitroimidazole allergy, meaning alternative treatments must be sought, 
typically involving topical intravaginal medications (Muzny et al., 2012). The screening of natural 
products extracts for antimicrobial activity against T. vaginalis has yielded some promising results, 
with one study of Brazilian indigenous medicinal plants reporting that the aqueous extracts of one 
plant species had high activity against T. vaginalis, with an MIC of 4.0mg/mL having 100% efficacy 
(Brandelli et al., 2013). The identification of novel compounds with antimicrobial activity against T. 
vaginalis derived from natural products could potentially prove invaluable in the search for the 
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alternative therapies necessary to manage nitroimidazole resistant T. vaginalis strains, or in 
individuals with nitroimidazole allergy. 
 
5.1.8. Conclusion 
 
The pathogenic effect caused by the colonisation of the genital tract by T. vaginalis results from 
damage to the genital epithelia, which the parasite causes in a variety of ways, including mechanical 
damage, the secretion of apoptosis inducing proteases, the disturbance of the junctional complexes 
in the monolayer, and the instigation of an inflammatory response. The virulence of the infection, 
and disease severity, is similarly complex, and governed by a range of factors. Infection of the female 
genital tract is capable of significant modification of the vaginal microbiome, potentially resulting in 
bacterial vaginosis, worsening the symptoms of the infection (Fichorova et al., 2013). As well as 
organisms present in the vaginal environment, T. vaginalis infection can be impacted by the 
presence of the intracellular symbionts  M. hominis or TVV, which modulate T. vaginalis gene 
expression in a process thought to increase virulence (Fichorova et al., 2013; Fiori et al., 2013; Fraga 
et al., 2012).  
T. vaginalis infection is most common non-viral STI worldwide, and of the viral STI’s only genital 
human papillomavirus (HPV) is more prevalent (Bruni et al., 2010) . There are an estimated total 
number of 276.4 million cases per year world-wide, more than the 106.1 million new cases of N. 
gonorrhoeae infection, and 105.7 new C. trachomatis infections combined (World Health 
Organisation, 2012). T. vaginalis infection is a widespread, global concern, prevalent in Europe 
(5.8%), the Americas (22%) and Africa (20.2%). The high prevalence of T. vaginalis infection in Africa 
is of a particular concern, as the parasite has been implicated in increasing the likelihood of both 
becoming infected by, and transmitting, HIV (Mavedzenge et al., 2010). Despite the high frequency, 
and ubiquitous geographic spread of this disease, it has received a much smaller public health 
response than the next most prevalent curable STI’s, C. trachomatis and N. gonorrhoeae (Van Der 
Pol, 2007). This has been due in part to the consideration of trichomoniasis as a mild “nuisance” 
infection, compared with the more serious tubal infertility risk associated with chlamydia infections 
in women, and the obvious symptoms caused by gonorrhoea. Growing evidence that T. vaginalis 
infection can increase the risk of disease states associated with high morbidity, such as HIV infection, 
in both male and female patients is increasing the interest in the detection and treatment of this 
parasite. The development of sensitive NAAT tests for T. vaginalis has opened up the possibility of 
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testing asymptomatic patients, who often have low organism loads, undetectable with less sensitive 
diagnostic methods. In the UK, the cost of offering this service in a sexual health screen is thought to 
outweigh the benefit of detecting these asymptomatic infections, due to the relatively low 
prevalence of this organism in the general population (Ng and Ross, 2012). However, in the US, 
where the prevalence is much higher, this could be a viable strategy. The testing of males, who tend 
to have a lower organism load, by traditional methods such as microscopy or culture, is less sensitive 
than in females, and the increased sensitivity afforded by NAATs allows for the sensitive testing of 
this group. The continuing development and improvement of POC NAAT testing, and the imminent 
release of T. vaginalis assays for existing POC platforms, will provide the opportunity for the 
provision of sensitive rapid testing for this organism, with all the inherent benefits of testing at the 
POC. 
 
 
 
 
 
 
 
 
 
 
 
 
Aims 
 
 To maintain the culture of T. vaginalis, in order to provide a source of T. vaginalis DNA and 
cell suspensions to ourselves and also Public Health England 
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 To provide confirmation of the suitability of the magnetic silica based extraction system for 
the purification of nucleic acids from T. vaginalis. 
 To determine the limits of detection of the T. vaginalis DNA rpt LAMP assay designed by 
PHE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2. Methods 
 
5.2.1. Media 
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Modified Diamonds (TYM) Media was formulated as shown in Table 5.2; 
 
Component Weight/volume per 100ml 
Trypticase digest 2g 
Yeast extract 1g 
Maltose 0.5g 
L-Cysteine hydrochloride 0.11g 
L-Ascorbic acid 0.02g 
K2HPO4 0.08g 
KH2PO4 0.08g 
Agar 0.05g 
Inactivated foetal bovine serum 10ml 
Table 5.2. Modified Diamonds (TYM) Media components 
 
All components apart from the agar and inactivated bovine serum were dissolved into a final volume 
of 90ml of distilled water. The pH was adjusted to 7.2-7.4, using sodium hydroxide or hydrochloric 
acid. The agar was added, and the media autoclaved at 121oC for 10 minutes, and allowed to cool to 
around 49oC. A 10ml volume of foetal bovine serum was inactivated by heating to 56oC, and added 
to the media at this point. The media was then divided between 7ml bijoux’s in 7ml aliquots. The 
media could then be refrigerated at 4oC until use. Media was stored no longer than 3 weeks. 
Trichomonas Media Number 2 (TMN2) was purchased commercially from Oxoid (UK); the 
composition is shown in Table 5.3 (Atlas et al., 2004). 
 
 
 
Component Weight/volume per 100ml 
Glucose 2.25g 
Liver digest 1.8g 
Pancreatic digest of casien 1.7g 
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NaCl 0.5g 
Pancreatic digest of soybean meal 0.3g 
K2HPO4 0.25g 
Chloramphenicol 0.0125g 
Calcium pantothenate (0.5% solution) 0.1ml 
Horse serum  25ml 
Table 5.3. Trichomonas Media Number 2 components 
 
The media was supplied in individual 7ml glass bijoux’s. These were stored at 4oC, and used no later 
than the use by date on each bottle, typically around 60 days after the purchase. 
 
5.2.2. Culture conditions 
 
Trichomonas vaginalis (ATCC 30001) was cultured in a variety of liquid culture media, at 37oC. The 
vessels used were 7ml Bijoux bottles, filled with 7ml of media, in order to minimise the air volume 
under the lid of the vessel. The lids on the bottles were tightened and sealed with parafilm. 
 
5.2.3. Counting of cells 
 
The bijoux or vessel containing the cells was gently mixed so as not to damage the trichomonads. An 
aliquot was removed from the mid-point of the culture, and the organisms were quantified using a 
Neubauer improved counting chamber. Any motile cells, or non motile cells exhibiting movement of 
the flagellae or undulating membrane were considered to be viable cells. Any trichomonads that did 
not fall into these categories were considered non viable. If the concentration of cells was 
considered too high to count, another aliquot was taken and diluted with sterile saline. Once the 
aliquot of cells was taken, the culture was resealed and placed back in the incubator if further 
required. 
5.2.4. LAMP Reactions 
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LAMP reactions were set up using reagents from a Mast Isoplex DNA amplification kit (Mast Group 
Ltd, UK), as follows; 5µl five times LAMP reaction buffer, 1µl intercalating dye (propriety dye, 
emission in FAM channel), 1µl of 8U/µl Bst polymerase (New England Biolabs, USA), 1µl of primer 
mix containing 40pmol of FiP and BiP primers, and 5pmol of F3 and B3 primers, 12µl molecular grade 
water. Finally 5µl of DNA sample or water was added to the reaction. Reactions were carried out in 
an ESEQuant Tube Scanner (Qiagen Inc., CA), at 63oC for 60 minutes. Reactions were terminated by 
heating to 80oC for 1 minute in order to denature the Bst polymerase. The ESEQuant Tube Scanner 
allows for real-time monitoring of the LAMP reactions, via optical detection of the fluorescent 
intercalating dye through the FAM channel. The “Tube Scanner Studio” software package was used 
to analyse the real time data and produce a manually set threshold line for the purposes of 
determining time to amplification (Ta). 
 
5.2.5. Microscopic evaluation of T. vaginalis culture 
 
Aliquots of 3µl T. vaginalis culture were added to glass slides, and coverslips applied. Images were 
obtained using an Olympus (model) inverted microscope, using the x40 lens. Images were acquired 
using the in-built camera system. 
 
5.2.6. Scanning electron micrographs of T. vaginalis 
 
A 1ml aliquot of T. vaginalis culture, containing 1 x 105 cells, was centrifuged at 2000 x g for 5 
minutes, and the supernatant removed. Cells were washed in PBS, pH 7, and re-centrifuged under 
the same conditions as previously. Cells were then resuspended in 2.5% gluteraldehyde solution, and 
fixed for one hour at 4oC. The fixed cells were then washed by centriging the sample at 2000 x g for 5 
minutes, resuspending in molecular grade water, and repeating 5 times. The cells then underwent 
an ethanol dehydration gradient, and a 5µl aliquot of the suspension of fixed cells was added to an 
SEM specimen mount and coated with 15nm thick gold/palladium, then observed using a 
(Make/Model) SEM. 
 
5.2.7. Growth of T.vaginalis in TYM media 
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Trichomonas vaginalis cells (ATCC 30001) were cultivated overnight in Diamonds (TYM) media. This 
culture was then quantified, and used to inoculate 7ml aliquots of fresh Diamonds media with a final 
density of 10,000 trichomonads per ml. The cultures were then incubated at 37oC for a period of 120 
hours. Every 24 hours, an aliquot was taken from the same 3 cultures, and the cells were counted as 
described. Additionally, 1 culture was taken, and the pH monitored using a pH meter. This culture 
was then disregarded due to the contamination risk.   
 
5.2.8. Public Health England T. vaginalis DNA rpt LAMP primer set 
 
Sequences were provided by Public Health England for their T. vaginalis DNA rpt LAMP primer set. 
The primer sequences are shown in Table 5.4. 
 
Primer Sequence Length (bp) 
T. vaginalis DNA rpt 
F3 
GGTCGACAACTTTGTTGAAAG 21 
T. vaginalis DNA rpt 
B3 
CGTCATGAGTGCGTCAAT 18 
T. vaginalis DNA rpt 
FiP 
AAGACCAATGTTCGACAATAGGTTTTCTCCTTTTGTTTTGAAGTACG 47 
T. vaginalis DNA rpt 
BiP 
AGTTCGCAAAGGCAGTCCTTGTTCTCATAGTAAACCTTCACTT 43 
T. vaginalis DNA rpt 
LoopF 
GTTACTAAGCCACTTTGACCTTGA 24 
T. vaginalis DNA rpt 
LoopB 
GACAACTACAACAAATTCTTCTCCG 25 
Table 5.4. Sequences of the Public Health England T. vaginalis DNA rpt LAMP primer sets 
 
 
5.2.9. Sensitivity of the DNA rpt LAMP assay in conjunction with magnetic silica total nucleic acid 
extraction 
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T. vaginalis cells were cultured in Trichomonas Media Number 2 (Oxoid, UK) for 48 hours. The cell 
count of the culture was determined using an improved Neubauer counting chamber, and the 
culture diluted to 5 x 105 cells per ml. The culture was then sequentially diluted 1:10 in sterile 
Diamonds Media, and a total nucleic acid extraction using the Kingfisher system was carried out o 
200µl of each dilution. LAMP reactions were carried out using the T. vaginalis DNA rpt primer set, 
with 5µl of each sample of extracted nucleic acid. Molecular grade water and extracted DNA from T. 
vaginalis free media were used in place of DNA as negative controls. Reaction products PCR 
reactions were then separated using agarose gel electrophoresis (2% w/v gel), and visualised. LAMP 
reactions were monitored in real-time using the ESEQuant tube scanner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3. Results 
 
5.3.1. Microscopic evaluation of T. vaginalis culture 
T. vaginalis culture was examined microscopically in order to ensure culture viability and motility. 
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Fig.5.1. Image of motile T. vaginalis cells, 100x magnification. Flagella (F) can be seen. Cell 
morphology varies between the classic tear drop shape (T), and a more spherical form (S). 
Microscopic examination of T. vaginalis culture in Diamonds TYM media, 24 hours post-inoculation, 
revealed highly motile cells (Fig.5.1.). Cell morphology varied considerably, between the typical tear-
drop shape and a more circular morphology. Flagella were visible, and motile. No amoeboid cell 
morphology was evident. Parasite:parasite interactions are known to occur in this organism, and 
some cell to cell contact was occurring between the T. vaginalis cells.  
The cultured T. vaginalis cells were also seen to form aggregates in Diamonds TYM media, 
comprising of between 5 and 20 cells (Fig.5.2.).  
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Fig.5.2. As when cultured alongside epithelial cells, aggregates (A) of T. vaginalis also form in axenic 
culture. Enlarged cell in centre of aggregate indicated by arrow. 
 
Fig.5.3. Lysis of a T. vaginalis cell (L). During cell death, the T. vaginalis cell enlarges, and the 
membrane integrity is lost, resulting in the ejection of the cytoplasmic contents into the extracellular 
environment (C). 
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Lysis of the T. vaginalis cells could be observed under the microscope in late stage (72 hours post 
inoculation) culture in Diamonds TYM media (Fig.5.3.). The cells enlarged in size, which was followed 
by the rupture of the outer cell membrane, and release of cytoplasmic contents into the media.  
 
5.3.2. Scanning electron micrographs of T. vaginalis 
 
Scanning electron microscopy (SEM) images of T. vaginalis cells were obtained in order to observe 
the morphological aspects of the cellular structure in more detail. 
 
 
Fig.5.4. SEM of T. vaginalis cell, at a magnification of 23,000x. The flagella are visible (F), as is the 
origin of the undulating membrane. 
 
Observation of the T. vaginalis cell using the SEM revealed the structure of the flagella, undulating 
membrane (Fig.5.4.) and axostyle (Fig.5.5.) in more detail. 
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Fig.5.5. SEM of T. vaginalis cell, at a magnification of 15,522x. The axostyle is visible as a projection 
from the proximal tip of the cell. 
 
5.3.3. Growth characteristics of T. vaginalis 
 
The growth of T. vaginalis in Modified Diamonds Media (Fig.5.6.) shows that proliferation continued 
steadily for 48 hours post inoculation. During the first 48 hour period post inoculation, the 
generation time was ~4 hours, with the number of live cells increased from 1 x 104 to 1.3 x 106 
during this period. At 72 hours the number of live cells had decreased from 1.3 x 106 to 7 x 104. By 96 
hours no live trichomonads were visible. The pH shifted over the 96 hour period from 6.2 to 4.62. 
After 24 hours, ~1 x 104 cells were non-motile, or obviously dead, representing ~5% of the total 
biomass. The number of dead cells increased to 6.9 x 105 cells, or 33% of the total cell count, after 48 
hours. The pH of the media decreased during the trichomonads growth, from 6.2 (0 hours), 6.06 (24 
hours), 4.95 (48 hours), 4.64 (72 hours), to 4.62 (96 hours).  
A 
 
A 
331 
 
 
Fig.5.6. The growth of T. vaginalis in Modified Diamonds Media.  
When cultured in TMN2, the number of motile trichomonads increased from 1 x 104 to 2.7 x 105 
after 24 hours, and 2.8 x 106 after 48 hours. The number of live cells then decreased to 2 x 104 at 72 
hours, and 0 at 96 hours. No non motile cells were observed at the 0 hours, 24 hours or 48 hours 
time points. At 72 hours post inoculation 4.7 x 106 dead cells were observed, decreasing to 3.85 x 106 
dead cells after 96 hours. The pH decreased during the growth of the culture, from 6.2 (0 hours), 
5.69 (24 hours), 5.7 (48 hours), 4.9 (72 hours), and 4.8 (96 hours).  
 
Fig.5.7. The growth of T. vaginalis in TMN2.  
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5.3.4. Sensitivity of the DNA rpt LAMP assay in conjunction with magnetic silica total nucleic acid 
extraction 
 
The sensitivity of the T. vaginalis DNA rpt LAMP assay, in conjunction with the magnetic silica based 
total nucleic acid extraction method, was tested by carrying out nucleic acid extractions on 1:10 
sequential dilutions of T. vaginalis cultured in Diamonds Media. The cell counts per extraction were 
1x105, 1x104, 1x103, 1x102, 10, and 1. Each extraction was assayed using the T. vaginalis DNA rpt 
LAMP assay. The reactions were monitored in real-time (Fig.5.8), and the reaction products were 
examined via agarose gel electrophoresis (Fig.5.9.). 
 
 
Fig.5.8. LAMP amplification plot showing the detection limits of the TV DNA rpt DL1 assay. 
 
The extractions containing 1 x 105 to 10 T. vaginalis cells all generated an amplification in the 
subsequent LAMP assays. The examination of the reaction products by electrophoresis agreed with 
the real time amplification data, with all reactions that generated an amplification curve also 
generating visible characteristic ladder like reaction products when separated on the gel (Fig.5.9). 
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The limit of detection of the assay was found to be 10 T. vaginalis cells per extraction, with the LAMP 
reaction from a single T. vaginalis cell failing to generate a detectable amplification. 
Both the negative control reactions did not generate an amplification, indicating primer specificity 
and also the absence of contamination of both the LAMP reaction and extraction reagents.  
 
 
Fig.5.9. Agarose gel electrophoresis (2%) of LAMP products from the T. vaginalis DNA rpt LAMP 
assay, corresponding to the real-time data displayed in Fig.5.8. 
 
The theoretical number of cells per reaction, worked out using the number of cells in the extraction, 
and elution volume, are shown in Table 5.5. The lowest number of cells per extraction that were 
detectable by the downstream LAMP assay was 10. This is equivalent to 0.4 cells per individual 
reaction, as 5µl of the 75µl of eluted nucleic acid is transferred to the LAMP assay. 
 
 
 
1             2           3            4           5            6         NC1      NC2 
 
1             2           3            4           5            6         NC1      NC2 
400 bp 
 
400 bp 
1000 bp 
 
1000 bp 
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Table 5.5. Limit of detection of the T. vaginalis DNA rpt LAMP assay, in terms of cells per extraction 
and theoretical cells per reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample TV cell 
count 
(per ml) 
Volume 
used in 
extraction 
Cells used 
in 
extraction 
Elution 
Volume 
Volume 
amplified 
Equivalent 
number of 
cells 
Results 
1 500,000 200µl 100,000 75µl 5µl 7,000 POS 
2 50,000 200µl 10,000 75µl 5µl 700 POS 
3 5,000 200µl 1,000 75µl 5µl 70 POS 
4 500 200µl 100 75µl 5µl 7 POS 
5 50 200µl 10 75µl 5µl 0.7 POS 
6 5.0 200µl 1 75µl 5µl 0.07 NEG 
7 0 200µl 0 75µl 5µl 0 NEG 
Negative 0 200µl 0 75µl 5µl 0 NEG 
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5.4. Discussion 
5.4.1. Microscopic evaluation of T. vaginalis culture 
 
Examination of the T. vaginalis culture in Diamonds TYM media at 24 hours post inoculation 
revealed the variable cellular morphology of the trichomonads, with some cells displaying the classic 
teardrop morphology commonly seen in axenic culture (Petrin et al., 1998) and other cells were 
more spherical in structure (Fig.5.1.). Under unfavourable culture conditions, T. vaginalis is known to 
return to a more spherical form, whilst internalising the flagella and reducing motility, in a process 
hypothesised to conserve energy until more conditions improve (Honigberg, 1990). The spherical 
parasites pictured (Fig.5.1.) were still equally motile as the teardrop shaped cells, and also retained 
the extracellular flagella, so it unlikely these morphological changes were to the energy conserving 
form previously described.  
Aggregates of T. vaginalis cells (Fig.5.2.) occur during co-culture with epithelial cells during a process 
in which the parasites adhere to the epithelial cells, and congregate, resulting in damage to the 
epithelial cells involved (Tasca, 2002). It is possible that the enlarged cell in the centre of the 
aggregate (indicated by arrow) is in the process of cell death, and the other T. vaginalis cells are 
involved in this process. T. vaginalis are known to engage in parasite:parasite interactions, involving 
the use of exosomes to transfer proteins between cells (Twu et al., 2013), and it’s also possible that 
it is this process that is responsible for these aggregates, and the cell to cell contact seen in fig.5.1. 
By examining cultures that have started to enter in the death phase, after a period of 72 hours, it is 
possible to observe cell lysis (Fig.5.3.). Due to an exhaustion of nutrients in the media by this stage of 
the culture, the cells have internalised their flagella, ceased motility, and become more spherical in 
shape. There is a debate on whether these forms can be considered pseudocysts, or whether it is a 
stage in the process of degeneration of the T. vaginalis cell (Petrin et al., 1998). 
 
5.4.2. Scanning electron micrographs of T. vaginalis 
 
The use of SEM enables observations of T. vaginalis morphology in more detail, due to the higher 
magnification possible with this method. It is able to clearly view the flagella and undulating 
membrane (Fig.5.4.) and axostyle (Fig.5.5.), which are not as easily visible using conventional 
microscopy. SEM has proven an invaluable tool during research into T. vaginalis, and important 
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studies on phagocytosis (Pereira-Neves and Benchimol, 2007) and cytopathogenicity (Mirhaghani 
and Warton, 1996) have been heavily reliant on SEM.  
 
5.4.3. Growth characteristics of T. vaginalis 
 
As an obligate human pathogen, incapable of survival and proliferation outside of the extracellular 
environment of the human genital epithelia, T. vaginalis is incapable of the synthesis of a range of 
macromolecules, and these need to be present in any culture media in order to support growth. The 
presence of serum in any media is particularly important, as this provides a source of lipids, fatty 
acids, and amino acids. T. vaginalis is also incapable of de novo synthesis of purines or pyrimidines, 
and relies on the phagocytosis of epithelial or bacterial cells to provide a source of these essential 
molecules in vivo. T. vaginalis is capable of releasing ectonucleotideases in order to hydrolyse 
extracellular nucleotides and nucleosides, bypassing phagocytosis, enabling the uptake of these 
molecules from serum during culture. These enzymes have been demonstrated to be significantly 
up-regulated in low serum culture conditions (Frasson et al., 2012). Successful culture of the 
organism also relies on the availability of iron in the culture media; growth of the parasite in media 
containing excess iron is three times greater than that achieved in iron-limited media (Lehker and 
Alderete, 1992). Undefined concentrations of iron will be present in the serum, liver digest and yeast 
extract used in the Diamonds Media, or Trichomonas Media Number 2 (TMN2) (Table.5.2.). 
The most significant difference between the two media tested, Diamonds Media and TMN2, was the 
concentration of serum, which was 10% and 25%, respectively. TMN2 supported the growth of a 
maximum cell density of 2.9 x 106 cells per ml, whereas Diamonds media supported the maximum 
cell density of 1.4 x 106 cells, representing a 52% decrease. This is likely to be due to the reduced 
serum concentration in the Diamonds Media increasing the generation time, and reducing overall 
growth. There are intrinsic benefits to the use of media with a lower concentration of serum; serum 
is expensive, and has a finite shelf life. Additionally, T. vaginalis grows more slowly in a low serum 
media, and therefore exhausts the other nutrients in the media more slowly, enabling a sustained 
period of growth. This is not desired for a diagnostic culture procedure, but is useful for the long 
term propagation of cells in a research setting. Although a lower cell density was reached in the 
Diamonds Media, cell viability was not retained for any longer, with no motile cells observed in 
either media after 96 hours. A higher number of motile cells were observed in the Diamonds Media 
after 72 hours; 7 x 104 per ml, compared with 2 x 104 per ml in the TMN2. 
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The Diamonds media contains 1g per 100ml of yeast extract (Table.5.1.), which has been shown to 
enhance growth of T. vaginalis in serum free media, but have less effect in the presence of serum 
(Smith et al., 1982). 
During the growth of T. vaginalis in Diamonds TYM, the largest increases in biomass occurred 
between 24 and 48 hours post inoculation, with the cell count per increasing from 2.2 x 105 to 1.3 x 
106 per ml during this period (Fig. 5.6.). This was accompanied by the largest shift in pH; from 6.06 to 
4.95. In TMN 2, the growth during this period was greater, with the number of trichomonads per ml 
increasing from 2.7 x 105 to 2.9 x 106 (Fig.5.7.). Despite this, the accompanying pH change was less 
pronounced, with a shift from 5.96 to 5.7 occurring between these time points. The reduced pH 
change could be a possibly explanation for the large reduction in cell death that occurred in this 
media; no non motile cells were observed at 48 hours post inoculation in TMN 2, compared with 6.9 
x 105 in the Diamonds media. T. vaginalis is known to be sensitive to acidic pH, and the pH reduction 
generated during batch culture is known to be detrimental to the organism (Lehker and Alderete, 
1992). This pH sensitivity is apparent in vivo; During the colonization of the vagina by T. vaginalis, 
the pH is raised from the usual level of around pH 4 to as high as pH 7, in order to provide optimal 
conditions for the parasites growth (Cudmore et al., 2004). The parasite achieves this by the 
disruption of the commensal lactobacilli community present in the vagina (Cudmore et al., 2004). 
The absence of cell death seen during the first 48 hours post inoculation in the TMN2 media makes 
this media better suited for further experiments to determine the limits of detection of the assay. 
The non-motile cells make the accurate determination of cell count more difficult, as cells may have 
degraded before the count takes place, releasing nucleic acid into the media, which would then be 
picked up by downstream testing by LAMP. This would could potentially cause an artificial increase 
in assay sensitivity, as a larger amount of target nucleic acid would be present in the sample than the 
cell count would suggest. 
 
5.4.4. Sensitivity of the DNA rpt LAMP assay in conjunction with magnetic silica total nucleic acid 
extraction 
 
The sensitivity of the DNA rpt LAMP assay was determined in conjunction with the magnetic silica 
extraction method, which would be used in the final test. This was decided to be a more accurate 
assessment of the combined protocols performance, than by measuring the extracted DNA 
spectrophotometrically and then testing the assay against the DNA dilutions. This was compounded 
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by the lack of access to a spectrophotometer capable of accurately measuring DNA concentration in 
small volumes at the time. It was found that the minimum number of parasites detectable were 10 
per 200µl extraction (Fig.5.8.), which is equivalent to  50 per ml of sample, or 0.7 per extraction 
(Table.5.5.). Separation of reaction products via electrophoresis enabled the visualisation of the 
characteristic ladder like DNA fragments, in all of the reactions determined positive using real-time 
fluorescence detection (Fig.5.9.). There was no obvious difference in the level of product generated 
between the reactions.  The sensitivity of the DNA rpt LAMP assay, in conjunction with the silica 
extraction method is in agreement with previous molecular tests. The combination of a simple 
chelex based extraction method with an 18S rRNA PCR assay was found to have a sensitivity 
equivalent to 1 cell per 25µl reaction (Mayta et al., 2000). A commercially available combination of 
spin column based extraction kit and PCR assay (Urine-Based Trichomonas vaginalis Detection Kit, 
Norgen Biotek Corp, Canada), for the extraction of DNA and subsequent detection of T. vaginalis in 
urine, has a detection limit of 100 cells per ml; twofold higher than the DNA rpt LAMP assay. Other 
commercial PCR assays have been determined as having a detection limit of 10 copies per reaction 
(LightMix Kit Trichomonas vaginalis, Tib MolBiol, Germany).  
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Final Summary 
The extraction method described in the first chapter of this thesis proved to be a robust and rapid 
system for the extraction of nucleic acid from both urine and swab samples. The system was able to 
withstand concentrations of inhibitors such as BSA, non-target bacteria, and red blood cells at higher 
concentrations than would be expected in STI samples. The system was modelled using the 
Kingfisher ML automated extraction system, which enables the magnetic transfer of beads between 
various buffer wells, in a process that fairly closely mimics the magnetic movements of the beads on 
the LabDisk. There are some differences between the systems however, and it is possible that more 
beads will be lost during the process on the disk, as the movement of the beads between the buffers 
is more complex, as the beads need to be guided through the channels in liquid suspension. 
Additionally, the pre-elution drying step on the LabDisk may be more problematic, as it is taking 
place in an enclosed chamber, rather than open air. Heat is being applied to assist in the drying 
process, but this is something that will require further optimisation once the extraction method is 
utilised in the LAbDisk. The application of the extraction methodology, and reagent formulations 
described in this thesis, will be combined with the LabDisk that has been designed to house these 
reagents. This will be carried out by MAST group Ltd, prior to the clinical evaluation of the test. 
The N. gonorrhoea ORF1 LAMP assay is the first report of a LAMP assay designed for this organism, 
and would enable the use of sensitive NAAT diagnostics without the need for thermal cycling 
equipment. The remarkable tolerance of the assay to urea, demonstrated in this work, shows that 
unprocessed urine samples could be used without the need for complex DNA extraction 
methodologies. Therefore, this assay may be of particular use in the developing world, where access 
to the materials needed for PCR testing can be limited. LAMP assays for leishmaniasis, tuberculosis 
and malaria have all been successfully applied in the developing world, illustrating the suitability of 
LAMP for this environment. The availability of sensitive molecular diagnostics for N. gonorrhoeae is 
of increasing importance, due to the rapid development and spread of multi drug resistance in this 
organism.  
The M. genitalium pdhD LAMP assay reported in this thesis is potentially a welcome addition to the 
diagnostic options for this organism, which is undetectable by culture and serological tests, and have 
solely relied upon PCR. The assay was as sensitive as the PCR assays that were used as a comparison, 
whist being faster and being more amenable for application in a decentralised setting.  
Whilst the analytical sensitivity of the assays was determined during the work presented in this 
thesis, in order to thoroughly validate the assays prior to clinical use it would be necessary to repeat 
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these experiments with a greater number of dilutions and replicates. A suggested experimental plan 
for a robust evaluation would include the testing of between ten and 16 dilutions, with between five 
and ten replicates per dilution. This would enable a full probit analysis to be carried out, to 
determine an accurate LOD.  
A significant step towards the goal of a fully functioning diagnostic platform will be the integration of 
the nucleic acid extraction process with the chosen LAMP assays on the LabDisk, which is currently 
being undertaken at MAST Group Ltd. Once the automated system is operational, it will be 
evaluated against a gold standard test for each organism. This will provide data on the sensitivity, 
specificity, and positive and negative predictive value of the test, which are the qualities that will 
determine whether the platform is of clinical use, and recommended for application in a healthcare 
setting. 
If the test performs well in these clinical evaluations, and is considered sufficiently sensitive to act as 
a first line molecular test, it could see clinical use in GUM clinics, GP surgeries, and other sites where 
STI consultations occur. This would enable same day diagnosis and treatment, reducing the non-
return rate, and the risk that positive patients infect further people during this time. This would act 
to save the time of healthcare practitioners and could have a cost benefit to healthcare providers. 
One obstacle to the uptake of point of care tests such as these is the training of the users, who often 
have little laboratory experience, and also the QA of results. The responsibility for these practices 
will reside with the end user, who will need to instigate proficiency testing of staff, and also ensure 
that the system is delivering quality results, most likely through the use of external quality 
assessment providers such as the United Kingdom National External Quality Assessment Services 
(UK NEQAS). Organisations such as this provide blind samples for testing, to ensure the 
diagnostic accuracy of the service, making sure that the information generated is sound enough 
to base therapeutic decisions on.  
 
 
 
 
 
